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A B S T R A C T
Background
Even low levels of substance misuse by people with a severe mental illness can have detrimental effects.
Objectives
To assess the effects of psychosocial interventions for reduction in substance use in people with a serious mental illness compared with
standard care.
Search methods
The Information Specialist of the Cochrane Schizophrenia Group (CSG) searched the CSG Trials Register (2 May 2018), which is based on
regular searches of major medical and scientific databases.
Selection criteria
We included all randomised controlled trials (RCTs) comparing psychosocial interventions for substance misuse with standard care in
people with serious mental illness.
Data collection and analysis
Review authors independently selected studies, extracted data and appraised study quality. For binary outcomes, we calculated standard
estimates of risk ratio (RR) and their 95% confidence intervals (CIs) on an intention-to-treat basis. For continuous outcomes, we calculated
the mean difference (MD) between groups. Where meta-analyses were possible, we pooled data using a random-effects model. Using the
GRADE approach, we identified seven patient-centred outcomes and assessed the quality of evidence for these within each comparison.
Main results
Our review now includes 41 trials with a total of 4024 participants. We have identified nine comparisons within the included trials and
present a summary of our main findings for seven of these below. We were unable to summarise many findings due to skewed data or
because trials did not measure the outcome of interest. In general, evidence was rated as low- or very-low quality due to high or unclear
risks of bias because of poor trial methods, or inadequately reported methods, and imprecision due to small sample sizes, low event rates
and wide confidence intervals.
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1. Integrated models of care versus standard care (36 months)
No clear differences were found between treatment groups for loss to treatment (RR 1.09, 95% CI 0.82 to 1.45; participants = 603; studies
= 3; low-quality evidence), death (RR 1.18, 95% CI 0.39 to 3.57; participants = 421; studies = 2; low-quality evidence), alcohol use (RR 1.15,
95% CI 0.84 to 1.56; participants = 143; studies = 1; low-quality evidence), substance use (drug) (RR 0.89, 95% CI 0.63 to 1.25; participants
= 85; studies = 1; low-quality evidence), global assessment of functioning (GAF) scores (MD 0.40, 95% CI -2.47 to 3.27; participants = 170;
studies = 1; low-quality evidence), or general life satisfaction (QOLI) scores (MD 0.10, 95% CI -0.18 to 0.38; participants = 373; studies = 2;
moderate-quality evidence).
2. Non-integrated models of care versus standard care
There was no clear difference between treatment groups for numbers lost to treatment at 12 months (RR 1.21, 95% CI 0.73 to 1.99; partic-
ipants = 134; studies = 3; very low-quality evidence).
3. Cognitive behavioural therapy (CBT) versus standard care
There was no clear difference between treatment groups for numbers lost to treatment at three months (RR 1.12, 95% CI 0.44 to 2.86;
participants = 152; studies = 2; low-quality evidence), cannabis use at six months (RR 1.30, 95% CI 0.79 to 2.15; participants = 47; studies =
1; very low-quality evidence) or mental state insight (IS) scores by three months (MD 0.52, 95% CI -0.78 to 1.82; participants = 105; studies
= 1; low-quality evidence).
4. Contingency management versus standard care
We found no clear differences between treatment groups for numbers lost to treatment at three months (RR 1.55, 95% CI 1.13 to 2.11;
participants = 255; studies = 2; moderate-quality evidence), number of stimulant positive urine tests at six months (RR 0.83, 95% CI 0.65
to 1.06; participants = 176; studies = 1) or hospitalisations (RR 0.21, 95% CI 0.05 to 0.93; participants = 176; studies = 1); both low-quality
evidence.
5. Motivational interviewing (MI) versus standard care
We found no clear differences between treatment groups for numbers lost to treatment at six months (RR 1.71, 95% CI 0.63 to 4.64; partici-
pants = 62; studies = 1). A clear difference, favouring MI, was observed for abstaining from alcohol (RR 0.36, 95% CI 0.17 to 0.75; participants
= 28; studies = 1) but not other substances (MD -0.07, 95% CI -0.56 to 0.42; participants = 89; studies = 1), and no differences were observed in
mental state general severity (SCL-90-R) scores (MD -0.19, 95% CI -0.59 to 0.21; participants = 30; studies = 1). All very low-quality evidence.
6. Skills training versus standard care
At 12 months, there were no clear differences between treatment groups for numbers lost to treatment (RR 1.42, 95% CI 0.20 to 10.10;
participants = 122; studies = 3) or death (RR 0.15, 95% CI 0.02 to 1.42; participants = 121; studies = 1). Very low-quality, and low-quality
evidence, respectively.
7. CBT + MI versus standard care
At 12 months, there was no clear difference between treatment groups for numbers lost to treatment (RR 0.99, 95% CI 0.62 to 1.59; partic-
ipants = 327; studies = 1; low-quality evidence), number of deaths (RR 0.60, 95% CI 0.20 to 1.76; participants = 603; studies = 4; low-quality
evidence), relapse (RR 0.50, 95% CI 0.24 to 1.04; participants = 36; studies = 1; very low-quality evidence), or GAF scores (MD 1.24, 95% CI
-1.86 to 4.34; participants = 445; studies = 4; very low-quality evidence). There was also no clear difference in reduction of drug use by six
months (MD 0.19, 95% CI -0.22 to 0.60; participants = 119; studies = 1; low-quality evidence).
Authors' conclusions
We included 41 RCTs but were unable to use much data for analyses. There is currently no high-quality evidence to support any one psy-
chosocial treatment over standard care for important outcomes such as remaining in treatment, reduction in substance use or improving
mental or global state in people with serious mental illnesses and substance misuse. Furthermore, methodological difficulties exist which
hinder pooling and interpreting results. Further high-quality trials are required which address these concerns and improve the evidence
in this important area.
P L A I N   L A N G U A G E   S U M M A R Y
Psychosocial interventions for people with both severe mental illness and substance misuse.
What is the aim of this review?
The aim of this Cochrane Review is to find out if psychosocial interventions aimed at reducing substance abuse in people with a serious
mental illness improve patient outcomes compared to standard care. Researchers in the Cochrane collected and analysed all relevant
Psychosocial interventions for people with both severe mental illness and substance misuse (Review)









Cochrane Database of Systematic Reviews
studies that randomly allocated people with severe mental illness and substance misuse to a psychosocial treatment or standard care to
answer this question and found 41 relevant studies.
Key message
From these 41 studies we did not find any high-quality evidence to support any one psychosocial intervention over standard care. However,
the differences in study designs made comparisons between studies problematic.
What was studied in the review?
“Dual” diagnosis is the term used to describe people who have a mental health problem and also have problems with drugs or alcohol.
In some areas, over 50% of all those with a serious mental illness (these include schizophrenia, bipolar disorders and major depression)
will have problems with drugs or alcohol that have negative and damaging effects on the illness symptoms and the way their medication
works. People who have substance misuse problems can be treated via a variety of psychosocial interventions. These include motiva-
tional interviewing, or MI, that looks at people’s motivation for change; cognitive behavioural therapy, or CBT, which helps people adapt
their behaviour by improving coping strategies; contingency management which rewards patients to abstain from taking substances, psy-
cho-education for patients and their carers or family, group and individual skills training. Other interventions include provider-oriented
long-term interventions unifying services to provide integrated treatment so patients do not have to negotiate separate mental health
and substance abuse treatment programmes. Integrated care is often linked to assertive community treatment (ACT) for patients with a
dual diagnosis. There are a variety of psychosocial interventions that can be added to routine care and these can be provided individually
or in various combinations. Currently, we do not know if any psychosocial treatment is better or worse than standard care or if they work
better given in combination or individually.
What are the main results of the review?
The review found 41 relevant studies with a total of 4024 people. These studies looked at a variety of different psychosocial interventions
(including CBT, MI, skills training, integrated models of care and contingency management) and compared them to standard care (the care
a participant in the trial would normally receive). Main results showed there was:
1. no real difference in terms of numbers lost to treatment (low-quality evidence);
2. no real difference in terms of death (low-quality evidence);
3. no real difference in alcohol or substance used (low-quality evidence);
4. no real difference in global functioning or general life satisfaction (low- to moderate-quality evidence).
In addition, studies had high numbers of people leaving early, differences in outcomes measured, and differing ways in which psychosocial
interventions were delivered. More large-scale, high-quality and better reported studies are required to address these shortcomings. This
will better address whether psychosocial interventions are effective for people with serious mental illness and substance misuse problems.
How up-to-date is this review?
The review authors searched for studies that had been published up to October 2018.
Psychosocial interventions for people with both severe mental illness and substance misuse (Review)




























































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Integrated models of care compared to standard care for both severe mental illness and substance
misuse
INTEGRATED MODELS OF CARE compared to STANDARD CARE for both severe mental illness and substance misuse
Patient or population: people with both severe mental illness and substance misuse
Settings: outpatient
Intervention: INTEGRATED MODELS OF CARE
Comparison: STANDARD CARE
Illustrative comparative risks* (95% CI)









































Data were available for 36 months only
Substance use: any
change - Alcohol use
(not in remission) 
Follow-up: mean 36
months








Data were available for 36 months only
Substance use: any
change - Drug use
(not in remission) 
Follow-up: mean 36
months








Data were available for 36 months only
Mental state See comment See comment Not estimable 0
(3 studies)

























































































































































(GAF scale of 1 -
100)Follow-up: mean
12 months
  The mean global assessment
of functioning in the intervention
groups was 0.70 higher (-2.07





NOTE: The GAF measures functioning on
a scale of 1 to 100 and the difference de-







Quality of Life Inter-




  The mean general life satisfaction
in the intervention groups was
0.02 higher





The scale is from 1 to 7 and the very
small difference was not statistically
significant and is not of clinical impor-
tance.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
1 Risk of bias: Rated as SERIOUS: Blinding of participants and personnel in all three trials was not possible and performance bias was rated as unclear risk of bias. Similarly, all
trials were at an unclear risk of detection bias.
2 Imprecision: Rated as SERIOUS: The number of events is less than 300 and the overall sample size is small.
3 Risk of bias: Rated as SERIOUS: Blinding of participants and personnel in both trials was not possible and performance bias was rated as unclear risk of bias. Similarly all trials
were at an unclear risk of detection bias as outcomes ratings were not blinded.
4 Imprecision: Rated as SERIOUS: The event rate is very low and the 95% confidence interval is wide.
5 Risk of bias: Rated as SERIOUS: Blinding of participants and personnel was not possible and performance bias was rated as unclear risk of bias. Similarly there was an unclear
risk of detection bias as outcomes ratings were not blinded.
6 Imprecision: Rated as SERIOUS: The confidence interval is very wide and the sample size small.
 
 
Summary of findings 2.   Non-integrated models of care - Assertive community treatment only/Intensive case management/Specialised case
management services versus standard care for both severe mental illness and substance misuse























































































































































Patient or population: people with both severe mental illness and substance misuse
Settings: outpatient





































Adverse event: Death -
not measured
See comment See comment Not estimable - See comment Death was not measured in any of the trials.
Substance use: Alcohol -
average score 
(C-DIS-R computer pro-





See comment See comment See comment Data were skewed from one trial and there
was no analysis of the difference between ran-
domised arms.
Substance use: Drug - av-
erage score 
C-DIS-R computer pro-





See comment See comment See comment Data were skewed from one trial and there


























































































































































on C-DIS-R computer pro-





See comment See comment See comment Data were skewed from one trial and there





high = better functioning)
Follow-up: mean 12
months












NOTE: the scale is 1 to 7 and the difference ob-
served is not of clinical importance and is not sta-
tistically significant.
Quality of life/life satis-
faction: (Quality of Life In-




See comment     Data were skewed from one trial and there
was no analysis of the difference between ran-
domised arms.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
1 Risk of bias: Rated as VERY SERIOUS: Random generation and allocation concealment was not adequately reported and the risk of bias is unclear. Both performance and
detection bias was unclear as blinding was not performed or was unclearly reported. Attrition was unclear or very high (57% in Bond-Anderson 91) so overall the risk of bias
was rated as very serious.
2 Imprecision: Rated as SERIOUS: The confidence interval is wide and the sample size is very small.
3 Risk of bias: Rated as SERIOUS: Blinding of participants and personnel was not possible and performance bias was rated as unclear risk of bias. Similarly there was an unclear
risk of detection bias as outcomes ratings were participant/clinician mediated.
























































































































































Summary of findings 3.   Cognitive behavioural therapy versus standard care for both severe mental illness and substance misuse
COGNITIVE BEHAVIOUR THERAPY compared to STANDARD CARE for both severe mental illness and substance misuse
Patient or population: people with both severe mental illness and substance misuse
Settings: outpatient
Intervention: COGNITIVE BEHAVIOUR THERAPY
Comparison: STANDARD CARE
Illustrative comparative risks* (95% CI)
















Leaving the study early: Lost to treat-
ment
Follow-up: mean 3 months









Adverse event: Death See comment See comment Not estimable   See comment Death was not mea-
sured in any of the
trials.
Substance use: Alcohol See comment See comment Not estimable See comment See comment Naeem 2005 mea-
sured alcohol to-
gether with drug
use in the Health of
the Nation Outcome
(HoNOS) scale. Ed-
wards did not report
on alcohol.
Substance use: Drug (Cannabis)
Percentage of participants who used
cannabis in last 4 weeks
Follow-up: mean 6 months













Mental state: average score (Insight
scale)
Follow-up: by 3 months
  The mean mental state in the
intervention groups was
0.52 higher





























































































































































Social functioning: Average score*
The Social and Occupational Functioning
Scale (SOFAS): scale of 1 to 100
Follow-up: mean 6 months
  The mean global assessment of
functioning in the intervention
groups was
4.70 lower





* Global state data
were not reported by
the trials








Quality of life/ life satisfaction   See comment   Not estimable See comment No study measured
Quality of life
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
1 Risk of bias: Rated as SERIOUS: The participants and personnel were not blinded and performance bias may be present. Missing data were addressed by Last Observation
Carried Forward in Edward 2006 but attrition bias may be present as loss to follow-up was 30% at 9 months.
2 Imprecision: Rated as SERIOUS: The event rate is low and the confidence interval is wide.
3 Imprecision: Rated as VERY SERIOUS: The event rate is low, the sample size small and the confidence interval is wide.
4 Imprecision: Rated as VERY SERIOUS: The confidence interval is very wide and the sample size small.
 
 
Summary of findings 4.   Contingency management versus standard care for both severe mental illness and substance misuse
CONTINGENCY MANAGEMENT compared to STANDARD CARE for both severe mental illness and substance misuse









































































































































































Leaving the study early: Lost to
treatment
Follow-up: mean 3 months









Adverse event: Death - not measured See comment See comment Not estimable - See comment None of the trials measured
death as an outcome.
Substance use: Alcohol See comment See comment   Data were skewed and no be-
tween-arm comparison were re-
ported.
Substance use: Drug (non-alcohol) 
Number with stimulant-positive urine
test
Follow-up: mean 6 months











Follow-up: mean 6 months








Predefinded outcome of Mental
state data were skewed and un-
useable.
Global state See comment See comment Not estimable - See comment Neither trial measured Global
state
Quality of life/life satisfaction See comment See comment Not estimable - See comment Neither trial measured Quality of
life
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
1 Risk of bias: Rated as SERIOUS: Blinding was not possible so performance bias was rated as an unclear risk of bias. Primary outcome in both trials was urinalysis so detection
bias was unlikely, Attrition bias was an unclear risk and greater than 20% across groups in both trials.























































































































































3 Impresion: Rated as SERIOUS: The event rate is low (less than 300 according to GRADE) and the confidence interval includes 1 and appreciable benefit.
4 Imprecision: Rated as SERIOUS: The event rate is very low and the confidence interval is wide.
 
 
Summary of findings 5.   Motivational interviewing versus standard care for both severe mental illness and substance misuse
MOTIVATIONAL INTERVIEWING compared to STANDARD CARE for both severe mental illness and substance misuse
Patient or population: people with both severe mental illness and substance misuse
Settings: hospital and community
Intervention: MOTIVATIONAL INTERVIEWING
Comparison: STANDARD CARE
Illustrative comparative risks* (95% CI)
















Follow-up: mean 6 months










Follow-up: mean 18 months










Not abstaining from alcohol
Follow-up: mean 6 months











els measured by Opiate
Treatment Index (OT)
Follow-up: mean 12 months
  The mean drug (non-alcohol) use in the in-
tervention groups was
0.07 lower








vised - General Severity In-
dex: Scale 0 to 4: Average
score
Follow-up: mean 3 months
  The mean mental state in the intervention
groups was
0.19 lower









  The mean global assessment of functioning





The difference is un-























































































































































GAF scale of 1- 100
Follow-up: mean 12 months
2.30 higher
(1.30 lower to 5.90 higher)
significance given the
scale is from 1 to 100.
Quality of life/life satisfac-
tion - not measured
See comment See comment Not estimable - See comment None of the eight trials
contributing data to
this comparison mea-
sured general life satis-
faction.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
1 Risk of bias: Rated as SERIOUS: This single trial has unclear risk of allocation concealment and an unclear risk for performance bias.
2 Imprecision: Rated as VERY SERIOUS: The sample size is very small (N = 62), the event rate very low and the confidence interval very wide.
3 Risk of bias: Rated as SERIOUS: Allocation concealment was unclear and blinding was not possible so performance bias is unclear. Assessors were not blinded so there is a high
risk of detection bias. Attrition was 29% at 18 months.
4 Imprecision: Rated as VERY SERIOUS: The event rate is very small and the confidence interval is very wide.
5 Risk of bias: Rated as SERIOUS: Random generation, allocation concealment and performance bias (lack of blinding) posed an unclear risk of bias. Detection bias was likely
as assessors were not blinded.
6 Imprecision: Rated as VERY SERIOUS: The sample size was extremely small (N = 30), and the event rate very low.
7 Risk of bias: Rated as SERIOUS: Selection bias was unclear and performance bias may be present as personnel and participants were not blinded. Assessors were blinded.
Attrition bias is a high risk as 44% were lost to follow-up by 12 months.
8 Imprecision: Rated as VERY SERIOUS: The single trial has a very small sample size (N = 30) and imprecision is very likely.
9 Imprecision: Rated as VERY SERIOUS: The single trial sample size is very small (N = 54) and the confidence interval is very wide.
10 Risk of bias: Rated as VERY SERIOUS: Selection bias was a high risk as allocation concealment was modified to allow for participant refusal and to minimise disruption to the
treatment programme. Performance and detection bias were unclear as blinding was not possible for personnel and participants and assessor blinding was not reported.
 
 
Summary of findings 6.   Skills training versus standard care for both severe mental illness and substance misuse
SKILLS TRAINING compared to STANDARD CARE for both severe mental illness and substance misuse
Patient or population: people with both severe mental illness and substance misuse

























































































































































Illustrative comparative risks* (95% CI)















Leaving the study early: Lost to treat-
ment 
Follow-up: mean 12 months




















Follow-up: mean 12 months
See comment See comment Not estimable See comment See comment Data were skewed and
no estimate of effect
was calculated between
randomised arms.
Substance use: Drug (non-alcohol) 
(C-DIS-R average score)
Follow-up: mean 12 months
See comment See comment Not estimable See comment See comment Data were skewed and
no estimate of effect
was calculated between
randomised arms.
Mental state See comment See comment Not estimable     No data were available
for analyses.
Social functioning*:
Role Functioning Scale: scale 1 to 7
Follow-up: mean 12 months
  The mean assessment of
functioning in the inter-
vention groups was
1.07 higher





* Global state data were
not reported.
NOTE: the scale is 1 to
7 and the difference ob-
served is not of clinical
importance and is not
statistically significant.
Quality of life/life satisfaction - not mea-
sured
See comment See comment Not estimable - See comment Neither trial measured
general life satisfaction.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;























































































































































High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
1 Risk of Bias: Rated as VERY SERIOUS: Blinding was not possible and performance bias may be present. It was unclear whether assessors were blinded and detection bias may be
present. Attrition bias was a high risk in Hellerstein 1995 with 47% loss to follow-up at 4 months and 64% at 8 months with no reasons for drop-outs provided and not addressed
in analysis.
2 Imprecision: Rated as SERIOUS: The event rate was low (zero events in one trial) with a wide confidence interval.
3 Risk of Bias: Rated as SERIOUS: The trial outcomes were self-reported abstinence and there is no report of whether raters were blind to treatment allocation when assessing
the participant's self-report.
4 Inconsistency: this is not possible to evaluate as there is only a single study.
5 Imprecision: The single trial has a small sample size of 121 with very low event rates. The confidence interval crosses the line of no effect and appreciable harm.
6 Risk of Bias: Rated as SERIOUS: Blinding was not possible and performance bias may be present. It was unclear whether
7 Imprecision: Rated as VERY SERIOUS: The single trial has a very small sample size (N =47) and the confidence interval is wide.
 
 
Summary of findings 7.   Cognitive behavioural therapy + motivational interviewing versus standard care for both severe mental illness and
substance misuse
COGNITIVE BEHAVIOURAL THERAPY + MOTIVATIONAL INTERVIEWING compared to STANDARD CARE for both severe mental illness and substance misuse
Patient or population: people with both severe mental illness and substance misuse
Settings: outpatient
Intervention: COGNITIVE BEHAVIOUR THERAPY + MOTIVATIONAL INTERVIEWING
Comparison: STANDARD CARE
Illustrative comparative risks* (95% CI)
















Leaving the study ear-
ly: Lost to treatment
Follow-up: mean 12
months









Adverse event: Death 
Follow-up: mean 12
months






































































































































































See comment Moderate   46
(1 study)
See comment Data were skewed from
one trial and there was





(Average number of dif-
ferent drugs used dur-
ing the past month mea-




  32 per 1000
The average number of different drugs used
in past month in the intervention group was









Relapse at 3 months af-













change in mental state
not reported.
Global State:
GAF scale of 1- 100
Follow-up: mean 12
months
  The mean Global Assessment of Functioning
in the intervention groups was 1.24 higher





NOTE: The GAF mea-
sures functioning on a
scale of 1 to 100 and the
difference detected in
this single trial is not of
clinical importance.
Quality of life / life sat-
isfaction:
Brief Quality of Life Scale
Follow-up: mean 6
months
  The mean general life satisfaction in the inter-
vention groups was
0.58 higher






*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.























































































































































Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
1 Risk of bias: Rated as SERIOUS: The single trial which reported on 12 month loss to treatment had adequate random generation and allocation concealment. However, we
down-graded it for possible performance bias as participants and clinicians were not blinded. Detection bias was a low risk as outcome assessors were blinded.
2 Imprecision: Rated as SERIOUS: The event rate is low and the confidence interval is wide and includes the line of no effect and appreciable harm.
3 Risk of bias: Rated as SERIOUS: The four trials included in this meta-analysis were well-conducted. A lack of blinding is unlikely to affect measurement of death. However,
attrition was > 20% in all four trials and although missing data were balanced across groups, there is an unclear risk of bias due to attrition bias.
4 Risk of bias: Rated as SERIOUS: Random generation and allocation concealment were unclear and blinding was not possible for participants or clinicians. Attrition was high at
20% at 12 months, but missing outcome data were balanced between groups.
5 Imprecision: Rated as SERIOUS: The sample size is small and the confidence interval is wide.
6 Risk of bias: Rated as SERIOUS: The risk of attrition bias is unclear (22% across both groups at 18 months) despite missing outcome balanced between groups. A lack of blinding
of participants and clinicians may result in performance bias.
7 Imprecision: Rated as VERY SERIOUS: The event rate is extremely low in this very small single trial (N = 36) and the confidence interval is wide.
8 Risk of bias: Rated as SERIOUS: Attrition was > 20% in all four trials and although missing data were balanced across groups, there is an unclear risk of bias due to attrition bias.
9 Inconsistency: Rated as SERIOUS: Heterogeneity was present (ChiÂ2 = 5.20, df = 3 (P = 0.16); IÂ2 = 42%). One trial (Barrowclough) showed significant improvement in the treatment
group compared with the others, but we were unable to explain the reason for this.
10 Imprecision: Rated as SERIOUS: Four trials provided data for this meta-analysis. The confidence interval is wide.
11 Risk of bias: Rated as SERIOUS: Blinding of participants and clinicians was not possible and performance bias may be a risk. Attrition was 25% at 6 months and missing data
were not balanced across interventions. Missing outcomes are enough to induce clinically relevant bias in observed effect size.
12 Imprecision: Rated as SERIOUS: The sample size of the single trial is small and the confidence interval is wide.
 
 
Summary of findings 8.   Cognitive behavioural therapy + psychosocial rehabilitation versus standard care for both severe mental illness and
substance misuse
COGNITIVE BEHAVIOUR THERAPY and PSYCHOSOCIAL REHABILITATION compared to STANDARD CARE for both severe mental illness and substance misuse
Patient or population: people with both severe mental illness and substance misuse
Settings: jail and community
















































































































































































Leavint the study early: Loss
to Treatment
Follow-up: mean 12 months




Data were only reported per trial and not per ran-
domised arm.
Adverse event: Death - not
measured
See comment See comment Not estimable - See comment The trial did not measure death as an outcome.
Substance use: Alcohol - not
measured
See comment See comment Not estimable - See comment This trial focused on criminal outcomes of jail
and offences. Data were skewed and not com-
pared between arms.
Substance use: Drug (non-
alcohol) - not measured
See comment See comment Not estimable - See comment This trial focused on criminal outcomes of jail
and offences. The data were skewed and was not
compared between arms.
Mental state - not measured See comment See comment Not estimable - See comment This trial focused on criminal outcomes of jail
and offences. The data were skewed and was not
compared between arms.
Global State- not measured See comment See comment Not estimable - See comment This trial focused on criminal outcomes of jail
and offences. The data were skewed and was not
compared between arms.
Quality of life/life satisfac-
tion - not measured
See comment See comment Not estimable - See comment This trial focused on criminal outcomes of jail
and offences. The data were skewed and was not
compared between arms.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
1 Risk of bias: Rated as VERY SERIOUS: Although the random generation is reported as computer-generated the numbers in the arms vary and no report is made as to whether
randomisation was done in a ratio fashion. Blinding was not done and performance bias may be unclear and detection bias is high risk as the assessors were not blinded. There
is a high risk of selective reporting bias as few outcomes are reported per arm and mainly by site.

























































































































































Summary of findings 9.   Cognitive behavioural therapy + intensive case management versus standard care for both severe mental illness and
substance misuse
COMBINED COGNITIVE BEHAVIOUR THERAPY and INTENSIVE CASE MANAGEMENT compared to STANDARD CARE for both severe mental illness and substance mis-
use
Patient or population: people with both severe mental illness and substance misuse
Settings: jail and community

























Leaving the study early:
Loss to Treatment
Follow-up: mean 12 months




Unable to use data - (no breakdown by treat-
ment arms)
Adverse event: Death See comment See comment Not estimable - See comment The trial did not measure death.
Substance use: alcohol - not
measured
See comment See comment Not estimable - See comment This trial focused on criminal outcomes of jail
and offences. Data were skewed and not com-
pared between arms.
Substance use: Drug (non-
alcohol) - not measured
See comment See comment Not estimable - See comment This trial focused on criminal outcomes of jail
and offences. Data were skewed and not com-
pared between arms.
Mental state - not measured See comment See comment Not estimable - See comment This trial focused on criminal outcomes of jail
























































































































































Global State - not measured See comment See comment Not estimable - See comment This trial focused on criminal outcomes of jail
and offences. Data were skewed and not com-
pared between arms.
Quality of life/life satisfac-
tion - not measured
See comment See comment Not estimable - See comment This trial focused on criminal outcomes of jail
and offences. Data were skewed and not com-
pared between arms.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
1 Risk of bias: Rated as VERY SERIOUS: Although the random generation is reported as computer-generated the numbers in the arms vary and no report is made as to whether
randomisation was done in a ratio fashion. Blinding was not done and performance bias may be unclear and detection bias is high risk as the assessors were not blinded. There
is a high risk of selective reporting bias as few outcomes are reported per arm and mainly by site.
2 Risk of bias: Rated as VERY SERIOUS: Although the random generation is reported as computer-generated the numbers in the arms vary and no report is made as to whether
randomisation was done in a ratio fashion. Blinding was not done and performance bias may be unclear and detection bias is high risk as the assessors were not blinded. There




































































Cochrane Database of Systematic Reviews
B A C K G R O U N D
Description of the condition
Substance misuse among people with a severe mental illness is a
major concern, with prevalence rates over 50%. This figure varies
across studies, depending on location, methodologies and by the
way substance misuse problems and severe mental illness are de-
fined (Brunette 2018; Carra 2009; Green 2007; Gregg 2007; Hartz
2014; Lai 2012a; Lai 2012b; Lowe 2004; Morgan 2017; Regier 1990;
Todd 2004). Recent meta-analyses have shown high rates of co-
morbidity between substance use disorders (SUD) and schizophre-
nia (Hunt 2018), bipolar disorders (Hunt 2016) and major depres-
sion (Lai 2015). Improving services for people with a serious men-
tal illness (often labelled as having a 'dual diagnosis') is a priori-
ty as using drugs or consuming alcohol, even at low levels, is as-
sociated with a range of adverse consequences, including higher
rates of non-adherence, relapse, suicide, HIV, hepatitis, homeless-
ness, aggression, incarceration, and fewer social supports or finan-
cial resources (Donald 2005; Green 2007; Hunt 2002; Khokhar 2018;
Pettersen 2014; Schmidt 2011; Tsuang 2006). Further, co-morbidi-
ty places an additional burden on families, psychiatric and govern-
ment resources and is particularly challenging to those providing
services as these patients have lower rates of treatment completion
and higher rates of relapse (Khokhar 2018; Mueser 2013; Siegfried
1998; Tyrer 2004; Warren 2007).
Description of the intervention
It is important that co-occurring substance use is detected as
early as possible and that appropriate and effective treatment
is provided (Green 2007; Mueser 2013). Treatment has tradition-
ally been complicated by different approaches and philosophies
among mental health and drug services as they may differ in their
theoretical underpinnings, policies and protocols. Separate treat-
ment programmes have been offered in parallel or sequentially
by different clinicians, which may result in less than optimum pa-
tient care with the patient having to negotiate two separate treat-
ment systems (De Witte 2014; Drake 2008; Green 2007). Another ap-
proach to care is the integrated treatment model where mental
health and substance use treatments are brought together simul-
taneously by the same service, clinician or team of clinicians who
are competent in both service areas and place similar importance
on both (Drake 2004). Basic elements include an assertive style of
engagement, techniques of close monitoring, comprehensive ser-
vices (including inpatient, day hospital, community team and out-
patient care), supportive living environments, flexibility and spe-
cialisation of clinicians, step-wise treatment, and a long-term per-
spective and optimism (Bond 2015; Drake 1993; Drake 2008). As-
sertive Community Treatment (ACT) and residential programmes
are generally long term and can form a basis for integrated pro-
grammes (Mueser 2013).
How the intervention might work
As many substance users in the general population have benefit-
ed from a range of psychosocial interventions, it would follow that
these same interventions should also benefit people with psychosis
when their mental health problems are taken into account (Bar-
rowclough 2006a). Most, if not all, substances of abuse increase
dopaminergic activity in the brain (Koob 2010). Given that schizo-
phrenia and other forms of psychosis are characterised by height-
ened dopaminergic transmission and that neuroleptics decrease
activity or block dopamine receptors (Kapur 2005), it stands to rea-
son that most substances of abuse increase symptoms, the risk
of relapse and compromise the beneficial effects of neuroleptics
(Khokhar 2018; Large 2014; LeDuc 1995; Seibyl 1993). This is es-
pecially true for stimulant drugs like amphetamine, cocaine and
concentrated forms such as crack cocaine and methamphetamine
('ice') that can exacerbate or mimic psychotic symptoms and el-
evate risk of readmission (Callaghan 2012; Lappin 2016; McKetin
2013; Pluddemann 2013; Romer Thomsen 2018; Sara 2015). Sub-
stance use is also related to poor adherence with treatment, further
increasing the risk of relapse (Hunt 2002). Interventions that reduce
substance use are likely to improve symptoms, relapse rates, recov-
ery and other outcomes (Cleary 2009a; Drake 2008; Horsfall 2009).
Common psychosocial interventions to reduce substance use and
misuse include Twelve-Step recovery, which adopts a supportive
approach such as that used by Alcoholics Anonymous (AA); moti-
vational interviewing, which aims to increase an individual's moti-
vation for change; group and individual skills training; family psy-
cho-education regarding the signs and effects of substance use;
and individual or group psychotherapy involving cognitive or be-
havioural principles, or both, which aim to increase coping strate-
gies, awareness and self-monitoring behaviour (Mueser 2013). All of
these interventions can vary in intensity and duration, and can be
offered in a variety of settings, either individually or as part of an in-
tegrated programme. Integrated treatment ensures mental health
and substance misuse services are available in the same setting and
delivered in a coherent fashion.
Why it is important to do this review
While encouraging, results of trials assessing the effectiveness
of these psychosocial interventions for mental health consumers
are equivocal (for reviews, see: Bennett 2017; Bogenschutz 2006;
Cleary 2009a; De Witte 2014; Dixon 2010; Drake 1998b; Drake 2004;
Drake 2008; Horsfall 2009; Ley 2000; Mueser 2005; Mueser 2013;
NICE 2011). Many studies have been hampered by small heteroge-
neous samples, poor experimental design (for example non-ran-
dom assignment), high attrition rates, short follow-up periods, lack
of accuracy of measuring substance use, skewed data, use of non-
standardised outcome measures and unclear descriptions of treat-
ment components (Barrowclough 2006a; Cleary 2008; Hunt 2013).
When assessing integrated programmes, it can also be difficult to
determine exactly which part of the programme is the most effec-
tive, and control groups (particularly in the USA) may involve a
certain level of service integration, making interpretations difficult
(Drake 1996). Moreover, study methodologies, interventions and
outcome measures vary across studies, as do patterns of partici-
pants' readiness to change, severity and type of illness and sub-
stance use, all of which make combining results in a review prob-
lematic (De Witte 2014; Donald 2005; Drake 2008).
This current review updates the 2013 Cochrane Review on "Psy-
chosocial treatment programmes for people with both severe mental
illness and substance misuse". The previous review (Hunt 2013) in-
cluded any programme of substance misuse treatment and locat-
ed 32 randomised controlled trials (RCTs). The authors from three
previous reviews found no evidence to support any one substance
misuse programme as being superior to another (Cleary 2008; Hunt
2013; Ley 2000). We felt an update of this review was warranted as
there are several new studies that have been conducted in the last
five years.
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O B J E C T I V E S
To assess the effects of psychosocial interventions for reduction in
substance use by people with a serious mental illness compared
with standard care.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all relevant, randomised controlled trials (RCTs) with
or without blinding if they utilised a psychosocial intervention to
reduce substance use in people with severe mental illness and sub-
stance misuse compared with standard care. We excluded qua-
si-randomised trials, such as those where allocation was alternate
or sequential.
Types of participants
We included people diagnosed with a severe mental illness (for ex-
ample, mixed patient populations with schizophrenia, bipolar dis-
order, major depression and other psychosis) and concurrent prob-
lem of substance misuse. We have defined people with 'severe' ill-
ness as those with a chronic mental illness like schizophrenia who
present to adult services for long-term care. Those with an organ-
ic disorder, non-severe mental illness (for example, personality dis-
order, post-traumatic stress disorder (PTSD), anxiety disorders, de-
pressive symptoms based on scores from a scale) or those who sole-
ly abused tobacco were, if possible, excluded. Trials that included a
mixture of patients with a severe mental illness diagnosis were in-
cluded if a large proportion had a schizophrenia-like illness or psy-
chosis (see Characteristics of included studies). Studies were ex-
cluded if all of the participants had a diagnosis of bipolar disorder
or major depressive disorder from 2013 on, so they do not overlap
with affective disorder reviews.
Types of interventions
We anticipated that studies included in the review would use a wide
variety of psychosocial interventions for substance misuse, mak-
ing direct comparisons difficult. In order to enhance the utility of
the review, we developed a priori categories within which we made
planned comparisons. These categories were developed from the-
oretical models of the types of behavioural and psychosocial inter-
ventions offered to clients and the context in which they are deliv-
ered. The types of interventions were grouped in two strata, based
on duration and intensity of treatment. The first stratum describes
long-term interventions for dual diagnosis patients that offered an
array of services with different levels of integration and assertive
outreach (taking place over years rather than weeks or months),
and the second describes stand-alone psychosocial interventions
that clients received over shorter periods. We did not include inter-
ventions for informal carers (partner or family members) as sepa-
rate categories, though we did sometimes include them as part of
the treatments mentioned below.
1. Provider-oriented long-term interventions: integrated and
non-integrated care by community mental health teams for dual
diagnosis populations
1.1 Integrated models of care with assertive community treatment
(ACT)
Integrated treatment models for patients with a dual diagnosis uni-
fy services at the provider level rather than forcing clients to ne-
gotiate separate mental health and substance abuse treatment
programmes (Drake 1993; Drake 2008; Mueser 2013). The range of
services provided varies according to client needs and should be
able to handle patients at differing stages of readiness to change
(Tsuang 2006). Substance abuse treatments are integrated into an
array of direct services, such as frequent home visits, crisis inter-
vention, housing skills training, vocational rehabilitation, medica-
tion monitoring, and family psycho-education. Integrated treat-
ment means that the same clinicians or teams of clinicians in the
one setting provide long-term treatments in a co-ordinated fash-
ion (Barrowclough 2006a; Green 2007). Teams consist of three to
six clinicians and attempt to remain faithful to a specified model of
care. To the client, the services should appear seamless with a con-
sistent approach, philosophy and set of recommendations. Usual-
ly the caseloads of dual diagnosis teams are lower (approximately
10 to 15 clients shared within a team) than for standard case man-
agers (approximately 20 to 30). Integrated treatment is a process
that takes place over years rather than weeks or months. Stud-
ies included in this category must have clearly demonstrated the
following: 1) assertive community outreach to engage and retain
clients and to offer services to reluctant or uncooperative clients,
2) staged interventions to reduce substance use, and 3) adherence
to the integrated team philosophy. The intervention could be com-
munity-based or provided for special populations, such as home-
less people or forensic patients.
1.2 Non-integrated models of care (ACTO) or intensive case
management
Non-integrated treatment entails similar interventions by commu-
nity teams, as described above, except the same members do not
deliver them in a co-ordinated fashion and assertive community
outreach is not included. Normally, case managers in this category
are better trained and have higher clinical qualifications and bet-
ter therapeutic skills than standard case managers. Intensive case
management is defined as lower case load size (approximately 10
to 15 clients) than for standard case managers and tends to have
a 'psychodynamic' flavour (see Marshall 1998; Mueser 2013). To be
included in this category, part of the intervention had to address
the client's drug and alcohol misuse.
2. Patient or client focused short-term interventions for
substance misuse
These interventions can be broadly grouped into individual and
group modalities. They are offered in addition to routine care
(treatment as usual, standard case management) and are based
on different theoretical models. Although they could be part of
the provider-oriented packages described above, studies included
here were easier to evaluate since they described a simplified inter-
vention that can be easily reproduced. As some studies used more
than one intervention (for example, cognitive behavioural therapy
combined with motivational interviewing), these were included in
a separate category.
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2.1 Individual approaches
2.1.1 Cognitive behavioural therapies
Cognitive behavioural approaches include a variety of interven-
tions (Rector 2012; Work Group 2007). The defining features are:
1) emphasis on functional analysis of drug use, understanding the
reasons for use and consequences; and 2) skills training for recog-
nising the situations where a person is most vulnerable to drug use
and avoiding these situations. A cognitive behavioural intervention
seeks to establish links between drug misuse, irrational beliefs, and
misperceptions at a personal level and endeavours to correct the
thoughts, feelings and actions of the recipient with respect to and
the promotion of alternative ways of coping (Jones 2004; Jones
2012; Thoma 2015). The target symptom that is usually focused on
is reducing problematic substance use or harm minimisation, such
as reducing the risk of contracting HIV.
2.1.2 Motivational interviewing
Motivational interviewing takes a non-confrontational approach to
treating substance misuse and is intended to enhance the individ-
ual's intrinsic motivation for change, in patients who often find
it difficult to commit to change (Tsuang 2006). It matches the pa-
tient's level of problem recognition to change with specific strate-
gies and goals and can be delivered in brief sessions or over a num-
ber of weeks. It is based on four key principles: 1) expressing empa-
thy, 2) developing discrepancy, 3) supporting self-efficacy, and 4)
rolling with resistance (Chanut 2005); and is directed at five stages:
1) pre-contemplation, 2) contemplation, 3) preparation, 4) action,
and 5) maintenance (Tsuang 2006). A key hypothesis is that the pa-
tient's perspective on the importance of change is fundamental to
the patient's readiness to address the problem. Developing the pa-
tient's confidence in their ability to achieve the desired change is
also a key issue of motivational interviewing. This treatment is de-
livered individually or in small group settings.
2.1.3 Contingency management
Based on principals of operant conditioning, contingency manage-
ment (CM) offers incentives or rewards to reinforce specific goals
(reduced substance use, risky behaviours etc). Typically, rewards
are provided if a negative substance test is provided (urine test or
breath test). Rewards can vary widely, ranging from encouraging
statements ('keep up the good work') to large or small financial
prize (vouchers for food, cash etc). This approach has shown con-
sistent success with various drug use disorders: cannabis, opiate
and cocaine dependence and polysubstance use disorders (Dutra
2008). Contingency management has also been added with other
psychosocial interventions, for example, motivational interviewing
plus cognitive behavioural therapies (Bellack 2006). Thus, contin-
gency management was added to the previous review due to the
number of current and ongoing trials using this intervention.
2.2 Group approaches
2.2.1 Social skills training
These groups are aimed at helping clients develop interpersonal
skills for establishing and maintaining relationships with others,
dealing with conflict, and handling social situations involving sub-
stance misuse (Mueser 2004; Mueser 2013). They are taught in a
highly structured way by using role play, corrective feedback and
homework. This usually occurs in a group format, although the
methods can also be employed in individual work as a type of cog-
nitive behavioural counselling.
3. Standard care
For this review, standard care or 'treatment as usual' or 'routine'
care was defined as the care that a person would normally receive
had they not been included in the research trial. This could include
standard case management (e.g. see Dieterich 2017 Mas-Esposito
2015). Standard care varies between settings and can be supple-
mented by additional components, including psycho-educational
material, family therapy, or referral to self-help groups (for exam-
ple, Alcoholics Anonymous) or other agencies for substance abuse
treatment.
Types of outcome measures
We intended to group data into short-, medium- and long-term out-
comes. However, this would have resulted in much data loss as out-
come periods varied and therefore, we reported for the following
time periods: 3, 6, 9, 12, 18, 24 and 36 months (where applicable).
We endeavoured to report binary outcomes, recording clear and
clinically meaningful degrees of change (e.g. global impression of
much improved, or more than 50% improvement on a rating scale -
as defined within the trials) before any others. Thereafter we listed
other binary outcomes and then those that are continuous*.
We only extracted data from valid scales (see Data collection and
analysis).
For outcomes measured and scales used by included studies see
(Included studies).
Primary outcomes
1. Leaving the study early
1.1 Lost to treatment: this is a measure of stability and engagement
(number of participants who did not continue with the treatment
following randomisation; however, some may have provided da-
ta for the study. This varies with study design as some treatments
are ongoing for the study duration and some are short term. When
studies reported exactly the same data for both lost to treatment
and lost to evaluation (see below), and if there were no other stud-
ies with which to pool data, then we only reported the numbers lost
to treatment (to reduce the number of comparison tables). We did
not adjust numbers lost to treatment for death (see below).
2. Substance use: changes in substance use (alcohol or drugs, or both)
as defined by each of the studies
2.1 Clinically important change or any change in substance use
2.2 Average endpoint or change score on substance use scale
3. Mental state (mental health symptoms)
3.1 Clinically important change or any change in mental state
3.2 Average endpoint or change score on mental state scale
Secondary outcomes
1. Leaving the study early
1.1 Lost to evaluation (number of people lost to the study who did
not provide data at particular time points).
1.1.1. For any reason
1.1.2 For specific reason
2. Adverse events
2.1 Death (all causes)
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Some studies may not have reported on the number of partici-
pants dying over the treatment or evaluation period. If reported, we
recorded death in a separate table, but these cases were retained in
the lost to treatment and lost to evaluation figures as it is often un-
clear when the death occurred or the cause of death was not stated
as unlikely to be linked to the intervention.
3. Global state (a clinical measure of patient's psychological, social
and occupational functioning in a single measure)
3.1 Clinically important change or any change in global state
3.2 Average endpoint or change score on global state scale
4. Social functioning (social assessment measures and basic skills
necessary for community living)
4.1 Clinically important change or any change in social functioning
4.2 Average endpoint or change score on quality of life/life satisfac-
tion scale
5. Quality of life/life satisfaction (objective and subjective quality of
life satisfaction measures, measures of global patient satisfaction
with daily living and services provided)
5.1 Clinically important change or any change in quality of life/life
satisfaction
5.2 Average endpoint or change score on quality of life/life satisfac-
tion scale
6. Service use (including relapse)
Relapse is often used as an outcome measure. Relapse can be mea-
sured as a dichotomous event (re-admitted to hospital), or contin-
uous measure such as number of admissions over a specified peri-
od or time to admission (number of weeks, days).
6.1 Re-admission to hospital
6.2 Number of admissions
6.3 Number of days in community
7. Homelessness: homelessness is common in this patient population.
It is oLen used to measure a favourable outcome if a person finds
stable living accomodation over a specified period
7.1 Number of days in stable living accomodation
7.2 Number of days on street
8. Economic outcomes
8.1 Direct costs: e.g. costs to the patient for supplying a drug-free
urine sample
8.2 Indirect costs: e.g. savings based on number of days living in the
community, versus costs of inpatient treatment or days in jail
9. Compliance with treatment and medication (as defined by
individual studies)
'Summary of findings' table
We used the GRADE approach to interpret findings (Schünemann
2011); and used GRADEpro GDT to export data from our review
to create 'Summary of findings' tables. These tables provide out-
come-specific information concerning the overall certainty of evi-
dence from each included study in the comparison, the magnitude
of effect of the interventions examined, and the sum of available
data on all outcomes we rate as important to patient care and de-
cision making. We selected the following main outcomes for inclu-
sion in the 'Summary of findings' tables.
1. Leaving the study early: numbers lost to treatment (medium
term: 12 months; if these data were not available we used the
short-term data).
2. Adverse event: death.
3. Substance use: alcohol use (as measured in the trials). Described
as a clinically important reduction in alcohol use.
4. Substance use: drug use (as measured in the trials). Described
as a clinically important reduction in illicit drug use.
5. Mental state: (as measured in the trials, and if no specific scale
assessment was done we reported on relapse or hospitalisa-
tion).
6. Global state: (as measured in the trials) described as a clinically
important change in functioning.
7. Quality of life - life satisfaction: (as measured in the trials) de-
scribed as a clinically important change in satisfaction.
If data were not available for these pre-specified outcomes but
were available for ones that were similar, we presented the closest
outcome to the pre-specified one in the table but took this into ac-
count when grading the finding*.
* see Differences between protocol and review Note 5.
Search methods for identification of studies
Electronic searches
Cochrane Schizophrenia Group's Study-Based Register of Trials
On 2 May 2018, the Information Specialist searched the register us-
ing the following search strategy:
(*{PSY}* in Intervention) AND (*Substance Use* in Healthcare Con-
dition) of STUDY
In such a study-based register, searching the major concept re-
trieves all the synonyms and relevant studies because all the stud-
ies have already been organised based on their interventions and
linked to the relevant topics (Shokraneh 2017).
This register is compiled by systematic searches of major re-
sources (AMED, BIOSIS, CENTRAL, CINAHL, ClinicalTrials.Gov, Em-
base, MEDLINE, PsycINFO, PubMed, WHO ICTRP) and their monthly
updates, ProQuest Dissertations and Theses A&I and its quarterly
update, Chinese databases (CBM, CNKI, and Wanfang) and their an-
nual updates, handsearches, grey literature, and conference pro-
ceedings (see Group's website). There is no language, date, docu-
ment type, or publication status limitations for inclusion of records
into the register.
For previous searches, please see Appendix 1.
Searching other resources
1. Reference lists
We searched all references of articles selected for inclusion, ma-
jor review articles (Baker 2012; Bennett 2017; De Witte 2014; Dixon
2010; Drake 2008; Dutra 2008; Galletly 2016; Horsfall 2009; Kelly
2012), as well as recent guidelines (NICE 2011; Hasan 2015) on this
topic for further relevant trials.
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2. Journal databases
Further searches were completed (September 2018) by the princi-
pal review author (GEH) using the Cochrane Database of Systemat-
ic Reviews, MEDLINE (daily update, PREMEDLINE), and PsycINFO. A
separate search for randomised trials using contingency manage-
ment was completed as this was an additional intervention cate-
gory for the previous update. We also searched MEDLINE for recent
articles (2013 to 2018) by the first authors of all included studies in
order to get a more complete list of recent publications.
We also did 'forward' searches to identify trials that cited previously
included RCTs using Web of Science and Scopus. Scopus was used
to identify trials that cited the most recent versions of this review
(Cleary 2008, Hunt 2013) up to October 2018.
3. Trials registries
In addition, web sites and journals that list ongoing trials in the
USA, UK, Australia and various European countries were searched
for RCTs through the Cochrane Schizophrenia Group Trials Regis-
ter. The principal review author (GEH) searched www.clinicaltrial-
s.gov for protocols of current and previously included studies for
proposed outcome measures to assess selective reporting bias.
4. Personal contact
We contacted the first author (or corresponding author) of newly
included studies for this update regarding their knowledge of on-
going or unpublished trials.
Data collection and analysis
Methods for data collection and analysis methods employed for the
2018 search are below. For data collection and analysis methods in
earlier versions see Appendix 2 and Appendix 4.
Selection of studies
Review authors GEH and MC inspected all citations from the new
electronic search and identified relevant abstracts, full-text articles
and trials against the inclusion criteria. To ensure reliability, KM in-
spected all full-text articles for inclusion. Where there were uncer-
tainties or disagreements, two additional review authors provided
resolution (NS and CB-S). Where disputes could not be resolved,
these studies remained as awaiting assessment or ongoing studies
and we contacted the authors for clarification.
Data extraction and management
1. Extraction
GEH and KM extracted data from the included studies. We resolved
disputes by discussion and adjudication from the other review au-
thors (NS and MC) when necessary. If it was not possible to extract
data or if further information was needed, we attempted to contact
the authors. We extracted data presented only in graphs and figures
whenever possible, but the data were included only if two review
authors independently had the same result. When further informa-
tion was necessary, we contacted authors of studies in order to ob-
tain missing data or for clarification of methods.
2. Management
2.1 Forms
We extracted data onto standard, simple forms.
2.2 Scale-derived data
We included continuous data from rating scales only if:
a) the psychometric properties of the measuring instrument have
been described in a peer-reviewed journal (Marshall 2000); and
b) the measuring instrument has not been written or modified by
one of the trialists for that particular trial;
c) the instrument should be a global assessment of an area of func-
tioning and not sub-scores which are not, in themselves, validated
or shown to be reliable. However there are exceptions, we included
sub-scores from mental state scales measuring positive and nega-
tive symptoms of schizophrenia.
Ideally the measuring instrument should either be i. a self-report
or ii. completed by an independent rater or relative (not the thera-
pist). We realise that this is not often reported clearly, we noted in
Description of studies if this was the case or not.
2.3 Endpoint versus change data
There are advantages of both endpoint and change data. Change
data can remove a component of between-person variability from
the analysis. On the other hand, calculation of change needs two
assessments (baseline and endpoint) which can be difficult in un-
stable and difficult-to-measure conditions such as schizophrenia.
We decided primarily to use endpoint data, and only use change
data if the former were not available. We combined endpoint and
change data in the analysis as we preferred to use mean differences
(MD) rather than standardised mean differences (SMD) throughout
(Deeks 2011).
2.4 Skewed data
Continuous data on clinical and social outcomes are often not nor-
mally distributed. To avoid the pitfall of applying parametric tests
to non-parametric data, we applied the following standards to rel-
evant data before inclusion.
Please note, we entered data from studies of at least 200 partici-
pants in the analysis, because skewed data pose less of a problem
in large studies. We also entered all relevant change data as when
continuous data are presented on a scale that includes a possibility
of negative values (such as change data), it is difficult to tell whether
data are skewed or not.
For endpoint data from studies < 200 participants:
(a) when a scale starts from zero, we subtracted the lowest possi-
ble value from the mean, and divided this by the standard deviation
(SD). If this value was lower than 1, it strongly suggests a skew and
we excluded these data. If this ratio was higher than one but below
2, there is suggestion of skew. We entered these data and tested
whether its inclusion or exclusion change the results substantial-
ly. Finally, if the ratio was larger than 2 we included these data, be-
cause skew is less likely (Altman 1996; Higgins 2011).
(b) if a scale starts from a positive value such as the Positive and
Negative Syndrome Scale (PANSS, Kay 1986), which can have val-
ues from 30 to 210, we modified the calculation described above
to take the scale starting point into account. In these cases skew is
present if 2 SD > (S-S min), where S is the mean score and 'S min'
is the minimum score.
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2.5 Common measure
Where relevant, to facilitate comparison between trials, we con-
verted variables that can be reported in different metrics, such as
days in hospital (mean days per year, per week or per month) to a
common metric (e.g. mean days per month).
2.6 Conversion of continuous to binary
Where possible, we converted continuous outcome measures to
dichotomous data. This can be done by identifying cut-oI points
on rating scales and dividing participants accordingly into 'clinical-
ly improved' or 'not clinically improved'. It is generally assumed
that if there is a 50% reduction in a scale-derived score such as the
Brief Psychiatric Rating Scale (BPRS, Overall 1962) or the Positive
and Negative Syndrome Scale (PANSS, Kay 1986), this can be con-
sidered as a clinically important response (Leucht 2005b). If data
based on these thresholds were not available, we used the primary
cut-oI presented by the original authors.
2.7 Direction of graphs
Where possible, we entered data in such a way that the area to
the leG of the line of no effect indicated a favourable outcome for
the psychosocial intervention. Where keeping to this made it im-
possible to avoid outcome titles with clumsy double-negatives (e.g.
'Not un-improved'), we presented data where the leG of the line
indicates an unfavourable outcome and noted this in the relevant
graphs.
Assessment of risk of bias in included studies
Review authors (GEH, NS, CB-S) independently assessed risk of
bias within the included studies by using criteria described in the
Cochrane Handbook for Systematic Reviews of Interventions to as-
sess trial quality (Higgins 2011a). This set of criteria is based on evi-
dence of associations between overestimate of effect and high risk
of bias of the article such as sequence generation, allocation con-
cealment, blinding, incomplete outcome data and selective report-
ing.
If the raters disagreed, we made the final rating by consensus with
all review authors. Where inadequate details of randomisation and
other characteristics of trials were provided, we contacted authors
of the studies contacted in order to obtain further information. If
non-concurrence occurred, we reported this.
We noted the level of risk of bias in the text of the review and in
Figure 1; Figure 2 and 'Summary of findings' tables.
 
Figure 1.   'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
 
 
Psychosocial interventions for people with both severe mental illness and substance misuse (Review)









Cochrane Database of Systematic Reviews
Figure 2.   'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
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Figure 2.   (Continued)
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Figure 2.   (Continued)
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Measures of treatment e?ect
1. Binary data
For binary outcomes we calculated a standard estimation of the
risk ratio (RR) and its 95% confidence interval (CI). It has been
shown that RR is more intuitive (Boissel 1999) than odds ratios as
odds ratios tend to be interpreted as RR by clinicians (Deeks 2000).
2. Continuous data
For continuous outcomes we estimated mean difference (MD) be-
tween groups. We preferred not to calculate effect size measures
(standardised mean difference SMD). However, if scales of very con-
siderable similarity were used, we presumed there was a small
difference in measurement, and calculated effect size and trans-
formed the effect back to the units of one or more of the specific
instruments.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ 'cluster randomisation' (such as ran-
domisation by clinician or practice), but analysis and pooling of
clustered data poses problems. Authors often fail to account for in-
tra-class correlation in clustered studies, leading to a 'unit of analy-
sis' error (Divine 1992) whereby P values are spuriously low, confi-
dence intervals unduly narrow and statistical significance overesti-
mated. This causes type I errors (Bland 1997; Gulliford 1999).
None of the presently included trials used cluster randomisation.
For the purposes of future updates of this review, where clustering
is not accounted for in primary studies we planned to present da-
ta in a table with a (*) symbol to indicate the presence of a prob-
able unit of analysis error. In subsequent versions of this review,
should we include cluster-RCTs, we will seek to contact first authors
of studies to obtain intra-class correlation coefficients (ICCs) for
their clustered data and to adjust for this by using accepted meth-
ods (Gulliford 1999). Where clustering has been incorporated into
the analysis of primary studies, we plan to present these data as if
from a non-cluster randomised study but adjust for the clustering
effect.
We have sought statistical advice and have been advised that the
binary data as presented in a report should be divided by a 'design
effect'. This is calculated using the mean number of participants
per cluster (m) and the ICC (design effect = 1 + (m - 1)*ICC) (Don-
ner 2002). If the ICC is not reported we will assume it to be 0.1 (Uk-
oumunne 1999).
If we had identified cluster trials, we would have analysed them tak-
ing into account ICCs and relevant data documented in the report.
Synthesis with other studies would have been possible using the
generic inverse variance technique.
2. Cross-over trials
None of the presently included studies employed a cross-over tri-
al design. For the purposes of future updates of the review, a ma-
jor concern of cross-over trials is the carry-over effect. It occurs if
an effect (for example, pharmacological, physiological or psycho-
logical) of the treatment in the first phase is carried over to the sec-
ond phase. As a consequence, on entry to the second phase the par-
ticipants can differ systematically from their initial state despite a
wash-out phase. For the same reason cross-over trials are not ap-
propriate if the condition of interest is unstable (Elbourne 2002). As
both effects are very likely in severe mental illness, we proposed to
only use the data of the first phase of cross-over studies.
3. Studies with multiple treatment groups
Where a study involves more than two treatment arms, if relevant,
we presented the additional treatment arms in comparisons. If da-
ta were binary we simply added and combined within the two-by-
two table. If data were continuous we combined data following the
formula in Chapter 7 of the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011). We did not use data where the
additional treatment arms were not relevant.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up data must lose credibility (Xia
2009). We chose that, for any particular outcome, should more than
50% of data be unaccounted for, we would not reproduce these da-
ta or use them within analyses. If, however, more than 50% of those
in one arm of a study were lost, but the total loss was less than
50%, we addressed this within the 'Summary of findings' tables by
down-rating quality. We also planned to downgrade quality within
the 'Summary of findings' tables should loss be 25% to 50% in total.
2. Binary
In the case where attrition for a binary outcome is between 0%
and 50% and where these data are not clearly described, we pre-
sented data on a 'once-randomised-always-analyse' basis (an in-
tention-to-treat (ITT) analysis). We assumed all those leaving the
study early to have the same rates of negative outcome as those
who completed - except for the outcomes of death and adverse ef-
fects - for these outcomes we used the rate of those who stayed in
the study (in that particular arm of the trial) for those who did not.
We undertook a sensitivity analysis to test how prone the prima-
ry outcomes were to change by comparing data only from people




We reported and used data where attrition for a continuous out-
come was between 0% and 50%, and data only from people who
completed the study to that point were reported.
3.2 Standard deviations
If standard deviations (SDs) were not reported, we first tried to ob-
tain the missing values from the authors. If not available, where
there were missing measures of variance for continuous data, but
an exact standard error (SE) and confidence intervals available for
group means, and either 'P' value or 't' value available for differ-
ences in mean, we calculated them according to the rules described
in the Cochrane Handbook for Systemic reviews of Interventions (Hig-
gins 2011): When only the SE is reported, SDs are calculated by the
formula SD = SE * square root (n). The Cochrane Handbook for Sys-
temic reviews of Interventions (Higgins 2011) present detailed for-
mulae for estimating SDs from P values, t or F values, confidence
intervals, ranges or other statistics. If these formulae did not apply,
we calculated the SDs according to a validated imputation method
which is based on the SDs of the other included studies (Furukawa
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2006). Although some of these imputation strategies can introduce
error, the alternative would be to exclude a given study’s outcome
and thus to lose information. We nevertheless examined the valid-
ity of the imputations in a sensitivity analysis excluding imputed
values.
3.3 Assumptions about participants who leL the trials early or were
lost to follow-up
Various methods are available to account for participants who leG
the trials early or were lost to follow-up. Some trials just present the
results of study completers, others use the method of last obser-
vation carried forward (LOCF), while more recently methods such
as multiple imputation or mixed-effects models for repeated mea-
surements have become more of a standard. While the latter meth-
ods seem to be somewhat better than LOCF (Leon 2006), we feel
that the high percentage of participants leaving the studies early
and differences in the reasons for leaving the studies early between
groups is often the core problem in randomised schizophrenia tri-
als. We therefore did not exclude studies based on the statistical
approach used. However, we preferred to use the more sophisticat-
ed approaches. (e.g. MMRM or multiple-imputation) and only pre-
sented completer analyses if some kind of ITT data were not avail-
able at all. Moreover, we addressed this issue in the item "incom-
plete outcome data" of the 'Risk of bias' tool.
Assessment of heterogeneity
1. Clinical heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge clinical heterogeneity. We simply inspected
all studies for clearly outlying people or situations which we had not
predicted would arise. When such situations or participant groups
arose, we fully discussed these.
2. Methodological heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge methodological heterogeneity. We simply in-
spected all studies for clearly outlying methods which we had not
predicted would arise. When such methodological outliers arose,
we fully discussed these.
3. Statistical heterogeneity
3.1 Visual inspection
We visually inspected graphs to investigate the possibility of statis-
tical heterogeneity.
3.2 Employing the I2 statistic
We investigated heterogeneity between studies by considering the
I2 statistic alongside the Chi2 P value. The I2 provides an estimate of
the percentage of inconsistency thought to be due to chance (Hig-
gins 2003). The importance of the observed value of I2 depends on:
i) magnitude and direction of effects, and ii) strength of evidence for
heterogeneity (for example, P value from Chi2 test, or a confidence
interval for I2). An I2 estimate greater than or equal to around 50%
accompanied by a statistically significant Chi2 statistic was inter-
preted as evidence of substantial levels of heterogeneity (Higgins
2011). When substantial levels of heterogeneity were found in the
primary outcome, we explored reasons for the heterogeneity (Sub-
group analysis and investigation of heterogeneity).
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
These are described in Chapter 10. of the Cochrane Handbook for
Systemic reviews of Interventions (Sterne 2011).
1. Protocol versus full study
We tried to locate protocols of included randomised trials. If the
protocol was available, we compared outcomes in the protocol and
in the published report. If the protocol was not available, we com-
pared outcomes listed in the methods section of the trial report
with actually reported results.
2. Funnel plot
We are aware that funnel plots may be useful in investigating re-
porting biases but are of limited power to detect small-study ef-
fects. We did not use funnel plots for outcomes where there were
10 or fewer studies, or where all studies are of similar size. In future
versions of this review, if funnel plots are possible, we will seek sta-
tistical advice in their interpretation.
Data synthesis
We understand that there is no closed argument for preference
for use of fixed-effect or random-effects models. The random-ef-
fects method incorporates an assumption that the different stud-
ies are estimating different, yet related, intervention effects. This
often seems to be true to us and the random-effects model takes
into account differences between studies, even if there is no statis-
tically significant heterogeneity. There is, however, a disadvantage
to the random-effects model: it puts added weight onto small stud-
ies, which often are the most biased ones. Depending on the direc-
tion of effect, these studies can either inflate or deflate the effect
size. We chose the random-effects model for main analyses (see al-
so Sensitivity analysis)
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses - only primary outcomes
1.1 Clinical state, stage or problem
We proposed to undertake this review and provide an overview
of the effects of psychosocial interventions for people with schizo-
phrenia and other psychoses, in general. In addition, however, we
tried to report data on subgroups of people in the same clinical
state, stage and with similar problems.
2. Investigation of heterogeneity
If inconsistency was high, we have reported this. First, we inves-
tigated whether data had been entered correctly. Second, if data
were correct, we visually inspected the graph and successively re-
moved outlying studies to see if homogeneity was restored. For this
review we decided that should this occur, with data contributing
to the summary finding of no more than around 10% of the total
weighting, we would present the data. If not, then we did not pool
the data and discussed the issues. We know of no supporting re-
search for this 10% cut-oI, but we use prediction intervals as an al-
ternative to this unsatisfactory state.
When unanticipated clinical or methodological heterogeneity was
obvious we simply stated hypotheses regarding these for future re-
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views or versions of this review. We do not anticipate undertaking
analyses relating to these.
Sensitivity analysis
We conducted sensitivity analyses on outcomes of comparisons
with four or more trials where studies with different quality were
combined to ascertain if there were substantial differences in the
results when lesser quality trials or those comprising participants
with schizophrenia (or other psychoses) were compared to trials of
higher quality or using mixed diagnostic groups. We applied all sen-
sitivity analyses to the primary outcomes based on randomised se-
quence, allocation concealment and blinding of outcome measure-
ment. We only conducted sensitivity analyses on comparisons with
four or more studies as analyses with less than four trials would
provide unclear decisions on whether there have been any possible
biases in the estimate of effects.
1. Implication of randomisation
We aimed to include trials in a sensitivity analysis if they were de-
scribed in some way so as to imply randomisation. For the primary
outcomes, we included these studies and if there was no substan-
tive difference when the implied randomised studies were added to
those with a better description of randomisation then we entered
all data from these studies.
2. Assumptions for lost binary data
Where assumptions had to be made regarding people lost to fol-
low-up (see Dealing with missing data), we compared the findings
of the primary outcomes when we used our assumptions and when
we used data only from people who completed the study to that
point. If there was a substantial difference, we reported the results
and discussed them but continued to employ our assumption.
Where assumptions had to be made regarding missing sSD data
(see Dealing with missing data), we compared the findings of the
primary outcomes when we used our assumptions and when we
used data only from people who completed the study to that point.
A sensitivity analysis was undertaken to test how prone results were
to change when completer-only data were compared to the imput-
ed data using the above assumption. If there was a substantial dif-
ference, we reported results and discussed them but continued to
employ our assumption.
3. Risk of bias
We analysed the effects of excluding trials that were judged to be
at high risk of bias across one or more of the domains of randomi-
sation (see Assessment of risk of bias in included studies) for the
meta-analysis of the primary outcomes. If the exclusion of trials at
high risk of bias did not substantially alter the direction of effect or
the precision of the effect estimates, then we included data from
these trials in the analysis.
4. Imputed values
A sensitivity analysis to assess the effects of including data from tri-
als where we used imputed values for ICC in calculating the design
effect in cluster-randomised trials was not carried out as there are
no cluster-randomised trials included in the review.
5. Fixed- and random-e1ects
We synthesised data using a random-effects model; however, we
also synthesised data for the primary outcomes using fixed-effect
method to evaluate whether this altered the significance of the re-
sults.
If we noted substantial differences in the direction or precision of
effect estimates in any of the sensitivity analyses listed above, we
did not pool data from the excluded trials with the other trials con-
tributing to the outcome but presented them separately.
R E S U L T S
Description of studies
Results of the search
A total of 4866 citations were found using the search strategy de-
vised for the original version of this review. The inclusion of the
word 'drug' in the search strategy produced a vast number of ir-
relevant references. For the current update 113 additional rele-
vant records were scrutinised which resulted in an additional nine
studies considered for inclusion (Barrowclough 2014; Bogenschutz
2014; Eack 2015; Gouzoulis-Mayfrank 2015; Graham 2016; McDonell
2017; O'Connell 2018; Petry 2013; Rosenblum 2014). Together with
the 32 studies from previous reviews, the current review included
41 studies. See also Figure 3.
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Figure 3.   Study flow diagram for 2018 search
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Included studies
In the previous review (Hunt 2013), 32 randomised controlled tri-
als (RCTs) were selected for inclusion. Three studies (Godley 1994;
Maloney 2006; Morse 2006) from the first update (Cleary 2008) con-
tained only skewed data (shown as 'other data' within the Data
and analyses). The remaining trials provided usable data (either
dichotomous or continuous parametric data). For the current up-
date, nine new trials were selected for inclusion thus in total, 41
RCTs were included in the current review.
1. Design
Three trials were set exclusively in hospital (Baker 2002; Bechdolf
2011; Swanson 1999) and 26 in the community. Ten trials recruited
patients or were conducted in both the community (outpatients)
and in hospital (Bellack 2006; Bonsack 2011; Gouzoulis-Mayfrank
2015; Graeber 2003; Graham 2016; Hellerstein 1995; Hjorthoj 2013;
Kavanagh 2004; Madigan 2013; Naeem 2005), and two were set in
the community and in jail (Chandler 2006; Maloney 2006).
Most studies randomly allocated participants to one of two treat-
ment conditions; the exceptions were Barrowclough 2014; Burnam
1995; Jerrell 1995a; Jerrell 1995b; Maloney 2006; Morse 2006 and
O'Connell 2018). These trials randomly allocated participants to
one of three or four (Maloney 2006) interventions. We have used
only two of the intervention arms in Burnam 1995 as the other did
not fit into any a priori category described for inclusion in this re-
view. Data are shown in additional tables. Study durations ranged
from three months to three years and the length of the interven-
tions ranged from less than one hour to three years. There were 25
trials from the USA, six from Australia, five from the UK, two from
Germany and one each from Denmark, Ireland and Switzerland.
2. Participants
A total of 4024 people participated in the trials after giving informed
consent and were randomised into one of the treatment arms. All
participants were adults (aged 18 to 65 years) who were 'severely
mentally ill' with the majority having a diagnoses of schizophrenia,
schizoaffective disorder or psychosis (affective and non-affective).
All had a current diagnosis of substance use disorder or had docu-
mented evidence of substance misuse. Some were homeless or had
a history of unstable accommodation (Burnam 1995; Essock 2006;
Morse 2006; Tracy 2007), and some were incarcerated at the time
of the study (Chandler 2006; Maloney 2006).
3. Interventions
1. Integrated models of care (four RCTs).
2. Non-integrated models of care (four RCTs).
3. Combined cognitive behavioural therapy and motivational in-
terviewing (nine RCTs).
4. Cognitive behavioural therapy (two RCTs).
5. Motivational interviewing (nine RCTs).
6. Skills training (six RCTs).
7. Contingency management (four RCTs).
4. Outcomes
Where possible, we included dichotomous data relating to loss to
treatment, loss to evaluation, death, abstinence or reduced sub-
stance use, relapse, attendance at aftercare, and arrests.
All of the outcome scales and their abbreviations are listed in Table
1, together with the reference of the source of the scale. See below
for descriptions of the continuous data scales that reported data
used in the analyses. For a full list of the scales mentioned in each
of the studies see Characteristics of included studies.
4.1 Substance use scales
a. Drug and alcohol scales from Addiction Severity Index (ASI)
The ASI (McLellan 1980) provides two summary scores of problems
of functioning in seven areas, including psychiatric problems, and
those concerning drug and alcohol use. Severity ratings range from
zero to nine and are assessments of lifetime and current problem
severity derived by the interviewer. Composite scores are mathe-
matically derived and are based on client responses to a set of items
based on the last 30 days. Although difficulties have been reported
concerning the use of the ASI with people who have severe mental
illness (Corse 1995), the psychometric properties of the subscales
with this population have been reported by a number of authors
(Appleby 1997; Hodgins 1992; Zanis 1997). Given that the problems
encountered by the scale are likely to be encountered by any other
similar instrument based on self-reports of those with severe and
persistent mental illness, it was decided to include data obtained
with the ASI (used in Barrowclough 2001; Bechdolf 2011; Bellack
2006; Drake 1998a; Eack 2015; Essock 2006; Hellerstein 1995 and
Lehman 1993).
b. Alcohol Use Inventory (AUI)
This inventory assesses alcohol use (Horn 1987) (used by Hickman
1997).
c. Alcohol Use Scale (AUS)
A five-point scale based on clinicians' ratings of severity of disorder,
ranging from one (abstinence) to five (severe dependence) (Mueser
1995). This was used in Drake 1998a and Essock 2006.
d. Alcohol Use Disorders Identification Test (AUDIT)
The AUDIT is a 10-item questionnaire covering the domains of al-
cohol consumption, drinking behaviour and alcohol-related prob-
lems (Saunders 1993). Responses to each question are scored from
zero to 4. A sum score of 8 or more indicates hazardous or harmful
alcohol use. This was used in Graham 2016.
e. Cannabis and Substance Use Assessment Schedule (CASUAS)
(modified from the SCAN)
This measures cannabis use and includes similar information to
the ASI, such as percentage of days using cannabis in the past four
weeks, frequency of cannabis use, and an index of severity (range
zero to 4) with higher scores indicating greater severity (Wing 1990)
(used by Edwards 2006).
f. Drug Use Scale (DUS)
A five-point scale based on clinicians' ratings of severity of disorder,
ranging from one (abstinence) to five (severe dependence) (Mueser
1995) (used in Drake 1998a and Essock 2006).
g. Opiate Treatment Index (OTI)
The OTI has six domains reflecting treatment outcomes of: drug
use, HIV risk-taking behaviour, social functioning, criminality,
health status and psychological adjustment (Darke 1991; Darke
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1992). The drug use domain consists of 11 items measuring drug
use over the last three days (recent drug use) or previous month (28
days) for alcohol, cannabis, amphetamines, cocaine, opiates and
other drugs. Clients are asked to estimate the number of drinks or
usage of drugs on the two most recent use days in the previous
month. The quantity over the two days (q1 + q2) is divided by day
interval (t1 + t2). Thus, an OTI score of 1.0 indicates one drink, in-
jection or joint per day; 0.14 to 0.99 more than once a week; 0.01 to
0.13 once a week or less, and 2.0 or more indicates use more than
once a day. Higher scores indicate a greater degree of dysfunction
or substance use. Baker 2002 and Baker 2006 used the OTI to mea-
sure substance use over the previous month.
h. Substance Abuse Treatment Scale (SATS)
An eight-point scale indicating progression toward recovery rang-
ing from one (early stages of engagement) to eight (relapse preven-
tion). Higher scores indicate greater progression (McHugo 1995).
This was used by Drake 1998a, Essock 2006 and Graham 2016.
i. Alcohol and drug use disorders section of the Structured Clinical
Interview for DSM-III-R (Patient Edition) (SCID)
Items relate to substance use in the past month (Spitzer 1990).
Higher scores indicate a greater degree of dysfunction (used by
Baker 2002).
j. Substance Use Severity Scale (USS)
This is a five-point scale, ranging from one (not using) to five (meets
criteria for severe use) (Carey 1996), used by Morse 2006.
4.2 Mental state assessment
a. Beck Depression Inventory (BDI)
This contains 21 self-report items which measure the severity of
depression (Beck 1972). Each item comprises four statements (rat-
ed from zer to 4) describing increasing severity on how they felt
over the preceding week. Scores range from zero to 84, with higher
scores indicating more severe symptoms (used in Baker 2006; Ed-
wards 2006 used the short form of this scale (BDI-SF)).
b. Brief Psychiatric Rating Scale (BPRS)
Used to assess the severity of a range of psychiatric symptoms, in-
cluding psychotic symptoms (LukoI 1986), the scale has 24 items,
of which 14 are based on the person's self-report in the last two
weeks and 10 on the person's behaviour during the interview. Each
item can be defined on a seven-point scale from one (not present)
to seven (extremely severe). Total scoring ranges from 24 to 168 and
there are five subscales with minimum scores ranging from three to
four depending on the subscale (used in Baker 2006; Drake 1998a;
Eack 2015; Edwards 2006; and Essock 2006).
c. Brief Symptom Inventory (BSI)
This measures psychiatric symptomatology (Derogatis 1983a). A
brief rating scale is used by an independent rater to assess severi-
ty of psychiatric symptoms. Scores range from zero to 4 with high-
er scores indicating more symptoms (used by Baker 2002, Bogen-
schutz 2014, McDonell 2013, McDonell 2017 and Petry 2013).
d. Comprehensive Psychopathological Rating Scale (CPRS)
This is an interview rating scale covering a wide range of psychi-
atric symptoms, and can be used in total or as subscales. The Mont-
gomery Asperg Depression Rating Scale (MADRS), Brief Scale for
Anxiety (BSA) and the Schizophrenia Change Scale (SCR) are all
subscales of the CPRS. It comprises 65 items that cover the range
of psychopathology over the preceding week (40 symptom items
are rated by the participant) (Asberg 1978). Each item is rated on
a zero to 3 scale, varying from 'not present' to 'extremely severe',
with high scores indicating more severe symptoms and a worse out-
come (used by Naeem 2005).
Global state: (a clinical measure of patient's psychological, social and
occupational functioning in a single measure)
e. Global Assessment of Functioning (GAF)
The Global Assessment of Functioning is a revised version of the
Global Assessment Scale (GAS) (Endicott 1976). The (GAF) scale al-
lows the clinical progress of the patient to be expressed in glob-
al terms using a single measure. The GAF allows the clinician to
express the patient's psychological, social and occupational func-
tioning on a continuum extending from superior mental health,
with optimal social and occupational performance, to profound
mental impairment when social and occupational functioning is
precluded. Developed by DSM-IV to report global assessment of
functioning on the Axis V (DSM-IV), it ranges from 1 to 100 (zero
is used to acknowledge inadequate information). Higher scores in-
dicate a better outcome; scores ranging from 1 to 20 indicate a
person unable to function independently; 21 to 40 indicate major
impairment, severely impaired by delusions; 41 to 60 moderate-
ly impaired, having serious symptoms and these patients usually
need continuous treatment in a partial hospitalisation or outpa-
tient setting; 61 to 80 indicate slight or mild impairment with tran-
sient symptoms; and 81 to 100, good or superior functioning. Baker
2006, Barrowclough 2001, Barrowclough 2010, Barrowclough 2014,
Bechdolf 2011, Bonsack 2011, Essock 2006, Gouzoulis-Mayfrank
2015 and Madigan 2013 used this scale.
f. Hospital Anxiety and Depression Scale (HADS)
The HADS is a 14-item self-assessment scale developed to detect
states of depression and anxiety (Zigmond 1983). Each of the items
is rated on a four-point Likert scale (zero to 3) with half of the items
rated on a reverse scale (I feel cheerful, I can sit at ease and feel
relaxed). Scale scores can be categorised into non-cases (scores of
zero to 7), doubtful cases (8 to 10) and definite cases (>11) for de-
pression (HADS-D) and anxiety (HADS-A) (used by Graham 2016).
g. Health of the Outcome Nation Outcomes Scale (HoNOS)
HoNOS is a 12-item instrument on a scale of zero to 4 used to rate
patients' symptoms and progress towards health (Wing 1996). Item
3 can be used to rate drug and alcohol use (zero = no problem, 1 =
some over-indulgence but within social norm, 2 = loss of control, 3 =
marked craving, 4 = incapacitated by alcohol or drug problem) and
other items can be used to assess social functioning. Thus, ratings
range from zero to 48 and higher scores indicate a poorer outcome
(used by Naeem 2005).
h. Insight Scale
This is used to assess the patient's level of insight about their illness
(David 1992). Seven self-report items are scored from zero = no in-
sight to 2 = full insight. One additional self-report item is scored ze-
ro to 4 (used by Graham 2016 and Naeem 2005).
Psychosocial interventions for people with both severe mental illness and substance misuse (Review)









Cochrane Database of Systematic Reviews
i. The Positive and Negative Syndrome Scale (PANSS)
The PANSS was developed from the BPRS and the Psychopathol-
ogy Rating Scale (Kay 1987). It is used as a method for evaluating
positive, negative and other symptom dimensions in schizophre-
nia. The scale has 30 items and each item can be defined on a sev-
en-point scoring system, varying from one (absent) to seven (ex-
treme), so total scores range from 30 to 210. This scale can be di-
vided into three subscales for measuring the severity of general
psychopathology (range 16 to 112), positive symptoms (PANSS-P,
range 7 to 49) and negative symptoms (PANSS-N, range 7 to 49). A
low score indicates low levels of symptoms. This was used by Bar-
rowclough 2001, Barrowclough 2010, Barrowclough 2014, Bech-
dolf 2011, Bonsack 2011, Gouzoulis-Mayfrank 2015, Kemp 2007, Mc-
Donell 2017 and O'Connell 2018.
j. Psychiatric scale from Addiction Severity Index (ASI-psychiatric)
Psychiatric subscores (McLellan 1980) were reported in Lehman
1993 and Hellerstein 1995. See the ASI scoring above.
k. Scale for the Assessment of Negative Symptoms (SANS)
The scale assesses negative symptoms for schizophrenia (An-
dreasen 1982). This assesses five symptoms complexes to obtain
the clinical rating of negative symptoms over the preceding week.
They are affective blunting, alogia, apathy, anhedonia and distur-
bance of attention. Each item uses a six-point scale ranging from
zero (not at all) to 5 (indicating severe). High scores indicate a worse
outcome (used by Edwards 2006).
l. Symptom Checklist 90 (revised) (SCL-90-R)
Used to measure psychiatric symptoms (Derogatis 1983b), the
scale has 90 self-report items designed to measure nine symptom
dimensions. Each item has a five-point Likert scale ranging from
zero (mild or not at all) to 4 (severe or extremely distressing), with
higher scores indicating greater symptomatology (used by Hick-
man 1997).
4.3 Quality of life and client satisfaction; quality of life scales measure
objective and subjective quality of life satisfaction and global patient
satisfaction with daily living and services provided (see Results,
section 4.3).
a. The Quality of Life Interview (QOLI) and the Brief Quality of Life
Scale (BQOL)
The QOLI contains 153 items that measure global life satisfaction
as well as objective and subjective quality of life (Lehman 1988;
Lehman 1995). It has eight domains (for example, living situations,
daily activities and functioning, family relations, social relations).
Rated on a seven-point scale (1 = terrible, 2 = unhappy, 3 = mostly
dissatisfied, 4 = equally satisfied and dissatisfied, 5 = mostly satis-
fied, 6 = pleased, and 7 = delighted), with higher scores indicating
better quality of life. It was used by Baker 2006, Bellack 2006, Drake
1998a, Essock 2006 and Lehman 1993.
b. World Health Organization's Quality of Life scale (WHOQOL-BREF)
The WHOQOL-BREF is a 26-item scale (Skevington 2004) assess-
ing physical health, psychological well being, social relationships,
and environmental factors (for example, home environment, recre-
ation, access to health care, physical safety and financial re-
sources). It also contains two general items and each item is rat-
ed on a five-point scale (1 to 5, with higher scores = better quality)
(used by Madigan 2013).
c. Client Satisfaction Questionaire (CSQ)
The CSF questionnaire (CSQ) (Larsen 1979) is a self-report instru-
ment that consists of eight items designed to measure global pa-
tient satisfaction of services provided and if they met their needs or
approval. The items are rated on a four-point scale (minimum of 1
= no definitely not to maximum 4 = very satisfied), with a minimum
score of 8 and maximum of 32 and higher scores indicating greater
satisfaction (used by Hjorthoj 2013).
4.4 Social functioning: social function scales measure degree of social
assessment and basic skills necessary for community living (see
Results, section 4.4, Social functioning).
a. Role Functioning Scale (RFS)
This is a self-report scale whereby the total of four subscales
measures global role functioning (Green 1987). Scores reported
are summary scores derived from four independent raters. Higher
scores indicate better functioning (used by Jerrell 1995a and Jerrell
1995b).
b. Social Adjustment Scale for the Severely Mentally Ill (SAS-SMI)
An abbreviated version of the Social Adjustment Scale II is used
to assess social adjustment (Wieduwilt 1999), with a self-report-
ed scale composed of 24 items covering seven areas including so-
cial, family and work functioning designed specifically for use with
schizophrenic populations. Scores range from 1 to 7, with a high
score indicating poor outcome (used by Jerrell 1995a and Jerrell
1995b).
c. Social Functioning Scale (SFS)
A self-report scale developed for people with schizophrenia which
enumerates basic skills necessary for community living and per-
formance (Birchwood 1990), the SFS is a 79-item questionnaire
that uses a four-point rating scale (zero to 3) of frequency or abil-
ity. Items are grouped into seven domains. Raw scores for each
subscale are converted to a standard score; overall functioning is
based on the mean standard score (Burns 2007). Higher standard-
ised scores indicate better functioning (range 55 to 135) (Birchwood
1990). This was used by Barrowclough 2001 and O'Connell 2018.
d. The Social and Occupational Functioning Scale (SOFAS)
SOFAS was derived from the GAF scale and is used to assess levels of
physical and mental functioning in social and work settings (Burns
2007; Goldman 1992). Scored similarly to the GAF (see above) by
an observer it ranges from zero to 100 with zero representing inad-
equate information. Higher scores indicate better outcomes (used
by Bonsack 2011 and Edwards 2006).
e. Service Utilisation Rating Scale (SURS)
This measures inpatient and outpatient attendance and medica-
tion usage (Mihalopoulos 1999) (used by Edwards 2006).
Excluded studies
In the current update (May 2018 search), we excluded (with rea-
sons) 28 studies/reports or trials: six were not randomised, 15 did
not include participants with a concurrent diagnosis of severe men-
tal illness and substance misuse and five studies did not use a psy-
chosocial intervention. One study identified from an on-going trial
list Castle 2002 (was abandoned due to lack of funds according to
email from the primary author and excluded as there was no usable
data) and another from the 'to be assessed' list (Odom 2005) was
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excluded as feedback from the author indicated there was no us-
able or published data.
In the 2013 update, we excluded 46 studies or trials identified
through the initial search (July 2012 search): five were not ran-
domised, 30 did not include participants with a concurrent diag-
nosis of severe mental illness and substance misuse, 10 studies
used a non-psychosocial intervention or did not include a specific
substance misuse treatment programme, and one trial had no us-
able data. Four further full text articles that were identified through
subsequent searches (Bagoien 2013; Sigmon 2000; Smeerdijk 2012;
Weiss 2009) were excluded.
In the 2008 review, we excluded 68 studies (this did not include
related studies, please see Characteristics of excluded studies).
Twenty-six were not randomised or used a quasi-randomisation
method, 18 did not have participants with a concurrent diagnosis
of severe mental illness and substance misuse, and 14 used a non-
psychosocial intervention or did not include a specific substance
misuse treatment programme. A further 10 RCTs were excluded ei-
ther due to high attrition rates or unclear reporting (attempts were
made to contact all authors for further information). One study pre-
viously listed in the 2008 review as ongoing (Sitharthan 1999) was
excluded in the current review. Two studies previously included in
the 2008 review (Schmitz 2002; Weiss 2007) were excluded as all the
participants had bipolar disorder so this criteria was applied retro-
spectively as well as prospectively.
Two studies were listed as awaiting assessment (Meister 2010;
Odom 2005). Both are dissertations: one requires translation from
German to English. Further correspondence indicated no publica-
tion arose from latter dissertation so this was moved to the exclud-
ed category as there were no data available.
We found 12 studies where we require more information from au-
thors or text translated. WE have placed these in awaiting assess-
ment until we have a response.There are currently five ongoing
studies.
Risk of bias in included studies
For a summary of the overall risk of bias in the included trials please
see Figure 1 and Figure 2.
Allocation
1. Random generation
All 41 studies were stated to be randomised. Some used block-
ing or stratification methods in the sequence to obtain evenly
balanced groups or different proportions (2:1) for each interven-
tion, site, or to control for various demographic variables (type or
degree of substance use, gender or psychiatric diagnosis). Four-
teen studies stated the sequence was computer-generated (Bar-
rowclough 2001; Barrowclough 2010; Barrowclough 2014; Bonsack
2011; Chandler 2006; Eack 2015; Edwards 2006; Essock 2006; Gra-
ham 2016; Hjorthoj 2013; Madigan 2013; Maloney 2006; Naeem
2005; Petry 2013), but often it was unclear how the sequence was
generated (for example, random number table). Nine studies used
urn randomisation or placed cards in envelopes that were shuffled
to produce a random sequence (Bellack 2006; Bogenschutz 2014;
Gouzoulis-Mayfrank 2015; Jerrell 1995a; Jerrell 1995b; Kemp 2007;
Lehman 1993; McDonell 2013; McDonell 2017). Five other studies
mentioned that a numbered table or random sequence was used
to generate the sequence or that the sequence was stratified (Ka-
vanagh 2004; Nagel 2009; Rosenblum 2014; Swanson 1999; Tracy
2007), but it was not clear if a computer was involved as no further
details were provided. The 27 studies listed above (with the excep-
tion of Maloney 2006) were classified as low risk of selection bias
as they provided some details of the allocation process or further
particulars were provided by the researchers. Some participants in
the Maloney 2006 study were not randomised due to procedural dif-
ficulties. The remaining studies did not provide enough details of
how the allocation sequence was generated to make a judgement
so were classified as of unclear quality with a moderate risk of se-
lection bias and an overestimate of positive effect.
2. Allocation concealment
Two studies provided a full description of the methods used to
generate the random sequence and allocation concealment (Bar-
rowclough 2010; Barrowclough 2014). Ten studies provided some
details or made explicit their method used for allocation conceal-
ment. Two studies used urn method randomisation (Gouzoulis-
Mayfrank 2015; McDonell 2013), which has a low risk of bias if used
properly, and some confirmed this via personal emails. Eight tri-
als stated that allocation concealment was achieved by a third par-
ty or researcher who was independent of the treating team (Bar-
rowclough 2001; Chandler 2006; Eack 2015; Edwards 2006; Gra-
ham 2016; Hjorthoj 2013; Madigan 2013; Rosenblum 2014), but of-
ten no further details were provided. The studies listed above were
judged as low risk as it was implied that the allocation concealment
was adequate. Three trials (Maloney 2006; Hickman 1997; Swan-
son 1999 ) were judged high risk of bias as the researcher or ther-
apist was involved with allocating patients or affected randomi-
sation schedule. Six studies used sealed envelopes or patients se-
lected a card (Baker 2006; Bogenschutz 2014; Bonsack 2011; Kemp
2007; McDonell 2017; Naeem 2005). However, it was not clear if the
envelopes were opaque or if other measures were taken to ensure
concealment, so these were judged as unclear risk. The remaining
studies were classified as of unclear quality with a moderate risk of
selection bias and overestimate of positive effect as no details were
provided regarding allocation concealment, but this may be due to
incomplete reporting and not how the study was conducted.
Blinding
1. Performance bias
We classified blinding in respect to primary outcomes for perfor-
mance and detection bias. Due to intervention characteristics, that
is being a therapy or model of service, we assumed the participants
and clinicians as being implicitly not blind to treatment assignment
when considering performance bias. Therefore, we judged perfor-
mance bias of all trials to be of high risk of bias since it is not possi-
ble to blind participants or personnel for a psychosocial interven-
tion.
2. Detection bias
Overall, 20 studies stated that independent raters were blinded to
allocation when assessing clinical ratings of mental state or sub-
stance use, or the primary outcome involved urine or saliva sam-
ples. For 15 other studies it was unclear if the raters were blind to
treatment as this was not stated. Six studies (Gouzoulis-Mayfrank
2015; Graeber 2003; Kemp 2007; Maloney 2006; Nagel 2009; O'Con-
nell 2018) were judged at high risk of bias because it was not clear-
ly stated that the outcome assessors were blind to treatment al-
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location and it was therefore possible to assess the risk of bias in
these studies with higher confidence for clinical-based ratings. In
three of these studies blinding status would not influence the pri-
mary outcome data as these were administrative measures (hospi-
tal readmissions, convictions, time to first outpatient appointment
etc), however they were still judged high risk as less effort may have
been made to follow-up those in the control arm.
Incomplete outcome data
We only rated risk of incomplete outcome data in respect to the
primary outcome. The number of participants lost to treatment
or evaluation across studies ranged from 0% to 65%. The follow-
ing trials were judged as adequately addressing incomplete out-
come data and were rated as low risk of attrition bias because
there were no missing outcome data (Hickman 1997; Lehman 1993;
Swanson 1999), or less than 25% attrition with no differences be-
tween treatment groups (Barrowclough 2014; Bogenschutz 2014;
Graham 2016; Rosenblum 2014) and for one study (Graeber 2003)
there were no missing values for the primary outcome.
The following trials were rated as high risk. Bellack 2006 exclud-
ed 46 of 175 participants after they were randomised, a further 19
participants because they did not become engaged in treatment,
and a further 27 were lost to follow-up. Therefore, a high propor-
tion of participants (92/175, 53%) were excluded from the analy-
sis, which may have a clinically relevant bias in intervention effect
estimates. The attrition rate was greater than 50% for Hellerstein
1995 (at eight months), Gouzoulis-Mayfrank 2015 (at 12 months)
and Bond 1991a, Godley 1994 (at 18 months) and so data from these
trials were excluded from the analysis as per protocol. In the Chan-
dler 2006 trial the attrition rate for the primary outcome measure
was 37% (68/182); and for the controls no interviews were conduct-
ed to ascertain their whereabouts (moved from area, re incarcerat-
ed or died) and this may have led to severe bias. More than half the
urine samples for the primary outcome were missing in Petry 2013.
Six further trials were rated as high risk as more than 40% of partic-
ipants were lost to follow-up; no reasons were given for them being
missing or a full intention-to-treat (ITT) analysis was not reported
(Baker 2002; Eack 2015; Maloney 2006; Jerrell 1995a; Jerrell 1995b;
O'Connell 2018).
Many, but not all, included studies provided reasons for attrition.
Reasons given included: some of the participants died during the
trial, some could not be contacted or moved elsewhere, and some
withdrew. Eight studies reported their results based on a full ITT
analysis with all missing data imputed for primary outcomes using
appropriate methods (Barrowclough 2010; Bechdolf 2011; Bonsack
2011; Edwards 2006; Hjorthoj 2013; McDonell 2017; Naeem 2005;
Nagel 2009). These were rated as unclear as all imputation strate-
gies can bias study results. The remaining trials were rated as 'un-
clear'. They either did not address this issue, presented insufficient
information of attrition or exclusions to permit judgement (that is,
no reasons for missing data provided or numbers lost to evalua-
tion not stated for each group) or did not report a full ITT analy-
sis with imputed missing values (Baker 2006; Barrowclough 2001;
Bond 1991b; Burnam 1995; Drake 1998a; Essock 2006; Kavanagh
2004; Kemp 2007; Madigan 2013; Maloney 2006; McDonell 2013;
Morse 2006; Tracy 2007).
Selective reporting
The following studies were rated as high quality in reporting
outcomes with a low risk of reporting bias (Barrowclough 2001;
Barrowclough 2010; Barrowclough 2014;Eack 2015; Graham 2016;
Hjorthoj 2013; McDonell 2013; McDonell 2017; Petry 2013; Rosen-
blum 2014) as the pre-specified outcomes listed in the trial proto-
col were fully reported (cases or means, SD and number (n) for each
outcome at specific time points) in the study report. Conversely,
five studies were rated as low quality with a high risk of reporting
bias (Godley 1994; Maloney 2006; Morse 2006; O'Connell 2018; Tra-
cy 2007) as they presented data in a way we could not consider as
free of suggestion of selective outcome reporting. For these stud-
ies, there were no usable data or data were reported incompletely
for each treatment arm or in a way (for example, as correction ma-
trix, graphically or in a mixed-methods model) that they could not
be entered in a meta-analysis. For the rest of the studies the risk of
bias was assessed as unclear with a moderate risk of reporting bias
due to insufficient information to permit judgement of yes or no;
there was no protocol to assess the presence of selective reporting.
Other potential sources of bias
Overall risk of other potential sources of bias was rated as low or
unclear. Most were publicly funded trials. No declaration of inter-
est was made by authors, and we are assuming there was none to
be made. However, many study authors were active pioneers in de-
veloping and the implementation of the experimental intervention
model across the scientific community and clinical world. This rais-
es the issue of how researcher beliefs could affect the entire process
of evaluating an intervention in an RCT. Although conscious of this
issue, we decided not to make any attempt to rate it as it is very dif-
ficult to judge, and erroneous quantification could drive bias into
our conclusions.
E?ects of interventions
See: Summary of findings for the main comparison Integrated
models of care compared to standard care for both severe men-
tal illness and substance misuse; Summary of findings 2 Non-inte-
grated models of care - Assertive community treatment only/Inten-
sive case management/Specialised case management services ver-
sus standard care for both severe mental illness and substance mis-
use; Summary of findings 3 Cognitive behavioural therapy versus
standard care for both severe mental illness and substance misuse;
Summary of findings 4 Contingency management versus standard
care for both severe mental illness and substance misuse; Sum-
mary of findings 5 Motivational interviewing versus standard care
for both severe mental illness and substance misuse; Summary of
findings 6 Skills training versus standard care for both severe men-
tal illness and substance misuse; Summary of findings 7 Cognitive
behavioural therapy + motivational interviewing versus standard
care for both severe mental illness and substance misuse; Summa-
ry of findings 8 Cognitive behavioural therapy + psychosocial re-
habilitation versus standard care for both severe mental illness and
substance misuse; Summary of findings 9 Cognitive behaviour-
al therapy + intensive case management versus standard care for
both severe mental illness and substance misuse
Comparison 1: Integrated models of care versus standard care
See Summary of findings for the main comparison. Data for this
comparison came from four trials (Burnam 1995; Chandler 2006;
Drake 1998a; Essock 2006).
Psychosocial interventions for people with both severe mental illness and substance misuse (Review)









Cochrane Database of Systematic Reviews
1.1 Leaving the study early: 1. Lost to treatment - by 36 months
By the end of treatment (36 months) we found no clear difference
in the likelihood of participants being lost to treatment from the
pooled results of Chandler 2006; Drake 1998a and Essock 2006
(treatment group 24% lost, control group 21% lost) (risk ratio (RR)
1.09, 95% confidence interval (CI) 0.82 to 1.45; participants = 603;
studies = 3). Statistical heterogeneity was not present (Chi2 = 1.95,
df = 2 (P = 0.38); I2 = 0%). (Analysis 1.1).
1.2 Leaving the study early: 2. Lost to evaluation
The control group for Burnam 1995 were 46% more likely to be lost
to evaluation by three months (treatment group 15% lost, control
group 28% lost), although this is not a clear difference between
groups (RR 0.54, 95% CI 0.27 to 1.08; participants = 132; studies =
1). Six months data (Burnam 1995; Essock 2006) also did not reveal
any clear difference between groups (RR 0.69, 95% CI 0.27 to 1.73;
participants = 330; studies = 2). Numbers lost to evaluation at nine
months (RR 0.76, 95% CI 0.49 to 1.19; participants = 132; studies =
1), 12 months (RR 0.54, 95% CI 0.22 to 1.29; participants = 198; stud-
ies = 1), 24 months (RR 1.00, 95% CI 0.47 to 2.12; participants = 198;
studies = 1), and 36 (RR 0.76, 95% CI 0.35 to 1.66; participants = 603;
studies = 3) were also equivocal. For the 36-month data, we com-
bined the results from three studies (Chandler 2006; Drake 1998a;
Essock 2006) in a meta-analysis . There was considerable statistical
heterogeneity (Chi2 = 7.70, df = 2 (P = 0.02); I2 = 74%). Closer inspec-
tion of the forest plot indicated a higher retention rate in the treat-
ment group in Drake 1998a, likely to account for this heterogeneity.
(Analysis 1.2).
1.3 Adverse event: 1. Death - by 36 months
We found no clear differences in the pooled results of Drake 1998a
and Essock 2006 with regards to the likelihood of participants dying
by the end of 36 months of treatment (treatment 3% died, control
3% died; (RR 1.18, 95% CI 0.39 to 3.57; participants = 421; studies =
2). Statistical heterogeneity was not present (Chi2 = 0.68, df = 1, P =
0.41; I2 = 0%). (Analysis 1.3).
1.4 Substance use 1. Clinically important change (not in
remission) - by 36 months
Drake 1998a reported data for remission from substance use
(Analysis 1.4) The likelihood of participants not being in remission
for alcohol use in the group was treatment 57% and 50% in the
control group, which is not a clear difference between treatment
groups (RR 1.15, 95% CI 0.84 to 1.56; participants = 143; studies = 1).
The likelihood of participants not being in remission for drug use in
the treatment group was 58% and 65% in the control group, which
is also not a clear difference between treatment groups (RR 0.89,
95% CI 0.63 to 1.25; participants = 85; studies = 1).
1.5 Substance use: 2. Average score for progress towards
recovery (SATS, low = poor)
Drake 1998a reported average SATS scores (Analysis 1.5). No clear
difference in participants average SATS scores were found by six
months (mean difference (MD) 0.07, 95% CI -0.28 to 0.42; partici-
pants = 203; studies = 1) or 36 months (MD 0.11, 95% CI -0.41 to 0.63;
participants = 203; studies = 1).
1.6 - 1.11 Substance use: skewed data
Further outcome data related to substance use (Analysis 1.6; Analy-
sis 1.7; Analysis 1.8; Analysis 1.9; Analysis 1.10) contained skewed
data and are presented in 'Other data' tables.
1.12 Mental state: 1. Average score (BPRS, high = poor) (skewed
data)
We found that the BPRS scores reported by Drake 1998a and Essock
2006 contained wide confidence intervals (skewed data) and have
presented these in 'Other data' tables (Analysis 1.12).
1.13 Global state: 1. Average score (GAF, low = poor)
Only Essock 2006 reported data for global state (Analysis 1.13). We
found no clear differences for average global functioning scores
(GAF) at six months (MD 1.10, 95% CI -1.58 to 3.78; participants =
162; studies = 1), 12 months (MD 0.70, 95% CI -2.07 to 3.47; partici-
pants = 171; studies = 1), 18 months (MD 1.00, 95% CI -1.58 to 3.58;
participants = 176; studies = 1), 24 months (MD 1.70, 95% CI -1.18 to
4.58; participants = 166; studies = 1), 30 months (MD -0.60, 95% CI
-3.56 to 2.36; participants = 164; studies = 1) or 36 months (MD 0.40,
95% CI -2.47 to 3.27; participants = 170; studies = 1).
1.14 Global state: 2. Forensic measures (skewed data)
Data reported by Chandler 2006 on arrests, convictions, felony, hos-
pitalisation and jail were skewed and are presented in 'Other data'
tables. (Analysis 1.14).
1.15 Quality of life/ life satisfaction: Average general score
(QOLI, range 1-7, low = poor)
The pooled results of Drake 1998a and Essock 2006 revealed no
clear difference between treatment groups in average general life
satisfaction (QOLI) scores by 6 months (MD -0.11, 95% CI -0.41 to
0.20; participants = 361; studies = 2), 12 months (MD 0.02, 95% CI
-0.28 to 0.32; participants = 372; studies = 2), 18 months (MD 0.09,
95% CI -0.27 to 0.44; participants = 377; studies = 2), 24 months (MD
0.02, 95% CI -0.29 to 0.33; participants = 370; studies = 2), 30 months
(MD 0.02, 95% CI -0.27 to 0.32; participants = 366; studies = 2), and
36 months (MD 0.10, 95% CI -0.18 to 0.38; participants = 373; studies
= 2). Statistical heterogeneity was not present at any of the six time
points (for example, 24 months: Chi2 = 1.09, df = 1, P = 0.30; I2 = 8%).
(Analysis 1.15).
1.16 Service use: 1. Days in stable community residences (not in
hospital)
We found that the pooled results of two studies (Drake 1998a; Es-
sock 2006) for average number of days spent in stable communi-
ty residences (not in hospital) by 12 months were equivocal (MD
-10.00, 95% CI -38.61 to 18.60; participants = 378; studies = 2), and
also at 24 months (MD 7.40, 95% CI -6.32 to 21.12; participants = 203;
studies = 1), and 36 months (MD 5.17, 95% CI -9.20 to 19.55; partic-
ipants = 364; studies = 2). Statistical heterogeneity was not present
(Chi2 = 0.31, df = 1, P = 0.58; I2 = 0%). (Analysis 1.16).
1.17 Service use: 2. Number hospitalised - during the 36-month
study period
(Essock 2006) found no clear differences between treatment groups
for the likelihood of hospitalisation by 36 months (treatment 42%
hospitalised, control 48% hospitalised; RR 0.88, 95% CI 0.64 to 1.19;
participants = 198; studies = 1) (Analysis 1.17 ).
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1.18 Service use: 3. Relapse (hospitalisation days and crisis care)
- 36 months (skewed data)
Data for relapse (measured as average number of hospitalisation
days and crisis care) were skewed and are presented in 'Other data'
tables (Analysis 1.18).
1.19 Service use: 4. Medication hours - 36 months (skewed data)
Data reported by Chandler 2006 for average number of hours re-
quiring medication were skewed and are presented in 'Other data'
tables (Analysis 1.19).
1.20 Service use: 5. Various measures (skewed data)
These data were also skewed and presented in 'Other data' tables
(Analysis 1.20).
1.21 - 1.24 Homelessness (skewed data)
Data regarding per cent of time on the street (Analysis 1.21) and
time in independent housing (Analysis 1.22), average number of
days in stable housing (Analysis 1.23) other various measures of
homelessness (Analysis 1.24) were skewed and are presented in
'Other data' tables.
Comparison 2: Non-integrated models of care Assertive
community treatment/Intensive case management/
Specialised management services versus standard care
See Summary of findings 2. Four trials reported useable data for
this comparison (Bond 1991a; Bond 1991b; Jerrell 1995b; Lehman
1993).
2.1 Leaving the study early 1. Lost to treatment
Pooled results of Bond 1991a; Bond 1991b and Jerrell 1995b
showed no clear difference between groups in numbers lost to
treatment by six months (treatment 27% lost, control 22% lost; RR
1.23, 95% CI 0.73 to 2.06; participants = 134; studies = 3) Longer-
term evaluations at 12 months (treatment 28% lost, control 24%
lost; RR 1.21, 95% CI 0.73 to 1.99; participants = 134; studies = 3),
and 18 months (treatment 51% lost, control 37% lost; RR 1.35, 95%
CI 0.83 to 2.19; participants = 134; studies = 3) also did not re-
veal any important difference between groups. Statistical hetero-
geneity was not present at six months, 12 months, 18 months, 24
months, 30 months or 36 months. (Analysis 2.1)
2.2 Leaving the study early 2. Lost to evaluation
We found no meaningful difference in the pooled results (Bond
1991b; Jerrell 1995b; Lehman 1993) for lost to evaluation by six
months (treatment 10% lost, control 10% lost;(RR 1.00, 95% CI 0.38
to 2.60; participants = 121; studies = 3) and by 12 months (treatment
12% lost, control 12% lost; RR 1.00, 95% CI 0.43 to 2.35; participants
= 121; studies = 3) Pooled results (Bond 1991b; Jerrell 1995b) at
18 months also revealed no major differences between treatment
groups (treatment 43% lost, control 33% lost; RR 1.26, 95% CI 0.48
to 3.30; participants = 92; studies = 2). Statistical heterogeneity was
not present at six, 12, or 18 months. (Analysis 2.2)
2.3 - 2.4 Substance use
Data for substance use Analysis 2.3, and Analysis 2.4, were skewed
and are presented in 'Other data' tables.
2.5 Mental state: Average scores on various scales (skewed data)
Mental state data from various scales were skewed and are present-
ed in 'Other data' tables. (Analysis 2.5).
2.6 - 2.8 Global state: Foresnic measures (skewed data)
Data reported by Maloney 2006 on average number of arrests
(Analysis 2.6), convictions (Analysis 2.7) and days in jail ( Analysis
2.8) were skewed and are presented in 'Other data' tables.
2.9 Social functioning: 1. Average role functioning score (RFS,
high = better functioning)
There was no clear difference between the psychosocial inter-
vention and standard care group's average role functioning (RFS)
scores (Jerrell 1995b) by six months (MD -0.78, 95% CI -2.91 to 1.35;
participants = 50; studies = 1) or 12 months (MD 0.70, 95% CI -1.56
to 2.96; participants = 50; studies = 1), although by 18 months there
was a clear difference, favouring the standard care group (MD -2.67,
95% CI -5.28 to -0.06; participants = 29; studies = 1). The average
baseline means (SD) on the RFS were similar between groups so do
not explain this difference: baseline treatment 9.46 (4.11) to 10.77
(2.36) at 18 months; and baseline control 10.03 (3.87) to 13.44 (4.78)
at 18 months. Note that higher scores indicate better functioning.
(Analysis 2.9).
2.10 Social functioning: 2. Average social adjustment score (RFS,
high = better functioning)
There was no clear between treatment groups for average social
adjustment scores (SAS) (Jerrell 1995b) by 6 months (MD -0.93, 95%
CI -6.34 to 4.48; participants = 50; studies = 1), 12 months (MD 3.09,
95% CI -2.71 to 8.89; participants = 50; studies = 1) or 18 months (MD
-3.75, 95% CI -10.12 to 2.62; participants = 29; studies = 1). (Analysis
2.10).
2.11 Quality of life/lfe satisfaction: Average score (QOLI, high =
good) - 12 months (skewed data)
Data for average life satisfaction (QOLI) were skewed so are pre-
sented in 'Other data' tables. (Analysis 2.11).
2.12 Service use: Relapse (skewed data)
Bond 1991b reported % days in hospital but data were skewed and
are presented in 'Other data' tables. (Analysis 2.12).
2.13 Service use: 1. Various measures - 24 months (skewed data)
Data, reported by Morse 2006 relating to admissions and length of
stay were all skewed data and are presented in 'Other data' tables.
(Analysis 2.13). We found no pattern overall of one package of care
favoured over another.
2.14 Homlessness: Average number of days in stable housing
(skewed data)
Morse 2006 reported average number of days in stable housing but
data were skewed are presented in 'Other data' tables (Analysis
2.14).
Comparison 3: Cognitive behavioural therapy versus standard
care
See Summary of findings 3. Data for this comparison came from two
trials (Edwards 2006; Naeem 2005).
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3.1 Leaving the study early 1. Lost to treatment
We found that loss from treatment data (Edwards 2006; Naeem
2005) by three months were not clearly different (treatment 18%,
control 23% lost; (RR 1.12, 95% CI 0.44 to 2.86; participants = 152;
studies = 2). Statistical heterogeneity was not present (Chi2 = 0.00,
df = 1, P = 0.95; I2 = 0%). (Analysis 3.1).
3.2 Leaving the study early: 2. Lost to evaluation
The number of participants lost to evaluation (Edwards 2006) af-
ter nine months were similar in each group (treatment 30%, control
29%; (RR 1.04, 95% CI 0.43 to 2.51; participants = 47; studies = 1).
(Analysis 3.2).
3.3 Substance use: 1. Percentage of participants who used
cannabis - in last four weeks
Edwards 2006 reported % of participants using cannabis in the pre-
vious four weeks. No clear differences between treatment groups
were found at three months assessment (treatment 57%, control
54%; RR 1.04, 95% CI 0.62 to 1.74; participants = 47; studies = 1) or at
six months (RR 1.30, 95% CI 0.79 to 2.15; participants = 47; studies
= 1). (Analysis 3.3).
3.4 Substance use: 2. Average score (various scales) (skewed
data)
Various measures of substance use reporting skewed data are
shown in 'Other data' tables. (Analysis 3.4).
3.5 Mental state: 1. Average insight score (Insight scale, low =
poor) - by three months
There was no clear difference between treatment groups on insight
scores (Insight Scale) by three months (Naeem 2005) (MD 0.52, 95%
CI -0.78 to 1.82; participants = 105; studies = 1). (Analysis 3.5).
3.6 Mental state: 2. Average score (various scales) (skewed data)
Various measures of mental state reporting skewed data are shown
in 'Other data' tables. (Analysis 3.6).
3.7 Social Functioning: 1. Average score (SOFAS, low = poor)
There was no clear difference between treatment groups in average
social and occupational functioning scores (Edwards 2006) (SOFAS)
by three months (MD -0.80, 95% CI -9.95 to 8.35; participants = 47;
studies = 1) or by six months (MD -4.70, 95% CI -14.52 to 5.12; par-
ticipants = 47; studies = 1). (Analysis 3.7).
3.8 Social Functioning: 2. Average score (HONOS) (skewed data)
Average HONOS scores were skewed and are presented in 'Other
data' tables. (Analysis 3.8).
3.9 Service use: 1. Outpatient medication (SURS) (skewed data)
Outpatient medication data are shown in 'Other data' tables due to
skewed data. (Analysis 3.9).
Comparison 4: Contingency management versus standard care
See Summary of findings 4. Four trials assessed this comparison
(McDonell 2013; McDonell 2017; Petry 2013; Tracy 2007).
4.1 Leaving the study early: 1. Lost to treatment
No clear differences were found for lost to treatment by four to eight
weeks (Petry 2013; Tracy 2007) (treatment 4%, control 21%; (RR
0.34, 95% CI 0.04 to 2.81; participants = 49; studies = 2). However,
pooled results (McDonell 2013; McDonell 2017) reported that those
assigned to the contingency management group were more likely
not to complete the treatment period (leaving the study early) than
participants in the standard care group at three months (treatment
48%, control 31% lost; (RR 1.55, 95% CI 1.13 to 2.11; participants =
255; studies = 2, Z = 2.76, P = 0.0057). (Analysis 4.1).
4.2 Leaving the study early: 2. Lost to evaluation
No clear differences were found for lost to evaluation by six months
(McDonell 2013; McDonell 2017) (treatment 33%, control 24%; (RR
1.36, 95% CI 0.91 to 2.02; participants = 255; studies = 2, P = 0.13).
(Analysis 4.2).
4.3 Substance use: 1. Stimulant-positive urine test (higher = poor
outcome)
Clearly more participants in the standard care group had stimu-
lant-positive urine tests compared to participants in the psychoso-
cial group by 12 weeks (McDonell 2013) (treatment 10%, controls
25%; n = 176, (RR 0.34, 95% CI 0.17 to 0.68; participants = 176; stud-
ies = 1), Z = 3.04, P = 0.0024) but there was no difference at six
months (treatment 54%, control 65%; n = 176, (RR 0.83, 95% CI 0.65
to 1.06; participants = 176; studies = 1), Z = 1.46, P = 0.14. (Analysis
4.3).
4.4 Substance use: 2 Average number of continuous days alcohol
negative urine test (skewed data)
These data were skewed and are presented in 'Other data' tables.
(Analysis 4.4).
4.5 Substance use: 3. Injection use
Injection use during treatment was clearly lower in the psychoso-
cial arm compared to the standard care arm at three months (Mc-
Donell 2013) (treatment 37%, control 66%; (RR 0.57, 95% CI 0.42 to
0.77; participants = 176; studies = 1), Z = 3.62, P < 0.001), but was not
clearly different at the six-month follow-up (treatment 44%, control
56%; n = 107, (RR 0.78, 95% CI 0.53 to 1.15; participants = 107; stud-
ies = 1), Z = 1.24, P = 0.22). (Analysis 4.5).
4.6 Substance use: 4. Average scores on various measures
(skewed data)
Average scores on various substance use measures were skewed
and reported in 'Other data' tables. (Analysis 4.6).
4.7 Mental state: 1. Average scores (various scales) (skewed
data)
Average scores on various mental state scales were skewed and re-
ported in 'Other data' tables. (Analysis 4.7).
4.8 Service use: 1. Relapse (hospitalised - six months post-
randomisation)
Relapse rates (hospitalised within 6 months after randomisation)
were clearly lower in the psychosocial group compared to the stan-
dard care group (McDonell 2013) (treatment 2%, control 11%;(RR
0.21, 95% CI 0.05 to 0.93; participants = 176; studies = 1). (Analysis
4.8).
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Comparison 5: Motivational interviewing versus standard care
See Summary of findings 5. Data for this comparison came from
nine trials (Baker 2002; Bechdolf 2011; Bonsack 2011; Graeber 2003;
Graham 2016; Hickman 1997; Kavanagh 2004; Nagel 2009; Swanson
1999).
5.1 Leaving the study early: 1. Lost to treatment
Bonsack 2011 had an unusually long treatment period using mo-
tivational interviewing (six months). There were no differences in
numbers of participants lost to treatment at three months (RR 0.89,
95% CI 0.30 to 2.61; participants = 62; studies = 1) or six months (RR
1.71, 95% CI 0.63 to 4.64; participants = 62; studies = 1). Analysis 5.1).
5.2 Leaving the study early: 2. Lost to evaluation
Pooled results from seven studies (Baker 2002; Bechdolf 2011;
Graeber 2003; Graham 2016; Hickman 1997; Kavanagh 2004; Swan-
son 1999) revealed no difference in those lost to evaluation by three
months (treatment 15% lost, control 15% lost; (RR 1.08, 95% CI 0.69
to 1.70; participants = 457; studies = 7). Similarly, six-month da-
ta (Bechdolf 2011; Graeber 2003; Kavanagh 2004; Nagel 2009) (RR
0.85, 95% CI 0.29 to 2.53; participants = 164; studies = 4) and 12-
month data were not clearly different (RR 0.92, 95% CI 0.44 to 1.92;
participants = 247; studies = 3) between motivational interview-
ing and the standard care group. Statistical heterogeneity was not
present at three, six or 12 months. (Analysis 5.2).
5.3 Adverse event: 1. Death
We found no clear differences between the treatment groups in the
likelihood of death due to all causes by 18 months (Nagel 2009)
(treatment 4%, control 4%; RR 1.04, 95% CI 0.07 to 15.73; partici-
pants = 49; studies = 1). (Analysis 5.3).
5.4 Substance use: 1. Using substances - by class of drug - by
about12 months
We found that alcohol dependence and abuse were not clearly dif-
ferent between treatment groups (Baker 2002) (treatment 39%,
control 29%; (RR 1.35, 95% CI 0.62 to 2.92; participants = 52; studies
= 1). Also, we found no clear differences in the likelihood of partic-
ipants using amphetamine (treatment 9%, control 38%; (RR 0.24,
95% CI 0.03 to 1.92; participants = 19; studies = 1) or cannabis (treat-
ment 50%, control 65%; (RR 0.77, 95% CI 0.49 to 1.21; participants
= 62; studies = 1). (Analysis 5.4).
5.5 Substance use: 2. Polydrug consumption levels - by 12
months (OTI, high = poor)
Polydrug use was not found to be clearly different for three-month
(MD -0.41, 95% CI -0.91 to 0.09; participants = 89; studies = 1) and
12-month (MD -0.07, 95% CI -0.56 to 0.42; participants = 89; studies
= 1) evaluation data (OTI, high = poor) (Baker 2002). ( Analysis 5.5).
5.6 Substance use: 3. Any change - not abstinent or not improved
on all substances - by 12 months
We found no clear difference (Kavanagh 2004) between treatment
groups in the number of participants not abstaining or not im-
proved on all substances by 12 months (treatment 38%, control
75%; n = 25, (RR 0.51, 95% CI 0.24 to 1.10; participants = 25; studies
= 1). (Analysis 5.6).
5.7 Substance use: 4. Any change - not abstaining from alcohol
Three-month data reported by (Graeber 2003) did not reveal any
clear difference between treatment groups for numbers of partici-
pants not abstaining from alcohol (treatment 40%, control 77%; n =
28, (RR 0.52, 95% CI 0.26 to 1.03; participants = 28; studies = 1). How-
ever, by six months we found data from this small study (Graeber
2003) showed clearly more participants in the standard care group
were not abstaining from alcohol (treatment 42%, control 92%; (RR
0.36, 95% CI 0.17 to 0.75; participants = 28; studies = 1). (Analysis
5.7).
5.8 Substance use: 5. Change in cannabis use from baseline (T0,
lower scores indicate better outcome)
Change in cannabis use from baseline was lower in at three months
(Bonsack 2011) (n = 62, MD -12.81 CI -23.05 to -2.57, P = 0.014), six
months (n = 62, MD -9.64 CI -18.05 to -1.23, P = 0.025), but not at 12
months (n = 62, MD -5.82 CI -14.77 to 3.13). (Analysis 5.8).
5.9 Substance use: 6. Cannabis consumption past 30 days -
average score (ASI, high = poor) (skewed data)
Average ASI scores for cannabis consumption were skewed and are
presented in 'Other data' tables. (Analysis 5.9),
5.10 Substance use: 7. Engagement with substance misuse
treatment at three months (SATS, low = poor)
Data reported by (Graham 2016) showed engagement with sub-
stance misuse scores (SATS) at three months were not clearly dif-
ferent between groups (MD 0.30, 95% CI -0.47 to 1.07; participants
= 59; studies = 1). (Analysis 5.10).
5.11 Substance use: 8. Average scores (OTI, high = poor) (skewed
data)
Average substance use scores on the Opiate Treatment Index (OTI)
(Analysis 5.11) are reported in 'Other data' tables due to skewed da-
ta.
6.12 Substance use: 9. Other measures of alcohol use (various
scales, skewed data)
Other measures of alcohol use reported by (Bonsack 2011; Graeber
2003; Graham 2016; Hickman 1997) were skewed and are presented
as 'Other data tables'. (Analysis 5.12).
5.13 Mental state: 1. Average score (SCL-90-R, high = poor) - by
three months
We found that three-month data by Hickman 1997 revealed no clear
differences between treatment groups in average general severi-
ty scores (MD -0.19, 95% CI -0.59 to 0.21; participants = 30; studies
= 1), average positive distress symptoms scores (MD -0.19, 95% CI
-0.66 to 0.28; participants = 30; studies = 1), or average total positive
symptoms scores (MD -4.20, 95% CI -18.72 to 10.32; participants =
30; studies = 1) as measured by the SCL-90. (Analysis 5.13).
5.14 Mental state: 2. Average score (PANSS negative symptoms,
high = poor)
Average PANSS negative symptom scores reported by (Bonsack
2011) were not clearly different between treatment groups at three
months (MD -0.10, 95% CI -2.06 to 1.86; participants = 62; studies =
1) or six months (MD 0.00, 95% CI -1.80 to 1.80; participants = 62;
studies = 1). (Analysis 5.14).
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5.15 Mental state: 3. Average score (PANSS positive symptoms,
high = poor)
Average PANSS positive symptom scores reported by (Bonsack
2011) were not clearly different between treatment groups at three
months (MD -0.30, 95% CI -2.55 to 1.95; participants = 62; studies =
1) or six months (MD -0.10, 95% CI -2.58 to 2.38; participants = 62;
studies = 1). ( Analysis 5.15).
5.16 Mental state: 4. Average score (HADS and BSI, high = poor)
(skewed data)
Mental state data reported by Baker 2002; Graham 2016 were
skewed and are presented in 'Other data' tables, Analysis 5.16.
5.17 Global state: Average score (GAF, low = poor)
Average GAF scores reported by (Bonsack 2011) were not clearly dif-
ferent between treatment groups at three months (MD -0.40, 95%
CI -3.53 to 2.73; participants = 51; studies = 1), six months (MD -1.00,
95% CI -4.81 to 2.81; participants = 49; studies = 1) or 12 months (MD
2.30, 95% CI -1.30 to 5.90; participants = 54; studies = 1). (Analysis
5.17).
5.18 Global state: Forensic measures - average number of crimes
(skewed data)
Average number of crimes reported at six and 12 months were
skewed and are presented in 'Other data' tables (Analysis 5.18).
5.19 Social functioning: 1. Average score (OTI, high = poor)
Average OTI social functioning scores reported by (Baker 2002) did
not reveal any clear differences between treatment groups by six
months (MD -0.71, 95% CI -2.76 to 1.34; participants = 102; studies
= 1), or by 12 months (MD -1.42, 95% CI -3.35 to 0.51; participants =
102; studies = 1). (Analysis 5.19).
5.20 Social functioning: 2. Average score (SOFAS, high = poor)
Social occupational functioning (SOFAS) scores reported by (Bon-
sack 2011) were not clearly different between treatment groups at
three months (MD 0.10, 95% CI -3.02 to 3.22; participants = 62; stud-
ies = 1), six months (MD -0.10, 95% CI -3.51 to 3.31; participants =
62; studies = 1) or 12 months (MD 2.70, 95% CI -1.08 to 6.48; partic-
ipants = 62; studies = 1). (Analysis 5.20).
5.21 Service use: 1. Relapse (hospital readmission by 12 months)
We found no clear differences in hospital readmissions by 12
months (Bonsack 2011) (treatment 30%, control 34%) (RR 0.87,
95% CI 0.42 to 1.80; participants = 62; studies = 1). (Analysis 5.21).
6.22 Service use: 2. Lost to first aDercare appointment
We found participants in Motivational interviewing group were
more likely to attend their first aftercare appointment (Swanson
1999) (treatment 58%, control 84%; n = 93, (RR 0.69, 95% CI 0.53 to
0.90; participants = 93; studies = 1), compared with those receiving
standard care. (Analysis 5.22).
Comparison 6: Skills training versus standard care
See Summary of findings 6. Data for this comparison came from five
trials (Bogenschutz 2014; Eack 2015; Hellerstein 1995; Jerrell 1995a;
Rosenblum 2014).
6.1 Leaving the study early: 1. Lost to treatment
Our analyses found that the pooled results of Bogenschutz 2014
and Rosenblum 2014 showed no clear difference in lost to treat-
ment between skills training and standard care groups at three
months (treatment 16%, control 19%, (RR 0.97, 95% CI 0.68 to 1.36;
participants = 461; studies = 3). Data reported by Hellerstein 1995
and Jerrell 1995a showed a 51% greater likelihood that participants
would be lost to treatment from the standard care group by six
months which was clearly more than the skills training group (treat-
ment 16%, control 31%; (RR 0.49, 95% CI 0.24 to 0.97; participants
= 94; studies = 2), although this clear difference was not present at
12 months (treatment 33%, control 33%; (RR 1.42, 95% CI 0.20 to
10.10; participants = 122; studies = 3). By contrast, at 18 months we
found a clear difference between the treatment groups where par-
ticipants given skills training were twice as likely to be lost to treat-
ment (treatment 59%, control 24%; (RR 2.60, 95% CI 1.36 to 4.97;
participants = 75; studies = 2) (Analysis 6.1).
6.2 Lost to evaluation
Data reported by (Bogenschutz 2014) showed no clear differences
in lost to evaluation between groups at six months (RR 0.92, 95% CI
0.40 to 2.08; participants = 121; studies = 1), nine months (RR 1.05,
95% CI 0.47 to 2.33; participants = 121; studies = 1) and 12 months
(RR 1.14, 95% CI 0.55 to 2.36; participants = 121; studies = 1). Analy-
sis 6.2.
6.3 Adverse event: 1. Death
We found Bogenschutz 2014 showed no clear difference between
skills training and standard care with regards to the likelihood
of participants dying by 12 months of treatment (treatment 1.2%
died, control 8% died) (RR 0.15, 95% CI 0.02 to 1.42; participants =
121; studies = 1). Analysis 6.3.
6.4 Substance use: 1. Alcohol use: proportion days abstinent
from alcohol (TLFB method)
Proportion of days abstinent from alcohol was clearly higher in
the skills training group compared to standard care group at three
months (MD 0.02, 95% CI 0.00 to 0.04; participants = 107; studies =
1), but was clearly lower at six months (MD -0.05, 95% CI -0.07 to
-0.03; participants = 100; studies = 1), and there was no difference
between treatment groups at nine months (MD 0.01, 95% CI -0.01
to 0.03; participants = 98; studies = 1) or 12 months (MD 0.03, 95%
CI 0.00 to 0.06; participants = 93; studies = 1). (Analysis 6.4).
6.5 - 6.6 Substance use: (skewed data)
Average scores of various substance use scales (Analysis 6.5) or av-
erage days used (Analysis 6.6) were skewed and reported in 'Other
data' tables.
6.7 Social Functioning: 1. Average score (RFS, high = better
functioning)
Average role functioning scores reported in (Jerrell 1995a) showed
no clear differences between treatment groups by six months (MD
0.61, 95% CI -1.63 to 2.85; participants = 47; studies = 1), 12 months
(MD 1.07, 95% CI -1.15 to 3.29; participants = 47; studies = 1) or 18
months (MD -2.55, 95% CI -6.24 to 1.14; participants = 25; studies =
1). (Analysis 6.7).
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6.8 Social Functioning: 2. Average score (SAS, high = better
functioning)
No clear differences between treatment groups were observed
in social adjustment, measured as average SAS score by (Jerrell
1995a) at six months (MD -0.92, 95% CI -6.58 to 4.74; participants
= 47; studies = 1), 12 months (MD 2.58, 95% CI -3.39 to 8.55; partic-
ipants = 47; studies = 1) or 18 months (MD -4.66, 95% CI -15.29 to
5.97; participants = 25; studies = 1). (Analysis 6.8).
6.9 Service use: 1. Average days in hospital (skewed data)
Data from Hellerstein 1995 for days in hospital were skewed and are
presented in 'Other data' tables. (Analysis 6.9).
Comparison 7: Cognitive behavioural therapy + motivational
interviewing versus standard care
See Summary of findings 7. Data for this comparIson came
from nine trials (Baker 2006; Barrowclough 2001; Barrowclough
2010; Barrowclough 2014; Bellack 2006; Gouzoulis-Mayfrank 2015;
Hjorthoj 2013; Kemp 2007; Madigan 2013).
7.1 Leaving the study early: 1. Lost to treatment
We found that the results from Baker 2006 indicated that clearly
more participants assigned to CBT+ MI group were lost to treatment
by three months (treatment 12%, control 0%; n = 130, RR 17.00 95%
CI 1.00 to 288.56; participants = 130; studies = 1). In contrast, Madi-
gan 2013 reported no group difference in lost to treatment by three
months (treatment 29%, control 24%; n = 88, RR 1.19 95% CI 0.56
to 2.55; participants = 88; studies = 1), as did Gouzoulis-Mayfrank
2015 (treatment 30%, control 44%, n = 100, RR 0.68 95% CI 0.40 to
1.15; participants = 100; studies = 1). Combined, participants in the
CBT + MI groups were no more likely to be lost to treatment by three
months than participants in the standard care groups (treatment
23%, control 20%; RR 1.20, 95% CI 0.44 to 3.30; participants = 318;
studies = 3), but there was considerable statistical heterogeneity
(Chi2 = 6.71, df = 2, P = 0.03; I2 = 70%). Six month-data reported in
(Barrowclough 2010; Barrowclough 2014; Bellack 2006; Gouzoulis-
Mayfrank 2015; Hjorthoj 2013) revealed no difference between CBT
+ MI group and standard care for loss to treatment (treatment 29%,
control 28%; RR 0.90, 95% CI 0.66 to 1.22; participants = 815; stud-
ies = 5, P = 0.48). Similarly, we found nine- to 10-month data (Bar-
rowclough 2001; Barrowclough 2014; Hjorthoj 2013) were not clear-
ly different (treatment 25%, control 32%; (RR 0.80, 95% CI 0.52 to
1.22; participants = 211; studies = 3), nor were 12-month data (Bar-
rowclough 2010) (treatment 17.7%, control 17.8%; RR 0.99, 95% CI
0.62 to 1.59; participants = 327; studies = 1). Statistical heterogene-
ity was not present at six or nine to 10 months). (Analysis 7.1).
7.2 Leaving the study early: 2. Lost to evaluation
We found all lost to evaluation data to be equivocal between CBT
+ MI and standard care by three months (Baker 2006; Gouzoulis-
Mayfrank 2015) (treatment 17% lost, control 23% lost; RR 0.75, 95%
CI 0.46 to 1.21; participants = 230; studies = 2), by six months (Baker
2006; Barrowclough 2014; Bellack 2006; Gouzoulis-Mayfrank 2015;
Kemp 2007) (treatment 21% lost, control 26% lost; RR 0.80, 95%
CI 0.57 to 1.12; participants = 469; studies = 5), at nine months
(Barrowclough 2001; Barrowclough 2014) (treatment 24%, control
26%; RR 0.82, 95% CI 0.46 to 1.47; participants = 146; studies =
2), 12-14 months (Baker 2006; Barrowclough 2001; Barrowclough
2014; Gouzoulis-Mayfrank 2015; Madigan 2013) (treatment 34%,
control 34%; RR 0.99, 95% CI 0.73 to 1.34; participants = 464; studies
= 5), 18 months (Barrowclough 2001; Barrowclough 2010); (treat-
ment 20%, control 22%; RR 0.92, 95% CI 0.61 to 1.38; participants
= 363; studies = 2), and 24 months (Barrowclough 2010) (treatment
21%, control 28%; (RR 0.76, 95% CI 0.52 to 1.11; participants = 327;
studies = 1). Statistical heterogeneity was not present for any of the
above subgroup analyses. (Analysis 7.2).
7.3 Adverse event: 1. Death - by about one year
Pooled results from (Baker 2006; Barrowclough 2001; Barrow-
clough 2010; Barrowclough 2014) found no clear difference in num-
bers of participants dying in either the CBT + MI groups or standard
care groups by about one year (treatment 1.9%, control 3.2%; n =
603, RR 0.60, 95% CI 0.20 to 1.76; participants = 603; studies = 4).
Statistical heterogeneity was not present (Chi2 = 2.94, df = 3, P =
0.40; I2 = 0%). (Analysis 7.3).
7.4 Adverse event: 2. Death or hospitalisation by 24 months
Similarly, there was no clear difference for the likelihood of partic-
ipants hospitalised or dying versus alive and not admitted to hos-
pital by 24 months (Barrowclough 2010) (treatment 23%, control
20%; n = 326, RR 1.15, 95% CI 0.76 to 1.74; participants = 326; stud-
ies = 1). (Analysis 7.4).
7.5 Substance use: 1. Average number of di1erent drugs used
during past month
Polydrug usage was not clearly different between CBT + MI and
standard care groups by three months (Baker 2006) (MD 0.37, 95%
CI -0.01 to 0.75; participants = 119; studies = 1), or by six months (MD
0.19, 95% CI -0.22 to 0.60; participants = 119; studies = 1). (Analysis
7.5).
7.6 Substance use: 2. Cannabis use last 30 days
Moreover, cannabis use in the last 30 days was not clearly differ-
ent between the two treatment groups at three months the end of
treatment (MD -0.20, 95% CI -2.54 to 2.14; participants = 54; studies
= 1), or at 12 months (MD -0.30, 95% CI -2.84 to 2.24; participants =
42; studies = 1). (Analysis 7.6).
7.7 Substance use: 3. Clinically important change - change in
main substance use, abstinent or large decrease
Gouzoulis-Mayfrank 2015 reported data that showed no clear dif-
ference between CBT + MI and standard care groups for numbers
of participants with a large decrease in main substance use or were
abstinent (baseline to three months) (RR (Non-event) 0.67, 95% CI
0.43 to 1.04; participants = 100; studies = 1). (Analysis 7.7).
7.8 - 7.9 Substance use: skewed data
Average scores of various substance use measures that reported
skewed data are shown in 'Other data' tables (Analysis 7.8; Analysis
7.9).
7.10 Mental state: 1. Average score (PANSS total, high = poor)
No clear differences were found between CBI + MI and standard
care groups for average total PANSS scores by six months (Hjorthoj
2013; Kemp 2007) (n = 78, MD 0.99 CI -5.91 to 7.89), nine to 10
months (Barrowclough 2001; Hjorthoj 2013) (n = 92, MD -5.01 CI
-11.25 to 1.22), 12 months (Barrowclough 2010) (n = 274, MD 2.52 CI
-0.68 to 5.72) and by 24 months (Barrowclough 2010) (n = 247, MD
2.71 CI -0.58 to 6.00,). (Analysis 7.10).
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7.11 Mental state: 2. Average score (PANSS positive, high = poor)
No clear differences were found between CBI+MI and standard care
groups for average PANSS positive subscale scores at 12 months
(MD 0.03, 95% CI -1.18 to 1.24; participants = 274; studies = 1) or 24
months (MD 0.52, 95% CI -0.80 to 1.84; participants = 247; studies =
1). (Analysis 7.11).
7.12 Mental state: 3. Average score (PANSS negative, high =
poor)
No clear differences were found between CBI + MI and standard
care groups for average PANSS negative subscale scores at 12 (MD
0.39, 95% CI -0.65 to 1.43; participants = 274; studies = 1) or 24
months (MD 0.16, 95% CI -0.84 to 1.16; participants = 247; studies =
1). (Analysis 7.12).
7.13 Mental state: 4. Average score (various scales, high = poor)
(skewed data)
Average scores for other measures of mental state that reported
skewed data are presented in 'Other data' tables. (Analysis 7.13).
7.14 Global state: 1. Average score (GAF, low = poor)
Average global assessment scores for functioning (GAF) were not
clearly different by three months (Baker 2006; Gouzoulis-Mayfrank
2015; Madigan 2013) (MD -0.17, 95% CI -2.79 to 2.46; participants
= 277; studies = 3), six months (MD 1.65, 95% CI -2.46 to 5.76; par-
ticipants = 219; studies = 2), 12 months (Baker 2006; Barrowclough
2001; Barrowclough 2010; Madigan 2013) (MD 1.24, 95% CI -1.86
to 4.34; participants = 445; studies = 4), 18 months (MD 4.57, 95%
CI -3.07 to 12.21; participants = 72; studies = 2) or 24 months (MD
-0.21, 95% CI -2.93 to 2.51; participants = 234; studies = 1). Low-
er scores indicate poorer functioning. Statistical heterogeneity was
not present at any time period. (Analysis 7.14).
7.15 Global state: 2. Forensic measures - arrests reported - by six
months
The number of reported arrests (Bellack 2006) were not clearly dif-
ferent between the CBT + MI and standard care group by six months
(treatment 13%, control 27%; (RR 0.49, 95% CI 0.22 to 1.10; partici-
pants = 110; studies = 1). (Analysis 7.15).
7.16 Social functioning: 1. Average score (SFS, low = poor)
Barrowclough 2001 reported on social functioning using average
SFS scores. There was no clear difference between CBT+ MI and
standard care group scores by nine months (end of treatment) (MD
5.01, 95% CI -0.55 to 10.57; participants = 32; studies = 1). Howev-
er, by 12 months (three months following end of treatment) results
favoured the CBT+ MI group (high scores = better) (MD 7.27, 95% CI
0.86 to 13.68; participants = 32; studies = 1). (Analysis 7.16).
7.17 Quality of life/ life satisfaction: 1. Average score (BQOL,
general life satisfaction, low = poor) - by six months
Average general life satisfaction scores (BQOL) were higher for the
CBT + MI group (Bellack 2006) by six months (MD 0.58, 95% CI 0.00
to 1.16; participants = 110; studies = 1, P = 0.049), although confi-
dence intervals crossed the line of no effect. Differences in baseline
means (SD) did not account for this finding (treatment 4.25 (1.65)
to 4.79 (1.66) at 6 months, and control 3.96 (1.58) to 4.21 (1.43) at 6
months). Lower scores indicate less life satisfaction. (Analysis 7.17).
7.18 Quality of life/ life satisfaction: 2. Average score (BQOL,
overall quality of life, low = poor) - by six months
No clear differences between treatment groups were found in over-
all quality of life scores (BQOL) by six months (Bellack 2006) (MD
-0.02, 95% CI -0.61 to 0.57; participants = 110; studies = 1). (Analysis
7.18).
7.19 Quality of life/ life satisfaction: 3. Average score (WHOQOL,
BREF, higher scores = better QoL) - by six months
No clear differences between treatment groups were found in
WHOQOL Bref scores by six months (Kemp 2007) (MD -15.70, 95% CI
-36.19 to 4.79; participants = 16; studies = 1). (Analysis 7.19).
7.20 Quality of life/ life satisfaction: 4. Average score (MANSA,
higher scores = better QoL)
No clear differences between treatment groups were found in qual-
ity of life scores using the MANSA by six months (Hjorthoj 2013) (MD
-2.70, 95% CI -7.01 to 1.61; participants = 64; studies = 1) or by 10
months (MD 0.90, 95% CI -3.73 to 5.53; participants = 61; studies =
1). (Analysis 7.20).
7.21 Quality of life/ life satisfaction: 5. Average score (CSQ, client
satisfaction, higher = good)
One study (Hjorthoj 2013) reported client satisfaction using aver-
age CSQ score, there was a clear difference in scores, favouring the
CBT + MI group by 10 months (MD 6.40, 95% CI 3.87 to 8.93; partici-
pants = 62; studies = 1, P < 0.001). (Analysis 7.21).
7.22 Service use: 1. Relapse (hospitalised)
We were only able to include limited data for relapse and found
no major difference in the likelihood of relapse (measured by num-
ber of hospitalisations) between groups (Barrowclough 2001; Bar-
rowclough 2014) by end of nine-month treatment phase (treatment
17% relapsed, control 28% relapsed; RR 0.58, 95% CI 0.29 to 1.16;
participants = 107; studies = 2), or by 12 months (three months after
treatment finished (Barrowclough 2001) (treatment 33%, control
67%; (RR 0.50, 95% CI 0.24 to 1.04; participants = 36; studies = 1), or
18 months (nine months after treatment finished) (Barrowclough
2001; Barrowclough 2014) (treatment 20%, control 33%; (RR 0.61,
95% CI 0.34 to 1.10; participants = 105; studies = 2). (Analysis 7.22).
7.23 Economic outcomes: 1. Diret cost in US$ (BQOL, money
subscale) (skewed data)
The average direct cost subscale of the BQOL at six months report-
ed by Bellack 2006 was skewed and is presented in 'Other data' ta-
bles (Analysis 7.23).
Comparison 8: Cognitive behavioural therapy + psychological
rehabilitation versus standard care
8.1 - 8.3 Global state: Forensic measures
See also Summary of findings 8.
All outcome data regarding forensic measures were skewed da-
ta and are reported in 'Other data' tables (Maloney 2006). There
was no real indication that the number of arrests was less in the
cognitive behavioural therapy + psychosocial rehabilitation group
over all the time periods (Analysis 8.1), and this also applied to the
number of convictions (Analysis 8.2). The number of days in jail for
each group was also not really noticeably different (Analysis 8.3). It
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should be stressed that all data were skewed and not re-analysed,
and are merely reported again in this review.
Comparison 9: Combined cognitive behavioural therapy +
intensive case management versus standard care
9.1 - 9.3 Global state: Forensic measures
See Summary of findings 9.
All outcome data regarding forensic measures were skewed data
and are reported in 'Other data' tables (Maloney 2006). There is
some indication that the number of arrests was less in the cognitive
behavioural therapy + intensive case management group over all
the time periods (Analysis 9.1), and this also applied to the number
of convictions (Analysis 9.2). However, the number of days in jail for
each group was not noticeably different (Analysis 9.3). It should be
stressed that all data were skewed and not re-analysed, merely re-
ported again in this review.
Comparison 10: Sensitivity analyses
All of the included studies were described as randomised and ran-
dom sequence generation was judged as at low or unclear risk of
bias for all included trials. Therefore, we did not undertake the
anticipated sensitivity analysis. There were only two comparisons
(Analysis 7.14; Analysis 5.2) where four or more studies were report-
ed for a comparison and sensitivity analyses were undertaken for
these.
Analysis 10.2 grouped studies investigating motivational interview-
ing plus cognitive behavioural therapy according to risk of bias for
allocation concealment and Analysis 10.1 grouped studies inves-
tigating motivational interviewing according to diagnostic entry
criteria (mixed diagnoses versus schizophrenia only trials) for the
short to medium term (three to six months). Neither of these analy-
ses altered the overall result.
D I S C U S S I O N
Summary of main results
Comparison 1: Integrated models of care versus standard care
Please see Summary of findings for the main comparison. Over-
all, there was low-quality evidence of no difference between inte-
grated models of care and standard care in terms of numbers lost
to treatment or deaths by 36 months, although individually some
studies (Burnam 1995; Essock 2006) showed some effect for re-
taining participants in evaluation during the early stages of each
study. At the end of each treatment period differences were no
longer apparent. All four studies had sample sizes greater than 100
participants, drawn from homeless (Burnam 1995), forensic (Chan-
dler 2006) and community populations (Drake 1998a; Essock 2006).
Modified scales were used by Burnam 1995, precluding inclusion.
There was low-quality evidence of no difference in alcohol or sub-
stance use between integrated models of care and standard care in
terms of, or not, of remission by 36 months.
Moreover, there was low-quality evidence of no difference between
integrated models of care and standard care in terms of average
general global functioning scores and moderate-quality evidence
of no difference for quality of life scores.
Outcome measures of jail and hospital days, arrests and hours of
medication service were all skewed in Chandler 2006. This result-
ed in attrition being the only clear outcome measure which could
be analysed. We were able to include data from Essock 2006 and
Drake 1998a. They provided both treatment and controls groups
with a certain level of integrated care, the difference being that the
assertive community treatment (ACT) teams provided most out-
patient services themselves, while standard care (standard case
management) brokered services to other clinicians. The null results
found in this review suggest that providing services by the same
team may not be crucial to successful integration of services, al-
though readers are advised that the quality of evidence is low over-
all.
Morse 2006 was a three-arm study with about 50 people in each
arm. Interesting data were presented for important outcomes but
all were continuous and skewed. None gave the impression of a
real difference occurring between the psychosocial interventions
and the standard care. Again, considering the huge effort that must
have gone into the integrated assertive community treatment and
ACT, this might indicate how difficult this group of people are to
treat, or how standard care has as good an effect as anything in
terms of substance misuse and general housing outcomes.
Comparison 2: Non-integrated models of care - assertive
community treatment only (ACTO) or intensive case
management or specialised case management services versus
standard care
Please see Summary of findings 2. There was very low-quality evi-
dence of no difference between assertive community treatment or
intensive case management and standard care in terms of being
lost to treatment by 12 months. Death was not measured in any of
the trials. Alcohol or drug use as data were skewed or not reported.
Moreover, there was very low-quality evidence of no difference be-
tween treatment groups in terms of mental state, average general
global functioning or general life satisfaction.
The results showed no support for retaining participants at any
time period. We were only able to include little data as attrition
rates were high (Bond 1991a), adapted scales were used, and the
data were skewed or reporting was unclear (Bond 1991b; Lehman
1993; Jerrell 1995b). The role functioning (RFS) data provided by
Jerrell 1995b by the end of the study (18 months) favoured the
Twelve-Step recovery control group, with a small but significant
difference. The social adjustment scores were similar between
groups.
One small study (Godley 1994) presents data by site and, clearly,
practice by site does differ considerably. There is not really a clear
pattern in the data suggesting an effect, and where there is some
suggestion of a difference between groups the data are based on
very few people.
Comparison 3: Cognitive behavioural therapy (CBT) versus
standard care
Please see Summary of findings 3. There was low-quality evidence
of no difference between CBT and standard care in terms of num-
bers lost to treatment by three months. Death was not measured
in any of the trials. Neither trial reported alcohol use separately, so
this effect could not be estimated and evidence for substance use
by six months was very low quality.
Psychosocial interventions for people with both severe mental illness and substance misuse (Review)









Cochrane Database of Systematic Reviews
There was low-quality evidence of no difference between CBT and
standard care for mental state (BPRS) at six months, and evidence
was very low for global functioning at six months. No study report-
ed life satisfaction.
Support for retention in CBT was from the pooled results of Ed-
wards 2006 and Naeem 2005. One study (Edwards 2006) found a
30% increased likelihood of cannabis use by those in the treatment
group after 10 weekly sessions of CBT. No other differences were
observed on measures of substance use or mental state and func-
tioning, but again much of the data were unusable.
Comparison 4: Contingency management versus standard care
Please see Summary of findings 4. There was moderate-quality ev-
idence between contingency management and standard care in
terms of numbers lost to treatment by three months. Death was not
measured in any of the trials. There was also no useable data avail-
able for alcohol use (data skewed) and no clear difference between
treatment groups for substance use (stimulant-positive urine tests)
by six months.
Moreover, there was low-quality evidence of no difference be-
tween contingency management and standard care for mental
state (number hospitalised) at six months. Neither trial reported on
global assessment of functioning and general life satisfaction.
McDonell 2013 reported fewer participants with a stimulant-pos-
itive urine at the end of treatment (three months) for the contin-
gency management arm compared to standard care. However, by
six months (three months post-treatment) this was no longer signif-
icant. Moreover, they also reported less injection use at the end of
treatment (three months) for the active arm compared to standard
care, and again this was no longer significant at six months. Over
the six-month trial, fewer participants in the contingency managed
arm were hospitalised compared to standard care. Petry 2013 re-
ported longer consecutive weeks of cocaine abstinence in 10 par-
ticipants receiving contingency management compared to treat-
ment as usual (TAU) (n = 9). However, less than half the expected
samples were remitted and when missing samples were not includ-
ed, no between-group differences were apparent. McDonell 2017
reported longer durations of continuous alcohol abstinence in the
contingent intervention group at three months, however, these dif-
ferences were not statistically different at the three-month post-
treatment follow-up.
Comparison 5: Motivational interviewing (MI) versus standard
care
Please see Summary of findings 5. There was very low-quali-
ty evidence of no difference between motivational interviewing
and standard care in terms of numbers lost to treatment (six
months), lost to evaluation (12 months) or deaths (18 months).
There was very low-quality evidence of not abstaining from alcohol
(six months) or polydrug use (12 months).
There was very low-quality evidence of no difference between mo-
tivational interviewing and standard care in terms of mental state
(Symptom Checklist 90 (SCL-90), three months) and average global
functioning at 12 months. None of the trials measured general life
satisfaction.
Some support was found for the effectiveness of motivational inter-
viewing in reducing substance use, even though studies were gen-
erally small, interventions brief, and follow-up times shorter than
for other comparisons. Graeber 2003 found that there was more
likelihood that participants in the treatment group would abstain
from alcohol after only three sessions of motivational interview-
ing; by three months and six months this increased. Bonsack 2011
reported that individual sessions of motivational interviewing for
up to six months reduced the number of joints consumed at three
and six months, but not at 12 months follow-up. Similarly, partici-
pants in the treatment group of Kavanagh 2004 showed they were
more likely to be abstaining or had improved on all substances
by 12 months after three hours of motivational interviewing over
six to nine sessions. More participants in the treatment group of
Swanson 1999 attended their first aftercare appointment after one
15-minute and one one-hour session. Graham 2016 reported mar-
ginal improvements in engagement in treatment at three months
after a brief (two-week) inpatient intervention. Bechdolf 2011 al-
so reported higher chances of attending outpatients over a peri-
od of six months. In contrast, Baker 2002 reported little differences
between groups after one 45-minute session, which was more ap-
parent at 12 months than at three months when the treatment
showed some benefit. Hickman 1997 showed little difference in
mental state scores after one brief session. The results indicate that
multiple sessions of motivational interviewing may lead to short-
term reductions in substance use and increased attendance at out-
patient appointments.
Comparison 6: Skills training versus standard care
Please see Summary of findings 6. There was very low-quality evi-
dence of no difference between skills training and standard care in
terms of numbers lost to treatment by 12 months and low-quality
evidence of no difference for death. There were no useable data for
substance use by 12 months as the data were skewed. No clear dif-
ferences were reported in days abstinent from alcohol.
Moreover, there was very low-quality evidence of no difference be-
tween skills training and standard care for relapse (in mental state
symptoms) at eight months and no differences for global state at
12 months. No trial reported on general life satisfaction.
Pooled results from Bogenschutz 2014 and Rosenblum 2014 re-
ported no differences in lost to treatment at three months. Pooled
results of Hellerstein 1995 and Jerrell 1995a showed that control
group participants were more likely to be lost from the study at
six to nine months. However, by 18 months Jerrell 1995a and Eack
2015 reported that participants in their treatment programme were
more likely to be lost. Hellerstein 1995 offered their treatment
group a same site co-ordinated treatment approach and their con-
trol group were offered the same treatment, which was not case
co-ordinated. In the largest study to date, Rosenblum 2014 found
those in the double-trouble in recovery group self-reported fewer
days using alcohol or drugs over 30 days compared to waiting list
controls. However, the data were skewed and effects were not ap-
parent at both study sites. Eack 2015 also reported reductions in
alcohol use in the last 30 days (but not cannabis use) during cog-
nitive enhancement therapy in a small pilot study. In contrast, Bo-
genschutz 2014 reported no differences in abstinence from alcohol
or drugs in individuals following a 12 weeks of a 12-step facilitation
therapy.
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Comparison 7: Cognitive behavioural therapy + motivational
interviewing (CBT + MI) versus standard care
Please see Summary of findings 7. There was low-quality evidence
of no difference between cognitive behavioural therapy + motiva-
tional interviewing and standard care in terms of numbers lost to
treatment or deaths by 12 months. All the data for alcohol use were
skewed and evidence of no differences for drug use by six months
was low quality.
There was very low-quality evidence of no difference between cog-
nitive behavioural therapy + motivational interviewing and stan-
dard care in terms of mental state (relapse) and average global state
(GAF scores) at 12 months. Moreover, there was low-quality evi-
dence for no difference in quality of life scores at six months be-
tween treatment arms.
We found some support for the effectiveness of cognitive behav-
ioural therapy + motivational interviewing over standard care, yet,
findings were inconsistent and, again, much data were unable to
be used from all seven eligible studies. The Barrowclough 2001 was
a small study but showed an increased likelihood of relapse in the
control group up until 18 months. Global functioning was slight-
ly lower in the control group by nine months, although this differ-
ence was not sustained at later time periods (up to 18 months).
Gouzoulis-Mayfrank 2015 reported transient large decreases in
substance use at three months in treated participants compared to
standard care, but the sample size was small and attrition was high
(> 50% by 12 months). Bellack 2006 showed slightly decreased gen-
eral life satisfaction scores and a 51% increased likelihood of being
arrested in their reasonably sized control group by six months. By
contrast, Baker 2006 showed that participants were more likely to
leave the treatment group by three months. The treatment group
also seemed to have a slightly higher mean number of drugs used
by three months; this difference was not apparent by six months,
and Madigan 2013 showed no difference in cannabis use at three
or six months. Moreover, the phase-specific study by Barrowclough
2014 found no evidence that brief or long-term cognitive behav-
ioural therapy + motivational interviewing therapy conferred bene-
fit over standard care in reducing frequency or amount of cannabis
use at nine months or 18 months following a first episode of psy-
chosis. The largest study to date (Barrowclough 2010) reported no
differences between interventions and death or hospitalised ver-
sus not admitted to hospital and alive by 24 months. Nor did this
study report any differences in substance use, mental state (Pos-
itive and Negative Syndrome Scale (PANSS)), or other outcomes.
Hjorthoj 2013 reported higher satisfaction scores by 10 months, but
no differences were reported in quality of life scores or other out-
comes.
Further research is required to determine whether long-term cog-
nitive behavioural therapy combined with motivational interview-
ing is useful and cost-effective.
Comparison 8: Cognitive behavioural therapy + psychological
rehabilitation versus standard care
Please see Summary of findings 8. All of the outcomes for this com-
parison were very-low quality or the outcome was not measured. It
is problematic to interpret the skewed data and all data were from
one study (Maloney 2006) allocating less than 100 people to this
comparison. It is feasible that a subtle difference between treat-
ment groups could not be highlighted because of the limited pow-
er of the trial but, from what data we have, there is no indication
that the number of arrests is less in the cognitive behavioural thera-
py plus psychosocial rehabilitation group over all the time periods.
This also applies to the number of convictions and the number of
days in jail.
Comparison 9: Cognitive behavioural therapy + intensive case
management versus standard care
Please see Summary of findings 9. All of the outcomes for this com-
parison were very-low quality or the outcome was not measured.
Again Maloney 2006 reports useful outcomes relating to function-
ing in society but again the data are skewed and difficult to inter-
pret. Unlike the preceding comparison, however, there is a sugges-
tion that there may be some positive effect for people allocated
to the cognitive behavioural therapy + intensive case management
group. The number of arrests is less in the cognitive behavioural
therapy + intensive case management group over all time periods,
and this also applies to the number of convictions at 12 and 30
months. However, the number of days in jail for each group is not
noticeably different. This may give some hope that the very inten-
sive approach does have some benefit in terms of these important
outcomes but, again, these findings from such a small study should
be replicated before making any change in policy. Economic analy-
ses would also be of interest for this package of care that is likely
to be expensive.
Sensitivity analysis
Sensitivity analyses were conducted to ascertain if there were sub-
stantial differences in the results when lesser quality trials were
excluded. There were relatively few trials to conduct the sensitivi-
ty analysis due to the small numbers of trials in each intervention
and the large number of outcome measures at variable time points.
There was no indication that trials of lesser quality or those recruit-
ing patients with severe mental illness other than schizophrenia in-
fluenced the overall outcomes in this review.
Overall completeness and applicability of evidence
Many of the included studies were described as pilot studies which
included small samples sizes. Eighteen trials involved more than
100 participants and three of these involved more than 200 par-
ticipants after randomisation (Barrowclough 2010; Drake 1998a;
Rosenblum 2014). However, the overall power for a particular com-
mon outcome and comparison was low due to the variety of inter-
ventions and outcomes measured.
Examination of the summary of findings indicates that several crit-
ical or important outcomes were not measured by any of the stud-
ies, and therefore no power exists. Future research could examine
these comparisons in order to bring to light any potential benefits
in the management of patients with a dual diagnosis.
The majority of studies presented medium-term data; with six
months to one year follow-up. This is a reasonable length of time to
assess differences in the intervention effects. Longer-term studies
(one to three years) employed integrated and assertive community
care interventions. These types of studies are important to engage
patients in treatment programmes that help recovery from serious
mental illness.
All study participants had a diagnosis of severe mental illness and
substance misuse. Participants were from a wide range of settings,
so the results of this review will be applicable to similar patients,
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particularly those in the USA (25 trials). Some generalisation can be
assumed for the UK (five trials) and Australia (six trials) for cognitive
behavioural therapy and motivational interviewing as the studies
from these areas examined these interventions. Integrated, non-in-
tegrated, and skills-training intervention findings may apply else-
where only if the intervention is delivered in a similar manner. How-
ever, as there are differences between the USA (Bond 2017) and oth-
er countries' services, including education and training of health
service staI, generalisation to other areas must be interpreted with
caution (Donald 2005; Lowe 2004; Tyrer 2004). This is also true for
resource-constrained settings. We did not identify any trials from
low- or middle-income countries.
Quality of the evidence
Primary outcome measures selected for this review were: remain-
ing in treatment, substance use, and mental state. Pooled results
demonstrated no consistent evidence to support any one treat-
ment intervention over standard care. Some support for motiva-
tional interviewing was found from individual studies for substance
use reduction. When motivational interviewing was offered in con-
junction with cognitive behavioural therapy there was little sup-
port for improved mental state. These findings suggest that moti-
vational interviewing is a crucial component to the effectiveness
of treatment with cognitive behavioural therapy. However, it was
challenging to identify the key aspects of each intervention given
that these are mostly complex, multi-faceted interventions. Little
attention was paid to reporting the fidelity of the delivery of each
intervention so quality was difficult to gauge.
Missing outcomes or too few data
Out of the primary outcome measures, studies only reported num-
bers lost to treatment clearly enough to allow pooling of results in
each of the comparisons. Often the other primary outcome mea-
sures (substance use, mental state) were reported as continuous
rather than binary data and much of these data were problemat-
ic. With this particular population, skewed data may be unavoid-
able and, as such, is problematic to present and manage in a meta-
analysis. However, opportunities were missed to report simple and
useful binary outcomes.
Potential biases in the review process
It is possible that we failed to identify small negative trials, and
we would be most interested if readers know of these. We endeav-
oured to reduce this potential bias by conducting a wide search, du-
plicate extraction, multiple checking, and handsearching key refer-
ences and journals. We also contacted many of the authors of these
trials over the years, and for this review we asked if they knew of any
recently completed or ongoing trials. The introduction of web sites
and journals to register trials hopefully will reduce the 'file drawer'
phenomenon, as negative trials are less likely to be published.
A limitation of this review is that there was substantial variation be-
tween studies as to what constituted standard care, in addition to
some differences between the interventions themselves. For exam-
ple, fidelity, duration, and intensity of treatment conditions varied,
furthermore the outcome reporting periods also differed. This re-
sulted in difficulties in grouping and interpreting data. There was a
high volume of problematic data due to skew, use of non-validated
scales, or unclear reporting. Further high-quality randomised trials
are required which employ large samples, use validated and clini-
cally relevant measures, and present data in a way that can be in-
corporated into a meta-analysis.
It is possible that our consideration of these data have been biased
by our foreknowledge of the past work (Cleary 2008; Hunt 2013; Ley
2000). It is difficult to know what to do about this except to state
that we do make every effort to be open to any new information or
interpretation.
Agreements and disagreements with other studies or
reviews
The findings of this review agree with other narrative syntheses of
the literature, which have come to the same conclusions. There is
little evidence from trials to support any one psychosocial treat-
ment over another to reduce substance use or improve mental
state for people with a serious mental illness (Baker 2012; Cleary
2009a; Crockford 2017; Dixon 2010; Drake 1998b; Hjorthoj 2009;
Horsfall 2009; NICE 2011).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
This review is larger than the previous or original review (41 as op-
posed to 32 and six studies, respectively), although all three have
similar results. The findings reveal no compelling evidence to sup-
port any one psychosocial treatment to reduce substance use or to
improve mental state for people with severe mental illnesses. Some
support for substance use reduction came from one small study
assessing motivational interviewing, where more participants re-
ceiving this treatment abstained from alcohol. Further, more par-
ticipants receiving motivational interviewing attended their first af-
tercare appointment. In combination with cognitive behavioural
therapy, motivational interviewing also improved mental state, life
satisfaction and social functioning. Little support was found for in-
tegrated, non-integrated, or skills-training programmes being su-
perior to standard care. A recent study (McDonell 2013) reported
reduced stimulant use in homeless people randomised to contin-
gency management. This intervention was combined in another
study (Bellack 2006) with motivational interviewing and cognitive
behavioural therapy, with some positive outcomes.
However, methodological difficulties exist which hinder pooling
and interpreting results and include high attrition rates; varying
fidelity of interventions; varying outcome measures, settings and
samples (sample size, participant level of substance use, motiva-
tion to change, diagnoses, age, gender, cultural, socioeconomic
and contextual influences); and, in some cases, comparison groups
may have received higher levels of treatment than usual standard
care. Therefore, it is not yet possible to reach clear conclusions, al-
though it is pleasing to see that the field is developing with an in-
crease in high-quality randomised controlled trials offering high-fi-
delity programmes and reporting more usable data. However, the
largest trial to date (Barrowclough 2010) did not find that motiva-
tional interviewing combined with cognitive behavioural therapy
significantly improved patient outcomes.
1. For people with severe mental illness and substance misuse
problems, and their carers
People with both severe mental health and substance misuse prob-
lems should be aware that at present there is little evidence to sup-
port any particular psychosocial intervention over another or over
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standard care. This does not mean that particular treatments do
not help, but that data are few and the little supportive evidence
found in these studies need further studies to support their use. No-
one can suggest to people entering a service that one form of sup-
port should really take precedence over another.
2. For clinicians
Clinicians need to keep up-to-date on the latest research findings
in this area because as new trials are published, the evidence base
should rapidly build to support particular interventions for this
challenging group of patients. Interventions for substance reduc-
tion may need to be further developed and adapted for people with
a serious mental illness. Clinicians who seek to offer existing inter-
ventions over and above standard care should take the opportunity
to work with trial researchers to generate useful data.
3. For policy makers and commissioners of care
Developments in specific treatments and in models of service de-
livery are still taking place. While there is no evidence that the inno-
vative integrated services that have been developed in the USA are
helpful, conversely there is also no convincing evidence that they
lead to a worse outcome. The development of such services may be
unlikely in other countries, such as the UK where the general poli-
cy is to build on the existing links and to use mainstream services
as far as possible (Haddock 2014; Seivewright 2005). This may be a
function of methodological problems within the studies or it may
be that there is, in fact, no effect. Policies in this difficult area are
needed. These policies should be either based on good evidence or
in their implementation should generate the relevant evidence.
Implications for research
1. General
1.1 Reporting of outcome measures
Only validated and non-adapted scales should be used in future
trials. Clear reporting of data during treatment and at various fol-
low-up periods with an indication that they meet the assumptions
of the analyses undertaken would be helpful. Wherever possible,
dichotomous data should be reported in addition to continuous da-
ta, as the use of outcomes such as retention in treatment, relapse,
hospitalisation and abstinence rates are relevant to the topic and
are preferable to reporting skewed data (Jones 2004).
1.2 Methodology
Clear and strict adherence to the CONSORT statement (Altman
2001; Begg 1996; Moher 1998; Turpin 2005) for methodology and all
outcomes should be the goal of future trials. A full description of
the number of participants lost to treatment and evaluation after
the randomisation process should be completed at each time point
for both treatment arms. A clear description of the randomisation
process and blinding is also not difficult and is now necessary. The
use of intention-to-treat analysis can assist with minimising bias re-
sulting from missing data. Double-blind evaluation of outcomes of
psychosocial interventions is not possible due to the nature of the
intervention. However, researchers should take every precaution
to minimise the effect of bias by at least using raters blind to group
assignment.
2. Specific
Consistent with our suggestions for more high-quality randomised
controlled trials, other recently published reviews advocate a need
for more consistent and methodologically rigorous trials on this
topic to test both individual components and integrated pro-
gramme (Bennett 2017; Boniface 2018; De Witte 2014; Donald 2005;
Drake 2004; Lubman 2010; Mueser 2005; Murthy 2012; Tiet 2007). Al-
so worth noting are recent treatment recommendations and guide-
lines on psychosocial interventions for substance reduction modi-
fied for people with a mental illness (Baandrup 2016; Baker 2012;
Crockford 2017; Dixon 2010; Galletly 2016; Hasan 2015; Kelly 2012;
NICE 2011; Work Group 2007; Ziedonis 2005).
Future high-quality trials in this area will contribute to the grow-
ing body of data and will allow future reviews to tease out find-
ings. Assessing brief interventions (such as motivational interview-
ing) over standard care will allow the identification of cost-effective
and easy-to-implement components that can be quickly integrat-
ed into standard care. New trials should aim to recruit sufficiently
large sample sizes and collect data that can be reported and, if ap-
propriate, synthesised in meta-analyses. Informed consent of par-
ticipants should include statements that all anonymous data will
be publicly available. The use of measurement scales should be
of clinical value, in common use, and have demonstrated reliabili-
ty and validity. We suggest a design for a future trial with the key
methodological points highlighted in Table 2. Future reviews may
explore differences between subgroups (determined a priori), such
as differences between levels of substance use (misuse versus de-
pendence), differences between substances used, and differences
between age groups (for example, first-episode schizophrenia ver-
sus older patients).
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Location: Hunter region, NSW, Australia.
Participants Diagnosis: 37% schizophrenia with SCID abuse or dependence (alcohol 54%, cannabis 51%, ampheta-
mine 22%, benzodiazepine 11%).*
N = 160.
Age: mean ˜ 31 years.
Sex: 120 M, 40 F.
Ethnicity: not reported.
Inclusion criteria: acute in-patient, SCID abuse or dependence for alcohol, cannabis or amphetamine,
self-report of hazardous use during last month of one or more of these drug types on OTI.
Interventions 1. Psychosocial intervention: Motivational interviewing (MI): Individual 30-45 minutes of MI plus stan-
dard care. N = 79.
2. Standard care: standard care plus informed that they were using substances at hazardous level and
should reduce their consumption. N = 81.
Outcomes Leaving the study early: lost to evaluation.
Substance use: SCID - alcohol, amphetamine and cannabis**, OTI - polydrug use.
Social functioningr OTI .***
Unable to use
Adverse event: death (not reported by group).
Substance use: OTI - alcohol, cannabis, and amphetamine (data skewed).
Mental state: BSI (data skewed).
Forensic: OTI - crime (data skewed).
Notes Not ITT analysis.
* Some participants were dependent on more than one of these substances.
Paid AUD$20 each assessment.
Baker 2002 
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** Data reported on subset who participated in all 3 evaluation points and also met SCID abuse/depen-
dence criteria at start of study.
*** Data reported on subset who participated in evaluation at 6 and 12 months.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised. No further details.
Allocation concealment
(selection bias)





High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk Lost to follow-up 44% (71/160) 1 year.
Number of lost to follow-up reported, but no reasons for missing data provid-
ed.
Full ITT analysis with imputed data for all missing values not reported.
Selective reporting (re-
porting bias)
Unclear risk All outcomes of interest fully reported for each intervention. No protocol avail-
able.








Location: Hunter region, NSW, Australia.
Participants Diagnosis: 75% ICD-10 schizophrenia or schizoaffective disorder with SCID-1 diagnosis of abuse or de-
pendence past 12 months (alcohol 69%, cannabis 74%, amphetamine 42%).*
N = 130.
Age: mean 29 years.
Sex: 102 M, 28 F.
Ethnicity: not reported.
Inclusion criteria: SCID abuse or dependence for alcohol, cannabis or amphetamine during preceding
month, age at least 15 years, ability to speak English, having a confirmed ICD-10 psychotic disorder, no
organic brain impairment, and not intending to move from area within 12 months.
Baker 2006 
Psychosocial interventions for people with both severe mental illness and substance misuse (Review)









Cochrane Database of Systematic Reviews
Interventions 1. Psychosocial intervention: CBT + MI (10 weekly one-hour sessions). N = 65.
2. Standard care: standard care plus self-help books. N = 65.
Outcomes Leaving the study early: lost to evaluation.
Adverse event: death.
Substance use: OTI (polydrug use only).
Global state: GAF.
Unable to use
Leaving the study early: lost to treatment (no control group data).
Substance use: OTI (alcohol, cannabis, amphetamine - skewed data).
Mental state: BPRS, BDI-II (data skewed).
Notes Not ITT analysis. Authors report that a separate ITT analysis was run with similar results.
*Some participants were dependent on more than one of these.
Participants paid AUD $20 for each assessment interview.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Participants drew a card from an envelope but no details provided regarding




Unclear risk Patients drew a card from an envelope. No further details provided so it is un-





High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Lost to follow-up 20% (26/130) 1 year.
Number and reason for missing data clearly reported in flow sheet. Missing
outcome data balanced across groups. Full ITT analysis with imputed data for
all missing values not reported.
Selective reporting (re-
porting bias)
Unclear risk In the report, the results are fully reported. There is no protocol.





Design: single-centre (three sites).
Duration: 12, 18* months.
Setting: own homes.
Barrowclough 2001 
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Location: Tameside & Glossop, Stockport and Oldham, UK.
Participants Diagnosis: ICD-10 & DSM-IV schizophrenia or schizoaffective disorder with DSM-IV substance abuse or
dependence.
N = 36.
Age: 18-65 years, mean ˜ 31 years.
Sex: 33 M, 3 F.
Ethnicity: white European.
Inclusion criteria: current substance abuse, in current contact with mental health services, min. 10
hours face-to-face contact with the caregiver per week, no organic brain disease or other serious med-
ical illness or learning disability.
Interventions 1. Psychosocial intervention: MI with annualised individual CBT for the participant and CBT for fami-
ly/caregiver for 9 months (plus routine care with family support worker). N = 18.
2. Standard care: routine care plus family support worker. N = 18.
Outcomes Leaving the study early: lost to treatment, lost to evaluation.
Adverse events: death.




Substance use: ASI - % days abstinent (no mean/SD).
Mental state: PANSS (some data skewed).
Relapse: duration of relapse (only median and range supplied).
Other: SFS 18-month (only adjusted means reported).
Notes Part ITT analysis.
*18-month data (see secondary reference Haddock et al 2003).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated list stratified for sex and three types of substance use.
Allocation concealment
(selection bias)





High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Lost to follow-up: 22% (8/36) 18 months.
Missing outcome data balanced in numbers across intervention groups, with
similar reasons for missing data across groups.
Selective reporting (re-
porting bias)
Low risk No selective reporting evident between study protocol (N0244032344) and
published article.
Barrowclough 2001  (Continued)
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Design: multi-centre (six large NHS mental health trusts).
Duration: 24 months.
Setting: Community (most patients received home treatment).
Location: London, Lancashire and Manchester, UK.
Participants Diagnosis: ICD-10 & DSM-IV non-affective psychotic disorder (schizophrenia, schizoaffective etc) and
DSM-IV diagnosis of dependence on or abuse of drugs, alcohol or both.
N = 327
Age: 17-67 years, mean ˜38.
Sex: 283 M, 44 F.
Ethnicity: 81% (n = 266) white.
Inclusion criteria: English speaking, fixed abode, and no history of organic factors implicated in the ae-
tiology of psychotic symptoms.
Interventions 1. Psychosocial intervention: CBT + MI (up to 26 individual therapy sessions delivered over 12 months
(manual based) plus routine care. N = 164.*
2. Standard care: routine care plus access to community-based rehabilitation activities. N = 163.




Substance use: Inventory of drug use consequences, days abstinent, readiness to change.
Service use: relapse (admissions last 12 months), hospitalisation (for psychosis) or death versus not ad-
mitted and alive.
Unable to use
Substance use: proportion days abstinent from all substances (skewed data).
Notes *One case was misdiagnosed (affective) and excluded from the analysis (CBT + MI).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated, algorithm taking into account substance type (alcohol
alone, drugs alone, or alcohol and drugs) and NHS trust.
Barrowclough 2010 
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Allocation concealment
(selection bias)






High risk Clinician-/participant-mediated and participants and personnel not blinded.It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk For the primary outcome of hospital admission, data were obtained from par-
ticipant psychiatric case notes and is unlikely to be affected by blinding. For
other outcomes involving self-report, precautions were taken to maintain the
blindness. Throughout the trial, 135 breaks in the blindness of an assessor
were reported in total. However, only one assessment was completed unblind-




Unclear risk Lost to follow-up: 25% (81/327) 2 years.
Flow sheet provided describing reasons for incomplete data and deaths. Even-
ly balanced between treatment groups. No missing values for primary out-
come measure (re-hospitalisation/or death).
Selective reporting (re-
porting bias)
Low risk All outcomes of interest fully reported and these match the trial protocol.






Duration: 18 months (up to 9 months post treatment).
Setting: community.
Location: Manchester and Lancaster, England.
Participants Diagnosis: DSM-IV non-affective psychotic disorder (schizophrenia, N = 76, 69%) and cannabis abuse or
dependence.
N = 110.
Age: 24 (range 16-35 years).
Sex: 98 M, 12 F.
Ethnicity: white (N = 102, 93%).
Inclusion criteria: early intervention centre referrals with recent cannabis misuse in the last 3 months.
Interventions 1. Psychosocial intervention: CBT + MI: Brief MI + CBT, 12 sessions of integrated MI-CBT over 4.5
months. N = 38.
2. Psychosocial intervention: CBT + MI: Long-term MI + CBT, 24 sessions of integrated MI - CBT over 9
months. N = 37.*
3. Standard care: TAU. N = 35.
Barrowclough 2014 
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Outcomes Leaving the study early: lost to treatment, lost to evaluation.
Substance use: proportion days abstinent from cannabis, all substances,
Global state: GAF.
Relapse: in previous 9 months, number of hospitalisations and time to first hospitalisation.
Unable to use
Mental State: PANSS (skewed data),
Notes Funded by NIHS.
Trial identifier: ISRCTN88275061.
“ReCAP” Rethinking Choices After Psychosis
*For some of the analyses, the brief- and long-term groups were combined.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomised permuted blocks
Allocation concealment
(selection bias)





High risk Participants and providers were aware of receipt of allocation to MI-CBT, or
long MI-CBT or standard care. It is not possible to blind a psychosocial inter-
vention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The outcome was number of days abstinent from cannabis and the outcome
assessors were housed in different locations and participants and care co-
ordinators were reminded not to divulge information that might lead to 'un-
blinding'. However, the actual outcome was done via self-report and there is
a chance that participants may report based on social desirability bias. We




Low risk Attrition for brief MI-CBT was 12/38 (31.6%); attrition for long MI-CBT was 9/37
(24.3%); attrition in TAU was 13/35 (37.1%). Attrition for the combined MI-CBT
(21/75, 28%) and TAU less than 10% which is acceptable for low risk.
Selective reporting (re-
porting bias)
Low risk No selective reporting evident between study protocol (ISRCTN88275061) and
published article.







Setting: Inpatient, some of the treatment could be as outpatient.
Bechdolf 2011 
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Location: Cologne, Germany.
Participants Diagnosis: ICD-10 schizophrenia or schizoaffective disorder (n = 50, 83.3%) or substance-induced psy-
chosis (n = 10) with substance abuse or dependence.
N = 60.
Age: mean 31.5 years.
Sex: 43 M, 17 F.
Ethnicity: not reported.
Inclusion criteria: German speaking and excluded if they were close to discharge.
Interventions 1. Psychosocial intervention: MI (4 individual sessions of 50 minutes each given as an inpatient) plus
routine care. N = 30.
2. Standard care: routine care plus 4 sessions of non-specific supportive sessions (Supportive Therapy,
ST). N = 30.
Outcomes Leaving the study early: lost to evaluation (3 and 6 months).
Unable to use
Mental state: PANSS (no means or SDs reported).
Global state: GAF (no means or SDs reported).
Substance use: ASI alcohol, cannabis consumption (skewed data).
Service use: relapse (hospitalisations) (not reported).
Notes All analyses were performed by intention-to-treat conditions.
Text was translated from German to English by internal translators.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Unclear risk Researcher not involved in the study generated sequence. Insufficient infor-





High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Lost to follow-up: 25% (15/60) 6 months.
Missing data have been imputed using appropriate methods (LOCF), but these
can still have unclear risk effects.
Selective reporting (re-
porting bias)
Unclear risk Rating of mental state not fully reported (numerical data not provided for
PANSS, GAF) both secondary outcomes reported as not significantly different
between groups over time.
Other bias Low risk None according to authors.
Bechdolf 2011  (Continued)
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Methods Allocation: randomised (adaptive urn procedure).
Design: single-centre.
Duration: 6 months.
Setting: community clinics and Veterans Affairs Medical Center.
Location: Baltimore, Md, USA.
Participants Diagnosis: 38% DSM-IV schizophrenia or schizoaffective disorder, 55% major affective disorder. DSM-
IV substance abuse or dependence (predominate drug of abuse was 69% cocaine, 25% opiates, 7%
cannabis).
N = 175.**
Mean age: 43 years.
Sex: 111 M, 64 F.
Ethnicity: 75% African American.
Inclusion criteria: meeting criteria for severe and persistent mental illness and current dependence on
cocaine, heroin or cannabis.
Interventions 1. Psychosocial intervention: CBT + MI: BTSAS: Behavioural Treatment for Substance Abuse in severe
and persistent mental illness (SPMI). BTSAS consisted of motivational interviewing at baseline, 3 and 6
months and includes MI and CBT approaches. N=61.*
2. Standard care: routine care which included Supportive Treatment for Addiction Recovery (STAR)
which includes some psycho education and group discussion regarding substance misuse. N=49.
Outcomes Leaving the study early: lost to treatment, **lost to evaluation.
Global state: forensic measures (arrests by 6 months).
Quality of life / life satisfaction: BQOL.
Unable to use
Substance use: urinalysis (no means, SDs or time period given).
Mental state: ASI (data skewed).
Hospitalisation. (psychiatric and substance use admissions combined).
Other: SFS (only 1 subscale score used), BQOL money subscale (data skewed).
Notes Not ITT analysis.
*Participants paid for clean urine test average payment per person USD 60.
** n = 175 randomised, however 46 patients failed to initiate treatment and 19 failed to become en-
gaged (analysis was based on subset of 110 patients who were engaged in treatment).
Authors have kindly provided further data.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised using an adaptive urn procedure adjusted for sex, psychiatric di-
agnosis, drug of choice and number of substance use disorders. Separate ran-
domisation was conducted for participants from community clinics and VA
centre. No further details.
Allocation concealment
(selection bias)




High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Bellack 2006 
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All outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Primary outcome was urinalysis results so the review authors judge that this
outcome is not likely to be influenced by a lack of blinding. Moreover, raters




High risk Lost to follow-up: 25% (27/110) 6 months of "engaged" participants.
46 patients failed to initiate treatment and 19 failed to become engaged
(analysis was based on subset of 110 patients who were engaged in treatment)
so ITT analysis was not completed. Missing data were not balanced across in-




Unclear risk No protocol was available. Author states there were conflicting data on sub-
stance use between self-report, drug screens and clinical ratings (SCID) of de-
pendence.






Duration: 12 weeks with follow up 9 months post-treatment.
Setting: outpatient dual diagnosis programme.
Location: Albuquerque, NM, USA.
Participants Diagnosis: serious mental illness (Schizophrenia/psychotic, 18%, Bipolar, 36% and Major depression,
46%) with alcohol dependence or abuse.
N = 121.
Age: ˜ 42 years.
Sex: 64 M 57 F.
Ethnicity: Hispanic (39%), white (48%) and other (13%).
Inclusion criteria: attending outpatient dual diagnosis program having a psychotic or major affective
disorder and alcohol abuse or dependence active within the last month.
Interventions 1. Psychosocial intervention: Skills training: 12-step facilitation (TSF) for the dually diagnosed for 12
weeks. Several topics were covered including social skills training to help patients tolerate group meet-
ings. N=83.
2. Standard care: described as treatment as usual (TAU). N = 38.
Outcomes Leaving the study early: lost to treatment, lost to evaluation.
Adverse event: death.
Substance use: alcohol abstinence for a given period, drinks per drinking day using time-line follow
back (TLFB) to confirm self-report of substance use.
Unable to use
Bogenschutz 2014 
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Mental State: Brief Symptom Inventory (BSI) (baseline only reported).
Service use: 12-step attendance on drinking.
Notes Trial identifier, NCT00583440
Attendees received $40 for baseline interview, and 40$ for each follow-up assessment at 12, 24, 36 and
48 weeks and $10 for brief assessments (weeks 4 and 8). Funded by NIAAA. There was limited 12-step
participation in both groups due to limited availability of 12-step meetings.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Urn-randomisation procedure with 2:1 ratio using block randomisation (al-
though this is not reported as computerised or with a real urn).
Allocation concealment
(selection bias)
Unclear risk No further details regarding concealment. If a real urn, foreknowledge of the





High risk Participants and providers were aware of their allocation. It is not possible to
blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Substance use by self-report of abstinent from alcohol or number of drinks per





Low risk Lost to follow-up was 14/121 (12%) after 12 weeks of treatment and 28/121
(23%) at 9 months post-treatment.
Selective reporting (re-
porting bias)
Unclear risk No selective reporting evident between study protocol (NCT00583440) and
published article. Blood alcohol levels were measured at each visit but not re-
ported or used in data analysis so rated unclear.





Design: single-centre (two sites, see Bond-Evansville).
Duration: 18 months.
Setting: community centre.
Location: Anderson, SC, USA.
Participants Diagnosis: 57% DSM-III-R schizophrenia with co-occurring substance disorder.
N = 42.*
Age: 18 - 45 years, mean ˜ 30 years.
Sex: 14 M, 7 F (only 21 received treatment).
Ethnicity: 14% black.
Inclusion criteria: chronic, DSM-III-R or documented evidence of substance abuse / dependence, exten-
sive hospital/crisis service use over previous year.
Bond 1991a 
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Interventions 1. Psychosocial intervention: non-integrated ACT. Includes reference groups to encourage attendance
at CMHC'S, peer support group meetings several times/week, not focused exclusively on substance
abuse, used successful members as role models, also home and community visits throughout project
period. N = 21.
2. Standard care: routine care. N = 21.**
Outcomes Leaving the study early: lost to treatment.
No other usable data (57% lost to follow-up).
Notes ITT analysis.
* Control group same as Bond-Evansville 91.
Only 21 received treatment (all figures given are for those 21 who received treatment).
** 4 received assistance from a case management program.
Authors have kindly provided further data.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised, no further details.
Allocation concealment
(selection bias)





High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk Lost to follow-up: 57% (24/42 18 months and 50% (21/42) did not receive treat-
ment as planned and no reasons given for missing or lost to follow-up.
Selective reporting (re-
porting bias)
Unclear risk No protocol to compare outcomes reported. In the published auricles, means
and SD were not reported, but were kindly provided by the author.





Design: single-centre (two sites).
Duration: 18 months.
Setting: community centre.
Location: Evansville, Indiana, USA.
Participants Diagnosis: 53% DSM-III-R schizophrenia/schizoaffective disorder with co-occurring substance disorder.
Bond 1991b 
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N = 42.*
Age: 18 - 45 years, mean ˜ 30 years.
Sex: 23 M, 7 F.
Ethnicity: 26 white.
Inclusion criteria: chronic, DSM-III-R or documented evidence of substance abuse / dependence, exten-
sive hospital/crisis service use over previous year.
Interventions 1. Psychosocial intervention: non-integrated ACT with emphasis on replacement activities (e.g. em-
ployment), stressed assistance in medication and money management, applied principles of individu-
alised planning and client choice. N = 21.
2. Standard care: routine care. N = 21.**
Outcomes Leaving the study early: lost to treatment, lost to evaluation.
Unable to use
Substance use: DAPS (adapted version of this scale, not peer-reviewed).
Service use: relapse (hospitalisation) - number of days by 6 months (data skewed), number of days at >
6 months (no SD).
Other: LSC (adapted version of this scale, not peer reviewed scale), medication compliance: > 50% loss.
Notes ITT analysis.
*Only 30 received treatment (all figures given are for those 30 who received treatment).
** 4 received assistance from a case management program.
Control group same as Bond-Anderson 91.
Authors have kindly provided further data.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised, no further details.
Allocation concealment
(selection bias)





High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Lost to follow-up: 33% (14/42) 18 months. No ITT analysis and no reasons giv-
en for missing or lost to follow-up.
Selective reporting (re-
porting bias)
Unclear risk No protocol to compare outcomes reported. In the published auricles, means
and SD were not reported, but were kindly provided by the author.
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Methods Allocation: randomised.
Design: single-centre.
Duration: 12 months (6 months post treatment).
Setting: inpatient and outpatient.
Location: Lausanne Switzerland.
Participants Diagnosis: DSM-IV for schizophrenia, schizoaffective, schizotypal and brief psychotic disorder (n = 57,
92%) and cannabis misuse, 82% (n = 50) met criteria for cannabis dependence.
N = 62.
Age: mean 26.4 years (range 18-35 years).
Sex: 54 M, 8 F.
Ethnicity: not stated.
Inclusion criteria: current cannabis use (current alcohol or other drugs excluded) and good command
of French.
Interventions 1. Psychosocial intervention: MI (individual sessions and optional group sessions for up to 6 months).
N = 30.
2. Standard care: TAU which included case management, early intervention and mobile team when
needed. N = 32.
Outcomes Leaving the study early: lost to treatment, lost to evaluation.
Substance use: change in cannabis use from baseline.
Mental state: PANSS (total, positive, negative symptoms).
Global state: Global Assessment of functioning (GAF)
Social functioning: Social and Occupational Social Functioning Scale (SOFAS)
Service use: Hospital readmissions (12 months).
Unable to use
Substance use: Cannabis and alcohol use (ASI) (skewed data).
Notes Authors have kindly provided further data.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated, blocks of 8.
Allocation concealment
(selection bias)
Unclear risk Numbered sealed envelopes held by administration staI not involved with the






High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Bonsack 2011 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Lost to follow-up: 13% (8/62) 1 year. Used ITT and replaced missing values with
LOCF. Missing values balanced across treatments, however can still have un-
clear risk with imputations.
Selective reporting (re-
porting bias)
Unclear risk Reports fully all outcomes of interest (means, SD and n) mentioned in the
Methods. No protocol.








Location: West Los Angeles county, Ca, USA.
Participants Diagnosis: schizophrenia and or major affective disorder with co-occurring substance disorder.*
N = 276 (132 were included in analysis).
Age: mean ˜ 37 years.
Sex: 232 M, 44 F.
Ethnicity: 58% white.
Inclusion criteria: homeless, substance abuse within past year.
Interventions 1. Psychosocial intervention: integrated mental health and substance use treatment. Residential: ed-
ucational groups, 12-step programmes including AA or NA, discussion groups, individual counselling,
case management, psychiatric consultation, ongoing medication management, general community ac-
tivities. N = 67.
2. Psychosocial intervention: non-residential: above model operating 1-9 PM 5 days/week, more case
management for basic needs. N = 144.**
3. Standard care: routine care with no special intervention but free to access other services (shelters,
mental health clinics, AA groups). N = 65.
Outcomes Leaving the study early: lost to evaluation.
Unable to use
Substance use: level of alcohol in previous 30 days (modified measure used).
Mental state: SCL-90 and PERI ( modified version of scales used).
Homelessness: number of days living in independent housing (data skewed).
Notes ITT analysis.
* Schizophrenia, 6%; major affective disorder, 60%, both 34%.
** Only residential and control group data used. Non residential intervention did not meet a priori cate-
gory.
Authors kindly provided further data.
Participants paid $10 for each assessment interview.
Risk of bias
Burnam 1995 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised, no further description. Assignment to non-residential group was
set at twice that of the other groups requiring a larger sample size.
Allocation concealment
(selection bias)





High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Lost to follow-up: 38% (50/132) 9 months.
No reasons given for dropouts.
Selective reporting (re-
porting bias)
Unclear risk No protocol to compare outcomes reported. In the published articles, means
and SD were not reported, but were kindly provided by the author.







Setting: community and jail.
Location: Alameda county, San Francisco, Ca, USA.




Ethnicity: 66% African American.
Inclusion criteria: current serious mental illness and substance use disorder, US resident, not sen-
tenced to prison, not on parole, not currently enrolled in another program, GAF ≤ 50, English or Spanish
speaking, have at least 2 jail episodes in 2 years prior.
Interventions 1. Psychosocial intervention: integrated mental health and substance use treatment. In custody stan-
dard care + brief aftercare + Integrated Dual Disorders Treatment. Post-custody; MI, substance abuse
counselling, group treatment oriented to both disorder, family psycho-education regarding dual disor-
ders, multidisciplinary team, integrated substance abuse specialists, stage wise interventions, time un-
limited services, outreach etc. N = 103.
2. Standard care: service as usual. In custody standard care + usual post-custody services + 60 days of
post-release case management and housing assistance. N = 79.
Outcomes Leaving the study early: lost to treatment, lost to evaluation.
Unable to use
Global state: forensic measures - arrests, convictions, felonies, jail days, hours of medication services
(data skewed).
Chandler 2006 
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Service use: relapse (hospitalisation) (data skewed).
Notes * Schizophrenia, schizoaffective disorder or psychosis 56%, major depression 26%, bipolar 10%, other
8%.
Not ITT analysis.
Authors have kindly provided further data.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised, computer-generated in blocks of two, then blocks of three.
Allocation concealment
(selection bias)
Low risk Randomisation used an algorithm [template] supplied by the evaluator. A re-
search assistant maintained the data which documented eligibility and ran-






High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Primary outcomes: clinician-/participant-mediated - rating - unclear. Se-
condary outcomes: some clinician-/participant-mediated -rating - unclear.




High risk Lost to follow-up: 37% (68/182) 3 years.
Did not employ direct evaluation of substance use to assess the impact of the
intervention. Unknown attrition rate among controls no interview was con-
ducted leading to high risk of bias.
Selective reporting (re-
porting bias)
Unclear risk Relied on administrative data to analyse results not taking into consideration
moving out of area, recovered or death. Controls had less follow-up time post-
release due to randomisation procedure.





Design: multi-centre (7 sites: 2 urban and 5 rural).
Duration: 36 months.
Setting: community.
Location: New Hampshire, USA.
Participants Diagnosis: 53% DSM-III-R schizophrenia with active DSM-III-R substance use disorder (73% alcohol
abuse, 42% drug abuse).*
N = 223.
Age: 18 - 60 years, mean ˜ 34 years.
Sex: 165 M, 58 F.
Ethnicity: 96% white.
Drake 1998a 
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Inclusion criteria: active DSM-III-R substance use disorder in past 6 months; no other medical condi-
tions or mental retardation.
Interventions 1. Psychosocial intervention: integrated ACT: community-based, high intensity, direct substance
abuse treatment by team members, use of stage-wise dual-disorder model, dual-disorder treatment
groups and exclusive team focus on patients for those with dual disorders. Caseload ˜ 12. N = 109.
2. Standard care: standard case management: community-based, team working with client's support
system and vigorously addressing co-occurring substance use. Caseload ˜ 25. N = 114.
Outcomes Leaving the study early: lost to treatment, lost to evaluation.
Adverse event: death.
Substance use: SATS, Not in remission, progress towards recovery.
Homelessness: number of days living in stable community residences.
Quality of life/life satisfaction: QOLI (General Life Satisfaction Scale).
Unable to use
Substance use: AUS, DUS, no of days when misusing (data skewed).
Mental state: BPRS (data skewed).
Service use: Relapse (hospitalisation) (data skewed).
Quality of life / life satisfaction: QOLI (subscales).
Notes Not ITT analysis.
Authors have kindly provided further data.
*Some participants had more than one dependence.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised. No further details.
Allocation concealment
(selection bias)





High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Primary outcome: clinician-/participant-mediated rating - unclear. Secondary
outcomes: some are clinician-/participant-mediated – rating – unclear. Inter-




Unclear risk Lost to follow-up: 9% (20/223) 3 years.
Number of lost to follow-up is reported, but reasons for missing data are not
reported for each group.
Selective reporting (re-
porting bias)
Unclear risk Pre-specified outcomes of interest are reported. No protocol to compare re-
sults.
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Location: Pittsburgh, PA, USA.
Participants Diagnosis: Schizophrenia, N = 17 or schizoaffective disorder (n = 14) and 29 (94%) with SCID substance
abuse or dependence with moderate to higher addiction severity for cannabis or alcohol on the Addic-
tion Severity Index.
N = 31.
Age: mean 38 years (range 18- 60 years).
Sex: 22 M, 9 F.
Ethnicity: not reported.
Inclusion criteria: patients with schizophrenia and SUD were stable on antipsychotic medication, IQ >
80 and not dependent on cocaine or opioids.
Interventions 1. Psychosocial intervention: routine care plus Cognitive Enhancement Therapy (CET) with individual
and 45 group training sessions in social cognition and 60 hours of computer-assisted training in atten-
tion and problem solving and additional psycho-educational content on substance use. N = 22.
2. Standard care: routine care only, N = 9
Outcomes Leaving the study early: lost to treatment, lost to evaluation.
Substance use: alcohol or cannabis use last 30 days (unable to use analysis due to small participant
number).
Mental State: BPRS, GAF (unable to use, composite scores only).
Notes Trial identifier: NCT01292577.
Participants received payment for research assessments.
Authors have kindly provided further data.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Low risk Assignments were maintained by an independent data manager and con-





High risk Particpants and providers would be aware of the group allocation. It is not
possible to blind a psychosocial intervention.
Eack 2015 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk All assessments were conducted by trained raters and assessors were blind-
ed to treatment allocation. Substance use was by last 30 days recall so was by




High risk Large difference between groups for attrition with CET group = 47% (9/19) and
TAU = 20% (1/9). Although, this is reported in the text as not significantly differ-
ent (P = 0.148).
Selective reporting (re-
porting bias)
Low risk NCT01292577. No indication of selective reporting bias.








Location: Melbourne, Victoria, Australia.
Participants Diagnosis: 72% DSM-IV schizophrenia/schizophreniform, 11% affective psychosis, 17% NOS/delusion-
al /other actively using cannabis.
N = 47.
Age: mean ˜ 21 years.
Sex: 34 M, 13 F.
Ethnicity: not stated.
Inclusion criteria: DSM-IV diagnosis of a psychotic disorder, informed consent for research participa-
tion, adequate English language comprehension and patients continuing to use cannabis at 10 weeks
post-initial clinical stabilisation.
Interventions 1. Psychosocial intervention: cannabis-focused intervention (cannabis and psychosis therapy, CAP)
for individuals with first-episode psychosis. CAP consisted of a cognitive-behavioural-oriented program
delivered in weekly sessions by trained clinicians over 3 months. N = 23.
2. Standard care: involving psycho-education plus standard Early Psychosis Prevention and Interven-
tion Centre (EPPIC) care. EPPIC includes case management, regular psychiatric review and medication,
access to mobile assessment and treatment, family work, group programs, and a prolonged recovery
clinic. N = 24.
Outcomes Leaving the study early: lost to treatment, lost to evaluation.
Substance use: % of patients using cannabis in the last 4 weeks.
Social functioning: SOFAS.
Unable to use
Substance use: RTCQ-C (adapted scale), CASUAS (modified SCAN) (all data skewed).
Mental state: BDI-SF, SANS (all data skewed), BPRS (some data skewed, unvalidated subscales).
Service use: outpatient attendance and medication: SURS (data skewed).
Notes ITT analysis.
Risk of bias
Bias Authors' judgement Support for judgement
Edwards 2006 
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Random sequence genera-
tion (selection bias)
Low risk Randomised codes were computer-generated and placed in sealed envelopes.
Allocation concealment
(selection bias)






High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Lost to follow-up: 30% (14/47) 9 months.
Missing data were handled using LOCF and analyses of cases with complete
data were also undertaken. Due to positive skewness some variables were
transformed (untransformed scores are displayed). The LOCF can still produce
unclear risk of bias effects
Selective reporting (re-
porting bias)
Unclear risk Pre-specified outcomes of interest are reported. No protocol to make judge-
ment on selective reporting.
Other bias Low risk Funded by the Victorian Government Dept of Human Services. No information





Design: multi-centre, 2 urban sites.
Duration: 36 months.
Setting: community (two sites).
Location: Bridgeport and Hartford, Connecticut, USA.
Participants Diagnosis: 76% DSM-III-R schizophrenia, 17% mood disorder with co-occurring DSM-III-R substance use
disorder ( 74% alcohol abuse, 81% other substances).*
N = 198.
Age: mean ˜ 37 years.
Sex: 142 M, 56 F.
Ethnicity: 55%, African American, 27% White, 14% Hispanic, 4% other.
Inclusion criteria: major psychotic disorder and active substance use disorder within past 6 months,
high service use in the past two years, homelessness or unstable housing, poor independent living
skills, no pending legal charges, no medical conditions or mental retardation that would preclude par-
ticipation, if inpatient, discharge scheduled.
Interventions 1. Psychosocial intervention: integrated ACT with a direct substance use component. N = 99.
2. Standard care: standard case management.** N = 99.
Outcomes Leaving the study early: lost to treatment, lost to evaluation.
Adverse event: death.
Service use: relapse (number of patients hospitalised during study).
Global state: GAS (see GAF).
Quality of life/life satisfaction: QOLI (General Life Satisfaction Scale).
Essock 2006 
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Homelessness: number of days living in stable community residences.
Unable to use
Substance use: AUS, DUS, SATS, number of days using in the past 6 months (skewed data).
Mental state: Expanded BPRS Hospitalisation: days in hospital and days in hospital or in jail (skewed
data).
Notes Not ITT analysis.
* Some participants had more than one dependence.
*Participants paid US $15 for each interview and additional $5 for each urine and saliva sample.
** Refer to correspondence regarding clinical case management team (Kanter 2006).
Authors kindly provided additional data.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Lost to follow-up: 14% (27/198) 3 years.
Insufficient reporting of missing data (numbers and reasons for missing data
are reported for the total sample, not for each intervention group). Seven ran-
domised participants were lost for administrative reasons, but their interven-
tion allocation was not reported.
Selective reporting (re-
porting bias)
Unclear risk Listed outcomes of interest are fully reported for each site, one site had better
outcomes than the other. Author provided further data of combined sites for
each treatment.




Methods Allocation: part randomised within larger study.
Design: multi-centre (6 sites, 4 sites not randomised).
Duration: 24 months.
Setting: community (6 sites, 4 sites not randomised).
Location: Illinois, USA.
Godley 1994 
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Participants Diagnosis: DSM-III R major psychiatric and substance abuse/dependence disorder.
N = 97 (2 randomised sites).
Age: mean ˜ 35 years.
Sex: 77 M, 20 F.
Ethnicity: white 38%, Hispanic 38%, other 24%.
Inclusion criteria: DSM-III R major psychiatric and substance abuse/dependence disorder.
Interventions 1. Psychosocial intervention: specialised case management services for mentally ill substance
abusers (N = 52).
2. Standard care: standard care (N = 45).
Outcomes No usable data*:
Substance use: drug and alcohol questionnaire (unpublished scale).
Global state: Area of Difficulty Checklist (unpublished scale), Vocational Outcomes Form (adapted
scale), GAF (data not reported).
Homelessness: number of state-operated facility admissions, number of state-operated facility days,
and average length of stay (data skewed).
Notes Not ITT analysis.
*No usable data, only skewed data reported for the 2 randomised sites.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No description of the process.
Allocation concealment
(selection bias)





High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk Lost to follow-up: 37% (36/97) 1 year, >51% at 18 and 24 months for ran-
domised groups.
Insufficient reporting of missing data (numbers and reasons for missing data
are reported not for each intervention group).
Selective reporting (re-
porting bias)
High risk Results are presented for each site, not combined for each treatment. Com-
bined data from randomised and non-randomised sites. Unusable.
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Duration: follow-up at 3, 6 and 12 months.
Setting: inpatient and outpatient.
Location: Cologne, Germany.




Sex: 84 M, 16 F.
Ethnicity: not reported.
Inclusion criteria: voluntary inpatients with schizophrenia and substance misuse or dependence
Interventions 1. Psychosocial intervention: integrated treatment, 6- minute group therapy sessions once per week
stating in hospital and continued as outpatient with extra 90-minute sessions in manual based CBT
plus psycho-education of substance use. N = 50. Duration of treatment was not set
2. Standard care: TAU. N = 50.
Outcomes Leaving the study early: lost to treatment, lost to evaluation.
Global state: GAF
Unable to use (Skewed data)
Substance use: use of cannabis and alcohol in previous month (T1-T3) (3, 6 months); abstinent or
change in intensity of the main substance use (non-standard, self-rating with small samples sizes)
Mental State: PANSS (total)
Service use: relapse (readmission to hospital (number of re-admissions)) (skewed data)
Quality of life/life satisfaction: Satisfaction questionnaire was not standardised.
Notes Trial identifier: U1111-1119-5851
ITT analysis (LOCF)
T3 (12-month) outcome had high attrition rate (> 50%), not used in mean difference analyses
Authors have kindly provided further data.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Envelopes prepared with papers with sequential numbers and placed in box
and shaken before pulled out alternately to create two groups.
Allocation concealment
(selection bias)
Low risk Researcher not involved in the trial prepared sealed envelopes with group allo-





High risk Participants and providers would be aware of assignment given it was ward-
dependent. It is not possible to blind a psychosocial intervention.
Gouzoulis-Mayfrank 2015  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk This was based on self-report of use in past 30 days. Urine samples were done




High risk This was > 50% at 12 months and close to 50% at 3 months (although similar
between groups). LOCF may not be best use over time
Selective reporting (re-
porting bias)
Unclear risk The article reports on the same outcomes as on the registry DRKS 00000671.
However, the authors state that the primary outcome was measured using
multimodal parameters including urine samples. However, these do not ap-
pear to be incorporated into the final outcome which measured % change in
abstinence based on days of use pre month x mean daily dose (this is assumed
to be self-report). We would expect that the urine results should be reported in
the article.




Methods Allocation: randomised (in a yoked fashion).
Design: single-centre.
Duration: 6 months.
Setting: VA medical centre.
Location: Albuquerque, New Mexico, USA.
Participants Diagnosis: 100% DSM-IV schizophrenia and met criteria for an alcohol use disorder within the 3-month
period prior to study enrolment; patients with additional non-alcohol substance use (except active in-
travenous drug abuse) were eligible for protocol enrolment.
N = 30.
Age: mean ˜ 42.87 years.
Sex: 29 M, 1 F.
Ethnicity: 40% White, 40% Hispanic, 20%, African American.
Inclusion criteria: as above.
Interventions 1. Psychosocial intervention: three-session MI intervention, focused on personal choice and responsi-
bility and de-emphasised labelling, with the therapist assuming a directive and client-centred style. N =
15.
2. Standard care: three-session Educational Treatment - didactic, focused on the material being deliv-
ered with the therapist assuming a directive interpersonal style. N = 15.
Outcomes Leaving the study early: lost to evaluation.
Substance use: abstinence rates.
Unable to use
Substance use: BDP (data skewed).
Notes Not ITT analysis.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised in a yoked fashion, no further details.
Graeber 2003 
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Allocation concealment
(selection bias)





High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Lost to follow-up: 7% (2/30) 6 months. No missing data for primary outcome.
Selective reporting (re-
porting bias)
Unclear risk Pilot study, no protocol to make judgement on selective reporting.
Other bias Low risk No evidence other bias are occurring. With only two therapists, each nested






Design: Single National Health Service (NHS) Trust.
Duration: 2-week intervention with 3-month follow-up.
Setting: inpatient and community.
Location: Birmingham and West Midlands, UK.
Participants Diagnosis: ICD-10 Schizophrenia (n = 36), Schizoaffective (N = 5), Bipolar disorder (N = 17) psychosis (N




Sex: 50 M 9 F.
Ethnicity: Caucasian (48%), Asian (17%), Black (25%), mixed (10%)
Inclusion criteria: New admissions with DSM or ICD diagnosis of psychosis and DSM substance related
disorder over the last 6 months.
Interventions 1. Psychosocial intervention: Brief integrated MI consisting of 4-6 (15-30 minute) sessions over 2
weeks. N = 30.
2. Standard care: TAU. N = 29.
Outcomes Leaving the study early: lost to evaluation.
Substance use: number of substances used last 30 days (none vs. one or more).
Graham 2016 
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engagement Substance Abuse Treatment Scale (SATs).
Unable to use
Substance use: number of days substances used and severity of substance use, AUDIT, SDS (skewed
data)
Mental State: HADS (skewed data)
Notes Trial identifier: ISRCTN43548483
Funded by Institute for Health Research
Authors have kindly provided further data.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Reported as 'randomisation'. Authors confirmed randomised via computer
(string was derived in Stats Direct Software)
Allocation concealment
(selection bias)
Low risk Stated as "central" and by email which implies a separation between the allo-
cation sequence and the person who is allocating the patient (The researcher





High risk Participants and providers would be aware of what types of intervention they
received. It is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk The primary outcome was based on 'observable behaviours' using the Sub-
stance Addiction Treatment Scale (SATS) reported by the primary clinician.
The trial is reported as 'independent rater blinded' but it would seem likely
that the primary clinician would be aware of the allocation as it was likely to




Low risk 2% (1/59) at 3 months. Raw SATS data (primary outcome) for each group were
provided by the author.
Selective reporting (re-
porting bias)
Low risk Report outcomes compare well to protocol registered on ISRCTN 43548483







Setting: community, outpatient; Beth Israel Medical Center.
Location: New York, NY, USA.
Participants Diagnosis: RDC schizophrenia with 74% DSM-III-R psychoactive substance abuse/dependence.
N = 47.
Age: 18-50 years, mean ˜ 32 years.
Hellerstein 1995 
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Sex: 36 M, 11 F.
Ethnicity: 43% African American, 32% Hispanic.
Inclusion criteria: psychoactive substance abuse/dependence, desire for substance abuse treatment,
no life-threatening medical illness or need for long-term hospitalisation.
Interventions 1. Psychosocial intervention: skills training - group outpatient psychotherapy and psycho-education
plus drug treatment all at same site, twice weekly. N = 23.
2. Standard care: comparable levels of psychiatric care and substance abuse treatment from separate
sites without formal case co-ordination. N = 24.
Outcomes Leaving the study early: lost to treatment.
Unable to use
Substance use: ASI-drug (change data).
Mental state: ASI-psychiatric (change data).
Service use: relapse (days in hospital) (data skewed).
Notes ITT analysis.
Further data collected and mentioned in 2001 paper.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised, no further details.
Allocation concealment
(selection bias)





High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk Lost to follow-up: 47% (22/47) 4 months, 64% (30/47) 8 months.




Unclear risk Raw means were not reported for primary outcome, only change from baseline
scores.
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Location: Indiana University, In, USA.
Participants Diagnosis: 80% DSM -IV schizophrenia or schizoaffective disorder with co-occurring substance disorder.
N = 30.
Age: mean ˜ 37 years.
Sex: 26 M, 4 F.
Ethnicity: 97% white.
Inclusion criteria: recent alcohol abuse, leading to need for treatment.
Interventions 1. Psychosocial intervention: routine care (see below) plus a brief MI, structured one-time presenta-
tion of personal feedback on alcohol intake. N = 15.
2. Standard care: routine care alone (involving pharmacotherapy, case management services, sub-
stance abuse treatment groups). N = 15.
Outcomes Leaving the study early: lost to evaluation.
Mental state: SCL-90-R.
Unable to use
Substance use: self-report alcohol volume in prior 3 months, AUI subscale (data skewed).
Notes ITT analysis.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No details. Randomised from the group of people attending relevant treat-
ment programs at the time the experiment was conducted.
Allocation concealment
(selection bias)
High risk No details provided. Comment: "Procedure selection was modified to allow






High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Lost to follow-up: 0% (0/30) 3 months. No missing outcome data.
Selective reporting (re-
porting bias)
Unclear risk PhD thesis, study did not undergo peer review via publication. No protocol to
make judgement on selective reporting.






Duration: 10 months: 6 months treatment, 4-month follow-up.
Setting: Hospital, community and early intervention services.
Hjorthoj 2013 
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Location: Copenhagen, Denmark.
Participants Diagnosis: ICD-10 schizophrenia spectrum psychosis (F2) and ICD-10 cannabis use disorder.
N = 103.
Age: mean ˜ 21 years (range 17-42).
Sex: 78 M, 25 F.
Ethnicity: Not stated.
Inclusion criteria: cannabis use, those dependent on alcohol, opioids or cocaine were excluded.
Interventions 1. Psychosocial intervention: CBT + MI, CapOpus consisted of individual and group based motivation-
al interviewing and CBT with 24 sessions, 1-2 weekly over 6 months and incorporates both family and
case manager. N = 52.
2. Standard care: TAU. N = 51.
Outcomes Leaving the study early: lost to treatment, lost to evaluation.
Substance use: number of cannabis-using days in the past month.
Quality of life/life satisfaction: Client satisfaction (CSQ).
Unable to use
Substance use: days cannabis use, joints/30 days (skewed data).
Mental state: PANSS 6 months and 10 months (data skewed).
Notes ITT analysis, missing data were estimated for each analysis using log-linear replacement.
Authors kindly provided additional data.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk computer-generated random sequence stratified by cannabis use per day
and type of TAU (some had case management or ACT depending on referral
source), block size varied between 6, 8 and 10.
Allocation concealment
(selection bias)
Low risk Researcher not involved in the study generated the sequence, was known only





High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Lost to follow-up: 34% (35/103) 10 months. Detailed flow chart provided, rea-
sons for missing values are provided for each group. Full ITT analysis provided




Low risk Outcomes fully reported and were not different to trial protocol.
Other bias Low risk No evidence other bias occurring.
Hjorthoj 2013  (Continued)
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Design: multi-centre (2 sites, see Jerrell-Calif 95b).
Duration: 18 months.
Setting: community.
Location: South Carolina, USA.
Participants Diagnosis: 62% DSM-III-R schizophrenia with co-occurring substance disorder.
N = 47.
Age: 18-59 years, mean ˜ 34 years.
Sex: 33 M, 14 F.
Ethnicity: 64% white.
Inclusion criteria: substance abuse disorder, previous inpatient or residential psychiatric treatment,
plus either poor work/life skill history last 2 years, history of intervention by mental health authorities
or police for inappropriate social behaviour.
Interventions 1. Psychosocial intervention: behavioural skills programme: psycho-educational approach with self-
management skills, repeated practice and reinforcement. Weekly group sessions with two licensed
clinicians. N = 22.
2. Standard care: TAU plus 12-step recovery programme: clinical staI (some 'recoverers') offered
mock AA meetings within the Mental Health Centre, took or referred clients to community AA meetings,
facilitated a sponsor relationship and provided counselling. N = 25.
Outcomes Leaving the study early: lost to treatment.
Social functioning: RFS (SAS-SMI) Social Adjustment Scale.
Unable to use
Substance use: C-DIS-R (data skewed and no author analysis of randomised cohort).
Mental state: C-DIS-R (data skewed and no author analysis of randomised cohort).
Social functioning: SLS (not peer-reviewed scale).
Notes Part ITT analysis.
Data reported are for randomised cohort only - kindly supplied by the authors.
Control group same as Jerrell-Calif 95b.
Participants paid for each assessment interview.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised (using the urn method) balanced for age, ethnicity, diagnosis,
substance use severity and level of psychiatric functioning. Non-randomised








High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
Unclear risk Unclear if raters were blind to allocation.
Jerrell 1995a 
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High risk Lost to follow-up: 47% (22/47) 18 months. No ITT analysis with missing values
imputed. No reasons given for lost to evaluation.
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement of 'yes' or 'no' as no protocol was
available.








Location: South Carolina, USA.
Participants Diagnosis: 72% DSM-III-R schizophrenia with co-occurring substance disorder.
N = 50.
Age: 18-59 years, mean ˜ 33 years.
Sex: 38 M, 12 F.
Ethnicity: 66% white.
Inclusion criteria: substance abuse disorder, previous inpatient or residential psychiatric treatment,
plus either poor work/life skill history last 2 years, history of intervention by mental health authority or
police for inappropriate social behaviour.
Interventions 1. Psychosocial intervention: routine care plus intensive case management: intensive assistance with
housing, daily living, legal problems, money management, personal relationships and leisure activities.
N = 25.
2. Standard care: routine care plus 12-step recovery programme: clinical staI (some 'recoverers') of-
fered mock AA meetings within the Mental Health Centre, took or referred clients to community AA
meetings, facilitated a sponsor relationship and provided counselling. N = 25.
Outcomes Leaving the study early: lost to treatment, lost to evaluation.
Social functioning: RFS SAS-SMI Social Adjustment Scale.
Unable to use
Substance use: C-DIS-R (data skewed and no author analysis of randomised cohort).
Mental state: C-DIS-R (data skewed and no author analysis of randomised cohort).
Social functioning: SLS (not peer-reviewed scale).
Notes Part ITT analysis.
Data reported are for randomised cohort only - kindly supplied by the authors.
Control group same as Jerrell-Calif 95a.
Participants paid for each assessment interview.
Risk of bias
Bias Authors' judgement Support for judgement
Jerrell 1995b 
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Random sequence genera-
tion (selection bias)
Low risk Randomised (using the urn method) balanced for age, ethnicity, diagnosis,
substance use severity and level of psychiatric functioning. Non-randomised








High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk Lost to follow-up: 42% (21/50) 18 months.




Unclear risk Insufficient information to permit judgement of 'yes' or 'no' as no protocol was
available.





Design: single-centre (3 hospital sites, Royal Brisbane, Logan or Wolston Park).
Duration: 12 months.
Setting: hospital and community.
Location: Brisbane, Qld, Australia.
Participants Diagnosis: 100% DSM-IV psychotic disorder with a current DSM-IV substance use disorder (88% alcohol,
76% cannabis, 12% inhalants, 8% cocaine or heroin).
N = 25.
Age: 17-31 years, mean: 23 years.
Sex: 15 M, 10 F.
Ethnicity: 84% Anglo-Saxon.
Inclusion criteria: 16-35 years, consensus diagnosis of a DSM-IV psychotic disorder; a current DSM-IV
substance use disorder; < 3 years since the first psychotic episode, less than 3 previous episodes of psy-
chosis, able to converse in English without an interpreter, no diagnosis of developmental disability or
amnesic disorder, not currently receiving other treatment for substance abuse, and, not currently tak-
ing heroin or methadone.
Interventions 1. Psychosocial intervention: routine care plus Start Over and Survive (SOS). Brief motivational in-
tervention comprising 3 hours of individual treatment over 6-9 sessions usually completed within 7-10
days as an inpatient. N = 13.
2. Standard care: comprised pharmacotherapy, access to in-patient programmes and aftercare involv-
ing either case management or general practice consultations. N = 12.
Outcomes Leaving the study early: lost to evaluation.
Substance use: number of participants abstinent or improved on all substances at 12 months.
Kavanagh 2004 
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Notes ITT analysis.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Permutations table for each site.
Allocation concealment
(selection bias)





High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Lost to follow-up: 32% (8/25) 1 year.
One SC participant had baseline data carried forward as missing data at 3, 6,
and 12 month follow-ups.
Selective reporting (re-
porting bias)
Unclear risk Pilot study, no protocol. Five SOS participants did not proceed beyond initial
rapport building stage so two analyses were done; one with all SOS subjects
(n=13) and another one including SOS treated (n=8)







Setting: community based early intervention programme.
Location: Western Sydney, NSW, Australia.
Participants Diagnosis: DSM-IV psychotic illness and current alcohol or cannabis use based on AUDIT or DAST
scores.
N = 19.
Age: mean ˜ 21 years, range 17-25 years.
Sex: 13 M, 3 F (3, Unknown).
Ethnicity: not stated.
Inclusion criteria: young English speaking, living within the area health sector and not homeless.
Interventions 1. Psychosocial intervention: MI + CBT, Stop using stuI (SUS) manualised 4-6 hours. N = 10.
2. Standard care: TAU, standard care included case management and has a significant focus on sub-
stance reduction. N = 9.
Outcomes Leaving the study early: lost to evaluation.
Kemp 2007 
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Mental state: PANSS total.
Unable to use
Mental State: DASS (some data skewed).
Substance use: AUDIT, DAST-10 frequency and quantity of cannabis or alcohol use (skewed data).
Notes Authors have kindly provided additional data.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised, cards were shuffled, numbered and placed in sealed envelopes.
Allocation concealment
(selection bias)
Unclear risk Numbered sealed envelopes with the allocation placed into a box by a third
person. Envelopes were then drawn in order from the box each time a patient





High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Measures that were clinician-rated were all performed by the clinician provid-




Unclear risk Lost to follow-up: 16% (3/19) 6 months. Three patients dropped out of the TAU
group, no explanation was given. No ITT analysis.
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement of 'yes' or 'no' as no protocol was
available.
Other bias Unclear risk Had extreme baseline imbalance in substance use (AUDIT), DASS and self-effi-








Location: Baltimore, Md, USA.
Participants Diagnosis: 67% DSM-III-R schizophrenia /schizoaffective disorder with co-occurring substance disorder.
N = 29.*
Age: 18-40 years, mean ˜ 31 years.
Sex: 22 M, 7 F.
Ethnicity: 70% Afro-American.
Inclusion criteria: current substance abuse or dependence disorder.
Lehman 1993 
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Interventions 1. Psychosocial intervention: routine care plus intensive case management: educational group ses-
sions on substance abuse/mental illness (5 hours per week), experiential "rap" session, on-site self-
help group, oI-site self-help group (AA/NA), social activities. 1:15 staI-patient ratio. N = 14.
2. Standard care: CMHC-based, psychosocial rehabilitation services, routine outpatient services, sup-
ported housing if needed, no organised substance abuse treatment. 1:25 staI-patient ratio. N = 15.
Outcomes Leaving the study early: lost to evaluation.
Unable to use
Lost to treatment: data reporting unclear.
Substance use: ASI-alcohol, ASI-drug (data skewed).
Mental state: ASI-psychiatric (data skewed).
Relapse: days in hospital (data skewed).
Other: QOLI (Life satisfaction) (all data skewed).
Notes ITT analysis.
* Data reported in this review are based only on those who had current (past 30 days) substance use
disorders (29 out of 54).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised using the urn method. No further details.
Allocation concealment
(selection bias)





High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Lost to follow-up: 0% (0/29) 1 year. No missing outcome data.
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement of 'yes' or 'no' as no protocol was
available.





Design: single-centre (3 sites).
Duration: 12 months.
Setting: inpatients and community.
Location: Dublin, Ireland.
Madigan 2013 
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Participants Diagnosis: DSM-IV diagnosis of psychosis (schizophrenia, n = 38; other psychosis, n = 30) major depres-
sion (n = 6) and bipolar disorder (n = 14) and DSM-IV current cannabis dependence.
N = 88.
Age: mean ˜ 28 years.
Sex: 69 M, 19 F.
Ethnicity: Not stated (homogenous group).
Inclusion criteria: without learning disability or organic brain damage.
Interventions 1. Psychosocial intervention: CBT + MI group sessions once per week for 12 weeks and invited back 6
weeks later (week 18) for a booster session. Interventions were held in community setting. N = 59.*
2. Standard care: TAU included care from multi-disciplinary team, 5 patients had counselling for opi-
ate more than one year prior to the present trial. N = 29.
Outcomes Leaving the study early: lost to treatment (3 months), lost to evaluation (9 months).
Substance use: frequency of cannabis use last 30 days.
Global state: GAF global functioning.
Quality of life/life satisfaction: subjective quality of life (WHOQOL, BREF).
Unable to use
Mental State: SANS. SAPS (positive, negative), Calgary Depression Scale for Schizophrenia (skewed da-
ta).
Notes * Note: 2:1 randomisation to CBT/MI arm.
A token voucher was given to participants to cover costs of attendance of assessments.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated, block randomised, 2:1 (CBT/MI:TAU) ratio.
Allocation concealment
(selection bias)
Unclear risk Randomisation was conducted by a researcher uninvolved in the provision or
assessment of interventions. Concealment not described in sufficient detail to





High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Lost to follow-up: 42% (37/88) 1 year.
Similar reasons for missing data across groups. Missing values were not imput-
ed for ITT analysis.
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement of 'yes' or 'no' as no protocol was
available.
Madigan 2013  (Continued)
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Design: single-centre (9 jails operated by LA county Sheriff's Dept).
Duration: 30 months.
Setting: jail and community.
Location: Los Angeles, Ca, USA.
Participants Diagnosis: assessed by the MINI Plus 46% bipolar disorders, 27% psychotic disorders, 21.5% depres-
sive disorders, 6% other with co-occurring substance disorder. Primary substance use diagnoses as as-
sessed by the CASAD, were: 51.8% cocaine dependence/abuse, 18.5% alcohol dependence/abuse, 4.4%
opoid dependence, and 3.7% other.
N = 135.
Age: mean ˜ 36 years.
Sex: 135 F.
Ethnicity: 51% Black, 33% non-Hispanic White, 12% Hispanic.
Inclusion criteria: inmates who had a major Axis 1 mental illness and co-occurring substance use disor-
der, age 18-50, history of at least 2 arrests, homeless or at risk of homelessness.
Interventions 1. Psychosocial intervention: (CBT + psychosocial rehabilitation) - the Intensive Jail (IJ) group re-
ceived a minimum of 3 weeks of specialised treatment during their qualifying incarceration. Housed in
a mental observation dormitory, IJ was a hybrid of psychosocial rehabilitation, cognitive-behavioural,
and harm-reduction approaches. Individual supportive counselling twice per week, crisis intervention
services and a series of 12 to 15 one-hour groups per week. Groups included 12-step sobriety mainte-
nance, relapse prevention, symptom and medication management, crime prevention, parenting, and
independent living. N = 18.
2. Psychosocial intervention: the Intensive Community Treatment (ICM). ICM treatment approach
provided intensive case management. Transition planning, which began while participants were still in
custody and continued after release, consisted of housing placement, pursuit of public entitlements,
linkage to psychiatric care, and transportation to pharmacy and residential placement post-release. In
addition, on-going consultations to ensure continuity of care, and interventions aimed at substance re-
covery maintenance, relapse prevention, psychiatric stability and reduction of re-arrests were provid-
ed. IC treatment was carried out in conjunction with a number of community agencies, including those
specializing in dual recovery, rehabilitation, housing, entitlement benefits, and childcare and parenting
etc. N = 58.
3. Psychosocial intervention: (CBT + ICM) - Combined treatment (COB) group received both intensive
jail and intensive community interventions as described above. N = 16.
4. Standard care: included psychiatric medication evaluation and follow-up, recreation therapy and
stress management groups, parenting classes, drug education, academic education and religious ser-
vices. N = 43.
Outcomes No usable data*:
Leaving the study early: lost to treatment, lost to evaluation (no breakdown by IJ, IC, COB treatment
arms).
Global state: forensic measures - number of arrests and convictions for new offences, number of days
in jail (skewed data), severity of offence (no data provided).
Notes Not ITT analysis.
* No usable data, only skewed data reported.
Risk of bias
Bias Authors' judgement Support for judgement
Maloney 2006 
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Random sequence genera-
tion (selection bias)
Unclear risk Randomised, computer-generated procedure with no matching proce-
dures. Participants were randomly assigned to one of four groups. Group sizes
were not equivalent due to early jail releases, which necessitated the dis-
continuation of new participants being randomly assigned to the treatment
groups after May 2003.
Allocation concealment
(selection bias)
High risk Randomisation and participants’ assignment to treatment groups were imple-





High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes





High risk Lost to follow-up: 14% (19/135) 30 months. No ITT analysis. Due to early jail
releases there was unequal discontinuation of new participants randomly as-
signed to the treatment groups after May 2003. These participants were not in-
cluded in the analysis.
Selective reporting (re-
porting bias)
High risk No usable data, many of the outcomes reported for site, not by treatment arm.








Location: Seattle, Washington, USA.
Participants Diagnosis: Schizophrenia spectrum (n = 69, 39%), bipolar disorder (n = 60, 34%) and major depression
(n = 47, 27%) and dependence on stimulants (cocaine, amphetamine, methamphetamine).
N = 176.
Age: mean 43 years.
Sex: 115 M, 61 F.
Ethnicity: 54% White, 30% Africian American, 16% other.
Inclusion criteria: used stimulants in the last 30 days. Exclusion criteria were organic brain disorder, de-
mentia or medical disorders or psychiatric symptoms severe enough to compromise safe participation.
Patients were excluded if current participation in methadone maintenance.
Interventions 1. Psychosocial intervention: Contingency Management (CM) for 3 months with urine submission for
3 months. Negative urine results reinforced with selecting prizes or varying value (given a message of
“well done” with no financial reward, or with a financial reward of 1 dollar, $20, or $80). A positive urine
was not reinforced with a chance for a selecting a prize. N = 91.
2. Standard care: TAU plus submission of urine for 3 months but received the reinforcement their
"yoked" partner in the active arm received, i.e., they were non-contingently reinforced.
Outcomes Leavind the study early: lost to treatment, lost to evaluation.*
McDonell 2013 
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Substance use: stimulant-negative urine test, (3 and 6 months), injection drug use (3 and 6 months).
Service use: hospitalised (6 months after randomisation).
Unable to use
Substance use: stimulant use days, alcohol use days (skewed data).
Mental state: Brief Symptoms Inventory (data skewed), PANSS excitement subscore (data skewed).
Notes Authors kindly provided additional data and comments on the randomisation procedure.
* There was a high attrition rate (see attrition bias) with imputed values for ITT analysis.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised using an urn randomised procedure balancing groups on gen-
der, substance use severity, mood vs psychotic disorder and psychiatric hos-
pitalisation in the past year. Further correspondence verified a computer pro-
gramme was used for randomisation.
Allocation concealment
(selection bias)
Unclear risk Researcher not involved in the study generated the sequence. No further de-





High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Primary outcome was urinalysis results so the review authors judge that this





Unclear risk Lost to follow-up: 28% (49/176) completed at least one assessment by 6
months.
Only 42% (n = 38) completed 12 weeks of CM and 65% (n = 55) completed TAU.
Imputed values were used for missing data.
Selective reporting (re-
porting bias)
Low risk The study protocol (NCT00809770) is available and all of the study's specified
(primary and secondary) outcomes that are of interest in the review have been
reported.
Other bias Low risk Five patients were forced into CM (to start yoking procedure) and two were ad-






Duration: 7 months (1 month induction, 3 months treatment, 3 month follow-up).
Setting: outpatients and community.
Location: Seattle, WA, USA.
McDonell 2017 
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Participants Diagnosis: serious mental illness DSM-IV-TR (schizophrenia, N = 24; bipolar, N = 29 and major depres-
sion, N = 26) and alcohol dependence.
N = 79.
Age: 45 years.
Sex: 50 M, 29 F.
Ethnicity: Caucasian (N = 44) African American (N = 23), other (N = 12).
Inclusion criteria: Alcohol use on > 4 days of the last 30 and enrolment in outpatient addiction group
treatment; those with comorbid drug dependence were excluded. There was a 4 week induction period
to increase retention.
Interventions 1. Psychosocial intervention: Contingency management (CM, 12 weeks) with three urine samples per
week reinforced with selecting prizes for varying magnitudes of reinforcement for testing negative for
alcohol, attending treatment sessions or refraining from alcohol use for one week. Prizes ranged from
zero value (“good job”), small ($1), large ($20) and jumbo ($80). N = 40.
2. Standard care: TAU in addition to 12 weeks of psycho-education and non-non contingent reinforce-
ment of submitted urine samples or treatment attendance. N = 39.
Outcomes Leaving the study early: lost to treatment, lost to evaluation
Unable to use
Substance use: negative urine sample tests of alcohol, self-reported alcohol use (skewed data)
Mental State: PANSS. BSI (Brief Symptom Inventory)(omnibus data provided by author not broken
down by treatment group)
Notes Trial identifier: NCT01567943
Patients received $20-30 for interviews. Funded by NIAAA, USA
Authors have kindly provided further data
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Urn-randomisation procedure generated by computer (author's note)
Allocation concealment
(selection bias)






High risk Participants and providers were aware of the group into which they were allo-
cated and the consequence of their actions on the contingency management.
It is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Urine samples were taken so the outcome was blinded. PANSS raters were not




Unclear risk Lost to follow-up: 10/40 (25%) CM arm and 9/39 (23%) in non-CM arm at 3
months. Attrition of primary outcome (alcohol abstinence based on urine test)
in first 12 weeks was 14/40 (35%) CM and 10/39 (26%) in non-CM arm as they
McDonell 2017  (Continued)
Psychosocial interventions for people with both severe mental illness and substance misuse (Review)









Cochrane Database of Systematic Reviews
missed at least 3 weeks (9 consecutive visits). ITT analysis used but may intro-
duce its own bias.
Selective reporting (re-
porting bias)
Low risk The protocol matches the report NCT01567943 [secondary outcomes are not
reported in terms of magnitude and direction, but only based on significance]
Other bias Low risk Funding was from the National Institute on Alcohol Abuse and Alcoholism and









Location: St. Louis, Mo, USA.
Participants Diagnosis: DSM-IV 48% schizophrenia, 19% schizoaffective disorder, 11% atypical psychotic disorder,
11% bipolar disorder, 9% major depression-recurrent disorder, 2% other. All had one or more sub-
stance use disorders; 46% substance dependence disorder for alcohol and/or drugs; 64% substance
abuse disorder for alcohol and/or drugs, 40% an alcohol-only diagnosis, 18% drug-only diagnosis, 42%
had both drug and alcohol disorders - cocaine most frequently used drug (34%) cannabis (19%).**
N = 196.*
Age: 18 - 66 years, mean ˜ 40 years.
Sex: 119 M, 30 F.
Ethnicity: 73% Afro-American, 25% Caucasian, 2% other.
Inclusion criteria: homeless, severe mental illness, DSM-IV substance use disorder, and not currently
enrolled in an intensive case management program.
Interventions 1. Psychosocial intervention: Integrated Assertive Community Treatment. N = 46.
2. Psychosocial intervention: Assertive Community Treatment Team only (ACTO). Referred clients
to other community providers for outpatient or individual substance abuse services and to 12-step
groups. N = 54.
3. Standard care: routine care, provided with a list of community agencies (mental health and sub-
stance abuse treatment) and staI provided linkage assistance to facilitate access. N = 49.
Outcomes Unable to use***
Leaving the study early: lost to treatment, lost to evaluation (not reported by group).
Substance use: USS (data skewed), number of days using substances (unclear measure).
Mental state: BPRS (averaged item scores reported, not totals).
Homelessness: number of days in stable housing (data skewed), client satisfaction (not peer-reviewed
scale).
Notes Not ITT analysis.
* Figures are based on the 149 who received treatment.
** Participants paid USD $5 for short and $10 for long interview.
*** No usable data, only skewed data reported.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised (no further description).
Morse 2006 
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Allocation concealment
(selection bias)





High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Lost to follow-up: 24% (47/196) 2 years. Full ITT analysis not reported.
Selective reporting (re-
porting bias)
High risk Lost to treatment and evaluation not reported by group. No usable data, only
skewed data are reported.





Design: multi-centre (6 sites, Belfast, Glasgow, Hackney, Newcastle, Southhampton and Swansea).
Duration: 3 months.
Setting: inpatients and community.
Location: Southhampton and Newcastle-upon-Tyne, UK.
Participants Diagnosis: 100% ICD-10 schizophrenia with co-occurring mild to moderate substance abuse according
to HoNOS Item 3* (alcohol 74%, drug use problem 26%**).
N = 105.
Age: 18 - 65 years.
Sex: 87 M, 18 F.
Ethnicity: 90% Caucasian.
Inclusion criteria: patients with schizophrenia, age 18-65 years; receiving treatment within mental
health services.
Interventions 1. Psychosocial intervention: CBT plus psycho-education: 6 sessions over 3 months and carers offered
3 sessions along with carer-oriented information. N = 67.***
2. Standard care: Routine care. N = 38.
Outcomes Leaving the study early: lost to treatment.
Mental state: Insight Scale.
Unable to use
Substance use: HoNOS item 3 (data skewed).
Mental state: BSA, SCR, CPRS, MADRS (all data skewed).
Other: HoNOS - general functioning (data skewed).
Notes ITT analysis.
*Patients were excluded if they met a diagnosis of drug or substance misuse dependence.
**Based on those participants who provided details (n = 70/105).
***There was a 2:1 ratio to include more participants into the CBT arm.
Naeem 2005 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised; random numbers computer-generated/sealed envelopes strati-
fied by site. Ratio of 2:1 for CBT:TAU.
Allocation concealment
(selection bias)
Unclear risk Sealed envelopes opened at the time of treatment allocation. Unclear if en-





High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Lost to follow-up: 14% (15/105) at 3 months.
No reasons are given for withdrawals; 10 participants dropped out of treat-
ment versus 5 participants from TAU. Missing values were imputed for full ITT
analysis but can have unclear bias effects.
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement of 'yes' or 'no' as no protocol was
available.





Design: single-centre (3 remote settings).
Duration: 18 months.
Setting: community.
Location: Northern Territory, Australia.
Participants Diagnosis: DSM-IV schizophrenia (39%, n = 19), major depression (45%, n = 22), substance-induced psy-
chosis (10%, n = 50 and bipolar disorder (6%, n = 30 and substance use (alcohol and cannabis) with psy-
chological dependence.
N = 49.*
Age: mean ˜ 21 years.
Sex: 28 M, 21 F.
Ethnicity: Indigenous Aboriginal.
Inclusion criteria: current patients with chronic mental illness attending a community health centre
were recruited as well as their carers. Patients with organic mental illness, intellectual disability, and
age less than 18 were excluded.
Interventions 1. Psychosocial intervention: MI (early intervention group), two brief sessions (1 hr) spaced 2-6 weeks
apart. Session two involved carers and 2 psycho-education videos presented. Followed up at 6, 12 and
18 months. N = 24.
2. Standard care: TAU, (late intervention group) had treatment (MI) after the 6 month assessment (T1)
and then followed up at 12 months (T2, 6 months F/up) and 18 months (T3, 1 yr). N = 25.
Nagel 2009 
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Outcomes Leaving the study early: lost to evaluation (6 months).
Adverse event: death (all causes).
Unable to use
Mental state: HoNOS, LSP-16, K-10 (no SD, n).
Substance use: SDS alcohol, cannabis (no means, SD, n).
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Block randomisation, random number sequence. No further details provided.
Allocation concealment
(selection bias)





High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Lost to follow-up: 29% (14/49) 18 months. Full ITT was conducted but this can
still have unclear bias effects.
Selective reporting (re-
porting bias)
Unclear risk The original protocol (NCR00192582) could not be accessed as only the final
article was listed. Selective reporting was unclear.
Other bias Unclear risk Follow-up data at 12 and 18 months confounded, as both groups received






Duration: 3 months, follow-up to 1 year.
Setting: outpatients.
Location: New Haven CT, USA.
Participants Diagnosis: DSM-IV diagnosis of schizophrenia spectrum or affective disorder with psychotic features
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Age: 38 years.
Sex: 91 M, 46 F.
Ethnicity: African-American (58%), white (20%), other (22%).
Inclusion criteria: At least one hospital admission in last year and eligible for public sector care (no pri-
vate insurance).
Interventions 1. Psychosocial intervention: standard care plus Manualised Skills training for persons with co-occur-
ring disorders. N = 48.
2. Psychosocial intervention: standard care plus Manualised Skills training for persons with co-occur-
ring disorders plus peer-led social engagement programme. N = 42.
3. Standard care: TAU, standard care plus transportation vouchers. N = 47.
Outcomes Leaving the study early: lost to treatment at 3 months (subject numbers by treatment group provided
by author email).
Unable to use
Lost to evaluation, at 9 months (greater than 50% lost to treatment).
Substance use: alcohol use last 30 days at 3 and 9 months. Days drank alcohol, experienced problems
(skewed data).
Mental State: PANSS, SFS (Social Functioning Scale), skewed data.
Readmission to hospital, 6 month and 1 year, no Ns provided.
Notes No trial identifier found.
Participats paid $25 per interview.
Funded by NIDA
Authors have kindly provided further data
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not reported (reported only as 'randomised').
Allocation concealment
(selection bias)





High risk Participants and providers were aware of their group allocation. It is not possi-
ble to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Outcome measures were administered by trained research assistants but no
report regarding attempt to blind them to group allocation. All outcomes were




High risk Overall attrition was 56/137 (41%). There is no flow diagram, but the three-
month loss of individuals is reported as not significantly different between any
of the 3 groups.
O'Connell 2018  (Continued)
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Selective reporting (re-
porting bias)
High risk No report of registration and protocol was not seen. Data unusable or pub-
lished in a form not able to use in meta-analysis as attrition was not reported
by treatment arm and Ns not provided for follow-up assessments.






Duration: 8 weeks (56 days).
Setting: outpatient.
Location: New Britain, CT, USA.




Sex: M F, not reported.
Ethnicity: White (68%).
Exclusion criteria: excluded if they were in recovery from pathological gambling.
Interventions 1. Psychosocial intervention: Contingency Management comprised of receiving $1 for each provided
sample plus draws to win prizes (varied from zero value, $20 up to $100) based on number of consecu-
tive negative urine samples for cocaine, N = 10.
2. Standard care: TAU, plus $1 for each urine sample provided twice per week. N = 9.
Outcomes Leaving the study early: lost to treatment.
Unable to use
Substance use (skewed data): proportion of samples cocaine negative, consecutive weeks cocaine neg-
ative (more than half the samples were not submitted).
Mental State: BSI (not reported as means, SD, N).
Notes Trial identifier: NCT01478815
Participants received $10 for baseline and $20 giG cards for post-treatment evaluation.
Funded by NIH
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computerised program used for stratification and assumed to be randomised
by computer.
Petry 2013 
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Allocation concealment
(selection bias)





High risk Participants and providers were aware of their group allocation. It is not possi-
ble to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk The overall lost to follow-up at 8 weeks was 2/19 (11%), 1 participant from
each group was lost to follow-up. The primary outcome was proportion of co-
caine-negative urine samples and longest duration of cocaine abstinence. Less
than half of the expected samples were remitted (in both groups) by 8 weeks.
Although analyses were completed on submitted and expected samples based
on positive or negative assumptions, attrition for the primary outcome was




Low risk NCT01478815. No indication of selective reporting






Duration: 3 and 6 months.
Setting: outpatient and residential.
Location: Grand Rapids, MI and New York, NY, USA.
Participants Diagnosis: serious mental illness (major depression, bipolar disorder, N = 97 and schizophrenia, N = 59)




Sex: 138 M, 65 F.
Ethnicity: Hispanic (13%), Black (32%) white (52%), other (5%).
Inclusion criteria: Those not meeting current misuse (alcohol > 4 drinks per day or illicit use last 90
days) were excluded.
Interventions 1. Psychosocial intervention: peer-supported 12-step self-help program called Double Trouble in Re-
covery (DTR), comprising one group meeting per week with a peer facilitator to help develop new skills
and coping behaviours, N = 113.
Rosenblum 2014 
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2. Standard care: TAU, received standard residential or day patient treatment and asked not to attend
DTR meetings until after follow-up interview, N = 163.
Outcomes Leaving the study early: lost to treatment, lost to evaluation.
Substance use: number of day any alcohol or drug use past 30 days.
Mental State: (QoL unable to use; not standard instrument).
Medication Adherence (MARS).
Notes Trial identifier: NCT01333280
139 excluded after randomisation as they did not meet recent substance misuse criteria. Primary psy-
chiatric diagnoses not reported. Attendees received $30 for baseline interview, $5 per meeting attend-
ed and $50-100 for follow-up interviews. Funded by NIDA. One author is director of NGO that receives
sales from distribution of DTR material.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random numbers table using block randomisation. However, within the 2 re-
gions participants in the two groups differed at baseline on PTSD and bipolar
diagnoses. [this issue is addressed in the new ROB2.0 as if randomisation was
done appropriately but did not create 2 identical groups then it may indicate
that the sequence was not successful (or could be a chance finding)]
Allocation concealment
(selection bias)
Low risk Allocation concealment was by sealed envelopes (assumed to be consecutive-





High risk Participants and providers were aware of their group allocation. It is not possi-
ble to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes





Low risk Attrition was 20% in the DTR group and 22% in the control condition with no
significant difference between groups. We judged this to be low risk
Selective reporting (re-
porting bias)
Low risk NCT01333280. No indication of selective reporting.





Design: single-centre (two inner city hospitals).
Duration: not stated; time to first appointment after discharge.
Setting: hospital.
Location: New York, NY, USA.
Swanson 1999 
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Participants Diagnosis: schizophrenia, psychosis, or schizo-affective disorder (45% of sample have substance abuse
problems).*
N = 93.
Age: mean ˜ 34 years.
Sex: 60 M, 33 F.
Ethnicity: 46% African-American, 45% Hispanic.
Inclusion criteria: voluntary inpatients with no organic brain disease or other serious medical illness,
learning disability or deafness.
Interventions 1. Psychosocial intervention: routine care plus 15 minute motivational interview at start of hospitali-
sation. Another one hour motivational interview 1 or 2 days before discharge. N = 48.
2. Standard care: routine care. N = 45.
Outcomes Leaving the study early: lost to evaluation.
Service use: attendance at first aftercare appointment following hospital discharge.
Notes Not ITT analysis.
*Data given only for those with substance abuse problems.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised (using random number table).
Allocation concealment
(selection bias)
High risk Therapist consulted a random number table to determine group assignment.





High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not clear if raters independent or blind to allocation. Primary outcome mea-




Low risk Lost to follow-up: 0%, (0/93) 3 months.
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement of 'yes' or 'no' as no protocol was
available.








Location: New Haven Connecticut, USA.
Tracy 2007 
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Participants Diagnosis: Met current or lifetime DSM-IV Axis 1 psychiatric disorder* and had a co-occurring current di-
agnosis of cocaine or alcohol abuse or dependence.
N = 30.
Age: not stated.
Sex: gender not stated.
Inclusion criteria: homeless or seeking shelter at least 18 years of age in addition to current SUD and
psychiatric diagnosis.
Interventions 1. Psychosocial intervention: Contingency management: Low-cost contingency management with
variable ratio reinforcement where patients received reinforcers** contingent upon demonstrating ab-
stinence from both alcohol and cocaine, as verified by breathalyser and cocaine-free urine specimens.
N = 15.
2. Standard care: TAU, assessment only. N = 15.
Outcomes Leaving the study early: lost to treatment (4 weeks).
Unable to use
Substance use: mean and SDs not provided for alcohol and substance use; percentages (and Chi2 sta-
tistics) are provided for some outcomes but not subject number (N) for each group.
Notes * Specific diagnoses are not reported, unknown seriousness or duration of psychiatric illness.
** Reinforcers were redeemable prizes ranging in value from no prize, $1, $20 and $100. All participants
received $30 for the screening, baseline and termination interviews and $5 for each weekly assessment.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised using a table. No further details.
Allocation concealment
(selection bias)





High risk Clinician-/participant-mediated and participants and personnel not blinded. It
is not possible to blind a psychosocial intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Lost to follow-up: 13% (4/30) 1 month.
Four patients in the TAU (assessment only) group did not complete the study,




High risk Gender, specific diagnoses and age not reported for participants. Mean and
SDs not provided for alcohol and substance use; percentages (and Chi2 statis-
tics) are provided for some outcomes but not participant number (N) for each
group.
Other bias Low risk No evidence other biases are occurring.
Tracy 2007  (Continued)
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F = Female, M = Male, N = Number
ITT - Intention-to-treat analysis
LOCF - Last observation carried forward
RDC - Research diagnostic criteria
SCID - Structured Clinical Interview for Diagnosis
Type of care
AA - Alcoholics Anonymous
ACT - Assertive Community Treatment
CBT - Cognitive Behaviour Therapy
NA - Narcotics Anonymous
For full list of diagnostic scales and abbreviations see Table 1.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Audier 2011 Allocation: not randomised.
Intervention: money for taking medication; not SUD focused.
Bachmann 1997 Allocation: not randomised.
Bagoien 2013 Allocation: randomised.
Participants: not severely mentally ill; not all participants had a current drug and alcohol use prob-
lem.
Barkhof 2013 Allocation: not randomised
Barrowclough 2006b Allocation: randomised.
Participants: people with severe mental illness; substance misuse not identified as the primary
problem.
Battersby 2013 Allocation: randomised.
Participants: veterans who misused alcohol (AUDIT > 8) and who also had a psychiatric or medical
condition. Not all participants had a serious psychotic illness (many had PTSD, panic or GAD).
Bechdolf 2004 Allocation: randomised.
Participants: people with schizophrenia and a primary diagnosis of drug and alcohol dependence
were excluded; no information provided on any participants with a dual diagnosis.
Beebe 2012 Allocation: randomised.
Participants: people with schizophrenia and co-occurring substance use disorders.
Intervention: MI to increase exercise, not to reduce substance use.
Bell 2011 Allocation: randomised.
Intervention: cognitive remediation, not SUD focused.
Bennett 2001 Allocation: not a randomised trial.
Bowen 2000 Allocation: randomised.
Participants: not severely mentally ill (panic disorder with or without agoraphobia).
Brooner 2013 Allocation: randomised.
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Study Reason for exclusion
Participants: received routine methadone maintenance, low percentage of participants had a co-
morbid psychotic disorder (< 5%).
Brown 2015 Allocation: randomised.
Participants: adolescents (aged 13-17) with psychiatric comorbidity, non-adult population. Pa-
tients were excluded it they had a psychotic disorder.
Carey 2004 Allocation: randomised.
Participants: people with severe mental illness; not all patients had a current drug and alcohol use
problem.
Castle 2002 No usable data. Email from author confirmed study abandoned; not enough participants to publish
the results.
Clarke 2000 Allocation: randomised.
Participants: people with severe mental illness; not all participants had a current drug and alcohol
use problem.
Clausen 2016 Allocation: not randomised
de Waal 2015 Allocation: randomised.
Intervention: to reduce victimisation in patients with a dual diagnosis. Not a intervention to reduce
SUD.
DeMarce 2008 Allocation: randomised.
Participants: substance abusers with co-occurring psychiatric disorder. No description of serious-
ness of psychiatric diagnoses.
Intervention: participants received a behavioural continuing care adherence intervention involving
contracting, prompting and reinforcing attendance or standard treatment.
Drake 2004a Allocation: original sample randomised.
Participants: people with severe mental illness and substance misuse.
Interventions: psychosocial.
Outcomes: no usable data (results from control group not reported).
Drake 2006 Allocation: original sample randomised.
Participants: people with severe mental illness and substance misuse.
Interventions: psychosocial.
Outcomes: no usable data (results from control group not reported).
Drebing 2005 Allocation: randomised.
Participants: only 11% (n = 2) of the veterans had a psychotic diagnosis, 74% had an affective disor-
der and 58% had an anxiety disorder. Did not fulfil the criteria for serious mental illness.
Drebing 2007 Allocation: randomised.
Participants: only 9% of the veterans had a psychotic diagnosis, 80% had major depression and
53% were given a PTSD diagnosis.
Eberhard 2009 Allocation: randomised.
Participants: ˜40% had affective disorder, ˜23% anxiety disorder and ˜13% PTSD, 7% personality
disorder. All patients were non-psychotic.
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Study Reason for exclusion
Faber 2012 Allocation: subanalysis from a larger randomised trial.
Participants: first-episode psychosis, but substance use was not an inclusion criteria.
Intervention: not a psychosocial intervention focused on reducing substance use.
Fiszdon 2016 Allocation: randomised.
Participants: people meeting criteria for substance abuse in last 30 days excluded, not a dual diag-
nosis population.
Gaughran 2017 Allocation: randomised care coordinators (n = 104) and the patients they cared for (406).
Participants: outpatients with a psychotic disorder; Not all participants had a SUD.
Intervention: to improve lifestyle choices, improve diet and reduce smoking (IMPACT health pro-
motion). Where applicable, intervention targeted alcohol, cannabis and other illegal substances.
Gleesen 2009 Allocation: randomised.
Participants: young people with first-episode psychosis; not all patients had a current or past drug
or alcohol use problem.
Intervention: individual and family CBT focused on relapse prevention, not SUD focused.
Goldstein 2005 Allocation: randomised.
Participants: only two participants had a diagnosis of schizophrenia.
Harrison 2017 Allocation: not randomised.
Havassy 2000 Allocation: randomised.
Participants: people with severe mental illness and substance misuse.
Interventions: two case0management programmes; no specific substance misuse treatment.
Herman 2000 Allocation: randomised.
Participants: people with severe mental illness and substance misuse.
Interventions: psychosocial.
Outcomes: no usable data.
Hulse 2002 Allocation: randomised.
Participants: not all severely mentally ill (10% psychotic); 26% did not have a dual diagnosis.
ISRCTN58667926 Allocation: randomised.
Participants: serious mental illness; substance use disorder not listed as an inclusion criteria.
James 2004 Allocation: not randomised (alternate allocation).
Jerrell 2000 Allocation: randomised.
Participants: people with severe mental illness and a co-occurring substance disorder.
Interventions: day treatment integrating mental health and substance use symptoms; community
group meetings, skill-building, 12-step groups, relapse prevention skills and case management ver-
sus treatment as usual.
Outcomes: no usable data - control group data not available.
Kelly 2002 Allocation: not randomised.
Kidorf 2013 Allocation: randomised.
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Study Reason for exclusion
Participants: attending methadone clinic who also had a psychiatric disorder; none were diag-
nosed with schizophrenia. Many had PTSD or antisocial personality disorder.
Intervention: not a SUD psychosocial intervention
Killackey 2013 Allocation: randomised.
Participants: young people with first episode psychosis; not all participants had a SUD
Intervention: vocational intervention (supported employment), not a SUD intervention
Lozano 2013 Allocation: not randomised.
Magura 2003 Allocation: not a randomised trial.
Mangrum 2006 Allocation: randomised.
Participants: co-occurring severe and persistent mental illness and substance use disorders.
Interventions: integrated versus parallel treatment.
Outcomes: no usable data (not broken down by site, only 2 of 3 sites were randomly assigned).
Martino 2000 Allocation: randomised.
Participants: people with psychotic or mood disorders and concurrent DSM-IV substance-related
disorders.
Interventions: pre-admission motivational interview versus standard pre-admission interview.
Outcomes: no usable data.
Martino 2006 Allocation: randomised.
Participants: dually diagnosed psychotic and drug-related disordered patients.
Interventions: pre-admission motivational interview versus standard preadmission interview.
Outcomes: no usable data.
McGurk 2009 Allocation: randomised.
Intervention: cognitive remediation, not a SUD focused intervention.
Mercer 1997 Allocation: not randomised.
Mueser 2001 Allocation: not a randomised trial.
Mueser 2009 Allocation: randomised.
Participants: family members of patients with a dual diagnosis.
Interventioin: family education programme, did not directly involve patients.
NCT00043693 Allocation: randomised.
Participants: family members of patients with a dual diagnosis.
Intervention: family education programme, did not directly involve patients.
NCT00316303 Allocation: randomised.
Participants: patients with psychosis and substance use disorder.
Intervention: focused on reducing harm (HIV, other risk behaviours); not specific for reducing sub-
stance use.
NCT00447720 Allocation: randomised.
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Study Reason for exclusion
Intervention: educational programme for case managers.
NCT00495911 Allocation: randomised.
Participants: people with first-episode psychosis;SUD was not listed as an inclusion criteria.
NCT01361698 Allocation: randomised.
Participants: substance use not an inclusion criteria.
Intervention: recovery focused (increased adherence); not specifically focused on SUD.
NCT02264327 Allocation: randomised.
Participants: not patient focused.
Intervention: training MI to staI in increasing MI knowledge and skill retention over time
Noordraven 2017 Allocation: randomised.
Intervention: financial incentives for improving adherence; not a psychosocial intervention to re-
duce substance use
Nuijten 2012 Allocation: randomised.
Participants: inpatients and outpatients with serious mental illness and SUD.
Interventioin: integrated treatment based on hospital status; inpatient or outpatient. No TAU
group.
Nuttbrock 1998 Allocation: quasi-randomised (treatment facilities retained the final acceptance).
Odom 2005 No useable data. Email from author confirmed results not published, supervisor leG
Penn 2000 Allocation: quasi-randomised (alternate allocation).
Petersen 2006 Allocation: randomised.
Participants: first-episode schizophrenia spectrum disorder; not all patients had substance use or
dependence (146 vs 401 patients).
Interventioin: enriched assertive community treatment vs standard care.
Petrakis 2005 Allocation: randomised.
Participants: patients with an Axis I psychiatric disorder and comorbid alcohol dependence.
Interventions: naltrexone versus disulphiram; not psychosocial.
Ries 2004 Allocation: randomised. This single-centre, two-armed, community-based RCT was conduced in
the USA.
Participants: 41 people with severe mental illness 
Intervention: 1) Contingency Management of supplementary social security income or food vouch-
er with a motivational message, or 2) treatment as usual.
Outcome: data were not reported per group for loss to treatment and no means, SD or sample sizes
were reported for number of weeks of substance use. The trial was excluded due to a lack of usable
data.
Rosenheck 1998 Allocation: randomised.
Participants: high users of inpatient services.
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Study Reason for exclusion
Interventions: intensive psychiatric community care; no specific substance misuse treatment pro-
gramme.
Rowe 2007 Allocation: randomised.
Participants: only 38% had a psychotic disorder and 30% did not a dual diagnosis.
Sacks 2004 Allocation: randomised.
Participants: only 63% of sample had a serious mental illness and no data provided separately for
this group.
Sacks 2008 Allocation: randomised.
Participants: majority of participants were diagnosed with major depression (65%) with other co-
morbidities (PTSD or anxiety) and history of alcohol or substance use. 27% had bipolar disorder
and no mention of other psychotic disorders.
Sacks 2011 Allocation: randomised.
Participants: diagnosed with HIV/AIDS and co-occurring mental and SUD.High percentage of home-
lessness, incarceration and IV drug use.
Intervention: aftercare focused to improve health status focusing on AIDS issues and adhere to
AIDS medication. Not a psychosocial intervention to reduce substance use.
Santa Ana 2007 Allocation: not a randomised trial, based on consecutive admissions.
Schmitz 2002 Allocation: randomised.
Participants: bipolar disorder exclusively; excluded due to none having a diagnosis of schizophre-
nia.
Shorey 2015 Allocation: randomised.
Participants: veterans with a primary alcohol use disorder, the majority did not have a psychotic
disorder.
Sigmon 2000 Allocation: not randomised.
Sitharthan 1999 Participants: study was discontinued, no participants were recruited.
Smeerdijk 2012 Allocation: randomised.
Participants: carers of people with a dual diagnosis.
Interventioin: MI for family carers, no direct contact with patients.
Smelson 2007 Allocation: randomised.
Intervention: designed to facilitate outpatient engagement, not psychosocial intervention to re-
duce substance use.
Somers 2015 Allocation: randomised.
Participants: homeless mentally ill adults, not all had a SUD,
Intervention: housing support was provided based on need, intervention was not SUD focused.
Stain 2016 Allocation: randomised, single-blind trial
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Study Reason for exclusion
Participants: young people with ultra-high risk of developing psychosis; not all patients had a cur-
rent or past drug or alcohol use problem.
Steadman 2005 Allocation: not randomised.
Swanson 2000 Allocation: randomised.
Participants: people with psychotic or major mood disorders and history of hospital recidivism
(50% substance misuse).
Interventions: involuntary out-patient commitment. No specific substance misuse treatment.
Tantirangsee 2015 Allocation: randomised.
Participants: not all participants had a drug or alcohol substance use disorder.
Intervention: to reduce tobacco smoking.
Teague 1995 Allocation: not a randomised trial.
Thornicroft 2007 Allocation: randomised.
Participants: case managers of people with a dual diagnosis.
Intervention: did not include direct patient contact.
Timko 2004 Allocation: quasi-randomised (not all patients randomly allocated to community treatment were
placed there).
Tyrer 2011 Allocation: randomised.
Participants: people with comorbid substance misuse and psychosis.
Interventions: nidotherapy is not a specific SUD focused intervention; nidotherapy was developed
mainly for people with personality disorders.
Weiss 2000 Allocation: not randomised (sequential allocation).
Weiss 2007 Allocation: randomised.
Participants: bipolar disorder exclusively; excluded due to none having a diagnosis of schizophre-
nia.
Weiss 2009 Allocation: randomised.
Participants: bipolar disorder exclusively; excluded due to none having a diagnosis of schizophre-
nia.
Woolderink 2015 Intervention: evaluation of E-mental health intervention for children of parents with a mental ill-
ness unrelated to SUD
AUDIT: Alcohol Use Disorders Identification Test; CBT: cognitive behavioural therapy; IV: intravenous; DSM-IV: Diagnostic & Statistical Man-
ual of Mental Disorders 4th edition; MI: motivational interviewing; PTSD: post-traumatic stress disorder; RCT: randomised controlled trial;
SD: standard deviation; SUD: substance use disorder; TAU: treatment as usual.
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Allocation: randomised
Location Nedlands, Western Australia
ACTRN12616000275460 
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Participants Inpatients with both a psychiatric disorder and substance use disorder
Interventions Brief Infromation Pack (BIP) intervention vs. Engagement Assistant Referral Therapy (EART)
Outcomes Change in mental state as assessed by the BSI.






Participants Comorbid schizophrenia and alcohol dependence, N = 154
Interventions Psychotheraeutic program, no further details in Abstract
Outcomes Reduced craving for alcohol




Methods German dissertation. Requires translation.
Allocation: randomised.
Design: cluster-RCT.
Participants Young people with first episode psychosis and substance misuse. N = 65.
Interventions 1. Group-based motivational behavioural therapy (MOVE); N = 36, 9 clusters.
2. TAU: Supportive treatment for addiction recovery (STAR); N = 29, 7 clusters.
Outcomes Days of alcohol and substance use, quality of life and client satisfaction.
Notes To be assessed, PhD dissertation needs translation from German to English. Supervisor (M Lam-





Location: UCLA, Los Angeles, CA
Participants Psychotic disorder with any past use of cannabis or stimulants and at least one heavy drinking day
in the past year, n = 188 out of 715 patients with a mental health
Interventions Screening, brief intervention and referral to treatment (SBIRT)
NCT01883791 
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Outcomes Reductions in substance use, ASSIST, AUDIT, DAST and increased of quality of life





Location: University of North Carolina, Chapel Hill and Boston University
Participants Jail detainees with drug or alcohol abuse/dependence and a serious mental illness
Interventions Dual-Diagnosis Motivational interviewing (DDMI) and integrated group therapy (IGT)
vs TAU.
Outcomes Substance use, mental state with 6-month follow-up






Participants People with first episode psychosis and regular cannabis user
Interventions CBT for cannabis cessation plus pharmacological treatment
Outcomes Cannabis cessation, Mental state (PANSS, HDRS, YMRS, HAM-A), psychosocial functioning (FAST)





Location: New York University
Participants Individuals with co-occurring substance use and mental health problems leaving residential treat-
ment settings
Interventions Critical time intervention-residential (CTI-R) vs usual discharge services-residential
Outcomes Completed treatment, Satisfaction, relapsed, substance use (ASI)




Psychosocial interventions for people with both severe mental illness and substance misuse (Review)









Cochrane Database of Systematic Reviews
Methods Allocation: cluster-randomised (wait list) control group design
Location: Darmouth college, Madison Wisconsin
Participants People with co-occurring substance use and mental health disorders
Interventions Integrated service
Outcomes Change in dual diagnosis capability in addiction treatment, change in ASI
Notes No contact person listed. Start date 2015- 2019
NCT03007940 
AUDIT: Alcohol Use Disorders Identification Test; BSI: Brief Symptom Inventory;; CBT: cognitive behavioural therapy; HAM-D:Hamilton
Rating Scale for Depression; PANSS: Positive and Negative Syndrome Scale; RCT: randomised controlled trial; TAU: treatment as usual
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Alcohol use disorders in schizophrenia, NCT00280813.
Methods Allocation: randomised.
Location: Maryland, USA.
Participants Expected total enrolment, n = 62.
Interventions Behavioural treatment (CBT+) for alcohol abuse in schizophrenia (BTAAS).
Outcomes Symptom ratings addiction severity, quality of life
Starting date 2007
Contact information Melanie Bennett, Mbennett@psych.umaryland.edu









Participants First episode psychosis and problematic cannabis use.
Expected: N = 68.
Interventions Contingency management versus TAU.
Outcomes Relapse
CIRCLE trial 
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Starting date 28/11/2011 to 2016. Study completed.
Contact information Dr Meghan Craig, Prof Sonia Johnson and Luke Sheridan Rains
University College London




Trial name or title Dual diagnosis - comparison of specialized treatment versus unspecified treatment.
Methods Allocation: randomised.
location: University of Konstanz, Germany.
Participants Diagnoses: schizophrenia and diagnoses with psychotic features; and misuse of cannabis during 12
months preceding hospital admission. Estimated N = 50.
Interventions Group educational programme to reduce consumption of cannabis.
Outcomes Mental health (PANSS) and cannabis consumption and detection (urine samples)
Starting date Jan 2006; estimated completion dated Jan 2010.
Contact information Hans Watzl




Trial name or title Effect of motivational therapy on schizophrenia with cannabis misuse (SCHIZOCAN).
Methods Allocation: randomised.
location: Paris, France.
Participants Diagnosis: schizophrenia and cannabis abuse/dependence.
Estimated n = 330.
Interventions Motivational therapy (MI) vs TAU.
Outcomes Non-specified.
Starting date Nov 2008; estimated completion date Sept 2011.
Contact information Caroline Dubertret
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Trial name or title NTR1083. Effects and indicators of CBT for cannabis use in psychosis.
Methods Allocation: randomised.
Location: Maastricht, the Netherlands.
Participants Target number of participants, n = 48.
Interventions MI+CBT versus TAU.
Outcomes Cannabis use and psychotic symptoms
Starting date 2007-2011
Contact information Cecile Henequet
Notes E-mail sent, no reply from author. 2018; no email address available. No publication found.
Verstappen 2007 
CBT: cognitive behavioural therapy; MI: motivational interviewing; PANSS: Positive and Negative Syndrome Scale; TAU: treatment as usual
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Integrated models of care versus standard care





Statistical method Effect size
1 Leaving the study early: 1. Lost to
treatment - by 36 months
3 603 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.82, 1.45]
2 Leaving the study early: 2. Lost to
evaluation
4   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 By 3 months 1 132 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.27, 1.08]
2.2 By 6 months 2 330 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.27, 1.73]
2.3 By 9 months 1 132 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.49, 1.19]
2.4 By 12 months 1 198 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.22, 1.29]
2.5 By 24 months 1 198 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.47, 2.12]
2.6 By 36 months 3 603 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.35, 1.66]
3 Adverse event: 1. Death - by 36
months
2 421 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.39, 3.57]
4 Substance use: 1. Clinically impor-
tant change (not in remission) - by
36 months
1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Alcohol use 1 143 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.84, 1.56]
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Statistical method Effect size
4.2 Drug use 1 85 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.63, 1.25]
5 Substance use: 2. Average score
for progress towards recovery
(SATS, low = poor)
1   Mean Difference (IV, Random,
95% CI)
Subtotals only
5.1 By 6 months 1 203 Mean Difference (IV, Random,
95% CI)
0.07 [-0.28, 0.42]
5.2 By 36 months 1 203 Mean Difference (IV, Random,
95% CI)
0.11 [-0.41, 0.63]
6 Substance use: 3a. Alcohol use: av-
erage score (AUS) (skewed data)
    Other data No numeric data
6.1 6 months     Other data No numeric data
6.2 12 months     Other data No numeric data
6.3 18 months     Other data No numeric data
6.4 24 months     Other data No numeric data
6.5 30 months     Other data No numeric data
6.6 36 months     Other data No numeric data
7 Substance use: 3b. Alcohol use:
average number of days using in last
6 months (skewed data)
    Other data No numeric data
7.7 6 month     Other data No numeric data
7.8 12 month     Other data No numeric data
7.9 18 month     Other data No numeric data
7.10 24 month     Other data No numeric data
7.11 30 month     Other data No numeric data
7.12 36 month     Other data No numeric data
8 Substance use: 4a. Drug use: aver-
age score (DUS) (skewed data)
    Other data No numeric data
8.1 6 months     Other data No numeric data
8.2 12 months     Other data No numeric data
8.3 18 months     Other data No numeric data
8.4 24 months     Other data No numeric data
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Statistical method Effect size
8.5 30 months     Other data No numeric data
8.6 36 months     Other data No numeric data
9 Substance use: 4b. Drug use: av-
erage number of days using in last 6
months (skewed data)
    Other data No numeric data
9.7 6 months     Other data No numeric data
9.8 12 months     Other data No numeric data
9.9 18 months     Other data No numeric data
9.10 24 months     Other data No numeric data
9.11 30 months     Other data No numeric data
9.12 36 months     Other data No numeric data
10 Substance use: 5. Avearage score
(SATS, low = poor) (skewed data)
    Other data No numeric data
10.1 6 months     Other data No numeric data
10.2 12 months     Other data No numeric data
10.3 18 months     Other data No numeric data
10.4 24 months     Other data No numeric data
10.5 30 months     Other data No numeric data
10.6 36 months     Other data No numeric data
11 Substance use: 6. Average score
( USS, high = poor) 1=client not ab-
stinent, 5 client mets criteria for se-
vere use) (skewed data)
    Other data No numeric data
11.1 6 months     Other data No numeric data
11.2 12 months     Other data No numeric data
11.3 18 months     Other data No numeric data
11.4 24 months     Other data No numeric data
12 Mental state: 1. Average score
(BPRS, high = poor) (skewed data)
    Other data No numeric data
12.1 6 months     Other data No numeric data
Psychosocial interventions for people with both severe mental illness and substance misuse (Review)









Cochrane Database of Systematic Reviews





Statistical method Effect size
12.2 12 months     Other data No numeric data
12.3 18 months     Other data No numeric data
12.4 24 months     Other data No numeric data
12.5 30 months     Other data No numeric data
12.6 36 months     Other data No numeric data
13 Global state: 1. Average score
(GAF, low = poor)
1   Mean Difference (IV, Random,
95% CI)
Subtotals only
13.1 By 6 months 1 162 Mean Difference (IV, Random,
95% CI)
1.10 [-1.58, 3.78]
13.2 By 12 months 1 171 Mean Difference (IV, Random,
95% CI)
0.70 [-2.07, 3.47]
13.3 By 18 months 1 176 Mean Difference (IV, Random,
95% CI)
1.0 [-1.58, 3.58]
13.4 By 24 months 1 166 Mean Difference (IV, Random,
95% CI)
1.70 [-1.18, 4.58]
13.5 By 30 months 1 164 Mean Difference (IV, Random,
95% CI)
-0.60 [-3.56, 2.36]
13.6 By 36 months 1 170 Mean Difference (IV, Random,
95% CI)
0.40 [-2.47, 3.27]
14 Global state: 2. Forensic mea-
sures (skewed data)
    Other data No numeric data
14.1 Arrests - 36 months     Other data No numeric data
14.2 Convictions - 36 months     Other data No numeric data
14.3 Felony - 36 months     Other data No numeric data
14.4 Hospital or jail - 3 months     Other data No numeric data
14.5 Jail days - 36 months     Other data No numeric data
15 Quality of life/ life satisfaction: 1.
Average general score (QOLI, range
1-7, low = poor)
2   Mean Difference (IV, Random,
95% CI)
Subtotals only
15.1 By 6 months 2 361 Mean Difference (IV, Random,
95% CI)
-0.11 [-0.41, 0.20]
15.2 By 12 months 2 372 Mean Difference (IV, Random,
95% CI)
0.02 [-0.28, 0.32]
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15.3 By 18 months 2 377 Mean Difference (IV, Random,
95% CI)
0.09 [-0.27, 0.44]
15.4 By 24 months 2 370 Mean Difference (IV, Random,
95% CI)
0.02 [-0.29, 0.33]
15.5 By 30 months 2 366 Mean Difference (IV, Random,
95% CI)
0.02 [-0.27, 0.32]
15.6 By 36 months 2 373 Mean Difference (IV, Random,
95% CI)
0.10 [-0.18, 0.38]
16 Service use: 1. Days in stable
community residences (not in hos-
pital)
2   Mean Difference (IV, Random,
95% CI)
Subtotals only
16.1 By 12 months 2 378 Mean Difference (IV, Random,
95% CI)
-10.00 [-38.61, 18.60]
16.2 By 24 months 1 203 Mean Difference (IV, Random,
95% CI)
7.40 [-6.32, 21.12]
16.3 By 36 months 2 364 Mean Difference (IV, Random,
95% CI)
5.17 [-9.20, 19.55]
17 Service use: 2. Number hospi-
talised - during the 36 month study
period
1 198 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.64, 1.19]
18 Service use: 3. Relapse (hospi-
talisation days and crisis care) - 36
months (skewed data)
    Other data No numeric data
19 Service use: 4. Medication hours -
36 months (skewed data)
    Other data No numeric data
20 Service use: 5. Various measures
(skewed data)
    Other data No numeric data
20.1 Days institutionalised (hospital
or incarcerated) - 36 months (site 2)
    Other data No numeric data
20.2 Days in hospital - 36 months
(site 2)
    Other data No numeric data
21 Homelessness: 1. Proportion of
time on the street - past 60 days
    Other data No numeric data
21.1 3 months     Other data No numeric data
21.2 6 months     Other data No numeric data
21.3 9 months     Other data No numeric data
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22 Homelessness: 2. Proportion of
time in independent housing - past
60 days
    Other data No numeric data
22.1 3 months     Other data No numeric data
22.2 6 months     Other data No numeric data
22.3 9 months     Other data No numeric data
23 Homelessness: 3. Average
number of days in stable housing
(skewed data)
    Other data No numeric data
23.1 6 months     Other data No numeric data
23.2 12 months     Other data No numeric data
23.3 18 months     Other data No numeric data
23.4 24 months     Other data No numeric data
24 Homelessness: 4. Various mea-
sures (skewed data)
    Other data No numeric data
24.3 Time on streets (%) - 3 months     Other data No numeric data
24.4 Time on streets (%) - 6 months     Other data No numeric data
24.5 Time on streets (%) - 9 months     Other data No numeric data
24.6 Days in stable community resi-
dence - 24 months
    Other data No numeric data
24.7 Time in independent housing in
past 60 days - 3 months
    Other data No numeric data
24.8 Time in independent housing in
past 60 days - 6 months
    Other data No numeric data
24.9 Time in independent housing in
past 60 days - 9 months
    Other data No numeric data
 
 
Analysis 1.1.   Comparison 1 Integrated models of care versus standard care,
Outcome 1 Leaving the study early: 1. Lost to treatment - by 36 months.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Chandler 2006 42/103 26/79 54.49% 1.24[0.84,1.83]
Drake 1998a 22/109 28/114 34.39% 0.82[0.5,1.35]
Favours treatment 20.5 1.50.7 1 Favours control
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Essock 2006 11/99 8/99 11.11% 1.38[0.58,3.27]
   
Total (95% CI) 311 292 100% 1.09[0.82,1.45]
Total events: 75 (Treatment), 62 (Control)  
Heterogeneity: Tau2=0; Chi2=1.95, df=2(P=0.38); I2=0%  
Test for overall effect: Z=0.57(P=0.57)  
Favours treatment 20.5 1.50.7 1 Favours control
 
 
Analysis 1.2.   Comparison 1 Integrated models of care versus standard
care, Outcome 2 Leaving the study early: 2. Lost to evaluation.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.2.1 By 3 months  
Burnam 1995 10/67 18/65 100% 0.54[0.27,1.08]
Subtotal (95% CI) 67 65 100% 0.54[0.27,1.08]
Total events: 10 (Treatment), 18 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.75(P=0.08)  
   
1.2.2 By 6 months  
Burnam 1995 18/67 17/65 57.08% 1.03[0.58,1.81]
Essock 2006 6/99 15/99 42.92% 0.4[0.16,0.99]
Subtotal (95% CI) 166 164 100% 0.69[0.27,1.73]
Total events: 24 (Treatment), 32 (Control)  
Heterogeneity: Tau2=0.31; Chi2=3.07, df=1(P=0.08); I2=67.4%  
Test for overall effect: Z=0.8(P=0.42)  
   
1.2.3 By 9 months  
Burnam 1995 22/67 28/65 100% 0.76[0.49,1.19]
Subtotal (95% CI) 67 65 100% 0.76[0.49,1.19]
Total events: 22 (Treatment), 28 (Control)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.2(P=0.23)  
   
1.2.4 By 12 months  
Essock 2006 7/99 13/99 100% 0.54[0.22,1.29]
Subtotal (95% CI) 99 99 100% 0.54[0.22,1.29]
Total events: 7 (Treatment), 13 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.39(P=0.17)  
   
1.2.5 By 24 months  
Essock 2006 12/99 12/99 100% 1[0.47,2.12]
Subtotal (95% CI) 99 99 100% 1[0.47,2.12]
Total events: 12 (Treatment), 12 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Favours treatment 100.1 50.2 20.5 1 Favours control
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.2.6 By 36 months  
Chandler 2006 42/103 26/79 41.56% 1.24[0.84,1.83]
Drake 1998a 4/109 16/114 24.78% 0.26[0.09,0.76]
Essock 2006 13/99 14/99 33.66% 0.93[0.46,1.87]
Subtotal (95% CI) 311 292 100% 0.76[0.35,1.66]
Total events: 59 (Treatment), 56 (Control)  
Heterogeneity: Tau2=0.34; Chi2=7.7, df=2(P=0.02); I2=74.02%  
Test for overall effect: Z=0.68(P=0.5)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.3.   Comparison 1 Integrated models of care versus
standard care, Outcome 3 Adverse event: 1. Death - by 36 months.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Drake 1998a 3/109 4/114 56.35% 0.78[0.18,3.42]
Essock 2006 4/99 2/99 43.65% 2[0.37,10.67]
   
Total (95% CI) 208 213 100% 1.18[0.39,3.57]
Total events: 7 (Treatment), 6 (Control)  
Heterogeneity: Tau2=0; Chi2=0.68, df=1(P=0.41); I2=0%  
Test for overall effect: Z=0.29(P=0.77)  
Favours treatment 1000.01 100.1 1 Favours control
 
 
Analysis 1.4.   Comparison 1 Integrated models of care versus standard care, Outcome
4 Substance use: 1. Clinically important change (not in remission) - by 36 months.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.4.1 Alcohol use  
Drake 1998a 43/75 34/68 100% 1.15[0.84,1.56]
Subtotal (95% CI) 75 68 100% 1.15[0.84,1.56]
Total events: 43 (Treatment), 34 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.87(P=0.38)  
   
1.4.2 Drug use  
Drake 1998a 26/45 26/40 100% 0.89[0.63,1.25]
Subtotal (95% CI) 45 40 100% 0.89[0.63,1.25]
Total events: 26 (Treatment), 26 (Control)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.68(P=0.49)  
Favours treatment 20.5 1.50.7 1 Favours control
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Analysis 1.5.   Comparison 1 Integrated models of care versus standard care, Outcome
5 Substance use: 2. Average score for progress towards recovery (SATS, low = poor).
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.5.1 By 6 months  
Drake 1998a 105 3.7 (1.3) 98 3.6 (1.2) 100% 0.07[-0.28,0.42]
Subtotal *** 105   98   100% 0.07[-0.28,0.42]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.4(P=0.69)  
   
1.5.2 By 36 months  
Drake 1998a 105 5 (1.9) 98 4.9 (1.9) 100% 0.11[-0.41,0.63]
Subtotal *** 105   98   100% 0.11[-0.41,0.63]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.41(P=0.68)  
Favours treatment 0.50.25-0.5 -0.25 0 Favours control
 
 
Analysis 1.6.   Comparison 1 Integrated models of care versus standard care,
Outcome 6 Substance use: 3a. Alcohol use: average score (AUS) (skewed data).
Substance use: 3a. Alcohol use: average score (AUS) (skewed data)
Study Intervention Mean SD N
6 months
Drake 1998a Treatment 3.12 1.03 70
Drake 1998a Control 2.97 1.09 65
Essock 2006 Treatment 2.90 1.30 68
Essock 2006 Control 3.00 1.10 61
12 months
Drake 1998a Treatment 3.17 1.05 75
Drake 1998a Control 2.84 1.23 66
Essock 2006 Treatment 2.80 1.30 64
Essock 2006 Control 3.10 1.0 62
18 months
Drake 1998a Treatment 3.07 1.15 75
Drake 1998a Control 2.79 1.10 65
Essock 2006 Treatment 2.80 1.20 65
Essock 2006 Control 2.90 1.20 65
24 months
Drake 1998a Treatment 2.98 1.07 73
Drake 1998a Control 2.79 1.16 67
Essock 2006 Treatment 2.60 1.20 60
Essock 2006 Control 3.0 1.20 63
30 months
Drake 1998a Treatment 2.86 1.09 72
Drake 1998a Control 2.96 1.18 65
Essock 2006 Treatment 2.80 1.20 58
Essock 2006 Control 2.80 1.20 59
36 months
Drake 1998a Treatment 2.70 1.12 74
Drake 1998a Control 2.82 1.16 68
Essock 2006 Treatment 2.70 1.0 58
Essock 2006 Control 2.80 1.30 60
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Analysis 1.7.   Comparison 1 Integrated models of care versus standard care, Outcome 7
Substance use: 3b. Alcohol use: average number of days using in last 6 months (skewed data).
Substance use: 3b. Alcohol use: average number of days using in last 6 months (skewed data)
Study Intervention Mean SD N
6 month
Drake 1998a Treatment 56.80 56.40 75
Drake 1998a Control 47.50 58.40 68
Essock 2006 Treatment 36.60 50.1 65
Essock 2006 Control 38.60 54.20 53
12 month
Drake 1998a Treatment 59.10 53.30 75
Drake 1998a Control 42.80 52.90 68
Essock 2006 Treatment 35.80 50.00 64
Essock 2006 Control 44.80 58.80 61
18 month
Drake 1998a Treatment 53.80 57.80 75
Drake 1998a Control 33.50 44.40 68
Essock 2006 Treatment 30.00 46.90 64
Essock 2006 Control 37.00 46.80 66
24 month
Drake 1998a Treatment 52.40 55.90 75
Drake 1998a Control 31.00 43.00 68
Essock 2006 Treatment 31.30 46.70 57
Essock 2006 Control 47.60 62.80 64
30 month
Drake 1998a Treatment 54.80 60.90 75
Drake 1998a Control 54.00 63.00 68
Essock 2006 Treatment 39.40 52.40 60
Essock 2006 Control 42.80 59.80 62
36 month
Drake 1998a Treatment 46.40 53.60 75
Drake 1998a Control 43.60 57.30 68
Essock 2006 Treatment 33.50 47.30 60
Essock 2006 Control 31.10 49.90 59
 
 
Analysis 1.8.   Comparison 1 Integrated models of care versus standard care,
Outcome 8 Substance use: 4a. Drug use: average score (DUS) (skewed data).
Substance use: 4a. Drug use: average score (DUS) (skewed data)
Study Intervention Mean SD N
6 months
Drake 1998a Treatment 3.07 1.10 45
Drake 1998a Control 3.26 1.03 39
Essock 2006 Treatment 3.50 1.10 81
Essock 2006 Control 3.30 1.20 61
12 months
Drake 1998a Treatment 2.93 1.10 45
Drake 1998a Control 3.17 1.15 39
Essock 2006 Treatment 3.10 1.20 75
Essock 2006 Control 3.20 1.20 61
18 months
Drake 1998a Treatment 2.80 1.23 45
Drake 1998a Control 2.90 1.16 39
Psychosocial interventions for people with both severe mental illness and substance misuse (Review)









Cochrane Database of Systematic Reviews
Substance use: 4a. Drug use: average score (DUS) (skewed data)
Study Intervention Mean SD N
Essock 2006 Treatment 3.10 1.30 76
Essock 2006 Control 3.10 1.50 62
24 months
Drake 1998a Treatment 2.73 1.21 44
Drake 1998a Control 2.94 1.15 39
Essock 2006 Treatment 2.80 1.30 67
Essock 2006 Control 3.10 1.40 63
30 months
Drake 1998a Treatment 2.71 1.28 43
Drake 1998a Control 3.03 1.19 40
Essock 2006 Treatment 3.10 1.40 71
Essock 2006 Control 2.90 1.50 55
36 months
Drake 1998a Treatment 2.61 1.23 44
Drake 1998a Control 2.89 1.12 40
Essock 2006 Treatment 2.80 1.30 67
Essock 2006 Control 2.90 1.40 59
 
 
Analysis 1.9.   Comparison 1 Integrated models of care versus standard care, Outcome 9
Substance use: 4b. Drug use: average number of days using in last 6 months (skewed data).
Substance use: 4b. Drug use: average number of days using in last 6 months (skewed data)
Study Intervention Mean SD N
6 months
Drake 1998a Treatment 42.60 53.50 45
Drake 1998a Control 45.30 44.30 40
Essock 2006 Treatment 40.80 50.90 75
Essock 2006 Control 44.10 57.70 55
12 months
Drake 1998a Treatment 26.90 33.40 45
Drake 1998a Control 47.30 54.50 40
Essock 2006 Treatment 36.80 55.30 76
Essock 2006 Control 36.30 51.70 60
18 months
Drake 1998a Treatment 41.60 54.90 45
Drake 1998a Control 34.40 53.30 40
Essock 2006 Treatment 37.70 54.20 78
Essock 2006 Control 39.90 51.70 64
24 months
Drake 1998a Treatment 35.50 48.00 45
Drake 1998a Control 37.00 48.80 40
Essock 2006 Treatment 28.20 47.20 69
Essock 2006 Control 39.10 56.20 66
30 months
Drake 1998a Treatment 33.90 50.00 45
Drake 1998a Control 46.40 53.10 40
Essock 2006 Treatment 35.00 51.30 73
Essock 2006 Control 35.90 54.50 60
36 months
Drake 1998a Treatment 38.20 54.70 45
Drake 1998a Control 51.50 67.20 40
Essock 2006 Treatment 31.70 47.80 71
Essock 2006 Control 32.10 49.00 60
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Analysis 1.10.   Comparison 1 Integrated models of care versus standard care,
Outcome 10 Substance use: 5. Avearage score (SATS, low = poor) (skewed data).
Substance use: 5. Avearage score (SATS, low = poor) (skewed data)
Study Intervention Mean SD N
6 months
Essock 2006 Treatment 3.3 1.60 93
Essock 2006 Control 3.3 1.50 83
12 months
Drake 1998a Treatment 3.99 1.60 105
Drake 1998a Control 4.10 1.59 98
Essock 2006 Treatment 3.80 1.70 87
Essock 2006 Control 3.40 1.50 84
18 months
Drake 1998a Treatment 4.19 1.77 105
Drake 1998a Control 4.32 1.75 98
Essock 2006 Treatment 4.00 1.90 88
Essock 2006 Control 3.90 1.80 84
24 months
Drake 1998a Treatment 4.50 1.76 105
Drake 1998a Control 4.51 1.73 98
Essock 2006 Treatment 4.20 2.0 79
Essock 2006 Control 3.7 1.90 83
30 months
Drake 1998a Treatment 4.76 1.92 105
Drake 1998a Control 4.48 1.88 98
Essock 2006 Treatment 4.10 2.0 80
Essock 2006 Control 4.0 1.9 75
36 months
Essock 2006 Treatment 4.40 1.80 78
Essock 2006 Control 4.30 2.10 79
 
 
Analysis 1.11.   Comparison 1 Integrated models of care versus standard care, Outcome 11 Substance use: 6.
Average score ( USS, high = poor) 1=client not abstinent, 5 client mets criteria for severe use) (skewed data).
Substance use: 6. Average score ( USS, high = poor) 1=client not abstinent, 5 client mets criteria for severe use) (skewed data)
Study Intervention Mean SD N
6 months
Morse 2006 Treatment (IACT) 3.15 1.09 46
Morse 2006        
Morse 2006 Control 2.93 1.19 49
12 months
Morse 2006 Treatment (IACT) 3.07 0.96 46
Morse 2006        
Morse 2006 Control 2.78 1.18 49
18 months
Morse 2006 Treatment (IACT) 2.83 1.30 46
Morse 2006        
Morse 2006 Control 2.69 1.10 49
24 months
Morse 2006 Treatment (IACT) 2.76 1.11 46
Morse 2006        
Morse 2006 Control 2.62 1.15 49
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Analysis 1.12.   Comparison 1 Integrated models of care versus standard care,
Outcome 12 Mental state: 1. Average score (BPRS, high = poor) (skewed data).
Mental state: 1. Average score (BPRS, high = poor) (skewed data)
Study Intervention Mean SD N
6 months
Drake 1998a Treatment 42.20 12.18 105
Drake 1998a Control 42.85 12.09 98
Essock 2006 Treatment 46.10 13.70 78
Essock 2006 Control 43.40 11.20 75
12 months
Drake 1998a Treatment 41.57 10.80 105
Drake 1998a Control 43.19 11.96 98
Essock 2006 Treatment 46.20 13.80 86
Essock 2006 Control 43.60 11.50 82
18 months
Drake 1998a Treatment 43.89 11.58 105
Drake 1998a Control 44.37 13.39 98
Essock 2006 Treatment 45.60 12.50 89
Essock 2006 Control 45.00 12.10 84
24 months
Drake 1998a Treatment 42.45 11.03 105
Drake 1998a Control 43.32 12.36 98
Essock 2006 Treatment 43.70 12.40 79
Essock 2006 Control 45.90 12.80 86
30 months
Drake 1998a Treatment 39.63 9.60 105
Drake 1998a Control 42.27 12.13 98
Essock 2006 Treatment 46.60 16.10 83
Essock 2006 Control 44.60 12.80 77
36 months
Drake 1998a Treatment 40.89 10.82 105
Drake 1998a Control 41.11 11.69 98
Essock 2006 Treatment 43.00 11.20 85
Essock 2006 Control 43.20 12.50 81
 
 
Analysis 1.13.   Comparison 1 Integrated models of care versus standard
care, Outcome 13 Global state: 1. Average score (GAF, low = poor).
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.13.1 By 6 months  
Essock 2006 87 41.9 (8.9) 75 40.8 (8.5) 100% 1.1[-1.58,3.78]
Subtotal *** 87   75   100% 1.1[-1.58,3.78]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.8(P=0.42)  
   
1.13.2 By 12 months  
Essock 2006 89 40.4 (9.9) 82 39.7 (8.6) 100% 0.7[-2.07,3.47]
Subtotal *** 89   82   100% 0.7[-2.07,3.47]
Heterogeneity: Not applicable  
Favours control 42-4 -2 0 Favours treatment
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Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for overall effect: Z=0.49(P=0.62)  
   
1.13.3 By 18 months  
Essock 2006 90 40.6 (10.1) 86 39.6 (7.2) 100% 1[-1.58,3.58]
Subtotal *** 90   86   100% 1[-1.58,3.58]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.76(P=0.45)  
   
1.13.4 By 24 months  
Essock 2006 81 41.7 (9.5) 85 40 (9.4) 100% 1.7[-1.18,4.58]
Subtotal *** 81   85   100% 1.7[-1.18,4.58]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.16(P=0.25)  
   
1.13.5 By 30 months  
Essock 2006 84 39.8 (9.4) 80 40.4 (9.9) 100% -0.6[-3.56,2.36]
Subtotal *** 84   80   100% -0.6[-3.56,2.36]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.4(P=0.69)  
   
1.13.6 By 36 months  
Essock 2006 85 43 (9.2) 85 42.6 (9.9) 100% 0.4[-2.47,3.27]
Subtotal *** 85   85   100% 0.4[-2.47,3.27]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.27(P=0.78)  
Favours control 42-4 -2 0 Favours treatment
 
 
Analysis 1.14.   Comparison 1 Integrated models of care versus standard
care, Outcome 14 Global state: 2. Forensic measures (skewed data).
Global state: 2. Forensic measures (skewed data)
Study Intervention Mean SD N
Arrests - 36 months
Chandler 2006 Treatment 2.21 4.06 103
Chandler 2006 Control 2.61 3.31 79
Convictions - 36 months
Chandler 2006 Treatment 0.59 0.90 103
Chandler 2006 Control 0.73 0.98 79
Felony - 36 months
Chandler 2006 Treatment 0.31 0.46 103
Chandler 2006 Control 0.28 0.50 79
Hospital or jail - 3 months
Essock 2006 Treatment 118 221 99
Essock 2006 Control 112 210 99
Jail days - 36 months
Chandler 2006 Treatment 60.71 73.03 103
Chandler 2006 Control 59.39 66.86 79
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Analysis 1.15.   Comparison 1 Integrated models of care versus standard care, Outcome
15 Quality of life/ life satisfaction: 1. Average general score (QOLI, range 1-7, low = poor).
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.15.1 By 6 months  
Drake 1998a 105 4.3 (1.6) 98 4.3 (1.4) 52.63% -0.02[-0.43,0.39]
Essock 2006 84 4.6 (1.5) 74 4.8 (1.3) 47.37% -0.2[-0.64,0.24]
Subtotal *** 189   172   100% -0.11[-0.41,0.2]
Heterogeneity: Tau2=0; Chi2=0.34, df=1(P=0.56); I2=0%  
Test for overall effect: Z=0.69(P=0.49)  
   
1.15.2 By 12 months  
Drake 1998a 105 4.3 (1.5) 98 4.3 (1.4) 59.34% -0.04[-0.43,0.35]
Essock 2006 88 4.7 (1.5) 81 4.6 (1.6) 40.66% 0.1[-0.37,0.57]
Subtotal *** 193   179   100% 0.02[-0.28,0.32]
Heterogeneity: Tau2=0; Chi2=0.2, df=1(P=0.65); I2=0%  
Test for overall effect: Z=0.11(P=0.91)  
   
1.15.3 By 18 months  
Drake 1998a 105 4.3 (1.4) 98 4.4 (1.3) 57.8% -0.07[-0.45,0.31]
Essock 2006 89 4.8 (1.6) 85 4.5 (1.6) 42.2% 0.3[-0.18,0.78]
Subtotal *** 194   183   100% 0.09[-0.27,0.44]
Heterogeneity: Tau2=0.02; Chi2=1.42, df=1(P=0.23); I2=29.58%  
Test for overall effect: Z=0.47(P=0.64)  
   
1.15.4 By 24 months  
Drake 1998a 105 4.3 (1.5) 98 4.5 (1.4) 57.16% -0.12[-0.51,0.27]
Essock 2006 81 4.7 (1.6) 86 4.5 (1.4) 42.84% 0.2[-0.26,0.66]
Subtotal *** 186   184   100% 0.02[-0.29,0.33]
Heterogeneity: Tau2=0; Chi2=1.09, df=1(P=0.3); I2=8.07%  
Test for overall effect: Z=0.11(P=0.91)  
   
1.15.5 By 30 months  
Drake 1998a 105 4.6 (1.2) 98 4.6 (1.4) 62.38% 0.04[-0.33,0.41]
Essock 2006 83 4.8 (1.6) 80 4.8 (1.5) 37.62% 0[-0.48,0.48]
Subtotal *** 188   178   100% 0.02[-0.27,0.32]
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.9); I2=0%  
Test for overall effect: Z=0.17(P=0.87)  
   
1.15.6 By 36 months  
Drake 1998a 105 4.6 (1.2) 98 4.5 (1.3) 65.74% 0.1[-0.25,0.45]
Essock 2006 85 4.8 (1.6) 85 4.7 (1.6) 34.26% 0.1[-0.38,0.58]
Subtotal *** 190   183   100% 0.1[-0.18,0.38]
Heterogeneity: Tau2=0; Chi2=0, df=1(P=1); I2=0%  
Test for overall effect: Z=0.7(P=0.49)  
Favours treatment 10.5-1 -0.5 0 Favours control
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Analysis 1.16.   Comparison 1 Integrated models of care versus standard care,
Outcome 16 Service use: 1. Days in stable community residences (not in hospital).
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.16.1 By 12 months  
Drake 1998a 105 151.7 (43.3) 98 151 (54.2) 65.02% 0.7[-12.86,14.26]





Subtotal *** 197   181   100% -10[-38.61,18.6]
Heterogeneity: Tau2=279.72; Chi2=2.48, df=1(P=0.11); I2=59.75%  
Test for overall effect: Z=0.69(P=0.49)  
   
1.16.2 By 24 months  
Drake 1998a 105 158.5 (48.1) 98 151.1 (51.4) 100% 7.4[-6.32,21.12]
Subtotal *** 105   98   100% 7.4[-6.32,21.12]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.06(P=0.29)  
   
1.16.3 By 36 months  
Drake 1998a 105 171.4 (52.6) 98 167.7 (58.1) 88.49% 3.7[-11.58,18.98]
Essock 2006 81 268.6 (128) 80 252.1
(145.7)
11.51% 16.5[-25.88,58.88]
Subtotal *** 186   178   100% 5.17[-9.2,19.55]
Heterogeneity: Tau2=0; Chi2=0.31, df=1(P=0.58); I2=0%  
Test for overall effect: Z=0.71(P=0.48)  
Favours control 10050-100 -50 0 Favours treatment
 
 
Analysis 1.17.   Comparison 1 Integrated models of care versus standard care,
Outcome 17 Service use: 2. Number hospitalised - during the 36 month study period.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Essock 2006 42/99 48/99 100% 0.88[0.64,1.19]
   
Total (95% CI) 99 99 100% 0.88[0.64,1.19]
Total events: 42 (Treatment), 48 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.85(P=0.39)  
Favours treatment 20.5 1.50.7 1 Favours control
 
 
Analysis 1.18.   Comparison 1 Integrated models of care versus standard care, Outcome 18
Service use: 3. Relapse (hospitalisation days and crisis care) - 36 months (skewed data).
Service use: 3. Relapse (hospitalisation days and crisis care) - 36 months (skewed data)
Study Intervention Mean SD N
Chandler 2006 Treatment 1.25 3.27 103
Chandler 2006 Control 5.03 13.88 79
Drake 1998a Treatment 10 31.62 105
Drake 1998a Control 12.45 35.65 98
Essock 2006 Treatment 23 68 99
Essock 2006 Control 26 48 99
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Analysis 1.19.   Comparison 1 Integrated models of care versus standard care,
Outcome 19 Service use: 4. Medication hours - 36 months (skewed data).
Service use: 4. Medication hours - 36 months (skewed data)
Study Intervention Mean SD N
Chandler 2006 Treatment 6.52 0.82 86
Chandler 2006 Control 3.02 0.60 49
 
 
Analysis 1.20.   Comparison 1 Integrated models of care versus standard
care, Outcome 20 Service use: 5. Various measures (skewed data).
Service use: 5. Various measures (skewed data)
Study Treatment Mean SD N Notes
Days institutionalised (hospital or incarcerated) - 36 months (site 2)
Essock 2006 Integrated models of
care
139 262 48 P = 0.02
using Mann Whitney U
test (non-parametric
test).
Essock 2006 TAU 158 254 50  
Days in hospital - 36 months (site 2)
Essock 2006 Integrated models of
care
32 91 48 P = 0.002
using Mann Whitney U
test (non-parametric
test).
Essock 2006 TAU 41 60 50  
 
 
Analysis 1.21.   Comparison 1 Integrated models of care versus standard care,
Outcome 21 Homelessness: 1. Proportion of time on the street - past 60 days.
Homelessness: 1. Proportion of time on the street - past 60 days
Study Intervention Mean SD N
3 months
Burnam 1995 Treatment 20.88 37.14 112
Burnam 1995 Control 19.85 40.68 45
6 months
Burnam 1995 Treatment 25.95 41.40 112
Burnam 1995 Control 21.04 42.44 47
9 months
Burnam 1995 Treatment 21.03 48.77 109
Burnam 1995 Control 25.14 39.45 36
 
 
Analysis 1.22.   Comparison 1 Integrated models of care versus standard care, Outcome
22 Homelessness: 2. Proportion of time in independent housing - past 60 days.
Homelessness: 2. Proportion of time in independent housing - past 60 days
Study Intervention Mean SD N
3 months
Burnam 1995 Treatment 14.32 40.80 112
Burnam 1995 Control 9.67 40.33 45
6 months
Burnam 1995 Treatment 18.98 41.64 112
Burnam 1995 Control 10.83 37.06 47
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Homelessness: 2. Proportion of time in independent housing - past 60 days
Study Intervention Mean SD N
9 months
Burnam 1995 Treatment 17.84 43.58 109
Burnam 1995 Control 26.31 46.83 36
 
 
Analysis 1.23.   Comparison 1 Integrated models of care versus standard care, Outcome
23 Homelessness: 3. Average number of days in stable housing (skewed data).
Homelessness: 3. Average number of days in stable housing (skewed data)
Study Intervention Mean SD N
6 months
Morse 2006 Treatment 8.19 9.68 46
Morse 2006 Control 5.02 8.62 49
12 months
Morse 2006 Treatment 14.18 12.33 46
Morse 2006 Control 11.34 12.04 49
18 months
Morse 2006 Treatment 17.01 12.51 46
Morse 2006 Control 10.55 12.87 49
24 months
Morse 2006 Treatment 18.29 12.12 46
Morse 2006 Control 12.59 13.27 49
 
 
Analysis 1.24.   Comparison 1 Integrated models of care versus standard
care, Outcome 24 Homelessness: 4. Various measures (skewed data).
Homelessness: 4. Various measures (skewed data)
Study Treatment Mean SD N Notes
Time on streets (%) - 3 months
Burnam 1995 Treatment 24.77 42.21 54  
Burnam 1995 Control 19.85 40.68 45  
Time on streets (%) - 6 months
Burnam 1995 Treatment 29.67 44.86 45  
Burnam 1995 Control 21.04 42.44 47  
Time on streets (%) - 9 months
Burnam 1995 Treatment 19.73 47.28 43  
Burnam 1995 Control 25.14 39.45 36  
Days in stable community residence - 24 months
Essock 2006 Treatment 264.30 130.40 89  
Essock 2006 Control 245.60 143.90 85  
Time in independent housing in past 60 days - 3 months
Burnam 1995 Treatment 1.72 33.79 54  
Burnam 1995 Control 9.67 40.33 45  
Time in independent housing in past 60 days - 6 months
Burnam 1995 Treatment 35.20 48.78 45  
Burnam 1995 Control 10.83 37.06 47  
Time in independent housing in past 60 days - 9 months
Burnam 1995 Treatment 16.30 45.84 43  
Burnam 1995 Control 26.31 46.83 36  
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Comparison 2.   Non-integrated models of care (Assertive Community Treatment / Intensive Case Management /
Specialised case management sercives) versus standard care





Statistical method Effect size
1 Leaving the study early: 1. Lost to treat-
ment
3   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
1.1 By 6 months 3 134 Risk Ratio (M-H, Random,
95% CI)
1.23 [0.73, 2.06]
1.2 By 12 months 3 134 Risk Ratio (M-H, Random,
95% CI)
1.21 [0.73, 1.99]
1.3 By 18 months 3 134 Risk Ratio (M-H, Random,
95% CI)
1.35 [0.83, 2.19]
2 Leaving the study early: 2. Lost to evalua-
tion
3   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
2.1 By 6 months 3 121 Risk Ratio (M-H, Random,
95% CI)
1.0 [0.38, 2.60]
2.2 By 12 months 3 121 Risk Ratio (M-H, Random,
95% CI)
1.0 [0.43, 2.35]
2.3 By 18 months 2 92 Risk Ratio (M-H, Random,
95% CI)
1.26 [0.48, 3.30]
3 Substance use: 1. Average scores on vari-
ous scales (skewed data)
    Other data No numeric data
3.1 Alcohol - 6 months (C-DIS-R)     Other data No numeric data
3.2 Alcohol - 12 months (C-DIS-R)     Other data No numeric data
3.3 Alcohol - 18 months (C-DIS-R)     Other data No numeric data
3.4 Drugs - 6 months (C-DIS-R)     Other data No numeric data
3.5 Drugs - 12 months (C-DIS-R)     Other data No numeric data
3.6 Drugs - 18 months (C-DIS-R)     Other data No numeric data
3.7 General - 12 months (ASI)     Other data No numeric data
4 Substance use: 2. Average score (USS,
high = poor (1=client not abstinent, 5 client
mets criteria for severe use) (skewed data)
    Other data No numeric data
4.1 6 months     Other data No numeric data
4.2 12 months     Other data No numeric data
4.3 18 months     Other data No numeric data
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Statistical method Effect size
4.4 24 months     Other data No numeric data
5 Mental state: 1. Average scores on various
scales (skewed data)
    Other data No numeric data
5.1 Depression symptoms - 6 months (C-
DIS-R)
    Other data No numeric data
5.2 Depression symptoms - 12 months (C-
DIS-R)
    Other data No numeric data
5.3 Depression symptoms - 18 months (C-
DIS-R)
    Other data No numeric data
5.4 General - average score - 12 months
(ASI)
    Other data No numeric data
5.5 Manic symptoms - 6 months (C-DIS-R)     Other data No numeric data
5.6 Manic symptoms - 12 months (C-DIS-R)     Other data No numeric data
5.7 Manic symptoms - 18 months (C-DIS-R)     Other data No numeric data
5.8 Schizophrenia symptoms - 6 months (C-
DIS-R)
    Other data No numeric data
5.9 Schizophrenia symptoms - 12 months
(C-DIS-R)
    Other data No numeric data
5.10 Schizophrenia symptoms - 18 months
(C-DIS-R)
    Other data No numeric data
6 Global state: 1. Forensic measures - num-
ber of arrests (skewed data)
    Other data No numeric data
6.1 12 months     Other data No numeric data
6.2 18 months     Other data No numeric data
6.3 24 months     Other data No numeric data
6.4 30 months     Other data No numeric data
7 Global state: 2. Forensic measures - num-
ber of convictions (skewed data)
    Other data No numeric data
7.1 12 months     Other data No numeric data
7.2 24 months     Other data No numeric data
7.3 30 months     Other data No numeric data
8 Global state: 3. Forensic measures - days
in jail (skewed data)
    Other data No numeric data
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Statistical method Effect size
8.1 12 months     Other data No numeric data
8.2 18 months     Other data No numeric data
8.3 24 months     Other data No numeric data
8.30 30 months     Other data No numeric data
9 Social functioning: 1. Average role func-
tioning score (RFS, high = better function-
ing)
1   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
9.1 By 6 months 1 50 Mean Difference (IV, Ran-
dom, 95% CI)
-0.78 [-2.91, 1.35]
9.2 By 12 months 1 50 Mean Difference (IV, Ran-
dom, 95% CI)
0.70 [-1.56, 2.96]
9.3 By 18 months 1 29 Mean Difference (IV, Ran-
dom, 95% CI)
-2.67 [-5.28, -0.06]
10 Social functioning: 2. Average social ad-
justment score (SAS, high = better func-
tioning)
1   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
10.1 By 6 months 1 50 Mean Difference (IV, Ran-
dom, 95% CI)
-0.93 [-6.34, 4.48]
10.2 By 12 months 1 50 Mean Difference (IV, Ran-
dom, 95% CI)
3.09 [-2.71, 8.89]
10.3 By 18 months 1 29 Mean Difference (IV, Ran-
dom, 95% CI)
-3.75 [-10.12, 2.62]
11 Quality of life/ life satisfaction: 1. Aver-
age score (QOLI, skewed data) - 12 months
    Other data No numeric data
12 Service use: 1. Relapse (skewed data)     Other data No numeric data
12.5 % days in hospital     Other data No numeric data
13 Service use: 2. Various measures - 24
months (skewed data)
    Other data No numeric data
13.1 State Operated admissions (site 1,
Robert Young)
    Other data No numeric data
13.2 State Operated admissions (site 2,
Pilsen-Little)
    Other data No numeric data
13.3 State operated days admitted (site 1)     Other data No numeric data
13.4 State Operated days admitted (site 2)     Other data No numeric data
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Statistical method Effect size
13.5 Private Hospital length of stay (site 1,
days)
    Other data No numeric data
13.6 Private Hospital length of stay (site 2,
days)
    Other data No numeric data
14 Homelessness: 1. Average number of
days in stable housing (skewed data)
    Other data No numeric data
14.1 6 months     Other data No numeric data
14.2 12 months     Other data No numeric data
14.3 18 months     Other data No numeric data
14.4 24 months     Other data No numeric data
 
 
Analysis 2.1.   Comparison 2 Non-integrated models of care (Assertive Community
Treatment / Intensive Case Management / Specialised case management sercives)
versus standard care, Outcome 1 Leaving the study early: 1. Lost to treatment.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.1.1 By 6 months  
Bond 1991a 12/21 9/21 70.59% 1.33[0.72,2.47]
Bond 1991b 6/21 6/21 29.41% 1[0.38,2.6]
Jerrell 1995b 0/25 0/25   Not estimable
Subtotal (95% CI) 67 67 100% 1.23[0.73,2.06]
Total events: 18 (Treatment), 15 (Control)  
Heterogeneity: Tau2=0; Chi2=0.25, df=1(P=0.62); I2=0%  
Test for overall effect: Z=0.77(P=0.44)  
   
2.1.2 By 12 months  
Bond 1991a 12/21 9/21 65.75% 1.33[0.72,2.47]
Bond 1991b 7/21 7/21 34.25% 1[0.43,2.35]
Jerrell 1995b 0/25 0/25   Not estimable
Subtotal (95% CI) 67 67 100% 1.21[0.73,1.99]
Total events: 19 (Treatment), 16 (Control)  
Heterogeneity: Tau2=0; Chi2=0.29, df=1(P=0.59); I2=0%  
Test for overall effect: Z=0.74(P=0.46)  
   
2.1.3 By 18 months  
Bond 1991a 14/21 10/21 44.91% 1.4[0.82,2.4]
Bond 1991b 6/21 8/21 23.72% 0.75[0.31,1.79]
Jerrell 1995b 14/25 7/25 31.37% 2[0.98,4.1]
Subtotal (95% CI) 67 67 100% 1.35[0.83,2.19]
Total events: 34 (Treatment), 25 (Control)  
Heterogeneity: Tau2=0.06; Chi2=2.92, df=2(P=0.23); I2=31.55%  
Favours treatment 20.5 1.50.7 1 Favours control
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=1.22(P=0.22)  
Favours treatment 20.5 1.50.7 1 Favours control
 
 
Analysis 2.2.   Comparison 2 Non-integrated models of care (Assertive Community
Treatment / Intensive Case Management / Specialised case management sercives)
versus standard care, Outcome 2 Leaving the study early: 2. Lost to evaluation.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.2.1 By 6 months  
Bond 1991b 6/21 6/21 100% 1[0.38,2.6]
Jerrell 1995b 0/25 0/25   Not estimable
Lehman 1993 0/14 0/15   Not estimable
Subtotal (95% CI) 60 61 100% 1[0.38,2.6]
Total events: 6 (Treatment), 6 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.2.2 By 12 months  
Bond 1991b 7/21 7/21 100% 1[0.43,2.35]
Jerrell 1995b 0/25 0/25   Not estimable
Lehman 1993 0/14 0/15   Not estimable
Subtotal (95% CI) 60 61 100% 1[0.43,2.35]
Total events: 7 (Treatment), 7 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.2.3 By 18 months  
Bond 1991b 6/21 8/21 46.77% 0.75[0.31,1.79]
Jerrell 1995b 14/25 7/25 53.23% 2[0.98,4.1]
Subtotal (95% CI) 46 46 100% 1.26[0.48,3.3]
Total events: 20 (Treatment), 15 (Control)  
Heterogeneity: Tau2=0.32; Chi2=2.91, df=1(P=0.09); I2=65.63%  
Test for overall effect: Z=0.48(P=0.63)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 2.3.   Comparison 2 Non-integrated models of care (Assertive Community
Treatment / Intensive Case Management / Specialised case management sercives) versus
standard care, Outcome 3 Substance use: 1. Average scores on various scales (skewed data).
Substance use: 1. Average scores on various scales (skewed data)
Study Intervention Mean SD N
Alcohol - 6 months (C-DIS-R)
Jerrell 1995b Treatment 2.99 3.09 24
Jerrell 1995b Control 2.80 3.49 25
Alcohol - 12 months (C-DIS-R)
Jerrell 1995b Treatment 2.03 2.82 24
Jerrell 1995b Control 2.95 3.50 25
Alcohol - 18 months (C-DIS-R)
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Substance use: 1. Average scores on various scales (skewed data)
Study Intervention Mean SD N
Jerrell 1995b Treatment 1.90 2.88 10
Jerrell 1995b Control 1.39 2.52 18
Drugs - 6 months (C-DIS-R)
Jerrell 1995b Treatment 4.56 4.94 24
Jerrell 1995b Control 4.84 5.69 25
Drugs - 12 months (C-DIS-R)
Jerrell 1995b Treatment 3.74 4.19 24
Jerrell 1995b Control 5.99 7.46  
Drugs - 18 months (C-DIS-R)
Jerrell 1995b Treatment 2.70 4.11 10
Jerrell 1995b Control 2.22 3.46 18
General - 12 months (ASI)
Lehman 1993 Treatment 39.80 89.80 14
Lehman 1993 Control 58.50 81.0  
 
 
Analysis 2.4.   Comparison 2 Non-integrated models of care (Assertive Community Treatment / Intensive Case
Management / Specialised case management sercives) versus standard care, Outcome 4 Substance use: 2.
Average score (USS, high = poor (1=client not abstinent, 5 client mets criteria for severe use) (skewed data).
Substance use: 2. Average score (USS, high = poor (1=client not abstinent, 5 client mets criteria for severe use) (skewed data)
Study Intervention Mean SD N
6 months
Morse 2006        
Morse 2006 Treatment (ACT) 2.98 1.31 54
Morse 2006 Control 2.93 1.19 49
12 months
Morse 2006        
Morse 2006 Treatment (ACT) 2.86 1.32 54
Morse 2006 Control (Standard care) 2.78 1.18 49
18 months
Morse 2006        
Morse 2006 Treatment (ACT) 3.02 1.26 54
Morse 2006 Control (Standard care 2.69 1.10 49
24 months
Morse 2006        
Morse 2006 Treatment (ACT) 2.70 1.28 54
Morse 2006 Control (Standard care) 2.62 1.15 49
 
 
Analysis 2.5.   Comparison 2 Non-integrated models of care (Assertive Community
Treatment / Intensive Case Management / Specialised case management sercives) versus
standard care, Outcome 5 Mental state: 1. Average scores on various scales (skewed data).
Mental state: 1. Average scores on various scales (skewed data)
Study Intervention Mean SD N
Depression symptoms - 6 months (C-DIS-R)
Jerrell 1995b Treatment 6.02 4.59 24
Jerrell 1995b Control 8.11 4.73 25
Depression symptoms - 12 months (C-DIS-R)
Jerrell 1995b Treatment 5.81 5.01 24
Jerrell 1995b Control 7.78 5.04 25
Depression symptoms - 18 months (C-DIS-R)
Psychosocial interventions for people with both severe mental illness and substance misuse (Review)









Cochrane Database of Systematic Reviews
Mental state: 1. Average scores on various scales (skewed data)
Study Intervention Mean SD N
Jerrell 1995b Treatment 4.40 4.33 10
Jerrell 1995b Control 8.42 5.99 18
General - average score - 12 months (ASI)
Lehman 1993 Treatment 0.30 0.22 14
Lehman 1993 Control 0.25 0.22 15
Manic symptoms - 6 months (C-DIS-R)
Jerrell 1995b Treatment 1.99 1.61 24
Jerrell 1995b Control 2.05 1.55 25
Manic symptoms - 12 months (C-DIS-R)
Jerrell 1995b Treatment 1.66 1.77 24
Jerrell 1995b Control 2.47 1.98 25
Manic symptoms - 18 months (C-DIS-R)
Jerrell 1995b Treatment 0.80 0.92 10
Jerrell 1995b Control 2.60 1.42 18
Schizophrenia symptoms - 6 months (C-DIS-R)
Jerrell 1995b Treatment 2.67 3.55 24
Jerrell 1995b Control 4.60 5.25 25
Schizophrenia symptoms - 12 months (C-DIS-R)
Jerrell 1995b Treatment 2.65 3.67 24
Jerrell 1995b Control 4.93 5.39 25
Schizophrenia symptoms - 18 months (C-DIS-R)
Jerrell 1995b Treatment 0.90 1.20 10
Jerrell 1995b Control 4.11 5.17 18
 
 
Analysis 2.6.   Comparison 2 Non-integrated models of care (Assertive Community Treatment /
Intensive Case Management / Specialised case management sercives) versus standard
care, Outcome 6 Global state: 1. Forensic measures - number of arrests (skewed data).
Global state: 1. Forensic measures - number of arrests (skewed data)
Study Intervention Mean SD N
12 months
Maloney 2006 Treatment 0.36 0.50 58
Maloney 2006 Control 0.58 1.00 43
18 months
Maloney 2006 Treatment 0.46 1.12 58
Maloney 2006 Control 0.20 0.41 43
24 months
Maloney 2006 Treatment 0.23 0.59 58
Maloney 2006 Control 0.34 0.81 43
30 months
Maloney 2006 Treatment 0.36 0.78 58
Maloney 2006 Control 0.51 0.88 43
 
 
Analysis 2.7.   Comparison 2 Non-integrated models of care (Assertive Community Treatment /
Intensive Case Management / Specialised case management sercives) versus standard
care, Outcome 7 Global state: 2. Forensic measures - number of convictions (skewed data).
Global state: 2. Forensic measures - number of convictions (skewed data)
Study Intervention Mean SD N
12 months
Maloney 2006 Treatment 0.30 0.48 58
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Global state: 2. Forensic measures - number of convictions (skewed data)
Study Intervention Mean SD N
Maloney 2006 Control 0.25 0.62 43
24 months
Maloney 2006 Treatment 0.20 0.88 58
Maloney 2006 Control 0.22 0.63 43
30 months
Maloney 2006 Treatment 0.27 0.66 58
Maloney 2006 Control 0.53 1.10 43
 
 
Analysis 2.8.   Comparison 2 Non-integrated models of care (Assertive Community
Treatment / Intensive Case Management / Specialised case management sercives) versus
standard care, Outcome 8 Global state: 3. Forensic measures - days in jail (skewed data).
Global state: 3. Forensic measures - days in jail (skewed data)
Study Intervention Mean SD N
12 months
Maloney 2006 Treatment 10.91 18.50 58
Maloney 2006 Control 12.90 30.12 43
18 months
Maloney 2006 Treatment 7.25 14.55 58
Maloney 2006 Control 20.92 39.46 43
24 months
Maloney 2006 Treatment 8.80 20.91 58
Maloney 2006 Control 7.28 14.07 43
30 months
Maloney 2006 Treatment 20.84 34.05 58
Maloney 2006 Control 24.59 38.27 43
 
 
Analysis 2.9.   Comparison 2 Non-integrated models of care (Assertive Community Treatment /
Intensive Case Management / Specialised case management sercives) versus standard care,
Outcome 9 Social functioning: 1. Average role functioning score (RFS, high = better functioning).
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.9.1 By 6 months  
Jerrell 1995b 25 11.4 (3.8) 25 12.2 (3.8) 100% -0.78[-2.91,1.35]
Subtotal *** 25   25   100% -0.78[-2.91,1.35]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.72(P=0.47)  
   
2.9.2 By 12 months  
Jerrell 1995b 25 12.7 (4.7) 25 12 (3.3) 100% 0.7[-1.56,2.96]
Subtotal *** 25   25   100% 0.7[-1.56,2.96]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.61(P=0.54)  
   
2.9.3 By 18 months  
Jerrell 1995b 11 10.8 (2.4) 18 13.4 (4.8) 100% -2.67[-5.28,-0.06]
Subtotal *** 11   18   100% -2.67[-5.28,-0.06]
Heterogeneity: Not applicable  
Favours control 42-4 -2 0 Favours treatment
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Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for overall effect: Z=2(P=0.05)  
Favours control 42-4 -2 0 Favours treatment
 
 
Analysis 2.10.   Comparison 2 Non-integrated models of care (Assertive Community Treatment /
Intensive Case Management / Specialised case management sercives) versus standard care,
Outcome 10 Social functioning: 2. Average social adjustment score (SAS, high = better functioning).
Study or subgroup Control Treatment Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.10.1 By 6 months  
Jerrell 1995b 25 74.6 (11.1) 25 75.6 (8.2) 100% -0.93[-6.34,4.48]
Subtotal *** 25   25   100% -0.93[-6.34,4.48]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.34(P=0.74)  
   
2.10.2 By 12 months  
Jerrell 1995b 25 76.2 (10.9) 25 73.1 (10) 100% 3.09[-2.71,8.89]
Subtotal *** 25   25   100% 3.09[-2.71,8.89]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.04(P=0.3)  
   
2.10.3 By 18 months  
Jerrell 1995b 11 72.5 (6.6) 18 76.2 (10.9) 100% -3.75[-10.12,2.62]
Subtotal *** 11   18   100% -3.75[-10.12,2.62]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.15(P=0.25)  
Favours treatment 105-10 -5 0 Favours control
 
 
Analysis 2.11.   Comparison 2 Non-integrated models of care (Assertive Community Treatment /
Intensive Case Management / Specialised case management sercives) versus standard care,
Outcome 11 Quality of life/ life satisfaction: 1. Average score (QOLI, skewed data) - 12 months.
Quality of life/ life satisfaction: 1. Average score (QOLI, skewed data) - 12 months
Study Intervention Mean SD N Notes
Lehman 1993 Treatment 4.6 1.98 14 QOLI min score=1
Lehman 1993 Control 5.94 0.85 15  
 
 
Analysis 2.12.   Comparison 2 Non-integrated models of care (Assertive Community
Treatment / Intensive Case Management / Specialised case management sercives)
versus standard care, Outcome 12 Service use: 1. Relapse (skewed data).
Service use: 1. Relapse (skewed data)
Study Intervention Mean SD N
% days in hospital
Bond 1991b Treatment 13.9 38.80 14
Bond 1991b Control 26.6 59.2 14
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Analysis 2.13.   Comparison 2 Non-integrated models of care (Assertive Community
Treatment / Intensive Case Management / Specialised case management sercives) versus
standard care, Outcome 13 Service use: 2. Various measures - 24 months (skewed data).
Service use: 2. Various measures - 24 months (skewed data)
Study Intervention Mean SD N
State Operated admissions (site 1, Robert Young)
Godley 1994 Treatment 0.21 0.43 14
Godley 1994 Control 0.29 0.61 22
State Operated admissions (site 2, Pilsen-Little)
Godley 1994 Treatment 1.53 1.46 17
Godley 1994 Control 2.82 4.31 11
State operated days admitted (site 1)
Godley 1994 Treatment 8.36 22.36 14
Godley 1994 Control 1.86 4.20 14
State Operated days admitted (site 2)
Godley 1994 Treatment 37.06 40.50 17
Godley 1994 Control 76.91 110.34 11
Private Hospital length of stay (site 1, days)
Godley 1994 Treatment 8.36 22.36 14
Godley 1994 Control 1.50 3.63 14
Private Hospital length of stay (site 2, days)
Godley 1994 Treatment 22.01 23.14 17
Godley 1994 Control 17.55 18.04 11
 
 
Analysis 2.14.   Comparison 2 Non-integrated models of care (Assertive Community Treatment /
Intensive Case Management / Specialised case management sercives) versus standard care,
Outcome 14 Homelessness: 1. Average number of days in stable housing (skewed data).
Homelessness: 1. Average number of days in stable housing (skewed data)
Study Intervention Mean SD N
6 months
Morse 2006 Treatment 5.77 7.42 54
Morse 2006 Control 5.02 8.62 49
12 months
Morse 2006 Treatment 13.87 11.66 54
Morse 2006 Control 11.34 12.04 49
18 months
Morse 2006 Treatment 18.19 11.61 54
Morse 2006 Control 10.55 12.87 49
24 months
Morse 2006 Treatment 17.78 12.68 54
Morse 2006 Control 12.59 13.27 49
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Comparison 3.   Cognitive behavioural therapy versus standard care





Statistical method Effect size
1 Leaving the study early: 1. Lost to treat-
ment
2   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
1.1 By 3 months 2 152 Risk Ratio (M-H, Random, 95%
CI)
1.12 [0.44, 2.86]
2 Leaving the study early: 2. Lost to evalua-
tion
1   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.1 By 9 months after start of treatment 1 47 Risk Ratio (M-H, Random, 95%
CI)
1.04 [0.43, 2.51]
3 Substance use: 1. Percentage of partici-
pants who used cannabis - in last 4 weeks
1   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
3.1 By 3 months 1 47 Risk Ratio (M-H, Random, 95%
CI)
1.04 [0.62, 1.74]
3.2 By 6 months 1 47 Risk Ratio (M-H, Random, 95%
CI)
1.30 [0.79, 2.15]
4 Substance use: 2. Average score (various
scales) (skewed data)
    Other data No numeric data
4.2 CASUAS     Other data No numeric data
4.3 HONOS - item 3     Other data No numeric data
5 Mental state: 1. Average insight score (In-
sight Scale, low = poor) - by 3 months
1 105 Mean Difference (IV, Random,
95% CI)
0.52 [-0.78, 1.82]
6 Mental state: 2. Average score (various
scales) (skewed data)
    Other data No numeric data
6.1 Anxiety symptoms - 3 months (BAS)     Other data No numeric data
6.2 Depressive symptoms - 3 months (BDI-
SF)
    Other data No numeric data
6.3 Depressive symptoms - 3 months
(MADRS)
    Other data No numeric data
6.5 Depressive symptoms - 6 months (BDI-
SF)
    Other data No numeric data
6.6 General symptoms total score - 3
months (BPRS)
    Other data No numeric data
6.7 General - 3 months (CPRS)     Other data No numeric data
6.8 General - 3 months (SCR)     Other data No numeric data
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Statistical method Effect size
6.9 General symptoms total score - 6
months (BPRS)
    Other data No numeric data
6.11 Negative symptoms - 3 months (SANS)     Other data No numeric data
6.12 Negative symptoms - 6 months (SANS)     Other data No numeric data
7 Social functioning: 1. Average score (SO-
FAS, low = poor)
1   Mean Difference (IV, Random,
95% CI)
Subtotals only
7.1 By 3 months 1 47 Mean Difference (IV, Random,
95% CI)
-0.80 [-9.95, 8.35]
7.2 By 6 months 1 47 Mean Difference (IV, Random,
95% CI)
-4.70 [-14.52, 5.12]
8 Social functioning: 2. Average score
(HONOS) (skewed data)
    Other data No numeric data
8.1 3 months     Other data No numeric data
9 Service use: 1. Outpatient medication
(SURS) (skewed data)
    Other data No numeric data
9.1 3 months     Other data No numeric data
9.2 6 months     Other data No numeric data
 
 
Analysis 3.1.   Comparison 3 Cognitive behavioural therapy versus
standard care, Outcome 1 Leaving the study early: 1. Lost to treatment.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.1.1 By 3 months  
Edwards 2006 1/23 1/24 11.9% 1.04[0.07,15.72]
Naeem 2005 10/67 5/38 88.1% 1.13[0.42,3.07]
Subtotal (95% CI) 90 62 100% 1.12[0.44,2.86]
Total events: 11 (Treatment), 6 (Control)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.95); I2=0%  
Test for overall effect: Z=0.24(P=0.81)  
Favours treatment 50.2 20.5 1 Favours control
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Analysis 3.2.   Comparison 3 Cognitive behavioural therapy versus
standard care, Outcome 2 Leaving the study early: 2. Lost to evaluation.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.2.1 By 9 months after start of treatment  
Edwards 2006 7/23 7/24 100% 1.04[0.43,2.51]
Subtotal (95% CI) 23 24 100% 1.04[0.43,2.51]
Total events: 7 (Treatment), 7 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.1(P=0.92)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 3.3.   Comparison 3 Cognitive behavioural therapy versus standard care, Outcome
3 Substance use: 1. Percentage of participants who used cannabis - in last 4 weeks.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.3.1 By 3 months  
Edwards 2006 13/23 13/24 100% 1.04[0.62,1.74]
Subtotal (95% CI) 23 24 100% 1.04[0.62,1.74]
Total events: 13 (Treatment), 13 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.16(P=0.87)  
   
3.3.2 By 6 months  
Edwards 2006 15/23 12/24 100% 1.3[0.79,2.15]
Subtotal (95% CI) 23 24 100% 1.3[0.79,2.15]
Total events: 15 (Treatment), 12 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.04(P=0.3)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 3.4.   Comparison 3 Cognitive behavioural therapy versus standard
care, Outcome 4 Substance use: 2. Average score (various scales) (skewed data).
Substance use: 2. Average score (various scales) (skewed data)
Study Intervention Time period Mean SD N
CASUAS
Edwards 2006 Treatment 3 months 1.4 1.4 23
Edwards 2006 Control   1.3 1.4 24
Edwards 2006 Treatment 6 months 1.4 1.4 23
Edwards 2006 Control   1.3 1.5 24
HONOS - item 3
Naeem 2005 Treatment 3 months 0.85 1.00 67
Naeem 2005 Control   0.88 0.88 38
Naeem 2005          
Naeem 2005          
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Analysis 3.5.   Comparison 3 Cognitive behavioural therapy versus standard care,
Outcome 5 Mental state: 1. Average insight score (Insight Scale, low = poor) - by 3 months.
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Naeem 2005 67 9.3 (3.3) 38 8.7 (3.2) 100% 0.52[-0.78,1.82]
   
Total *** 67   38   100% 0.52[-0.78,1.82]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.79(P=0.43)  
Favours control 42-4 -2 0 Favours treatment
 
 
Analysis 3.6.   Comparison 3 Cognitive behavioural therapy versus standard
care, Outcome 6 Mental state: 2. Average score (various scales) (skewed data).
Mental state: 2. Average score (various scales) (skewed data)
Study Intervention Mean SD N
Anxiety symptoms - 3 months (BAS)
Naeem 2005 Treatment 4.41 2.95 67
Naeem 2005 Control 4.31 3.41 38
Depressive symptoms - 3 months (BDI-SF)
Edwards 2006 Treatment 6.2 5.9 23
Edwards 2006 Control 7.8 8.1 24
Depressive symptoms - 3 months (MADRS)
Naeem 2005 Treatment 5.33 2.99 67
Naeem 2005 Control 5.96 3.56 38
Depressive symptoms - 6 months (BDI-SF)
Edwards 2006 Treatment 7.5 6.3 23
Edwards 2006 Control 6.3 7.2 24
General symptoms total score - 3 months (BPRS)
Edwards 2006 Treatment 44.1 13.8 23
Edwards 2006 Control 47.7 18.2 21
General - 3 months (CPRS)
Naeem 2005 Treatment 24.26 12.17 67
Naeem 2005 Control 24.46 13.85 38
General - 3 months (SCR)
Naeem 2005 Treatment 5.2 3.67 67
Naeem 2005 Control 4.9 4.3 38
General symptoms total score - 6 months (BPRS)
Edwards 2006 Treatment 45.6 13.5 23
Edwards 2006 Control 44.8 15.4 24
Negative symptoms - 3 months (SANS)
Edwards 2006 Treatment 21.8 14.9 23
Edwards 2006 Control 23.5 17 24
Negative symptoms - 6 months (SANS)
Edwards 2006 Treatment 23.7 17.2 23
Edwards 2006 Control 19.4 13.5 24
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Analysis 3.7.   Comparison 3 Cognitive behavioural therapy versus standard
care, Outcome 7 Social functioning: 1. Average score (SOFAS, low = poor).
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
3.7.1 By 3 months  
Edwards 2006 23 50.5 (17) 24 51.3 (14.9) 100% -0.8[-9.95,8.35]
Subtotal *** 23   24   100% -0.8[-9.95,8.35]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.17(P=0.86)  
   
3.7.2 By 6 months  
Edwards 2006 23 51.7 (18.3) 24 56.4 (15.9) 100% -4.7[-14.52,5.12]
Subtotal *** 23   24   100% -4.7[-14.52,5.12]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.94(P=0.35)  
Favours control 105-10 -5 0 Favours treatment
 
 
Analysis 3.8.   Comparison 3 Cognitive behavioural therapy versus standard
care, Outcome 8 Social functioning: 2. Average score (HONOS) (skewed data).
Social functioning: 2. Average score (HONOS) (skewed data)
Study Intervention Mean SD N
3 months
Naeem 2005 Treatment 9.23 4.26 67
Naeem 2005 Control 8.89 4.65 38
 
 
Analysis 3.9.   Comparison 3 Cognitive behavioural therapy versus standard
care, Outcome 9 Service use: 1. Outpatient medication (SURS) (skewed data).
Service use: 1. Outpatient medication (SURS) (skewed data)
Study Intervention Mean SD N
3 months
Edwards 2006 Treatment 13.4 8.8 23
Edwards 2006 Control 11.8 6.8 24
6 months
Edwards 2006 Treatment 11.6 11.4 23
Edwards 2006 Control 9.3 9.9 24
 
 
Comparison 4.   Contingency management versus standard care





Statistical method Effect size
1 Leaving the study early: 1. Lost to treatment 4   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
1.1 Week 4 - 8 (1 - 2 months) 2 49 Risk Ratio (M-H, Random,
95% CI)
0.34 [0.04, 2.81]
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Statistical method Effect size
1.2 Lost to treatment - 3 months 2 255 Risk Ratio (M-H, Random,
95% CI)
1.55 [1.13, 2.11]
2 Leaving the study early: 2. Lost to evaluation -
6 months
2 255 Risk Ratio (M-H, Random,
95% CI)
1.36 [0.91, 2.02]
3 Substance use: 1. Stimulant-positive urine test
(higher = poor outcome)
1   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
3.1 Stimulant-positive urine test - 3 months 1 176 Risk Ratio (M-H, Random,
95% CI)
0.34 [0.17, 0.68]
3.2 Stimulant-positive urine test - 6 months 1 176 Risk Ratio (M-H, Random,
95% CI)
0.83 [0.65, 1.06]
4 Substance use: 2. Number of continuous days
alcohol negative urine tests, 3 months (skewed
data)
    Other data No numeric data
5 Substance use: 3. Injection use 1   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
5.1 During treatment - 3 months 1 176 Risk Ratio (M-H, Random,
95% CI)
0.57 [0.42, 0.77]
5.2 During follow-up - 6 months 1 107 Risk Ratio (M-H, Random,
95% CI)
0.78 [0.53, 1.15]
6 Substance use: 4. Average scores on various
measures (skewed data)
    Other data No numeric data
6.1 Stimulant use days - 3 months (skewed data)     Other data No numeric data
6.2 Stimulant use days - 6 months (skewed data)     Other data No numeric data
6.3 Days of alcohol - 3 months     Other data No numeric data
6.4 Days of alcohol - 6 months     Other data No numeric data
6.5 5. Longest consecutive weeks of cocaine ab-
stinence
    Other data No numeric data
7 Mental state: 1. Average scores (various scales)
(skewed data)
    Other data No numeric data
7.1 Brief Symptom Inventory - 3 months     Other data No numeric data
7.2 Brief Symptom Inventroy - 6 months     Other data No numeric data
7.3 PANSS, excitement scale - 3 months     Other data No numeric data
7.4 PANSS, excitement scale - 6 months     Other data No numeric data
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Statistical method Effect size
8 Service use: 1. Relapse (hospitalised - 6
months post-randomisation





Analysis 4.1.   Comparison 4 Contingency management versus standard
care, Outcome 1 Leaving the study early: 1. Lost to treatment.
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.1.1 Week 4 - 8 (1 - 2 months)  
Petry 2013 1/10 1/9 53.29% 0.9[0.07,12.38]
Tracy 2007 0/15 4/15 46.71% 0.11[0.01,1.9]
Subtotal (95% CI) 25 24 100% 0.34[0.04,2.81]
Total events: 1 (Experimental), 5 (Control)  
Heterogeneity: Tau2=0.4; Chi2=1.21, df=1(P=0.27); I2=17.02%  
Test for overall effect: Z=1(P=0.32)  
   
4.1.2 Lost to treatment - 3 months  
McDonell 2013 53/91 30/85 84.49% 1.65[1.18,2.31]
McDonell 2017 10/40 9/39 15.51% 1.08[0.49,2.38]
Subtotal (95% CI) 131 124 100% 1.55[1.13,2.11]
Total events: 63 (Experimental), 39 (Control)  
Heterogeneity: Tau2=0; Chi2=0.94, df=1(P=0.33); I2=0%  
Test for overall effect: Z=2.76(P=0.01)  
Test for subgroup differences: Chi2=1.94, df=1 (P=0.16), I2=48.34%  
Favours CM 2000.005 100.1 1 Favours Standard Care
 
 
Analysis 4.2.   Comparison 4 Contingency management versus standard
care, Outcome 2 Leaving the study early: 2. Lost to evaluation - 6 months.
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
McDonell 2013 29/91 20/85 66.18% 1.35[0.83,2.2]
McDonell 2017 14/40 10/39 33.82% 1.37[0.69,2.7]
   
Total (95% CI) 131 124 100% 1.36[0.91,2.02]
Total events: 43 (Experimental), 30 (Control)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.99); I2=0%  
Test for overall effect: Z=1.51(P=0.13)  
Favours CM 1000.01 100.1 1 Favours Standard Care
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Analysis 4.3.   Comparison 4 Contingency management versus standard care,
Outcome 3 Substance use: 1. Stimulant-positive urine test (higher = poor outcome).
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.3.1 Stimulant-positive urine test - 3 months  
McDonell 2013 9/91 25/85 100% 0.34[0.17,0.68]
Subtotal (95% CI) 91 85 100% 0.34[0.17,0.68]
Total events: 9 (Experimental), 25 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.04(P=0)  
   
4.3.2 Stimulant-positive urine test - 6 months  
McDonell 2013 49/91 55/85 100% 0.83[0.65,1.06]
Subtotal (95% CI) 91 85 100% 0.83[0.65,1.06]
Total events: 49 (Experimental), 55 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.46(P=0.14)  
Test for subgroup differences: Chi2=5.69, df=1 (P=0.02), I2=82.44%  
Favours CM 100.1 50.2 20.5 1 Favours Standard Care
 
 
Analysis 4.4.   Comparison 4 Contingency management versus standard care, Outcome 4 Substance
use: 2. Number of continuous days alcohol negative urine tests, 3 months (skewed data).
Substance use: 2. Number of continuous days alcohol negative urine tests, 3 months (skewed data)
Study Intervention Mean SD N
McDonell 2017 Treatment 8.56 12.59 40
McDonell 2017 Control 4.11 1.22 39
 
 
Analysis 4.5.   Comparison 4 Contingency management versus
standard care, Outcome 5 Substance use: 3. Injection use.
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.5.1 During treatment - 3 months  
McDonell 2013 34/91 56/85 100% 0.57[0.42,0.77]
Subtotal (95% CI) 91 85 100% 0.57[0.42,0.77]
Total events: 34 (Experimental), 56 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.62(P=0)  
   
4.5.2 During follow-up - 6 months  
McDonell 2013 23/52 31/55 100% 0.78[0.53,1.15]
Subtotal (95% CI) 52 55 100% 0.78[0.53,1.15]
Total events: 23 (Experimental), 31 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.24(P=0.22)  
Test for subgroup differences: Chi2=1.68, df=1 (P=0.2), I2=40.43%  
Favours CM 1000.01 100.1 1 Favours Standard Care
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Analysis 4.6.   Comparison 4 Contingency management versus standard care,
Outcome 6 Substance use: 4. Average scores on various measures (skewed data).
Substance use: 4. Average scores on various measures (skewed data)
Study Intervention Mean SD N
Stimulant use days - 3 months (skewed data)
McDonell 2013 Treatment 0.91 2.4 91
McDonell 2013 Control 4.67 7.69 85
McDonell 2017 Treatment 0.57 4.30 40
McDonell 2017 Control 2.79 4.24 39
Stimulant use days - 6 months (skewed data)
McDonell 2013 Treatment 1.83 4.94 52
McDonell 2013 Control 3.65 7.15 55
McDonell 2017 Treatment 0.34 3.84 30
McDonell 2017 Control 1.95 3.84 30
Days of alcohol - 3 months
McDonell 2013 Treatment 1.84 4.77 91
McDonell 2013 Control 4.32 8.43 85
McDonell 2017 Treatment 3.72 9.92 40
McDonell 2017 Control 12.01 9.48 39
Days of alcohol - 6 months
McDonell 2013 Treatment 3.6 7.92 52
McDonell 2013 Control 4.21 7.86 55
McDonell 2017 Treatment 3.32 7.67 30
McDonell 2017 Control 10.73 7.61 30
5. Longest consecutive weeks of cocaine abstinence
Petry 2013 Treatment 2.9 1.7 10
Petry 2013 Control 0.6 1.7 9
 
 
Analysis 4.7.   Comparison 4 Contingency management versus standard care,
Outcome 7 Mental state: 1. Average scores (various scales) (skewed data).
Mental state: 1. Average scores (various scales) (skewed data)
Study Intervention Mean SD N
Brief Symptom Inventory - 3 months
McDonell 2013 Treatment 1.04 0.79 91
McDonell 2013 Control 1.24 0.71 85
Brief Symptom Inventroy - 6 months
McDonell 2013 Treatment 1.17 0.85 52
McDonell 2013 Control 1.25 0.79 55
PANSS, excitement scale - 3 months
McDonell 2013 Treatment 10.6 2.58 91
McDonell 2013 Control 11.69 3.42 85
PANSS, excitement scale - 6 months
McDonell 2013 Treatment 11.17 3.18 52
McDonell 2013 Control 11.57 3.01 55
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Analysis 4.8.   Comparison 4 Contingency management versus standard care,
Outcome 8 Service use: 1. Relapse (hospitalised - 6 months post-randomisation.
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
McDonell 2013 2/91 9/85 100% 0.21[0.05,0.93]
   
Total (95% CI) 91 85 100% 0.21[0.05,0.93]
Total events: 2 (Experimental), 9 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.05(P=0.04)  
Favours CM 1000.01 100.1 1 Favours Standard Care
 
 
Comparison 5.   Motivational interviewing versus standard care





Statistical method Effect size
1 Leaving the study early: 1. Lost
to treatment
1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 3 months 1 62 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.30, 2.61]
1.2 6 months 1 62 Risk Ratio (M-H, Random, 95% CI) 1.71 [0.63, 4.64]
2 Leaving the study early: 2.Lost
to evaluation
9   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 By 3 months 7 457 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.69, 1.70]
2.2 By 6 months 4 164 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.29, 2.53]
2.3 By 12 months 3 247 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.44, 1.92]
3 Adverse event: 1. Death, due
to all causes, by 18 months
1 49 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.07, 15.73]
4 Substance use: 1. Using sub-
stances - by class of drug - by
about 12 months
1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Alcohol abuse/dependence 1 52 Risk Ratio (M-H, Random, 95% CI) 1.35 [0.62, 2.92]
4.2 Amphetamine abuse/depen-
dence
1 19 Risk Ratio (M-H, Random, 95% CI) 0.24 [0.03, 1.92]
4.3 Cannabis abuse/depen-
dence
1 62 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.49, 1.21]
5 Substance use: 2. Polydrug
consumption levels - by 12
months (OTI, high = poor)
1   Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 By 3 months 1 89 Mean Difference (IV, Random, 95% CI) -0.41 [-0.91, 0.09]
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5.2 By 12 months 1 89 Mean Difference (IV, Random, 95% CI) -0.07 [-0.56, 0.42]
6 Substance use: 3. Any change
- not abstinent or not im-
proved on all substances - by 12
months
1 25 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.24, 1.10]
7 Substance use: 4. Any change -
not abstaining from alcohol
1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 By 3 months 1 28 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.26, 1.03]
7.2 By 6 months 1 28 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.17, 0.75]
8 Substance use: 5. Change in
cannabis use from baseline (T0)
(lower scores indicate better
outcome)
1   Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 3 months 1 62 Mean Difference (IV, Random, 95% CI) -12.81 [-23.05, -2.57]
8.2 6 months 1 62 Mean Difference (IV, Random, 95% CI) -9.64 [-18.05, -1.23]
8.3 12 months 1 62 Mean Difference (IV, Random, 95% CI) -5.82 [-14.77, 3.13]
9 Substance use: 6. Cannabis
consumption past 30 days (ASI,
high = poor) (skewed data)
    Other data No numeric data
9.1 By 3 months     Other data No numeric data
9.2 By 6 months     Other data No numeric data
10 Substance use: 7. Engage-
ment with substance misuse
treatment at 3 months (SATS,
low = poor))
1 59 Mean Difference (IV, Random, 95% CI) 0.30 [-0.47, 1.07]
11 Substance use: 8. Aver-
age scores (OTI, high = poor)
(skewed data)
    Other data No numeric data
11.1 Alcohol     Other data No numeric data
11.2 Amphetamine     Other data No numeric data
11.3 Cannabis     Other data No numeric data
11.4 Polydrug use     Other data No numeric data
12 Substance use: 9. Other mea-
sures of alcohol use (skewed da-
ta)
    Other data No numeric data
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12.1 Alcohol volume (AUI sub-
scale)
    Other data No numeric data
12.2 Drinking days - by 6 months     Other data No numeric data
12.3 Alcohol consumption, last
30 days (ASI) - 3 months
    Other data No numeric data
12.4 Alcohol consumption, last
30 days (ASI) - 6 months
    Other data No numeric data
12.5 Alcohol use (AUDIT) - 3
months
    Other data No numeric data
12.6 Alcohol use (CAUS) - 3
months
    Other data No numeric data
12.7 Drug use (CDUS) - 3 months     Other data No numeric data
12.8 Drug use (SDS) - 3 months     Other data No numeric data
13 Mental state: 1. Average
scores (SCL-90-R, high = poor) -
by 3 months
1   Mean Difference (IV, Random, 95% CI) Subtotals only
13.1 General severity index 1 30 Mean Difference (IV, Random, 95% CI) -0.19 [-0.59, 0.21]
13.2 Positive symptom distress
index
1 30 Mean Difference (IV, Random, 95% CI) -0.19 [-0.66, 0.28]
13.3 Positive symptom scores 1 30 Mean Difference (IV, Random, 95% CI) -4.20 [-18.72, 10.32]
14 Mental state: 2. Average
scores (PANSS negative symp-
toms, high = poor)
1   Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 By 3 months 1 62 Mean Difference (IV, Random, 95% CI) -0.10 [-2.06, 1.86]
14.2 By 6 months 1 62 Mean Difference (IV, Random, 95% CI) 0.0 [-1.80, 1.80]
15 Mental state: 3. Average
scores (PANSS positive symp-
toms, high = poor)
1   Mean Difference (IV, Random, 95% CI) Subtotals only
15.1 3 months 1 62 Mean Difference (IV, Random, 95% CI) -0.30 [-2.55, 1.95]
15.2 6 months 1 62 Mean Difference (IV, Random, 95% CI) -0.10 [-2.58, 2.38]
16 Mental state: 4. Average
score (HADS, BSI, high = poor)
(skewed data) - by 3 months
    Other data No numeric data
16.1 HADS-A, Anxiety     Other data No numeric data
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16.2 HADS-D, Depression     Other data No numeric data
16.3 BSI     Other data No numeric data
17 Global state: 1. Average score
(GAF, low = poor)
1   Mean Difference (IV, Random, 95% CI) Subtotals only
17.1 3 months 1 51 Mean Difference (IV, Random, 95% CI) -0.40 [-3.53, 2.73]
17.2 6 months 1 49 Mean Difference (IV, Random, 95% CI) -1.0 [-4.81, 2.81]
17.3 12 months 1 54 Mean Difference (IV, Random, 95% CI) 2.30 [-1.30, 5.90]
18 Global state: 2. Forensic
measures - average number of
crimes (skewed data)
    Other data No numeric data
18.1 6 months     Other data No numeric data
18.2 12 months     Other data No numeric data
19 Social functioning: 1. Aver-
age score (OTI, high = poor)
1   Mean Difference (IV, Random, 95% CI) Subtotals only
19.1 By 6 months 1 102 Mean Difference (IV, Random, 95% CI) -0.71 [-2.76, 1.34]
19.2 By 12 months 1 102 Mean Difference (IV, Random, 95% CI) -1.42 [-3.35, 0.51]
20 Social functioning: 2. Aver-
age score (SOFAS, low = poor)
1   Mean Difference (IV, Random, 95% CI) Subtotals only
20.1 3 months 1 62 Mean Difference (IV, Random, 95% CI) 0.10 [-3.02, 3.22]
20.2 6 months 1 62 Mean Difference (IV, Random, 95% CI) -0.10 [-3.51, 3.31]
20.3 12 months 1 62 Mean Difference (IV, Random, 95% CI) 2.70 [-1.08, 6.48]
21 Service use: Hospital admis-
sion to 12 months
1 62 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.42, 1.80]
22 Service use: Lost to first after-
care appointment
1 93 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.53, 0.90]
 
 
Analysis 5.1.   Comparison 5 Motivational interviewing versus standard
care, Outcome 1 Leaving the study early: 1. Lost to treatment.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.1.1 3 months  
Favours MI 100.1 50.2 20.5 1 Favours Usual Treatment
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bonsack 2011 5/30 6/32 100% 0.89[0.3,2.61]
Subtotal (95% CI) 30 32 100% 0.89[0.3,2.61]
Total events: 5 (Treatment), 6 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.21(P=0.83)  
   
5.1.2 6 months  
Bonsack 2011 8/30 5/32 100% 1.71[0.63,4.64]
Subtotal (95% CI) 30 32 100% 1.71[0.63,4.64]
Total events: 8 (Treatment), 5 (Control)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.05(P=0.29)  
Test for subgroup differences: Chi2=0.76, df=1 (P=0.38), I2=0%  
Favours MI 100.1 50.2 20.5 1 Favours Usual Treatment
 
 
Analysis 5.2.   Comparison 5 Motivational interviewing versus standard
care, Outcome 2 Leaving the study early: 2.Lost to evaluation.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.2.1 By 3 months  
Baker 2002 24/79 24/81 72.18% 1.03[0.64,1.65]
Bechdolf 2011 10/30 5/30 21.37% 2[0.78,5.15]
Graeber 2003 0/15 2/15 2.32% 0.2[0.01,3.85]
Graham 2016 0/30 1/29 2.03% 0.32[0.01,7.61]
Hickman 1997 0/15 0/15   Not estimable
Kavanagh 2004 0/13 1/12 2.1% 0.31[0.01,6.94]
Swanson 1999 0/48 0/45   Not estimable
Subtotal (95% CI) 230 227 100% 1.08[0.69,1.7]
Total events: 34 (Treatment), 33 (Control)  
Heterogeneity: Tau2=0.02; Chi2=4.14, df=4(P=0.39); I2=3.27%  
Test for overall effect: Z=0.35(P=0.72)  
   
5.2.2 By 6 months  
Bechdolf 2011 10/30 5/30 48.9% 2[0.78,5.15]
Graeber 2003 0/15 2/15 11.55% 0.2[0.01,3.85]
Kavanagh 2004 0/13 1/12 10.59% 0.31[0.01,6.94]
Nagel 2009 2/24 4/25 28.96% 0.52[0.1,2.59]
Subtotal (95% CI) 82 82 100% 0.85[0.29,2.53]
Total events: 12 (Treatment), 12 (Control)  
Heterogeneity: Tau2=0.4; Chi2=4.37, df=3(P=0.22); I2=31.42%  
Test for overall effect: Z=0.29(P=0.77)  
   
5.2.3 By 12 months  
Baker 2002 36/79 35/81 59.37% 1.05[0.75,1.49]
Bonsack 2011 5/30 3/32 20.87% 1.78[0.46,6.8]
Kavanagh 2004 2/13 6/12 19.76% 0.31[0.08,1.24]
Subtotal (95% CI) 122 125 100% 0.92[0.44,1.92]
Total events: 43 (Treatment), 44 (Control)  
Favours treatment 2000.005 100.1 1 Favours control
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0.21; Chi2=3.55, df=2(P=0.17); I2=43.58%  
Test for overall effect: Z=0.22(P=0.83)  
Test for subgroup differences: Chi2=0.25, df=1 (P=0.88), I2=0%  
Favours treatment 2000.005 100.1 1 Favours control
 
 
Analysis 5.3.   Comparison 5 Motivational interviewing versus standard
care, Outcome 3 Adverse event: 1. Death, due to all causes, by 18 months.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Nagel 2009 1/24 1/25 100% 1.04[0.07,15.73]
   
Total (95% CI) 24 25 100% 1.04[0.07,15.73]
Total events: 1 (Treatment), 1 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.03(P=0.98)  
Favours MI 200.05 50.2 1 Favours Usual Treatment
 
 
Analysis 5.4.   Comparison 5 Motivational interviewing versus standard care, Outcome
4 Substance use: 1. Using substances - by class of drug - by about 12 months.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.4.1 Alcohol abuse/dependence  
Baker 2002 11/28 7/24 100% 1.35[0.62,2.92]
Subtotal (95% CI) 28 24 100% 1.35[0.62,2.92]
Total events: 11 (Treatment), 7 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.75(P=0.45)  
   
5.4.2 Amphetamine abuse/dependence  
Baker 2002 1/11 3/8 100% 0.24[0.03,1.92]
Subtotal (95% CI) 11 8 100% 0.24[0.03,1.92]
Total events: 1 (Treatment), 3 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.34(P=0.18)  
   
5.4.3 Cannabis abuse/dependence  
Baker 2002 14/28 22/34 100% 0.77[0.49,1.21]
Subtotal (95% CI) 28 34 100% 0.77[0.49,1.21]
Total events: 14 (Treatment), 22 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.13(P=0.26)  
Favours treatment 100.1 50.2 20.5 1 Favours control
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Analysis 5.5.   Comparison 5 Motivational interviewing versus standard care, Outcome
5 Substance use: 2. Polydrug consumption levels - by 12 months (OTI, high = poor).
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.5.1 By 3 months  
Baker 2002 43 2.3 (1.2) 46 2.7 (1.3) 100% -0.41[-0.91,0.09]
Subtotal *** 43   46   100% -0.41[-0.91,0.09]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.61(P=0.11)  
   
5.5.2 By 12 months  
Baker 2002 43 2.6 (1.2) 46 2.7 (1.2) 100% -0.07[-0.56,0.42]
Subtotal *** 43   46   100% -0.07[-0.56,0.42]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.28(P=0.78)  
Favours treatment 10.5-1 -0.5 0 Favours control
 
 
Analysis 5.6.   Comparison 5 Motivational interviewing versus standard care, Outcome 6
Substance use: 3. Any change - not abstinent or not improved on all substances - by 12 months.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Kavanagh 2004 5/13 9/12 100% 0.51[0.24,1.1]
   
Total (95% CI) 13 12 100% 0.51[0.24,1.1]
Total events: 5 (Treatment), 9 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.72(P=0.09)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 5.7.   Comparison 5 Motivational interviewing versus standard
care, Outcome 7 Substance use: 4. Any change - not abstaining from alcohol.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.7.1 By 3 months  
Graeber 2003 6/15 10/13 100% 0.52[0.26,1.03]
Subtotal (95% CI) 15 13 100% 0.52[0.26,1.03]
Total events: 6 (Treatment), 10 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.86(P=0.06)  
   
5.7.2 By 6 months  
Graeber 2003 5/15 12/13 100% 0.36[0.17,0.75]
Subtotal (95% CI) 15 13 100% 0.36[0.17,0.75]
Total events: 5 (Treatment), 12 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.72(P=0.01)  
Favours treatment 50.2 20.5 1 Favours control
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Analysis 5.8.   Comparison 5 Motivational interviewing versus standard care, Outcome 8 Substance
use: 5. Change in cannabis use from baseline (T0) (lower scores indicate better outcome).
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.8.1 3 months  
Bonsack 2011 30 -12.5 (18.1) 32 0.3 (22.9) 100% -12.81[-23.05,-2.57]
Subtotal *** 30   32   100% -12.81[-23.05,-2.57]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.45(P=0.01)  
   
5.8.2 6 months  
Bonsack 2011 30 -14.7 (18.4) 32 -5.1 (15.1) 100% -9.64[-18.05,-1.23]
Subtotal *** 30   32   100% -9.64[-18.05,-1.23]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.25(P=0.02)  
   
5.8.3 12 months  
Bonsack 2011 30 -11.1 (19.7) 32 -5.3 (15.9) 100% -5.82[-14.77,3.13]
Subtotal *** 30   32   100% -5.82[-14.77,3.13]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.27(P=0.2)  
Test for subgroup differences: Chi2=1.04, df=1 (P=0.6), I2=0%  
Favours MI 10050-100 -50 0 Favours Usual Treatment
 
 
Analysis 5.9.   Comparison 5 Motivational interviewing versus standard care, Outcome 9
Substance use: 6. Cannabis consumption past 30 days (ASI, high = poor) (skewed data).
Substance use: 6. Cannabis consumption past 30 days (ASI, high = poor) (skewed data)
Study Intervention Mean SD N
By 3 months
Bonsack 2011 Treatment 4.6 9.4 30
Bonsack 2011 Control 3.8 9.6 30
By 6 months
Bonsack 2011 Treatment 5.3 10.4 30
Bonsack 2011 Control 4.43 8.4 30
 
 
Analysis 5.10.   Comparison 5 Motivational interviewing versus standard care, Outcome 10
Substance use: 7. Engagement with substance misuse treatment at 3 months (SATS, low = poor)).
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Graham 2016 30 4.4 (1.4) 29 4.1 (1.6) 100% 0.3[-0.47,1.07]
   
Total *** 30   29   100% 0.3[-0.47,1.07]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.77(P=0.44)  
Favours treatment 10050-100 -50 0 Favours control
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Analysis 5.11.   Comparison 5 Motivational interviewing versus standard care,
Outcome 11 Substance use: 8. Average scores (OTI, high = poor) (skewed data).
Substance use: 8. Average scores (OTI, high = poor) (skewed data)
Study Intervention Time period Mean SD N
Alcohol
Baker 2002 Treatment 3 months 2.55 5.29 28
Baker 2002 Control   1.51 2.05 23
Baker 2002 Treatment 6 months 4.26 6.59 28
Baker 2002 Control   4.19 7.74 23
Baker 2002 Treatment 12 months 2.98 3.11 28
Baker 2002     1.83 3.54 23
Amphetamine
Baker 2002 Treatment 3 months 0.32 1.05 11
Baker 2002 Control   0.01 0.03 8
Baker 2002 Treatment 6 months 0.14 0.31 11
Baker 2002 Control   0.17 0.35 8
Baker 2002 Treatment 12 months 0.06 0.17 11
Baker 2002     0.03 0.05 8
Cannabis
Baker 2002 Treatment 3 months 2.52 6.10 28
Baker 2002 Control   3.44 4.69 34
Baker 2002 Treatment 6 months 4.77 8.00 28
Baker 2002 Control   3.89 6.22 34
Baker 2002 Treatment 12 months 5.81 7.76 28
Baker 2002     4.47 6.09 34
Polydrug use
Baker 2002 Treatment 3 months 2.74 1.25 43
Baker 2002 Control   2.33 1.15 46
Baker 2002 Treatment 6 months 2.74 1.14 43
Baker 2002 Control   2.52 1.28 46
Baker 2002 Treatment 12 months 2.63 1.22 43
Baker 2002 Control   2.7 1.15 46
 
 
Analysis 5.12.   Comparison 5 Motivational interviewing versus standard care,
Outcome 12 Substance use: 9. Other measures of alcohol use (skewed data).
Substance use: 9. Other measures of alcohol use (skewed data)
Study Intervention Mean SD N
Alcohol volume (AUI subscale)
Hickman 1997 Treatment 18.1 9.93 15
Hickman 1997 Control 14.6 13.6 15
Drinking days - by 6 months
Graeber 2003 Treatment 3.10 6.24 15
Graeber 2003 Control 12.73 8.25 13
Alcohol consumption, last 30 days (ASI) - 3 months
Bonsack 2011 Treatment 6.2 9.1 30
Bonsack 2011 Control 5.13 8.2 30
Alcohol consumption, last 30 days (ASI) - 6 months
Bonsack 2011 Treatment 5.57 8.5 30
Bonsack 2011 Control 6.43 10 30
Alcohol use (AUDIT) - 3 months
Graham 2016 Treatment 15.11 7.71 9
Graham 2016 Control 13.09 7.92 11
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Substance use: 9. Other measures of alcohol use (skewed data)
Study Intervention Mean SD N
Alcohol use (CAUS) - 3 months
Graham 2016 Treatment 2.25 1.22 12
Graham 2016 Control 2.18 0.98 11
Drug use (CDUS) - 3 months
Graham 2016 Treatment 1.89 0.90 18
Graham 2016 Control 2.41 1.06 17
Drug use (SDS) - 3 months
Graham 2016 Treatment 4.64 4.18 14
Graham 2016 Control 5.31 3.68 13
 
 
Analysis 5.13.   Comparison 5 Motivational interviewing versus standard care,
Outcome 13 Mental state: 1. Average scores (SCL-90-R, high = poor) - by 3 months.
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.13.1 General severity index  
Hickman 1997 15 1.1 (0.5) 15 1.3 (0.6) 100% -0.19[-0.59,0.21]
Subtotal *** 15   15   100% -0.19[-0.59,0.21]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.94(P=0.35)  
   
5.13.2 Positive symptom distress index  
Hickman 1997 15 1.9 (0.5) 15 2 (0.8) 100% -0.19[-0.66,0.28]
Subtotal *** 15   15   100% -0.19[-0.66,0.28]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.79(P=0.43)  
   
5.13.3 Positive symptom scores  
Hickman 1997 15 50.3 (18.8) 15 54.5 (21.7) 100% -4.2[-18.72,10.32]
Subtotal *** 15   15   100% -4.2[-18.72,10.32]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.57(P=0.57)  
Favours treatment 105-10 -5 0 Favours control
 
 
Analysis 5.14.   Comparison 5 Motivational interviewing versus standard care,
Outcome 14 Mental state: 2. Average scores (PANSS negative symptoms, high = poor).
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.14.1 By 3 months  
Bonsack 2011 30 18 (4.7) 32 18.1 (2.9) 100% -0.1[-2.06,1.86]
Subtotal *** 30   32   100% -0.1[-2.06,1.86]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.1(P=0.92)  
   
5.14.2 By 6 months  
Bonsack 2011 30 17.4 (3.8) 32 17.4 (3.4) 100% 0[-1.8,1.8]
Subtotal *** 30   32   100% 0[-1.8,1.8]
Favours MI 10050-100 -50 0 Favours Usual Treatment
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Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Chi2=0.01, df=1 (P=0.94), I2=0%  
Favours MI 10050-100 -50 0 Favours Usual Treatment
 
 
Analysis 5.15.   Comparison 5 Motivational interviewing versus standard care,
Outcome 15 Mental state: 3. Average scores (PANSS positive symptoms, high = poor).
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.15.1 3 months  
Bonsack 2011 30 16.6 (4) 32 16.9 (5) 100% -0.3[-2.55,1.95]
Subtotal *** 30   32   100% -0.3[-2.55,1.95]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.26(P=0.79)  
   
5.15.2 6 months  
Bonsack 2011 30 16.2 (5.3) 32 16.3 (4.6) 100% -0.1[-2.58,2.38]
Subtotal *** 30   32   100% -0.1[-2.58,2.38]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.08(P=0.94)  
Test for subgroup differences: Chi2=0.01, df=1 (P=0.91), I2=0%  
Favours MI 10050-100 -50 0 Favours Usual Treatment
 
 
Analysis 5.16.   Comparison 5 Motivational interviewing versus standard care, Outcome
16 Mental state: 4. Average score (HADS, BSI, high = poor) (skewed data) - by 3 months.
Mental state: 4. Average score (HADS, BSI, high = poor) (skewed data) - by 3 months
Study Intervention Mean SD N
HADS-A, Anxiety
Graham 2016 Treatment 7.3 5.3 24
Graham 2016 Control 8.1 5.3 23
HADS-D, Depression
Graham 2016 Treatment 5.4 3.8 24
Graham 2016 Control 7.3 4.1 23
BSI
Baker 2002 Treatment 1.16 0.92 56
Baker 2002 Control 1.23 0.86 56
 
 
Analysis 5.17.   Comparison 5 Motivational interviewing versus standard
care, Outcome 17 Global state: 1. Average score (GAF, low = poor).
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.17.1 3 months  
Favours MI 10050-100 -50 0 Favours Usual Treatment
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Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Bonsack 2011 25 39.1 (4.8) 26 39.5 (6.5) 100% -0.4[-3.53,2.73]
Subtotal *** 25   26   100% -0.4[-3.53,2.73]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.25(P=0.8)  
   
5.17.2 6 months  
Bonsack 2011 22 40.3 (5.9) 27 41.3 (7.7) 100% -1[-4.81,2.81]
Subtotal *** 22   27   100% -1[-4.81,2.81]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.51(P=0.61)  
   
5.17.3 12 months  
Bonsack 2011 25 42.9 (6.5) 29 40.6 (7) 100% 2.3[-1.3,5.9]
Subtotal *** 25   29   100% 2.3[-1.3,5.9]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.25(P=0.21)  
Test for subgroup differences: Chi2=1.82, df=1 (P=0.4), I2=0%  
Favours MI 10050-100 -50 0 Favours Usual Treatment
 
 
Analysis 5.18.   Comparison 5 Motivational interviewing versus standard care, Outcome
18 Global state: 2. Forensic measures - average number of crimes (skewed data).
Global state: 2. Forensic measures - average number of crimes (skewed data)
Study Intervention Mean SD N
6 months
Baker 2002 Treatment 0.33 1.04 52
Baker 2002 Control 0.36 0.85 50
12 months
Baker 2002 Treatment 0.23 0.61 52
Baker 2002 Control 0.30 0.93 50
 
 
Analysis 5.19.   Comparison 5 Motivational interviewing versus standard
care, Outcome 19 Social functioning: 1. Average score (OTI, high = poor).
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.19.1 By 6 months  
Baker 2002 52 16.7 (6.2) 50 17.4 (4.2) 100% -0.71[-2.76,1.34]
Subtotal *** 52   50   100% -0.71[-2.76,1.34]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.68(P=0.5)  
   
5.19.2 By 12 months  
Baker 2002 52 15.9 (5.4) 50 17.3 (4.5) 100% -1.42[-3.35,0.51]
Subtotal *** 52   50   100% -1.42[-3.35,0.51]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.44(P=0.15)  
Favours treatment 105-10 -5 0 Favours control
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Analysis 5.20.   Comparison 5 Motivational interviewing versus standard
care, Outcome 20 Social functioning: 2. Average score (SOFAS, low = poor).
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.20.1 3 months  
Bonsack 2011 30 40.5 (5.5) 32 40.4 (7) 100% 0.1[-3.02,3.22]
Subtotal *** 30   32   100% 0.1[-3.02,3.22]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.06(P=0.95)  
   
5.20.2 6 months  
Bonsack 2011 30 42.3 (6.3) 32 42.4 (7.4) 100% -0.1[-3.51,3.31]
Subtotal *** 30   32   100% -0.1[-3.51,3.31]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.06(P=0.95)  
   
5.20.3 12 months  
Bonsack 2011 30 44.9 (7.2) 32 42.2 (8) 100% 2.7[-1.08,6.48]
Subtotal *** 30   32   100% 2.7[-1.08,6.48]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.4(P=0.16)  
Test for subgroup differences: Chi2=1.42, df=1 (P=0.49), I2=0%  
Favours Usual Treatment 105-10 -5 0 Favours MI
 
 
Analysis 5.21.   Comparison 5 Motivational interviewing versus standard
care, Outcome 21 Service use: Hospital admission to 12 months.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bonsack 2011 9/30 11/32 100% 0.87[0.42,1.8]
   
Total (95% CI) 30 32 100% 0.87[0.42,1.8]
Total events: 9 (Treatment), 11 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.37(P=0.71)  
Favours MI 100.1 50.2 20.5 1 Favours Usual Treatment
 
 
Analysis 5.22.   Comparison 5 Motivational interviewing versus standard
care, Outcome 22 Service use: Lost to first aLercare appointment.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Swanson 1999 28/48 38/45 100% 0.69[0.53,0.9]
   
Total (95% CI) 48 45 100% 0.69[0.53,0.9]
Total events: 28 (Treatment), 38 (Control)  
Favours treatment 20.5 1.50.7 1 Favours control
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=2.69(P=0.01)  
Favours treatment 20.5 1.50.7 1 Favours control
 
 
Comparison 6.   Skills training versus standard care





Statistical method Effect size
1 Leaving the study early: 1.
Lost to treatment
6   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 By 3 months 3 461 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.68, 1.36]
1.2 By 6-9 months 2 94 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.24, 0.97]
1.3 By 12 months 3 122 Risk Ratio (M-H, Random, 95% CI) 1.42 [0.20, 10.10]
1.4 By 18 months 2 75 Risk Ratio (M-H, Random, 95% CI) 2.60 [1.36, 4.97]
2 Leaving the study early: 2.
Lost to evaluation
1 363 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.66, 1.63]
2.1 1. By 6 months 1 121 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.40, 2.08]
2.2 2. By 9 months 1 121 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.47, 2.33]
2.3 3. By 12 months 1 121 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.55, 2.36]
3 Adverse event: 1. Death -
by 12 months
1 121 Risk Ratio (M-H, Random, 95% CI) 0.15 [0.02, 1.42]
4 Substance use: 1. Alco-
hol use: proportion days ab-
stinent from alcohol (TLFB
method)
1 398 Mean Difference (IV, Random, 95% CI) 0.00 [-0.04, 0.04]
4.1 1. 3 months 1 107 Mean Difference (IV, Random, 95% CI) 0.02 [0.00, 0.04]
4.2 2. 6 months 1 100 Mean Difference (IV, Random, 95% CI) -0.05 [-0.07, -0.03]
4.3 3. 9 months 1 98 Mean Difference (IV, Random, 95% CI) 0.01 [-0.01, 0.03]
4.4 4. 12 months 1 93 Mean Difference (IV, Random, 95% CI) 0.03 [0.00, 0.06]
5 Substance use: 2. Average
scores (C-DIS-R) (skewed
data)
    Other data No numeric data
5.1 Alcohol     Other data No numeric data
5.2 Drugs     Other data No numeric data
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Statistical method Effect size
6 Sustance use: 3. Average
days used (skewed data)
    Other data No numeric data
6.1 Any alcohol in last
30 days, at follow-up (6
months)
    Other data No numeric data
6.2 Any illicit drug in last
30 days, at follow-up (6
months)
    Other data No numeric data
7 Social functioning: 1. Av-
erage score (RFS, high = bet-
ter functioning)
1   Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 By 6 months 1 47 Mean Difference (IV, Random, 95% CI) 0.61 [-1.63, 2.85]
7.2 By 12 months 1 47 Mean Difference (IV, Random, 95% CI) 1.07 [-1.15, 3.29]
7.3 By 18 months 1 25 Mean Difference (IV, Random, 95% CI) -2.55 [-6.24, 1.14]
8 Social functioning: 2. Av-
erage score (SAS, high = bet-
ter functioning)
1   Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 By 6 months 1 47 Mean Difference (IV, Random, 95% CI) -0.92 [-6.58, 4.74]
8.2 By 12 months 1 47 Mean Difference (IV, Random, 95% CI) 2.58 [-3.39, 8.55]
8.3 By 18 months 1 25 Mean Difference (IV, Random, 95% CI) -4.66 [-15.29, 5.97]
9 Service use: 1. Days in
hospital (skewed data)
    Other data No numeric data
 
 
Analysis 6.1.   Comparison 6 Skills training versus standard
care, Outcome 1 Leaving the study early: 1. Lost to treatment.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.1.1 By 3 months  
Bogenschutz 2014 10/83 4/38 9.88% 1.14[0.38,3.42]
O'Connell 2018 31/90 16/47 49.35% 1.01[0.62,1.65]
Rosenblum 2014 22/113 20/90 40.77% 0.88[0.51,1.5]
Subtotal (95% CI) 286 175 100% 0.97[0.68,1.36]
Total events: 63 (Treatment), 40 (Control)  
Heterogeneity: Tau2=0; Chi2=0.25, df=2(P=0.88); I2=0%  
Test for overall effect: Z=0.2(P=0.84)  
   
6.1.2 By 6-9 months  
Favours treatment 500.02 100.1 1 Favours control
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Hellerstein 1995 7/23 15/24 100% 0.49[0.24,0.97]
Jerrell 1995a 0/22 0/25   Not estimable
Subtotal (95% CI) 45 49 100% 0.49[0.24,0.97]
Total events: 7 (Treatment), 15 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.04(P=0.04)  
   
6.1.3 By 12 months  
Eack 2015 9/19 1/9 39.36% 4.26[0.63,28.72]
Hellerstein 1995 12/23 18/24 60.64% 0.7[0.44,1.1]
Jerrell 1995a 0/22 0/25   Not estimable
Subtotal (95% CI) 64 58 100% 1.42[0.2,10.1]
Total events: 21 (Treatment), 19 (Control)  
Heterogeneity: Tau2=1.6; Chi2=4.19, df=1(P=0.04); I2=76.15%  
Test for overall effect: Z=0.35(P=0.73)  
   
6.1.4 By 18 months  
Eack 2015 9/19 1/9 11.58% 4.26[0.63,28.72]
Jerrell 1995a 15/22 7/25 88.42% 2.44[1.22,4.86]
Subtotal (95% CI) 41 34 100% 2.6[1.36,4.97]
Total events: 24 (Treatment), 8 (Control)  
Heterogeneity: Tau2=0; Chi2=0.32, df=1(P=0.57); I2=0%  
Test for overall effect: Z=2.88(P=0)  
Test for subgroup differences: Chi2=12.55, df=1 (P=0.01), I2=76.09%  
Favours treatment 500.02 100.1 1 Favours control
 
 
Analysis 6.2.   Comparison 6 Skills training versus standard
care, Outcome 2 Leaving the study early: 2. Lost to evaluation.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.2.1 1. By 6 months  
Bogenschutz 2014 14/83 7/38 29.93% 0.92[0.4,2.08]
Subtotal (95% CI) 83 38 29.93% 0.92[0.4,2.08]
Total events: 14 (Treatment), 7 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.21(P=0.83)  
   
6.2.2 2. By 9 months  
Bogenschutz 2014 16/83 7/38 31.53% 1.05[0.47,2.33]
Subtotal (95% CI) 83 38 31.53% 1.05[0.47,2.33]
Total events: 16 (Treatment), 7 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.11(P=0.91)  
   
6.2.3 3. By 12 months  
Bogenschutz 2014 20/83 8/38 38.54% 1.14[0.55,2.36]
Subtotal (95% CI) 83 38 38.54% 1.14[0.55,2.36]
Total events: 20 (Treatment), 8 (Control)  
Favours treatment 50.2 20.5 1 Favours control
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=0.37(P=0.71)  
   
Total (95% CI) 249 114 100% 1.04[0.66,1.63]
Total events: 50 (Treatment), 22 (Control)  
Heterogeneity: Tau2=0; Chi2=0.16, df=2(P=0.92); I2=0%  
Test for overall effect: Z=0.17(P=0.86)  
Test for subgroup differences: Chi2=0.16, df=1 (P=0.92), I2=0%  
Favours treatment 50.2 20.5 1 Favours control
 
 
Analysis 6.3.   Comparison 6 Skills training versus standard care, Outcome 3 Adverse event: 1. Death - by 12 months.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bogenschutz 2014 1/83 3/38 100% 0.15[0.02,1.42]
   
Total (95% CI) 83 38 100% 0.15[0.02,1.42]
Total events: 1 (Treatment), 3 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.65(P=0.1)  
Favours treatment 1000.01 100.1 1 Favours control
 
 
Analysis 6.4.   Comparison 6 Skills training versus standard care, Outcome 4
Substance use: 1. Alcohol use: proportion days abstinent from alcohol (TLFB method).
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
6.4.1 1. 3 months  
Bogenschutz 2014 73 0.8 (0.1) 34 0.8 (0) 25.91% 0.02[0,0.04]
Subtotal *** 73   34   25.91% 0.02[0,0.04]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.57(P=0.01)  
   
6.4.2 2. 6 months  
Bogenschutz 2014 69 0.7 (0) 31 0.8 (0) 25.66% -0.05[-0.07,-0.03]
Subtotal *** 69   31   25.66% -0.05[-0.07,-0.03]
Heterogeneity: Not applicable  
Test for overall effect: Z=5.78(P<0.0001)  
   
6.4.3 3. 9 months  
Bogenschutz 2014 67 0.7 (0) 31 0.7 (0.1) 24.59% 0.01[-0.01,0.03]
Subtotal *** 67   31   24.59% 0.01[-0.01,0.03]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.85(P=0.4)  
   
6.4.4 4. 12 months  
Bogenschutz 2014 63 0.7 (0) 30 0.7 (0.1) 23.84% 0.03[0,0.06]
Favours [control] 0.10.05-0.1 -0.05 0 Favours [experimental]
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Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Subtotal *** 63   30   23.84% 0.03[0,0.06]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.18(P=0.03)  
   
Total *** 272   126   100% 0[-0.04,0.04]
Heterogeneity: Tau2=0; Chi2=45.21, df=3(P<0.0001); I2=93.36%  
Test for overall effect: Z=0.1(P=0.92)  
Test for subgroup differences: Chi2=45.21, df=1 (P<0.0001), I2=93.36%  
Favours [control] 0.10.05-0.1 -0.05 0 Favours [experimental]
 
 
Analysis 6.5.   Comparison 6 Skills training versus standard care,
Outcome 5 Substance use: 2. Average scores (C-DIS-R) (skewed data).
Substance use: 2. Average scores (C-DIS-R) (skewed data)
Study Intervention Time period Mean SD N
Alcohol
Jerrell 1995a Treatment 6 months 0.99 1.92 21
Jerrell 1995a Control   2.80 3.49 25
Jerrell 1995a Treatment 12 months 2.24 2.83 21
Jerrell 1995a Control   2.95 3.50 25
Jerrell 1995a Treatment 18 months 1.43 2.70 7
Jerrell 1995a Countrol   1.39 2.52 18
Drugs
Jerrell 1995a Treatment 6 months 1.85 2.74 21
Jerrell 1995a Control   4.84 5.69 25
Jerrell 1995a Treatment 12 months 3.52 3.53 21
Jerrell 1995a Control   5.99 7.46 25
Jerrell 1995a Treatment 18 months 1.43 2.70 7
Jerrell 1995a Control   2.22 3.46 18
 
 
Analysis 6.6.   Comparison 6 Skills training versus standard care,
Outcome 6 Sustance use: 3. Average days used (skewed data).
Sustance use: 3. Average days used (skewed data)
Study Intervention Mean SD N
Any alcohol in last 30 days, at follow-up (6 months)
Rosenblum 2014 Treatment 3.1 6.4 91
Rosenblum 2014 Control 6.1 8.8 70
Any illicit drug in last 30 days, at follow-up (6 months)
Rosenblum 2014 Treatment 5.5 9.2 91
Rosenblum 2014 Control 8 10.6 70
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Analysis 6.7.   Comparison 6 Skills training versus standard care, Outcome
7 Social functioning: 1. Average score (RFS, high = better functioning).
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
6.7.1 By 6 months  
Jerrell 1995a 22 12.8 (4) 25 12.2 (3.8) 100% 0.61[-1.63,2.85]
Subtotal *** 22   25   100% 0.61[-1.63,2.85]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.53(P=0.59)  
   
6.7.2 By 12 months  
Jerrell 1995a 22 13.1 (4.3) 25 12 (3.3) 100% 1.07[-1.15,3.29]
Subtotal *** 22   25   100% 1.07[-1.15,3.29]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.95(P=0.34)  
   
6.7.3 By 18 months  
Jerrell 1995a 7 10.9 (4) 18 13.4 (4.8) 100% -2.55[-6.24,1.14]
Subtotal *** 7   18   100% -2.55[-6.24,1.14]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.35(P=0.18)  
Favours control 105-10 -5 0 Favours treatment
 
 
Analysis 6.8.   Comparison 6 Skills training versus standard care, Outcome
8 Social functioning: 2. Average score (SAS, high = better functioning).
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
6.8.1 By 6 months  
Jerrell 1995a 22 74.7 (11.2) 25 75.6 (8.2) 100% -0.92[-6.58,4.74]
Subtotal *** 22   25   100% -0.92[-6.58,4.74]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.32(P=0.75)  
   
6.8.2 By 12 months  
Jerrell 1995a 22 75.7 (10.8) 25 73.1 (10) 100% 2.58[-3.39,8.55]
Subtotal *** 22   25   100% 2.58[-3.39,8.55]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.85(P=0.4)  
   
6.8.3 By 18 months  
Jerrell 1995a 7 71.6 (12.6) 18 76.2 (10.9) 100% -4.66[-15.29,5.97]
Subtotal *** 7   18   100% -4.66[-15.29,5.97]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.86(P=0.39)  
Test for subgroup differences: Chi2=1.56, df=1 (P=0.46), I2=0%  
Favours control 105-10 -5 0 Favours treatment
 
 
Psychosocial interventions for people with both severe mental illness and substance misuse (Review)









Cochrane Database of Systematic Reviews
Analysis 6.9.   Comparison 6 Skills training versus standard
care, Outcome 9 Service use: 1. Days in hospital (skewed data).
Service use: 1. Days in hospital (skewed data)
Study Intervention Mean SD N
Hellerstein 1995 Treatment 5.4 10.4 16
Hellerstein 1995 Control 3.6 6.7 13
 
 
Comparison 7.   Cognitive behavioural therapy + motivational interviewing versus standard care





Statistical method Effect size
1 Leaving the study early 1. Lost to treat-
ment
8   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
1.1 By 3 months 3 318 Risk Ratio (M-H, Random, 95%
CI)
1.20 [0.44, 3.30]
1.2 By 6 months 5 815 Risk Ratio (M-H, Random, 95%
CI)
0.90 [0.66, 1.22]
1.3 By 9-10 months 3 211 Risk Ratio (M-H, Random, 95%
CI)
0.80 [0.52, 1.22]
1.4 By 12 months 1 327 Risk Ratio (M-H, Random, 95%
CI)
0.99 [0.62, 1.59]
2 Leaving the study early: 2. Lost to evalua-
tion
8   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.1 By 3 months 2 230 Risk Ratio (M-H, Random, 95%
CI)
0.75 [0.46, 1.21]
2.2 By 6 months 5 469 Risk Ratio (M-H, Random, 95%
CI)
0.80 [0.57, 1.12]
2.3 By 9 months 2 146 Risk Ratio (M-H, Random, 95%
CI)
0.82 [0.46, 1.47]
2.4 By 12-14 months 5 464 Risk Ratio (M-H, Random, 95%
CI)
0.99 [0.73, 1.34]
2.5 By 18 months 2 363 Risk Ratio (M-H, Random, 95%
CI)
0.92 [0.61, 1.38]
2.6 By 24 months 1 327 Risk Ratio (M-H, Random, 95%
CI)
0.76 [0.52, 1.11]
3 Adverse event: 1. Death - by about 1 year 4 603 Risk Ratio (M-H, Random, 95%
CI)
0.60 [0.20, 1.76]
4 Adverse event: 2. Death or hospitalisation
by 24 months
1 326 Risk Ratio (M-H, Random, 95%
CI)
1.15 [0.76, 1.74]
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Statistical method Effect size
5 Substance use: 1. Average number of dif-
ferent drugs used during the past month
(OTI, high = poor)
1   Mean Difference (IV, Random,
95% CI)
Subtotals only
5.1 By 3 months 1 119 Mean Difference (IV, Random,
95% CI)
0.37 [-0.01, 0.75]
5.2 By 6 months 1 119 Mean Difference (IV, Random,
95% CI)
0.19 [-0.22, 0.60]
6 Substance use: 2. Cannabis use last 30
days
1   Mean Difference (IV, Random,
95% CI)
Subtotals only
6.1 3 months (end of treatment) 1 54 Mean Difference (IV, Random,
95% CI)
-0.20 [-2.54, 2.14]
6.2 12 months 1 42 Mean Difference (IV, Random,
95% CI)
-0.30 [-2.84, 2.24]
7 Substance use 3. Clinically important
change -change in main substance use, ab-
stinent or large decease
1 100 Risk Ratio (M-H, Random, 95%
CI)
0.67 [0.43, 1.04]
7.1 From baseline to 3 months 1 100 Risk Ratio (M-H, Random, 95%
CI)
0.67 [0.43, 1.04]
8 Substance use: 4. Averages of various mea-
sures (skewed data)
    Other data No numeric data
8.1 Alcohol - estimated daily consumption -
past month - 3 months
    Other data No numeric data
8.2 Alcohol - estimated daily consumption -
past month - 6 months
    Other data No numeric data
8.3 Alcohol - estimated daily consumption -
past month - 12 months
    Other data No numeric data
8.4 Alcohol - frequency per month by 6
months
    Other data No numeric data
8.5 Alcohol quantity per session - 6 months     Other data No numeric data
8.6 Alcohol Assessment - AUDIT - 6 months     Other data No numeric data
8.7 General - ASI score - 6 months     Other data No numeric data
8.8 Drug abuse screening test - DAST-10 by 6
months
    Other data No numeric data
8.9 Amphetamine- estimated daily con-
sumption - past month - 6 months
    Other data No numeric data
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Statistical method Effect size
8.10 Amphetamine- estimated daily con-
sumption - past month - 3 months
    Other data No numeric data
8.11 Amphetamine- estimated daily con-
sumption - past month - 12 months
    Other data No numeric data
8.12 Cannabis- estimated daily consumption
- past month - 3 months
    Other data No numeric data
8.13 Cannabis- estimated daily consumption
- past month - 6 months
    Other data No numeric data
8.14 Cannabis- estimated daily consumption
- past month - 12 months
    Other data No numeric data
8.16 cannabis - days of use last month by 6
months
    Other data No numeric data
8.17 Cannabis - days of use last month by
10-12 months
    Other data No numeric data
8.18 Cannabis - joints last 30 days by 6
months
    Other data No numeric data
8.19 Cannabis - joints last 30 days by 10
months
    Other data No numeric data
8.20 Proportion of days abstinence from all
substances last 90 days by 6 months
    Other data No numeric data
8.21 Proportion of days abstinence from all
substances last 90 days by 12 months
    Other data No numeric data
8.22 Proportion of days abstinence from all
substances last 90 days by 18 months
    Other data No numeric data
8.23 Proportion of days abstinence from all
substances last 90 days by 24 months
    Other data No numeric data
9 Substance use: 5. Average change in %
days abstinent during & after treatment
    Other data No numeric data
10 Mental state: 1. Average score (PANSS, to-
tal, high = poor)
4   Mean Difference (IV, Random,
95% CI)
Subtotals only
10.1 By 6 months 2 78 Mean Difference (IV, Random,
95% CI)
0.99 [-5.91, 7.89]
10.2 By 9-10 months 2 92 Mean Difference (IV, Random,
95% CI)
-5.01 [-11.25, 1.22]
10.3 By 12 months 1 274 Mean Difference (IV, Random,
95% CI)
2.52 [-0.68, 5.72]
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10.4 By 24 months 1 247 Mean Difference (IV, Random,
95% CI)
2.71 [-0.58, 6.00]
11 Mental state: 2. Average score (PANSS
positive symptoms, high = poor)
1   Mean Difference (IV, Random,
95% CI)
Subtotals only
11.1 By 12 months 1 274 Mean Difference (IV, Random,
95% CI)
0.03 [-1.18, 1.24]
11.2 By 24 months 1 247 Mean Difference (IV, Random,
95% CI)
0.52 [-0.80, 1.84]
12 Mental state: 3. Average score (PANSS
negative symptoms, high = poor)
1   Mean Difference (IV, Random,
95% CI)
Subtotals only
12.1 by 12 months 1 274 Mean Difference (IV, Random,
95% CI)
0.39 [-0.65, 1.43]
12.2 by 24 months 1 247 Mean Difference (IV, Random,
95% CI)
0.16 [-0.84, 1.16]
13 Mental state: 4. Average score (various
scales, high = poor)) (skewed data)
    Other data No numeric data
13.1 Depressive symptoms - 3 months
(BDI-11)
    Other data No numeric data
13.2 Depressive symptoms - 6 months
(BDI-11)
    Other data No numeric data
13.3 Depressive symptoms - 12 months
(BDI-11)
    Other data No numeric data
13.4 Depressive symptoms - 3 months Cal-
gary Depression Scale
    Other data No numeric data
13.5 Depressive symptoms - 12 months Cal-
gary Depression Scale
    Other data No numeric data
13.6 General symptoms total score - 6
months (BPRS)
    Other data No numeric data
13.7 General symptoms total score - 12
months (BPRS)
    Other data No numeric data
13.8 General symptoms total score - 3
months (BPRS)
    Other data No numeric data
13.9 General symptoms - 18 months (PANSS)     Other data No numeric data
13.10 Total score - 3 months (PANSS)     Other data No numeric data
13.11 Total score - 6 months (PANSS)     Other data No numeric data
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13.12 Total score - 12 months (PANSS)     Other data No numeric data
13.13 Total score - 18 months (PANSS)     Other data No numeric data
13.14 Manic symptoms - 3 months (BPRS)     Other data No numeric data
13.15 Manic symptoms - 6 months (BPRS)     Other data No numeric data
13.16 Manic symptoms - 12 months (BPRS)     Other data No numeric data
13.17 Negative symptoms - 3 months (BPRS)     Other data No numeric data
13.18 Negative symptoms - 6 months (BPRS)     Other data No numeric data
13.19 Negative symptoms - 12 months
(BPRS)
    Other data No numeric data
13.20 Negative symptoms - 6 months
(PANSS)
    Other data No numeric data
13.21 Negative symptoms - 9-10 months
(PANSS)
    Other data No numeric data
13.22 Negative symptoms - 12 months
(PANSS)
    Other data No numeric data
13.23 Negative symptoms - 18 months
(PANSS)
    Other data No numeric data
13.24 Negative symptoms - 3 months (SANS)     Other data No numeric data
13.25 Negative symptoms - 12 months
(SANS)
    Other data No numeric data
13.26 Positive symptoms - 6 months (PANSS)     Other data No numeric data
13.27 Positive symptoms - 9-10 months
(PANSS)
    Other data No numeric data
13.28 Positive symptoms - 12 months
(PANSS)
    Other data No numeric data
13.29 Positive symptoms - 18 months
(PANSS)
    Other data No numeric data
13.30 Positive symptoms - 3 months (SAPS)     Other data No numeric data
13.31 Positive symptoms - 12 months (SAPS)     Other data No numeric data
14 Global state: 1. Average score (GAF, low =
poor)
6   Mean Difference (IV, Random,
95% CI)
Subtotals only
14.1 3 months 3 277 Mean Difference (IV, Random,
95% CI)
-0.17 [-2.79, 2.46]
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14.2 6 months 2 219 Mean Difference (IV, Random,
95% CI)
1.65 [-2.46, 5.76]
14.3 12 months 4 445 Mean Difference (IV, Random,
95% CI)
1.24 [-1.86, 4.34]
14.4 18 months 2 72 Mean Difference (IV, Random,
95% CI)
4.57 [-3.07, 12.21]
14.5 24 months 1 234 Mean Difference (IV, Random,
95% CI)
-0.21 [-2.93, 2.51]
15 Global state: 2. Forensic measures - ar-
rests reported - by 6 months
1 110 Risk Ratio (M-H, Random, 95%
CI)
0.49 [0.22, 1.10]
16 Social functioning: 1. Average score (SFS,
low = poor)
1   Mean Difference (IV, Random,
95% CI)
Subtotals only
16.1 By end of 9 month treatment 1 32 Mean Difference (IV, Random,
95% CI)
5.01 [-0.55, 10.57]
16.2 By 12 months (3 months following
treatment end)
1 32 Mean Difference (IV, Random,
95% CI)
7.27 [0.86, 13.68]
17 Quality of life/ life satisfaction: 1. Average
score (BQOL (general life satisfaction, low =
poor) - by 6 months
1 110 Mean Difference (IV, Random,
95% CI)
0.58 [0.00, 1.16]
18 Quality of life/ life satisfaction: 2. Aver-
age score (BQOL (overall quality of life, low =
poor) - by 6 months
1 110 Mean Difference (IV, Random,
95% CI)
-0.02 [-0.61, 0.57]
19 Quality of life/ life satisfaction: 3. Average
score (WHOQOL, Bref, higher scores = better
QoL) - by 6 months
1 16 Mean Difference (IV, Random,
95% CI)
-15.70 [-36.19, 4.79]
20 Quality of life/ life satisfaction: 4. Average
score (MANSA, higher scores = better QoL)
1   Mean Difference (IV, Random,
95% CI)
Subtotals only
20.1 By 6 months 1 64 Mean Difference (IV, Random,
95% CI)
-2.70 [-7.01, 1.61]
20.2 By 10 months 1 61 Mean Difference (IV, Random,
95% CI)
0.90 [-3.73, 5.53]
21 Quality of life/ life satisfaction: 5. Average
score (CSQ - client satisfaction, high = good)
- by 10 months
1 62 Mean Difference (IV, Random,
95% CI)
6.40 [3.87, 8.93]
22 Service use: 1. Relapse (hospitalised) 2   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
22.1 By end of 9 month treatment phase 2 107 Risk Ratio (M-H, Random, 95%
CI)
0.58 [0.29, 1.16]
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22.2 By 3 months after treatment finished -
12 months
1 36 Risk Ratio (M-H, Random, 95%
CI)
0.50 [0.24, 1.04]
22.3 By 9 months after treatment finished -
18 months
2 105 Risk Ratio (M-H, Random, 95%
CI)
0.61 [0.34, 1.10]
23 Economic outcomes: 1. Direct cost in US$
(BQOL, money subscale) (skewed data)
    Other data No numeric data
23.1 6 months     Other data No numeric data
 
 
Analysis 7.1.   Comparison 7 Cognitive behavioural therapy + motivational interviewing
versus standard care, Outcome 1 Leaving the study early 1. Lost to treatment.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
7.1.1 By 3 months  
Baker 2006 8/65 0/65 10.34% 17[1,288.56]
Gouzoulis-Mayfrank 2015 15/50 22/50 47.77% 0.68[0.4,1.15]
Madigan 2013 17/59 7/29 41.89% 1.19[0.56,2.55]
Subtotal (95% CI) 174 144 100% 1.2[0.44,3.3]
Total events: 40 (Treatment), 29 (Control)  
Heterogeneity: Tau2=0.48; Chi2=6.71, df=2(P=0.03); I2=70.19%  
Test for overall effect: Z=0.36(P=0.72)  
   
7.1.2 By 6 months  
Barrowclough 2010 17/164 14/163 13.94% 1.21[0.62,2.37]
Barrowclough 2014 16/75 11/35 14.48% 0.68[0.35,1.31]
Bellack 2006 61/107 31/68 30.19% 1.25[0.92,1.7]
Gouzoulis-Mayfrank 2015 20/50 27/50 23.58% 0.74[0.48,1.13]
Hjorthoj 2013 14/52 21/51 17.82% 0.65[0.38,1.14]
Subtotal (95% CI) 448 367 100% 0.9[0.66,1.22]
Total events: 128 (Treatment), 104 (Control)  
Heterogeneity: Tau2=0.06; Chi2=7.64, df=4(P=0.11); I2=47.63%  
Test for overall effect: Z=0.7(P=0.48)  
   
7.1.3 By 9-10 months  
Barrowclough 2001 1/18 2/18 3.35% 0.5[0.05,5.04]
Barrowclough 2014 11/37 11/35 36.86% 0.95[0.47,1.9]
Hjorthoj 2013 15/52 20/51 59.79% 0.74[0.43,1.27]
Subtotal (95% CI) 107 104 100% 0.8[0.52,1.22]
Total events: 27 (Treatment), 33 (Control)  
Heterogeneity: Tau2=0; Chi2=0.47, df=2(P=0.79); I2=0%  
Test for overall effect: Z=1.05(P=0.29)  
   
7.1.4 By 12 months  
Barrowclough 2010 29/164 29/163 100% 0.99[0.62,1.59]
Subtotal (95% CI) 164 163 100% 0.99[0.62,1.59]
Favours treatment 1000.01 100.1 1 Favours control
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 29 (Treatment), 29 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.03(P=0.98)  
Favours treatment 1000.01 100.1 1 Favours control
 
 
Analysis 7.2.   Comparison 7 Cognitive behavioural therapy + motivational interviewing
versus standard care, Outcome 2 Leaving the study early: 2. Lost to evaluation.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
7.2.1 By 3 months  
Baker 2006 5/65 4/65 14.68% 1.25[0.35,4.45]
Gouzoulis-Mayfrank 2015 15/50 22/50 85.32% 0.68[0.4,1.15]
Subtotal (95% CI) 115 115 100% 0.75[0.46,1.21]
Total events: 20 (Treatment), 26 (Control)  
Heterogeneity: Tau2=0; Chi2=0.76, df=1(P=0.38); I2=0%  
Test for overall effect: Z=1.19(P=0.24)  
   
7.2.2 By 6 months  
Baker 2006 5/65 2/65 4.25% 2.5[0.5,12.42]
Barrowclough 2014 16/75 11/35 23.27% 0.68[0.35,1.31]
Bellack 2006 15/61 12/49 22.96% 1[0.52,1.94]
Gouzoulis-Mayfrank 2015 20/50 27/50 48.15% 0.74[0.48,1.13]
Kemp 2007 0/10 3/9 1.38% 0.13[0.01,2.22]
Subtotal (95% CI) 261 208 100% 0.8[0.57,1.12]
Total events: 56 (Treatment), 55 (Control)  
Heterogeneity: Tau2=0.01; Chi2=4.35, df=4(P=0.36); I2=7.96%  
Test for overall effect: Z=1.31(P=0.19)  
   
7.2.3 By 9 months  
Barrowclough 2001 2/18 3/18 12.06% 0.67[0.13,3.53]
Barrowclough 2014 20/75 11/35 87.94% 0.85[0.46,1.57]
Subtotal (95% CI) 93 53 100% 0.82[0.46,1.47]
Total events: 22 (Treatment), 14 (Control)  
Heterogeneity: Tau2=0; Chi2=0.07, df=1(P=0.79); I2=0%  
Test for overall effect: Z=0.66(P=0.51)  
   
7.2.4 By 12-14 months  
Baker 2006 16/65 10/65 14.78% 1.6[0.79,3.26]
Barrowclough 2001 1/18 3/18 1.89% 0.33[0.04,2.91]
Barrowclough 2014 21/75 13/35 21.34% 0.75[0.43,1.32]
Gouzoulis-Mayfrank 2015 27/50 31/50 41.22% 0.87[0.62,1.22]
Madigan 2013 27/59 10/29 20.78% 1.33[0.75,2.35]
Subtotal (95% CI) 267 197 100% 0.99[0.73,1.34]
Total events: 92 (Treatment), 67 (Control)  
Heterogeneity: Tau2=0.03; Chi2=5.22, df=4(P=0.27); I2=23.36%  
Test for overall effect: Z=0.06(P=0.95)  
   
7.2.5 By 18 months  
Favours treatment 100.1 50.2 20.5 1 Favours control
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Barrowclough 2001 3/18 5/18 10.11% 0.6[0.17,2.14]
Barrowclough 2010 33/164 34/163 89.89% 0.96[0.63,1.48]
Subtotal (95% CI) 182 181 100% 0.92[0.61,1.38]
Total events: 36 (Treatment), 39 (Control)  
Heterogeneity: Tau2=0; Chi2=0.48, df=1(P=0.49); I2=0%  
Test for overall effect: Z=0.41(P=0.68)  
   
7.2.6 By 24 months  
Barrowclough 2010 35/164 46/163 100% 0.76[0.52,1.11]
Subtotal (95% CI) 164 163 100% 0.76[0.52,1.11]
Total events: 35 (Treatment), 46 (Control)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.43(P=0.15)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 7.3.   Comparison 7 Cognitive behavioural therapy + motivational interviewing
versus standard care, Outcome 3 Adverse event: 1. Death - by about 1 year.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Baker 2006 3/65 1/65 23.11% 3[0.32,28.09]
Barrowclough 2001 1/18 2/18 21.67% 0.5[0.05,5.04]
Barrowclough 2010 2/164 5/163 43.76% 0.4[0.08,2.02]
Barrowclough 2014 0/75 1/35 11.46% 0.16[0.01,3.78]
   
Total (95% CI) 322 281 100% 0.6[0.2,1.76]
Total events: 6 (Treatment), 9 (Control)  
Heterogeneity: Tau2=0; Chi2=2.94, df=3(P=0.4); I2=0%  
Test for overall effect: Z=0.93(P=0.35)  
Favours treatment 1000.01 100.1 1 Favours control
 
 
Analysis 7.4.   Comparison 7 Cognitive behavioural therapy + motivational interviewing
versus standard care, Outcome 4 Adverse event: 2. Death or hospitalisation by 24 months.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Barrowclough 2010 38/163 33/163 100% 1.15[0.76,1.74]
   
Total (95% CI) 163 163 100% 1.15[0.76,1.74]
Total events: 38 (Treatment), 33 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.67(P=0.5)  
Favours CBT + MI 100.1 50.2 20.5 1 Favours Usual Treatment
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Analysis 7.5.   Comparison 7 Cognitive behavioural therapy + motivational interviewing versus standard care,
Outcome 5 Substance use: 1. Average number of di?erent drugs used during the past month (OTI, high = poor).
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
7.5.1 By 3 months  
Baker 2006 58 2.8 (1.1) 61 2.4 (1.1) 100% 0.37[-0.01,0.75]
Subtotal *** 58   61   100% 0.37[-0.01,0.75]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.89(P=0.06)  
   
7.5.2 By 6 months  
Baker 2006 58 2.6 (1.1) 61 2.4 (1.2) 100% 0.19[-0.22,0.6]
Subtotal *** 58   61   100% 0.19[-0.22,0.6]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.9(P=0.37)  
Favours treatment 10.5-1 -0.5 0 Favours control
 
 
Analysis 7.6.   Comparison 7 Cognitive behavioural therapy + motivational interviewing
versus standard care, Outcome 6 Substance use: 2. Cannabis use last 30 days.
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
7.6.1 3 months (end of treatment)  
Madigan 2013 36 9.9 (4) 18 10.1 (4.2) 100% -0.2[-2.54,2.14]
Subtotal *** 36   18   100% -0.2[-2.54,2.14]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.17(P=0.87)  
   
7.6.2 12 months  
Madigan 2013 28 9.8 (3.9) 14 10.1 (4) 100% -0.3[-2.84,2.24]
Subtotal *** 28   14   100% -0.3[-2.84,2.24]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.23(P=0.82)  
Test for subgroup differences: Chi2=0, df=1 (P=0.95), I2=0%  
Favours CBT + MI 105-10 -5 0 Favours Usual Treatment
 
 
Analysis 7.7.   Comparison 7 Cognitive behavioural therapy + motivational interviewing versus standard care,
Outcome 7 Substance use 3. Clinically important change -change in main substance use, abstinent or large decease.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
7.7.1 From baseline to 3 months  
Gouzoulis-Mayfrank 2015 32/50 23/50 100% 0.67[0.43,1.04]
Subtotal (95% CI) 50 50 100% 0.67[0.43,1.04]
Total events: 32 (Treatment), 23 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.77(P=0.08)  
   
Favours [Control] 20.5 1.50.7 1 Favours [experimental]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total (95% CI) 50 50 100% 0.67[0.43,1.04]
Total events: 32 (Treatment), 23 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.77(P=0.08)  
Favours [Control] 20.5 1.50.7 1 Favours [experimental]
 
 
Analysis 7.8.   Comparison 7 Cognitive behavioural therapy + motivational interviewing versus
standard care, Outcome 8 Substance use: 4. Averages of various measures (skewed data).
Substance use: 4. Averages of various measures (skewed data)
Study Intervention Mean SD N
Alcohol - estimated daily consumption - past month - 3 months
Baker 2006 Treatment 4.92 4.69 21
Baker 2006 Control 3.35 4.10 31
Alcohol - estimated daily consumption - past month - 6 months
Baker 2006 Treatment 3.73 4.07 21
Baker 2006 Control 2.52 4.20 31
Alcohol - estimated daily consumption - past month - 12 months
Baker 2006 Treatment 3.58 4.80 18
Baker 2006 Control 2.19 3.04 28
Alcohol - frequency per month by 6 months
Kemp 2007 Treatment 3.1 3.8 10
Kemp 2007 Control 2.3 3.8 6
Alcohol quantity per session - 6 months
Kemp 2007 Treatment 4.7 2.9 10
Kemp 2007 Control 3.6 2.8 6
Alcohol Assessment - AUDIT - 6 months
Kemp 2007 Treatment 9.3 6.9 10
Kemp 2007 Control 4.8 5 6
General - ASI score - 6 months
Bellack 2006 Treatment 72.90 249 61
Bellack 2006 Control 74.10 155 49
Drug abuse screening test - DAST-10 by 6 months
Kemp 2007 Treatment 1.8 1.9 10
Kemp 2007 Control 3.5 2.4 6
Amphetamine- estimated daily consumption - past month - 6 months
Baker 2006 Treatment 0.19 0.41 11
Baker 2006 Control 1.47 2.28 9
Amphetamine- estimated daily consumption - past month - 3 months
Baker 2006 Treatment 0.34 0.53 11
Baker 2006 Control 0.25 0.57 9
Amphetamine- estimated daily consumption - past month - 12 months
Baker 2006 Treatment 0.14 0.26 9
Baker 2006 Control 0.01 0.25 8
Cannabis- estimated daily consumption - past month - 3 months
Baker 2006 Treatment 5.09 7.21 39
Baker 2006 Control 5.66 8.72 34
Cannabis- estimated daily consumption - past month - 6 months
Baker 2006 Treatment 5.37 11.75 39
Baker 2006 Control 4.67 8.68 34
Cannabis- estimated daily consumption - past month - 12 months
Baker 2006 Treatment 8.53 14.59 29
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Substance use: 4. Averages of various measures (skewed data)
Study Intervention Mean SD N
Baker 2006 Control 4.12 6.51 29
cannabis - days of use last month by 6 months
Hjorthoj 2013 Treatment 12 11.44 38
Hjorthoj 2013 Control 15.6 12.58 30
Cannabis - days of use last month by 10-12 months
Hjorthoj 2013 Treatment 11.1 11.19 37
Hjorthoj 2013 Control 13.7 13.31 31
Cannabis - joints last 30 days by 6 months
Hjorthoj 2013 Treatment 28.6 38.75 38
Hjorthoj 2013 Control 47.1 58.26 30
Kemp 2007 Treatment 38.8 113.1 10
Kemp 2007 Control 25.3 61.1 6
Cannabis - joints last 30 days by 10 months
Hjorthoj 2013 Treatment 26.8 38.21 37
Hjorthoj 2013 Control 44.6 58.46 31
Proportion of days abstinence from all substances last 90 days by 6 months
Barrowclough 2010 Treatment 34.27 34.01 147
Barrowclough 2010 Control 30.06 35.18 148
Proportion of days abstinence from all substances last 90 days by 12 months
Barrowclough 2010 Treatment 40.24 36.18 137
Barrowclough 2010 Control 34.51 34.18 136
Proportion of days abstinence from all substances last 90 days by 18 months
Barrowclough 2010 Treatment 38.17 37.23 129
Barrowclough 2010 Control 38.47 34.94 127
Proportion of days abstinence from all substances last 90 days by 24 months
Barrowclough 2010 Treatment 44.25 38.36 130
Barrowclough 2010 Control 37.18 36.89 117
 
 
Analysis 7.9.   Comparison 7 Cognitive behavioural therapy + motivational interviewing versus standard
care, Outcome 9 Substance use: 5. Average change in % days abstinent during & aLer treatment.
Substance use: 5. Average change in % days abstinent during & after treatment
Study Treatment Group Median range N Notes




4 time periods (to 12
months) and subtracted
from baseline.
Barrowclough 2001 TAU -6.52 -67.9-53.2 15  
 
 
Analysis 7.10.   Comparison 7 Cognitive behavioural therapy + motivational interviewing
versus standard care, Outcome 10 Mental state: 1. Average score (PANSS, total, high = poor).
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
7.10.1 By 6 months  
Hjorthoj 2013 34 67.4 (14.1) 28 66.3 (16.7) 78.46% 1.1[-6.69,8.89]
Kemp 2007 10 64.4 (15) 6 63.8 (14.5) 21.54% 0.6[-14.27,15.47]
Favours treatment 105-10 -5 0 Favours control
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Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Subtotal *** 44   34   100% 0.99[-5.91,7.89]
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.95); I2=0%  
Test for overall effect: Z=0.28(P=0.78)  
   
7.10.2 By 9-10 months  
Barrowclough 2001 17 58.9 (11.4) 15 65.5 (15.3) 43.5% -6.59[-16.04,2.86]
Hjorthoj 2013 34 61.6 (15.7) 26 65.4 (16.6) 56.5% -3.8[-12.09,4.49]
Subtotal *** 51   41   100% -5.01[-11.25,1.22]
Heterogeneity: Tau2=0; Chi2=0.19, df=1(P=0.66); I2=0%  
Test for overall effect: Z=1.58(P=0.12)  
   
7.10.3 By 12 months  
Barrowclough 2010 137 57.8 (14) 137 55.3 (13) 100% 2.52[-0.68,5.72]
Subtotal *** 137   137   100% 2.52[-0.68,5.72]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.54(P=0.12)  
   
7.10.4 By 24 months  
Barrowclough 2010 129 54.6 (14.7) 118 51.9 (11.6) 100% 2.71[-0.58,6]
Subtotal *** 129   118   100% 2.71[-0.58,6]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.62(P=0.11)  
Favours treatment 105-10 -5 0 Favours control
 
 
Analysis 7.11.   Comparison 7 Cognitive behavioural therapy + motivational interviewing versus
standard care, Outcome 11 Mental state: 2. Average score (PANSS positive symptoms, high = poor).
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
7.11.1 By 12 months  
Barrowclough 2010 137 14.6 (4.9) 137 14.6 (5.4) 100% 0.03[-1.18,1.24]
Subtotal *** 137   137   100% 0.03[-1.18,1.24]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.05(P=0.96)  
   
7.11.2 By 24 months  
Barrowclough 2010 129 14.1 (5.4) 118 13.6 (5.2) 100% 0.52[-0.8,1.84]
Subtotal *** 129   118   100% 0.52[-0.8,1.84]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.77(P=0.44)  
Test for subgroup differences: Chi2=0.29, df=1 (P=0.59), I2=0%  
Favours CBT + MI 105-10 -5 0 Favours Usual Treatment
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Analysis 7.12.   Comparison 7 Cognitive behavioural therapy + motivational interviewing versus
standard care, Outcome 12 Mental state: 3. Average score (PANSS negative symptoms, high = poor).
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
7.12.1 by 12 months  
Barrowclough 2010 137 13.4 (4.7) 137 13 (4.1) 100% 0.39[-0.65,1.43]
Subtotal *** 137   137   100% 0.39[-0.65,1.43]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.74(P=0.46)  
   
7.12.2 by 24 months  
Barrowclough 2010 129 12.6 (4.2) 118 12.5 (3.8) 100% 0.16[-0.84,1.16]
Subtotal *** 129   118   100% 0.16[-0.84,1.16]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.31(P=0.75)  
Test for subgroup differences: Chi2=0.1, df=1 (P=0.75), I2=0%  
Favours CBT + MI 105-10 -5 0 Favours Usual Treatment
 
 
Analysis 7.13.   Comparison 7 Cognitive behavioural therapy + motivational interviewing versus
standard care, Outcome 13 Mental state: 4. Average score (various scales, high = poor)) (skewed data).
Mental state: 4. Average score (various scales, high = poor)) (skewed data)
Study Intervention Mean SD N
Depressive symptoms - 3 months (BDI-11)
Baker 2006 Treatment 16.93 12.51 58
Baker 2006 Control 10.93 10.43 61
Depressive symptoms - 6 months (BDI-11)
Baker 2006 Treatment 14.10 11.38 58
Baker 2006 Control 9.92 9.29 61
Depressive symptoms - 12 months (BDI-11)
Baker 2006 Treatment 17.14 13.20 44
Baker 2006 Control 9.68 10.30 53
Depressive symptoms - 3 months Calgary Depression Scale
Madigan 2013 Treatment 4.4 4.3 40
Madigan 2013 Control 4.6 4.8 20
Depressive symptoms - 12 months Calgary Depression Scale
Madigan 2013 Treatment 4.3 4.4 33
Madigan 2013 Control 4.3 4.2 11
General symptoms total score - 6 months (BPRS)
Baker 2006 Treatment 35.47 9.34 58
Baker 2006 Control 34.52 8.53 61
General symptoms total score - 12 months (BPRS)
Baker 2006 Treatment 35.43 8.59 44
Baker 2006 Control 32.58 8.19 53
General symptoms total score - 3 months (BPRS)
Baker 2006 Treatment 35.31 9.04 58
Baker 2006 Control 34.46 11.24 61
General symptoms - 18 months (PANSS)
Barrowclough 2001 Treatment 21.13 6.39 15
Barrowclough 2001 Control 30.07 8.17 14
Barrowclough 2014 Treatment (long) 35.1 9.0 23
Barrowclough 2014 Control 31.6 8.5 21
Total score - 3 months (PANSS)
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Mental state: 4. Average score (various scales, high = poor)) (skewed data)
Study Intervention Mean SD N
Gouzoulis-Mayfrank 2015 Treatment 65.36 28.26 50
Gouzoulis-Mayfrank 2015 Control 77.42 31.55 50
Total score - 6 months (PANSS)
Gouzoulis-Mayfrank 2015 Treatment 61.92 26.823 50
Gouzoulis-Mayfrank 2015 Control 77.9 33.254 50
Total score - 12 months (PANSS)
Barrowclough 2001 Treatment 56.88 14.23 17
Barrowclough 2001 Control 63.40 17.96 15
Total score - 18 months (PANSS)
Barrowclough 2001 Treatment 52.20 11.12 15
Barrowclough 2001 Control 58.50 15.04 14
Manic symptoms - 3 months (BPRS)
Baker 2006 Treatment 6.43 2.46 58
Baker 2006 Control 7.39 3.51 61
Manic symptoms - 6 months (BPRS)
Baker 2006 Treatment 6.38 2.23 58
Baker 2006 Control 6.57 3.56 61
Manic symptoms - 12 months (BPRS)
Baker 2006 Treatment 6.07 1.63 44
Baker 2006 Control 6.18 2.32 53
Negative symptoms - 3 months (BPRS)
Baker 2006 Treatment 6.24 2.10 58
Baker 2006 Control 6.48 2.47 61
Negative symptoms - 6 months (BPRS)
Baker 2006 Treatment 6.00 1.52 58
Baker 2006 Control 6.08 1.54 61
Negative symptoms - 12 months (BPRS)
Baker 2006 Treatment 6.86 1.36 44
Baker 2006 Control 6.58 2.35 53
Negative symptoms - 6 months (PANSS)
Hjorthoj 2013 Treatment 16.3 5.92 34
Hjorthoj 2013 Control 15.3 5.35 28
Negative symptoms - 9-10 months (PANSS)
Barrowclough 2001 Treatment 12.47 4.12 17
Barrowclough 2001 Control 16.20 4.87 15
Hjorthoj 2013 Treatment 14.9 5.2 34
Hjorthoj 2013 Control 15.2 6.15 26
Negative symptoms - 12 months (PANSS)
Barrowclough 2001 Treatment 12.65 4.97 17
Barrowclough 2001 Control 14.67 6.02 15
Negative symptoms - 18 months (PANSS)
Barrowclough 2001 Treatment 10.27 2.25 15
Barrowclough 2001 Control 15.50 5.71 14
Barrowclough 2014 Treatment 13.7 3.9 23
Barrowclough 2014 Control 15.2 6.5 21
Negative symptoms - 3 months (SANS)
Madigan 2013 Treatment 3.8 2.4 40
Madigan 2013 Control 3.2 2.3 20
Negative symptoms - 12 months (SANS)
Madigan 2013 Treatment 4.6 3 32
Madigan 2013 Control 4.8 3.2 19
Positive symptoms - 6 months (PANSS)
Hjorthoj 2013 Treatment 15.6 5.09 34
Hjorthoj 2013 Control 17 5.01 28
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Mental state: 4. Average score (various scales, high = poor)) (skewed data)
Study Intervention Mean SD N
Positive symptoms - 9-10 months (PANSS)
Barrowclough 2001 Treatment 15.29 4.69 17
Barrowclough 2001 Control 16.40 4.29 15
Hjorthoj 2013 Treatment 14.4 5.22 34
Hjorthoj 2013 Control 16.2 4.99 26
Positive symptoms - 12 months (PANSS)
Barrowclough 2001 Treatment 13.35 4.57 17
Barrowclough 2001 Control 16.07 5.54 15
Positive symptoms - 18 months (PANSS)
Barrowclough 2001 Treatment 13.87 4.27 15
Barrowclough 2001 Control 12.93 4.23 14
Barrowclough 2014 Treatment (Long) 13.0 4.6 24
Barrowclough 2014 Control 12.7 5.1 21
Positive symptoms - 3 months (SAPS)
Madigan 2013 Treatment 4.8 3.7 42
Madigan 2013 Control 5.1 4.1 22
Positive symptoms - 12 months (SAPS)
Madigan 2013 Treatment 4.9 4 32
Madigan 2013 Control 5.1 4.2 17
 
 
Analysis 7.14.   Comparison 7 Cognitive behavioural therapy + motivational interviewing
versus standard care, Outcome 14 Global state: 1. Average score (GAF, low = poor).
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
7.14.1 3 months  
Baker 2006 58 64.8 (12) 61 67.5 (12.2) 35.32% -2.7[-7.05,1.65]
Gouzoulis-Mayfrank 2015 50 43.4 (9.9) 50 41.9 (11.6) 37.63% 1.52[-2.69,5.73]
Madigan 2013 39 37.4 (8) 19 36.6 (9.6) 27.05% 0.8[-4.19,5.79]
Subtotal *** 147   130   100% -0.17[-2.79,2.46]
Heterogeneity: Tau2=0.16; Chi2=2.06, df=2(P=0.36); I2=2.91%  
Test for overall effect: Z=0.12(P=0.9)  
   
7.14.2 6 months  
Baker 2006 58 67.4 (9.5) 61 67.5 (10.6) 59.32% -0.09[-3.7,3.52]
Gouzoulis-Mayfrank 2015 50 47.8 (12.2) 50 43.7 (13.8) 40.68% 4.18[-0.93,9.29]
Subtotal *** 108   111   100% 1.65[-2.46,5.76]
Heterogeneity: Tau2=4.03; Chi2=1.79, df=1(P=0.18); I2=44.19%  
Test for overall effect: Z=0.79(P=0.43)  
   
7.14.3 12 months  
Baker 2006 44 68.5 (10) 53 66.3 (11.2) 28.59% 2.17[-2.05,6.39]
Barrowclough 2001 17 58.4 (13.6) 15 48.1 (15.3) 8.2% 10.28[0.22,20.34]
Barrowclough 2010 135 35 (9.5) 134 35.6 (9.4) 46.09% -0.64[-2.89,1.61]
Madigan 2013 31 37.6 (8.3) 16 37.2 (11.5) 17.12% 0.4[-5.95,6.75]
Subtotal *** 227   218   100% 1.24[-1.86,4.34]
Heterogeneity: Tau2=4.1; Chi2=5.2, df=3(P=0.16); I2=42.33%  
Test for overall effect: Z=0.78(P=0.43)  
   
7.14.4 18 months  
Favours control 105-10 -5 0 Favours treatment
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Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Barrowclough 2001 15 60.1 (19) 13 53.4 (13) 41.13% 6.68[-5.24,18.6]
Barrowclough 2014 23 45 (17.2) 21 41.9 (16.5) 58.87% 3.1[-6.86,13.06]
Subtotal *** 38   34   100% 4.57[-3.07,12.21]
Heterogeneity: Tau2=0; Chi2=0.2, df=1(P=0.65); I2=0%  
Test for overall effect: Z=1.17(P=0.24)  
   
7.14.5 24 months  
Barrowclough 2010 115 36 (10.9) 119 36.2 (10.3) 100% -0.21[-2.93,2.51]
Subtotal *** 115   119   100% -0.21[-2.93,2.51]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.15(P=0.88)  
Favours control 105-10 -5 0 Favours treatment
 
 
Analysis 7.15.   Comparison 7 Cognitive behavioural therapy + motivational interviewing versus
standard care, Outcome 15 Global state: 2. Forensic measures - arrests reported - by 6 months.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bellack 2006 8/61 13/49 100% 0.49[0.22,1.1]
   
Total (95% CI) 61 49 100% 0.49[0.22,1.1]
Total events: 8 (Treatment), 13 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.73(P=0.08)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 7.16.   Comparison 7 Cognitive behavioural therapy + motivational interviewing
versus standard care, Outcome 16 Social functioning: 1. Average score (SFS, low = poor).
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
7.16.1 By end of 9 month treatment  
Barrowclough 2001 17 105 (6.4) 15 100 (9.2) 100% 5.01[-0.55,10.57]
Subtotal *** 17   15   100% 5.01[-0.55,10.57]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.77(P=0.08)  
   
7.16.2 By 12 months (3 months following treatment end)  
Barrowclough 2001 17 108.4 (8.4) 15 101.1 (9.9) 100% 7.27[0.86,13.68]
Subtotal *** 17   15   100% 7.27[0.86,13.68]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.22(P=0.03)  
Favours control 10050-100 -50 0 Favours treatment
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Analysis 7.17.   Comparison 7 Cognitive behavioural therapy + motivational
interviewing versus standard care, Outcome 17 Quality of life/ life satisfaction:
1. Average score (BQOL (general life satisfaction, low = poor) - by 6 months.
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Bellack 2006 61 4.8 (1.7) 49 4.2 (1.4) 100% 0.58[0,1.16]
   
Total *** 61   49   100% 0.58[0,1.16]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.97(P=0.05)  
Favours control 10.5-1 -0.5 0 Favours treatment
 
 
Analysis 7.18.   Comparison 7 Cognitive behavioural therapy + motivational interviewing versus standard care,
Outcome 18 Quality of life/ life satisfaction: 2. Average score (BQOL (overall quality of life, low = poor) - by 6 months.
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Bellack 2006 61 4.5 (1.7) 49 4.5 (1.5) 100% -0.02[-0.61,0.57]
   
Total *** 61   49   100% -0.02[-0.61,0.57]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.07(P=0.95)  
Favours control 10.5-1 -0.5 0 Favours treatment
 
 
Analysis 7.19.   Comparison 7 Cognitive behavioural therapy + motivational
interviewing versus standard care, Outcome 19 Quality of life/ life satisfaction:
3. Average score (WHOQOL, Bref, higher scores = better QoL) - by 6 months.
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Kemp 2007 10 89 (19.1) 6 104.7 (20.9) 100% -15.7[-36.19,4.79]
   
Total *** 10   6   100% -15.7[-36.19,4.79]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.5(P=0.13)  
Favours Usual Treatment 10050-100 -50 0 Favours CBT + MI
 
 
Analysis 7.20.   Comparison 7 Cognitive behavioural therapy + motivational interviewing versus standard
care, Outcome 20 Quality of life/ life satisfaction: 4. Average score (MANSA, higher scores = better QoL).
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
7.20.1 By 6 months  
Hjorthoj 2013 35 51.5 (8.5) 29 54.2 (9) 100% -2.7[-7.01,1.61]
Subtotal *** 35   29   100% -2.7[-7.01,1.61]
Heterogeneity: Not applicable  
Favours Usual Treatment 105-10 -5 0 Favours CBT + MI
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Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for overall effect: Z=1.23(P=0.22)  
   
7.20.2 By 10 months  
Hjorthoj 2013 33 55.1 (8.7) 28 54.2 (9.6) 100% 0.9[-3.73,5.53]
Subtotal *** 33   28   100% 0.9[-3.73,5.53]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.38(P=0.7)  
Test for subgroup differences: Chi2=1.24, df=1 (P=0.26), I2=19.56%  
Favours Usual Treatment 105-10 -5 0 Favours CBT + MI
 
 
Analysis 7.21.   Comparison 7 Cognitive behavioural therapy + motivational interviewing versus standard care,
Outcome 21 Quality of life/ life satisfaction: 5. Average score (CSQ - client satisfaction, high = good) - by 10 months.
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Hjorthoj 2013 36 26.1 (4.1) 26 19.7 (5.6) 100% 6.4[3.87,8.93]
   
Total *** 36   26   100% 6.4[3.87,8.93]
Heterogeneity: Not applicable  
Test for overall effect: Z=4.97(P<0.0001)  
Favours Usual Treatment 105-10 -5 0 Favours CBT + MI
 
 
Analysis 7.22.   Comparison 7 Cognitive behavioural therapy + motivational
interviewing versus standard care, Outcome 22 Service use: 1. Relapse (hospitalised).
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
7.22.1 By end of 9 month treatment phase  
Barrowclough 2001 5/18 10/18 67.57% 0.5[0.21,1.17]
Barrowclough 2014 4/36 5/35 32.43% 0.78[0.23,2.66]
Subtotal (95% CI) 54 53 100% 0.58[0.29,1.16]
Total events: 9 (Treatment), 15 (Control)  
Heterogeneity: Tau2=0; Chi2=0.34, df=1(P=0.56); I2=0%  
Test for overall effect: Z=1.54(P=0.12)  
   
7.22.2 By 3 months after treatment finished - 12 months  
Barrowclough 2001 6/18 12/18 100% 0.5[0.24,1.04]
Subtotal (95% CI) 18 18 100% 0.5[0.24,1.04]
Total events: 6 (Treatment), 12 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.86(P=0.06)  
   
7.22.3 By 9 months after treatment finished - 18 months  
Barrowclough 2001 7/18 12/18 77.3% 0.58[0.3,1.13]
Barrowclough 2014 4/36 5/33 22.7% 0.73[0.21,2.5]
Subtotal (95% CI) 54 51 100% 0.61[0.34,1.1]
Total events: 11 (Treatment), 17 (Control)  
Favours treatment 1000.01 100.1 1 Favours control
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0; Chi2=0.11, df=1(P=0.74); I2=0%  
Test for overall effect: Z=1.63(P=0.1)  
Favours treatment 1000.01 100.1 1 Favours control
 
 
Analysis 7.23.   Comparison 7 Cognitive behavioural therapy + motivational interviewing versus standard
care, Outcome 23 Economic outcomes: 1. Direct cost in US$ (BQOL, money subscale) (skewed data).
Economic outcomes: 1. Direct cost in US$ (BQOL, money subscale) (skewed data)
Study Intervention Mean SD N
6 months
Bellack 2006 Treatment 329 649 61
Bellack 2006 Control 180 201 49
 
 
Comparison 8.   Cognitive behavioural therapy + psychosocial rehabilitation versus standard care





Statistical method Effect size
1 Global state: 1. Forensic measures -
number of arrests (skewed data)
    Other data No numeric data
1.1 12 months     Other data No numeric data
1.2 18 months     Other data No numeric data
1.3 24 months     Other data No numeric data
1.4 30 months     Other data No numeric data
2 Global state: 2. Forensic measures -
number of convictions (skewed data)
    Other data No numeric data
2.1 12 months     Other data No numeric data
2.2 24 months     Other data No numeric data
2.3 30 months     Other data No numeric data
3 Global state: 3. Forensic measures -
days in jail (skewed data)
    Other data No numeric data
3.1 12 months     Other data No numeric data
3.2 18 months     Other data No numeric data
3.3 24 months     Other data No numeric data
3.30 30 months     Other data No numeric data
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Analysis 8.1.   Comparison 8 Cognitive behavioural therapy + psychosocial rehabilitation versus
standard care, Outcome 1 Global state: 1. Forensic measures - number of arrests (skewed data).
Global state: 1. Forensic measures - number of arrests (skewed data)
Study Intervention Mean SD N
12 months
Maloney 2006 Treatment 0.60 .84 18
Maloney 2006 Control 0.58 1.00 43
18 months
Maloney 2006 Treatment 0.31 0.60 18
Maloney 2006 Control 0.20 0.41 43
24 months
Maloney 2006 Treatment 0.17 0.51 18
Maloney 2006 Control 0.34 0.81 43
30 months
Maloney 2006 Treatment 0.56 1.29 18
Maloney 2006 Control 0.51 0.88 43
 
 
Analysis 8.2.   Comparison 8 Cognitive behavioural therapy + psychosocial rehabilitation versus
standard care, Outcome 2 Global state: 2. Forensic measures - number of convictions (skewed data).
Global state: 2. Forensic measures - number of convictions (skewed data)
Study Intervention Mean SD N
12 months
Maloney 2006 Treatment 0.22 0.44 18
Maloney 2006 Control 0.25 0.62 43
24 months
Maloney 2006 Treatment 0.33 1.19 18
Maloney 2006 Control 0.22 0.63 43
30 months
Maloney 2006 Treatment 0.44 1.20 18
Maloney 2006 Control 0.53 1.10 43
 
 
Analysis 8.3.   Comparison 8 Cognitive behavioural therapy + psychosocial rehabilitation
versus standard care, Outcome 3 Global state: 3. Forensic measures - days in jail (skewed data).
Global state: 3. Forensic measures - days in jail (skewed data)
Study Intervention Mean SD N
12 months
Maloney 2006 Treatment 8.78 16.88 18
Maloney 2006 Control 12.90 30.12 43
18 months
Maloney 2006 Treatment 19.19 30.01 18
Maloney 2006 Control 20.92 39.46 43
24 months
Maloney 2006 Treatment 4.67 18.59 18
Maloney 2006 Control 7.28 14.07 43
30 months
Maloney 2006 Treatment 19.33 34.49 18
Maloney 2006 Control 24.59 38.27 43
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Comparison 9.   Cognitive behavioural therapy + intensive case management versus standard care





Statistical method Effect size
1 Global state: 1. Forensic measures-
number of arrests (skewed data)
    Other data No numeric data
1.1 12 months     Other data No numeric data
1.2 18 months     Other data No numeric data
1.3 24 months     Other data No numeric data
1.4 30 months     Other data No numeric data
2 Global state: 2. Forensic measures -
number of convictions (skewed data)
    Other data No numeric data
2.1 12 months     Other data No numeric data
2.2 24 months     Other data No numeric data
2.3 30 months     Other data No numeric data
3 Global state: 3. Forensic measures -
days in jail (skewed data)
    Other data No numeric data
3.1 12 months     Other data No numeric data
3.2 18 months     Other data No numeric data
3.3 24 months     Other data No numeric data
3.4 30 months     Other data No numeric data
 
 
Analysis 9.1.   Comparison 9 Cognitive behavioural therapy + intensive case management versus
standard care, Outcome 1 Global state: 1. Forensic measures- number of arrests (skewed data).
Global state: 1. Forensic measures- number of arrests (skewed data)
Study Intervention Mean SD N
12 months
Maloney 2006 Treatment 0.11 0.33 16
Maloney 2006 Control 0.58 1.00 43
18 months
Maloney 2006 Treatment 0.07 0.28 16
Maloney 2006 Control 0.20 0.41 43
24 months
Maloney 2006 Treatment 0.31 0.63 16
Maloney 2006 Control 0.34 0.81 43
30 months
Maloney 2006 Treatment 0.15 0.38 16
Maloney 2006 Control 0.51 0.88 43
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Analysis 9.2.   Comparison 9 Cognitive behavioural therapy + intensive case management versus
standard care, Outcome 2 Global state: 2. Forensic measures - number of convictions (skewed data).
Global state: 2. Forensic measures - number of convictions (skewed data)
Study Intervention Mean SD N
12 months
Maloney 2006 Treatment 0.11 0.33 16
Maloney 2006 Control 0.25 0.62 43
24 months
Maloney 2006 Treatment 0.23 0.44 16
Maloney 2006 Control 0.22 0.63 43
30 months
Maloney 2006 Treatment 0.15 0.38 16
Maloney 2006 Control 0.53 1.10 43
 
 
Analysis 9.3.   Comparison 9 Cognitive behavioural therapy + intensive case management
versus standard care, Outcome 3 Global state: 3. Forensic measures - days in jail (skewed data).
Global state: 3. Forensic measures - days in jail (skewed data)
Study Intervention Mean SD N
12 months
Maloney 2006 Treatment 17.44 39.13 16
Maloney 2006 Control 12.90 30.12 43
18 months
Maloney 2006 Treatment 15.15 29.59 16
Maloney 2006 Control 20.92 39.46 43
24 months
Maloney 2006 Treatment 13.46 31.76 16
Maloney 2006 Control 7.28 14.07 43
30 months
Maloney 2006 Treatment 14.08 24.29 16
Maloney 2006 Control 24.59 38.27 43
 
 
Comparison 10.   Sensitivity analysis





Statistical method Effect size
1 Motivational interviewing versus standard care:
Leaving the study early: 1. Lost to evaluation short
term (3-6 months): Diagnostic criteria




1.1 Mixed diagnoses (Schizophrenia, bipolar, & de-
pressed patients )








2 Cognitive behavioural therapy + motivational inter-
viewing versus standard care: Global state: 1. Average
4   Mean Difference (IV, Random,
95% CI)
Subtotals only
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Statistical method Effect size
score (GAF, low = poor) at 12 months: Allocation con-
cealment










Analysis 10.1.   Comparison 10 Sensitivity analysis, Outcome 1 Motivational interviewing versus
standard care: Leaving the study early: 1. Lost to evaluation short term (3-6 months): Diagnostic criteria.
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
10.1.1 Mixed diagnoses (Schizophrenia, bipolar, & depressed pa-
tients )
 
Baker 2002 24/79 24/81 71% 1.03[0.64,1.65]
Graham 2016 0/30 1/29 1.59% 0.32[0.01,7.61]
Hickman 1997 0/15 0/15   Not estimable
Nagel 2009 2/24 4/25 6.2% 0.52[0.1,2.59]
Subtotal (95% CI) 148 150 78.79% 0.95[0.61,1.49]
Total events: 26 (Experimental), 29 (Control)  
Heterogeneity: Tau2=0; Chi2=1.11, df=2(P=0.57); I2=0%  
Test for overall effect: Z=0.23(P=0.82)  
   
10.1.2 Schizophrenia & other psychoses only  
Bechdolf 2011 10/30 5/30 17.75% 2[0.78,5.15]
Graeber 2003 0/15 2/15 1.82% 0.2[0.01,3.85]
Kavanagh 2004 0/13 1/12 1.64% 0.31[0.01,6.94]
Swanson 1999 0/48 0/45   Not estimable
Subtotal (95% CI) 106 102 21.21% 0.87[0.18,4.19]
Total events: 10 (Experimental), 8 (Control)  
Heterogeneity: Tau2=0.85; Chi2=3.24, df=2(P=0.2); I2=38.29%  
Test for overall effect: Z=0.18(P=0.86)  
   
Total (95% CI) 254 252 100% 1.03[0.69,1.54]
Total events: 36 (Experimental), 37 (Control)  
Heterogeneity: Tau2=0; Chi2=4.9, df=5(P=0.43); I2=0%  
Test for overall effect: Z=0.17(P=0.87)  
Test for subgroup differences: Chi2=0.01, df=1 (P=0.91), I2=0%  
Favours MI 2000.005 100.1 1 Favours Usual Treatment
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Analysis 10.2.   Comparison 10 Sensitivity analysis, Outcome 2 Cognitive
behavioural therapy + motivational interviewing versus standard care: Global
state: 1. Average score (GAF, low = poor) at 12 months: Allocation concealment.
Study or subgroup Experimental Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
10.2.1 Unclear risk of bias  
Baker 2006 44 68.5 (10) 53 66.3 (11.2) 69.35% 2.17[-2.05,6.39]
Madigan 2013 31 37.6 (8.3) 16 37.2 (11.5) 30.65% 0.4[-5.95,6.75]
Subtotal *** 75   69   100% 1.63[-1.89,5.14]
Heterogeneity: Tau2=0; Chi2=0.21, df=1(P=0.65); I2=0%  
Test for overall effect: Z=0.91(P=0.36)  
   
10.2.2 Low risk of bias  
Barrowclough 2001 17 58.4 (13.6) 15 48.1 (15.3) 39.51% 10.28[0.22,20.34]
Barrowclough 2010 135 35 (9.5) 134 35.6 (9.4) 60.49% -0.64[-2.89,1.61]
Subtotal *** 152   149   100% 3.67[-6.79,14.14]
Heterogeneity: Tau2=45.79; Chi2=4.31, df=1(P=0.04); I2=76.81%  
Test for overall effect: Z=0.69(P=0.49)  
Test for subgroup differences: Chi2=0.13, df=1 (P=0.72), I2=0%  
Favours TAU 105-10 -5 0 Favours MI
 
 
A D D I T I O N A L   T A B L E S
 
Name of tool Abbreviation Source of scale - reference
Diagnostic tools
Diagnostic and Statistical Manual of Mental Disorders, 4th edition DSM-IV  DSM-IV
The classification of mental and behavioural disorders ICD-10 ICD-10 
Structured Clinical Interview for Diagnosis SCID Spitzer 1990
Diagnostic Interview Schedule (DIS), computerised scoring for DSM-III-R cri-
teria
C-DIS-R DSM III-R
Substance use scales    
Addiction Severity Index ASI McLellan 1980; McLellan 1992
Alcohol Use Inventory AUI Horn 1987
Alcohol Use Scale AUS Mueser 1995
Alcohol Use Disorders Identification Test AUDIT Saunders 1993
Brief Drinker Profile BDP Miller 1987
Drug and Alcohol Problem Scale DAPS adapted non-peer reviewed ver-
sion of this scale used; see Bond
1991a
Table 1.   List of scales and abbreviations used in included studies 
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Drug Use Scale DUS Mueser 1995
Opiate Treatment Index OTI Darke 1991
Change Questionnaire-Cannabis RTCQ-C Rollnick 1992
Substance Abuse Treatment Scale SATS McHugo 1995
Schedule for Clinical Assessment in Neuropsychiatry SCAN Wing 1990
Substance Use Severity Scale USS Carey 1996
Mental state scales
Addiction Severity Index (psychiatric subscale) ASI McLellan 1980
Beck Depression Inventory - Short Form BDI-SF, BDI-11 Beck 1972
Brief Psychiatric Rating Scale BPRS LukoI 1986
Brief Scale for Anxiety BSA Tyrer 1984
Brief Symptom Inventory BSI Derogatis 1983a
Calgary Depression Scale CDS Addington 1992
Comprehensive Psychopathological Rating Scale CPRS Asberg 1978
Hamilton Rating Scale for Depression HAM - D Hamilton 1960
Hospital Anxiety and Depresion Scale HADS Zigmond 1983
Insight Scale   David 1992
Montgomery Asberg Depression Rating Scale MADRS Montgomery 1979
Positive & Negative Syndrome Scale for schizophrenia PANNS Kay 1987
Psychiatric Epidemiologic Research Interview PERI Dohrenwend 1980
Scale for the Assessment of Negative Symptoms SANS Andreasen 1982
Scale for the assessment of Positive Symptoms SAPS Norman 1996
Symptom Checklist 90 SCL-90 Derogatis 1973; Derogatis 1975
Symptom Checklist 90-revised SCL-90-R Derogatis 1983b
Schizophrenia Change Scale SCR Montgomery 1978
Young Mania Rating Scale YMRS Young 1978
General function scales
Global Assessment of Functioning GAF DSM-IV
Table 1.   List of scales and abbreviations used in included studies  (Continued)
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Health of the Nation Outcome Scale HoNOS Wing 1996
Role Functioning Scale RFS Green 1987
Social Adjustment Scale for the Severely Mentally Ill SAS-SMI Wieduwilt 1999
Social Functioning Scale SFS Birchwood 1990
The Social and Occupational Functioning Scale SOFAS Goldman 1992
Quality of life scales
Brief Quality of Life Scale BQOL Lehman 1995
Life Satisfaction Checklist LSC Bond 1988; Bond 1990
Manchester Short Assessment of Quality of Life MANSA Priebe 1999
Quality of Life Interview QOLI Lehman 1988
Satisfaction with Life Scale SLS Stein 1980
World Health Organization's Quality of Life assessment scale, short version WHOQOL-BREF Skevington 2004
Other
Client Satisfaction Questionnaire CSQ Larsen 1979
Medication Adherence Rating Scale MARS Thompson 2000
The Service Utilization Rating Scale SURS Mihalopoulos 1999
Table 1.   List of scales and abbreviations used in included studies  (Continued)
 
 
Methods Allocation: centralised sequence generation with table of random numbers or computer-generated
code, stratified by severity of substance use. Sequence concealed until interventions assigned.
Blinding: those recruiting and assigning participants, those assessing outcomes will be blind to
treatment allocation.
Duration: minimum of 1 year.
Participants Diagnosis: severe mental illness based on a diagnosis of schizophrenia, schizoaffective disorder,
and other psychotic disorders.
N = 440* recruited to obtain a minimum sample of 280 at 12 months given the high drop-out rate
for some of the outcome measures.
Age: adults 18-55 years.
Sex: men and women.
Setting: hospital and community.
Interventions 1. Standard care plus 3-5 sessions of motivational interviewing + 3 months of weekly CBT.
2. Standard care plus one motivational interview.
Outcomes Lost to treatment.
Death.
Substance use: number of patients using substances, OTI.
Mental state: BPRS, PANSS.
Table 2.   Suggested design for trial 
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Relapse: number of patients readmitted to hospital over a specified follow-up period.
Quality of life: BQOL.
Functioning: GAF.
Arrests, number homeless.
Notes * size of study to detect a 10% difference in improvement with 80% certainty.
If scales are used to measure outcome then there should be binary cut-oI points, defined before
study start, of clinically important improvement.
Table 2.   Suggested design for trial  (Continued)
BPRS: Brief Psychiatric Rating Scale
BQOL: Brief Quality of Life Scale
CBT: Cognitive behavioural therapy
GAF: Global Assessment of Functioning
OTI: Opiate Treatment Index
PANSS: Positive & Negative Syndrome Scale for schizophrenia
 
 
A P P E N D I C E S
Appendix 1. Search methods
Search for 2007 version
Electronic searching
1.1 We searched the Cochrane Schizophrenia Group Trials Register (May 2006) using the phrase:
[((*polydrug* or *substanc* or *alcoh* or *tranquiliz* or *narcot* or * abus* or *opiat* or *street drug* or *solvent* or *inhalan* or *intoxi*)
in REFERENCE) or ((substance abus* or drug abus* or *alcohol*) in STUDY)]
This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see Group Module).
1.2 We searched the Cochrane Schizophrenia Group Trials Register (August 2005) using the phrase:
[and (polydrug* or substance* or alcohol* or tranquil* or chemical* or narcotic* or opiat* or street drug* or solvent* or inhalant* or psy-
chotropic* or intoxica*) and (abus* or use* or misus* or using or utiliz* or utilis* or depend* or addict* or illegal* or illicit* or habit* or
withdraw* or behavi* or abstinence* or abstain* or rehab* or intoxica* or non-prescri*) or (dual* and diagnos*)]
1.3 We searched the Cochrane Schizophrenia Group Trials Register (April, 2002) using the phrase:
[(*substance abuse* or *substance*) in abstract or title or index terms of REFERENCE] or [Substance Abuse* IN HEALTH CARE CONDITION]
1.4 We searched the Cochrane Schizophrenia Group Trials Register (August and December, 2001) using the phrase:
[(*substance abuse* or *substance*) in abstract or title or index terms of REFERENCE] or [Substance Abuse* IN HEALTH CARE CONDITION]
1.5 We searched the Cochrane Schizophrenia Group Trials Register (April and August 2000) using the phrase:
(polydrug* or substance* or alcohol* or tranquil* or chemical* or narcotic* or opiat* or "street drug*" or solvent* or inhalant* or psy-
chotropic* or intoxica*) and (abus* or use* or misus* or using or utiliz* or utilis* or depend* or addict* or illegal* or illicit* or habit* or
withdraw* or behavi* or abstinence* or abstain* or rehab* or intoxica* or non-prescri*)) or (dual* and diagnos*) or substance-abuse or
drug-dependence or alcoholism or alcohol-abuse or drug-abuse-prevention or "drug use" or "drug user" or "drug users" or "drug misuse"
or "drug misuser" or "drug misusers" or "drug dependant" or "drug dependence" or "drug addict" or "drug addicts" or "drug addiction"
or "drug habit" or "drug habits" or "drug withdrawal" or "drug rehabilitation" or "non-prescription drugs" or "non-prescription drug" or
"illegal drug" or "illegal drugs" or "illicit drug" or "illicit drugs" or "intoxicating drug" or "intoxicating drugs" or "drug intoxication".
1.6 We searched the Cochrane Schizophrenia Group Trials Register (August 1998) using the phrase:
[and (polydrug* or substance* or alcohol* or tranquil* or chemical* or narcotic* or opiat* or street drug* or solvent* or inhalant* or psy-
chotropic* or intoxica*) and (abus* or use* or misus* or using or utiliz* or utilis* or depend* or addict* or illegal* or illicit* or habit* or
withdraw* or behavi* or abstinence* or abstain* or rehab* or intoxica* or non-prescri*) or (dual* and diagnos*)]
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1.7 We searched The Cochrane Library (Issue 3, 1998) using the Cochrane Schizophrenia Group's terms for schizophrenia combined with
the phrase:
[and (polydrug* or alcohol* or chemical* or narcotic* or opiat* or street drug* or solvent* or inhalant* or psychotropic* or intoxica*) and
(abus* or misus* or depend* or addict* or illegal* or illicit* or habit* or behavi* or abstinence* or abstain* or rehab* or intoxica* or non-
prescri*) or (dual* and diagnos*)]
1.8 We searched the Cochrane Central Register of Controlled Trials (CENTRAL, 2006 Issue 2) using the phrase:
[polydrug* or tranquiliz* or narcot* or opiat* or ((substanc* or alcohol* or solvent* or inhalan* or intoxi*) near/4 (abus* or misus*)) or
"street drug*" for publication dates 2001-2006]
1.9 We searched Biological Abstracts (1985 to February 1998) using the Cochrane Schizophrenia Group's terms for both randomised con-
trolled trials and schizophrenia combined with the phrase:
[and (drug* or polydrug* or substance* or alcohol* or tranquil* or chemical* or narcotic* or opiat* or street drug* or solvent* or inhalant*
or psychotropic* or intoxica*) and (abus* or use* or misus* or using or utiliz* or utilis* or depend* or addict* or illegal* or illicit* or habit*
or withdraw* or behavi* or abstinence* or abstain* or rehab* or intoxica* or non-prescri*) or (dual* near diagnos*)]
1.9 We searched CINAHL on Silver Platter (1982 to February 1998) using the Cochrane Schizophrenia Group's terms for both randomised
controlled trials and schizophrenia combined with the phrase:
[and (drug* or polydrug* or substance* or alcohol* or tranquil* or chemical* or narcotic* or opiat* or street drug* or solvent* or inhalant*
or psychotropic* or intoxica*) and (abus* or use* or misus* or using or utiliz* or utilis* or depend* or addict* or illegal* or illicit* or habit*
or withdraw* or behavi* or abstinence* or abstain* or rehab* or intoxica* or non-prescri*) or (dual* near diagnos*) or explode "sub-
stance-abuse"/ all subheadings/ all age subheadings or explode "drug-dependence"/ all subheadings/ all age subheadings or explode
"alcoholism"/ all topical subheadings / all age subheadings]
1.10 We searched EMBASE (January 1980 to February 1998) using the Cochrane Schizophrenia Group's terms for both randomised con-
trolled trials and schizophrenia combined with the phrase:
[and (polydrug* or substance* or alcohol* or tranquil* or chemical* or narcotic* or opiat* or street drug* or solvent* or inhalant* or psy-
chotropic* or intoxica*) and (abus* or use* or misus* or using or utiliz* or utilis* or depend* or addict* or illegal* or illicit* or habit* or with-
draw* or behavi* or abstinence* or abstain* or rehab* or intoxica* or non-prescri*) or (dual* near diagnos*) or explode "substance-abuse"/
all subheadings or explode "drug-dependence"/ all subheadings or explode "alcohol-abuse"/ all subheadings or explode "alcoholism"/
all subheadings]
1.11 We searched MEDLINE on Silver Platter (January 1966 to February 1998) using the Cochrane Schizophrenia Group's terms for both
randomised controlled trials and schizophrenia combined with the phrase:
[and (drug* or polydrug* or substance* or alcohol* or tranquil* or chemical* or narcotic* or opiat* or street drug* or solvent* or inhalant*
or psychotropic* or intoxica*) and (abus* or use* or misus* or usin* or utiliz* or utilis* or depend* or addict* or illegal* or illicit* or
habit* or withdraw* or behavi* or abstinence* or abstain* or rehab* or intoxica* or non-prescri*) or dual* near diagnos*)or explode "sub-
stance-abuse"/ all subheadings or explode "drug-dependence"/ all subheadings or explode "alcohol-abuse"/ all subheadings or explode
"alcoholism"/ all subheadings]
1.12 We searched PsycLIT on Silver Platter (January 1974 to February 1998) using the Cochrane Schizophrenia Group's terms for both
randomised controlled trials and schizophrenia combined with the phrase:
[and (drug* or polydrug* or substance* or alcohol* or tranquil* or chemical* or narcotic* or opiat* or street drug* or solvent* or inhalant*
or psychotropic* or intoxica*) and (abus* or use* or misus* or using or utiliz* or utilis* or depend* or addict* or illegal* or illicit* or habit* or
withdraw* or behavi* or abstinence* or abstain* or rehab* or intoxica* or non-prescri*) or (dual* near diagnos*) or explode "alcoholism"
or explode "drug-abuse" or explode "alcohol-abuse" or "drug-abuse-prevention" in de]
1.13 We searched Sociofile on Silver Platter (January 1974 to February 1998) using the Cochrane Schizophrenia Group's terms for both
randomised controlled trials and schizophrenia combined with the phrase:
[and (drug* or polydrug* or substance* or alcohol* or tranquil* or chemical* or narcotic* or opiat* or street drug* or solvent* or inhalant*
or psychotropic* or intoxica*) and (abus* or use* or misus* or using or utiliz* or utilis* or depend* or addict* or illegal* or illicit* or
habit* or withdraw* or behavi* or abstinence* or abstain* or rehab* or intoxica* or non-prescri*) or (dual* near diagnos*)or explode "sub-
stance-abuse" or explode "alcoholism" or explode "drug-abuse" or explode "drug-addiction" or explode "detoxification"]
1.14 We also searched CINAHL, EBM Reviews-Cochrane Register of Controlled Trials, and PsycINFO (December 2006) using the phrase:
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diagnosis-dual-psychiatry.mp (CINAHL, PsychINFO); dual diagnosis.mp (EBM Reviews); and schizo$ and (randomised or randomized) and
(drug or substance).mp (Ovid Medline). Other searches included the phrases; (RCT or randomised or randomized) and (motivational or
CBT or program or services) on (Ovid Medline)
1.14 ISI database - Social Sciences Citation Index
We sought each of the studies which went into the pool as a cited reference on the above database. Reports of articles that had cited these
studies were then inspected in order to identify further trials.
1.15 We hand searched Schizophrenia Bulletin (January 1990 - December 1998) and British Journal of Psychiatry (October 1989 - December
1998).
2. Additional search strategy by current authors
2.1 For the 2007 update, we performed an additional search in 2006-2007. The previous draG (2004) yielded 13 studies, and the updated
search yielded an additional 12 randomised controlled trials (n=25). The Cochrane Schizophrenia Group Trials Register 19-05-06 found 65
new references since the last search on 02-11-2004. CENTRAL: The Cochrane Librarys register of Clinical Trials Substance Misuse Search
19-05-2006. It is worth noting that the word 'drug' generates a large number of false positives. It also makes the search technically difficult
on large databases such as Medline and Embase. We undertook the EMBASE search without the word 'drug', as were searches of The
Cochrane Library and the Cochrane Schizophrenia Group's Register.
We undertook a further final search using the same search strategy as above in March 2007 during the study write-up by one of the authors
[GH]. In addition, we searched for all authors listed in the included trials using Ovid Medline, PubMED and ISI Web of Science (citation
search).
2.2 Reference lists
We inspected reference lists of all the studies and unpublished reports to identify any further relevant trials [MC, GH, SM] up until April 2007.
2.3 Personal contact
We contacted the authors of all studies initially selected for inclusion in order to identify further relevant trials. We simultaneously con-
ducted a Delphi survey of opinion of informed professionals in the UK who had knowledge and experience of people with severe mental
illness and substance misuse. As part of the recruitment letter, individuals were asked if they had conducted or knew of any ongoing, pub-
lished or unpublished trials. We contacted authors, during November and December 2006, of research studies rated at risk of low, medium
or high risk bias (A, B or C) to ascertain whether they knew of any relevant published, unpublished or currently ongoing trials [MC, GH, SM].
Search for 2013 version
Cochrane Schizophrenia Group Trials Register
The Trials Search Co-ordinator searched the Cochrane Schizophrenia Group Trials Register (July 2012) using the phrase:
[((*polydrug* or *substanc* or *alcoh* or *tranquiliz* or *narcot* or * abus* or *opiat* or *street drug* or *solvent* or *inhalan* or *intoxi*)
in title, abstract and indexing terms REFERENCE) or ((*substance abus* or drug abus* or *alcohol* or *cannabis*) in health care conditions
of STUDY)].
The Cochrane Schizophrenia Group Trials Register is compiled by systematic searches of major databases, handsearches of relevant jour-
nals and conference proceedings (see Group Module). Incoming trials are assigned to relevant existing or new review titles.
Appendix 2. Data collection methods (2004 and 2007)
2.1. Selection of trials
In the initial draG of this review (2004), AL performed the search for trials (original version of review) and the preliminary update was carried
out by MF. Nandi Siegfried (NS) inspected both included and excluded citations, in order to cross check according to the inclusion criteria.
For the (2007) update, JW performed the search, updated by GH. We read the titles, abstracts and descriptor terms of all downloaded
material from the electronic searches and discarded irrelevant reports. We (MC, GH, and SM) independently inspected all citations to
establish relevance of the article and whether or not it should be acquired. Where doubt remained we sought further information from
authors and added these trials to the list of those awaiting assessment.
2.2. Assessment of methodological quality
We allocated trials to one of three categories described in the Cochrane Reviewers' Handbook (Higgins 2006) This system is based on the
evidence of a strong relationship between the potential for bias in the results and allocation concealment (Schulz 1995). We included
only those trials that stated they were randomised with randomisation methods described or implied (categories A or B, not C). When
trials were included in the review, but provided no usable data for the analysis, we allocated these to Category D and did not assign them
to an intervention. Where disagreement occurred regarding which category a trial should be allocated, we attempted to resolve this by
discussion. If doubt remained we contacted authors for further information.
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In this review, we included randomised controlled trials that did not ensure blinded participants, clinicians and outcome raters due to
the nature of some self-report measures and the psychosocial treatments involved. However, we noted those randomised controlled
trials which did not specify or which stated specifically that raters were not blinded due to the possibility of bias in these studies (see
Characteristics of Included Studies Table). We were not blinded to the names of the authors, institutions, journal of publication or results
of the trials.
2.3. Data extraction
We (MC, GH and SM) extracted data from the selected trials independently. Again, we resolved any disputes by discussion. When it was not
possible to extract data, or further information was needed, we attempted to contact the authors.
2.4. Data synthesis
4.1 Data analysis
We analysed data using RevMan, The Cochrane Collaboration software for preparing and maintaining Cochrane reviews.
2.5 Incomplete data
Except for the analysis of lost to treatment, we did not use data from studies where overall attrition was greater than 50% because of the
strong likelihood of bias.
2.6 Dichotomous/binary data
Due to expected high heterogeneity between studies, we used a standard estimation of the random effects risk ratio (RR) with the 95%
confidence interval (CI). It has been shown that RR is more intuitive (Boissel 1999) than odds ratios and that odds ratios tend to be inter-
preted as RR by clinicians (Deeks 2000). This misinterpretation then leads to an overestimate of the impression of the effect. We calculated
numbers needed to treat/harm (NNT/NNH) where appropriate.
2.7 Continuous data
2.7.1 Summary statistic: again, due to expected high heterogeneity, we estimated the weighted mean difference (MD) between groups
using a random effects model.
2.7.2 Skewed data: continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying
parametric tests to non-parametric data, the following standards are applied to all data: (a) standard deviations and means were reported
in the paper or were obtainable from the authors; and (b) when a scale started from the finite number zero, the standard deviation, when
multiplied by two, was less than the mean as otherwise the mean was unlikely to be an appropriate measure of the centre of the distribution
(Altman 1996); (c) if a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS), which can have values
from 30 to 210), the calculation described above was modified to take the scale starting point into account. In these cases, skew is present
if 2SD>(S-Smin), where S is the mean score and Smin is the minimum score. Many of the studies included in this review reported skewed
data that fell outside of the above standards and as such were unable to be included in the analysis. We have, however, included skewed
data in tables and have reported any significant results from non-parametric tests (e.g. Mann-Whitney) applied by the authors.
2.7.3 Valid scales: continuous data from rating scales were included only if the measuring instrument had been described in a peer-re-
viewed journal and the instrument was either self-report or completed by an independent rater or relative (not the therapist). It has been
shown that the use of rating scales which have not been described in a peer-reviewed journal (Marshall 2000) are associated with bias,
therefore we excluded the results of such scales.
2.7.4 Change data: when continuous data are presented on a scale which includes a possibility of negative values (such as change on a
scale), there is no way of telling whether data are non-normally distributed (skewed) or not. It is thus preferable to use endpoint data,
which typically cannot have negative values.
2.7.5 Cluster trials
Studies increasingly employ cluster randomisation (such as randomisation by clinician or practice) but analysis and pooling of clustered
data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a unit-of-analysis error
(Divine 1992) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This
causes Type I errors (Bland 1997, Gulliford 1999).
Where clustering was not accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the presence of
a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra-class
correlation coefficients of their clustered data and to adjust for this using accepted methods (Gulliford 1999). Where clustering has been
incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study, but adjusted
for the clustering effect.
We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a design effect.
This is calculated using the mean number of participants per cluster (m) and the intraclass correlation co-efficient (ICC) [Design effect=1+
(m-1)*ICC] (Donner 2002). If the ICC was not reported it was assumed to be 0.1 (Ukoumunne 1999). If cluster studies had been appropriately
analysed taking into account intra-class correlation coefficients and relevant data documented in the report, we synthesised these with
other studies using the generic inverse variance technique.
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2.8 Investigation for heterogeneity
Consideration of all the included studies within any comparison was undertaken to judge clinical heterogeneity. Visual inspection of graphs
was used to investigate the possibility of statistical heterogeneity. This was supplemented employing, the I-squared statistic which pro-
vides an estimate of the percentage of variability due to heterogeneity rather than chance alone. Where the I-squared estimate was >75%,
this was interpreted as evidence of high levels of heterogeneity (Higgins 2003).
2.9 Addressing publication bias
We aimed to enter data from all included trials into a funnel graph (trial effect versus trial size) in an attempt to investigate the likelihood
of overt publication bias. We were unable to undertake this due to the very limited number of trials included in the analysis.
2.10 General
Where possible, we entered data into RevMan in such a way that the area to the leG of the 'line of no effect' indicated a 'favourable' outcome
for the psychosocial interventions. Where this was not possible, we labelled the graphs in MetaView accordingly so that the direction of
any effects was clear.
Appendix 3. Search methods (2012)
Cochrane Schizophrenia Group Trials Register
The Trials Search Co-ordinator searched the Cochrane Schizophrenia Group Trials Register (July 2012) using the phrase:
[((*polydrug* or *substanc* or *alcoh* or *tranquiliz* or *narcot* or * abus* or *opiat* or *street drug* or *solvent* or *inhalan* or *intoxi*)
in title, abstract and indexing terms REFERENCE) or ((*substance abus* or drug abus* or *alcohol* or *cannabis*) in health care conditions
of STUDY)].
The Cochrane Schizophrenia Group Trials Register is compiled by systematic searches of major databases, handsearches of relevant jour-
nals and conference proceedings (see Group Module). Incoming trials are assigned to relevant existing or new review titles.
Searching other resources
1. Reference lists
We searched all references of articles selected for inclusion, major review articles (Baker 2012; Dixon 2010; Drake 2008; Dutra 2008; Horsfall
2009; Kelly 2012) as well as recent guidelines (NICE 2011) on this topic for further relevant trials.
2. Journal databases
Two further searches were completed (8 October 2012 and 15 January 2013) by the principal reviewer (GEH) using the Cochrane Database
of Systematic Reviews, MEDLINE (daily update, PREMEDLINE), and PsycINFO. A separate search for randomised trials using contingency
management was completed as this was an additional intervention category for this update. We also searched MEDLINE for recent articles
(2008 to 2013) by the first authors of all included studies in order to get a more complete list of recent publications.
We also did 'forward' searches to identify trials that cited previously included RCTs using Web of Science and Scopus. Scopus was used to
identify trials that cited the most recent version of this review (Cleary 2008) up to 15 February 2013.
3. Trials registries
In addition, web sites and journals that list ongoing trials in the USA, UK, Australia and various European countries were searched for RCTs
through the Cochrane Schizophrenia Group Trials Register. The principal researcher (GEH) searched www.clinicaltrials.gov for protocols
of current and previously included studies for proposed outcome measures to assess selective reporting bias.
4. Personal contact
We contacted the first author (or corresponding author) of newly included studies for this update regarding their knowledge of ongoing
or unpublished trials.
Additional searches
Similar search methods were conducted by the reviewers as int previous update (Appendix 1 sections 1.3, 1.5, 1.6-1.8) using Ovid Medline
(Daily update), PsycINFO, CINAHL, Cochrane, Scopus and ISI Web of Science for recent updates for authors listed on ongoing trials, included
studies and for articles citing our previous review (Cleary 2008) between 2008 and 2013. For an example of an advanced search for RCTs
involving psychosocial interventions for dual diagnosis patients between 1980 and 2008 see Cleary 2009b.
Appendix 4. Data collection methods (2012)
1. Selection of studies
GEH inspected all citations from the new electronic search and identified relevant abstracts, full text articles and trials against the inclusion
criteria. To ensure reliability, KM inspected all full text articles for inclusion. Where there were uncertainties or disagreements, two addi-
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tional authors provided resolution (NS and MC). Where disputes could not be resolved, these studies remained as awaiting assessment or
ongoing studies and we contacted the authors for clarification.
1. Extraction
GEH and KM extracted data from the included studies. We resolved disputes by discussion and adjudication from the other review authors
(NS and MC) when necessary. If it was not possible to extract data or if further information was needed, we attempted to contact the
authors. We extracted data presented only in graphs and figures whenever possible, but the data were included only if two review authors
independently had the same result. When further information was necessary, we contacted authors of studies in order to obtain missing
data or for clarification of methods.
2. Management
2.1 Forms
We extracted data onto standard, simple forms.
2.2 Scale-derived data
We included continuous data from rating scales only if:
• the psychometric properties of the measuring instrument have been described in a peer-reviewed journal (Marshall 2000); and
• the measuring instrument has not been written or modified by one of the trialists for that particular trial.
Ideally the measuring instrument should either be: i) a self-report or ii) completed by an independent rater or relative (not the therapist).
We realise that this is not often reported clearly; we have noted whether or not this is the case in Characteristics of included studies.
2.3 Endpoint versus change data
There are advantages of both endpoint and change data. Change data can remove a component of between-person variability from the
analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and
difficult to measure conditions such as schizophrenia. We decided to primarily use endpoint data, and only use change data if the former
were not available. We combined endpoint and change data in the analysis as we used mean differences (MD) rather than standardised
mean differences throughout (Higgins 2011, Chapter 9.4.5.2).
2.4 Skewed data
Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to
non-parametric data, we aimed to apply the following standards to all data before inclusion:
• standard deviations and means are reported in the paper or obtainable from the authors;
• when a scale starts from the finite number zero, the standard deviation, when multiplied by two, is less than the mean (as otherwise
the mean is unlikely to be an appropriate measure of the centre of the distribution (Altman 1996));
• if a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS) which can have values from 30 to
210), we modified the calculation described above to take the scale starting point into account. In these cases skew is present if 2SD >
(S - S min), where S is the mean score and S min is the minimum score.
Endpoint scores on scales often have a finite start and endpoint and these rules can be applied. We entered skewed endpoint data from
studies of fewer than 200 participants as 'other data; within Data and analyses rather than into a statistical analysis. Skewed data pose
less of a problem when looking at mean if the sample size is large; we entered such endpoint data into the syntheses.
When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell
whether data are skewed or not; we entered skewed change data into analyses regardless of size of study.
2.5 Common measure
To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital
(mean days per year, per week or per month) to a common metric (for example, mean days per month).
2.6 Conversion of continuous to binary
Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut-oI points on
rating scales and dividing participants accordingly into ’clinically improved’ or ’not clinically improved’. It is generally assumed that if
there is a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS) (Overall 1962) or the PANSS (Kay 1986;
Kay 1987) this could be considered as a clinically significant response (Leucht 2005a; Leucht 2005b). If data based on these thresholds were
not available, we used the primary cut-oI presented by the original authors.
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2.7 Direction of graphs
Where possible, we entered data in such a way that the area to the leG of the line of no effect indicated a favourable outcome for the
treatment intervention. Where keeping to this made it impossible to avoid outcome titles with clumsy double-negatives (for example, 'Not
improved') we reported data where the leG of the line indicates an unfavourable outcome. This was noted in the relevant graphs.
Assessment of risk of bias in included studies
GEH worked independently by using criteria described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011) to
assess trial quality. This new set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the
article, such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting.
Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the studies in order
to obtain additional information.
We noted the level of risk of bias in the text of the review.
Measures of treatment e?ect
1. Binary data
For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown
that RR is more intuitive (Boissel 1999) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (Deeks 2000).
The Number Needed to Treat or Harm (NNT or H) statistic with its CIs is intuitively attractive to clinicians but is problematic both in its
accurate calculation in meta-analyses and interpretation (Hutton 2009). For binary data presented in the 'Summary of findings' tables,
where possible, we calculated illustrative comparative risks.
2. Continuous data
For continuous outcomes we estimated mean difference (MD) between groups. We would prefer not to calculate effect size measures
(standardised mean difference (SMD)). However, if scales of very considerable similarity were used, we presumed there was a small differ-
ence in measurement, and we would have calculated effect size and transformed the effect back to the units of one or more of the specific
instruments.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), but analysis and pooling of clustered
data poses problems. Authors often fail to account for intra-class correlation in clustered studies, leading to a 'unit of analysis' error (Divine
1992) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type
I errors (Bland 1997; Gulliford 1999).
None of the presently included trials used cluster randomisation. For the purposes of future updates of this review, where clustering is
not accounted for in primary studies we planned to present data in a table with a (*) symbol to indicate the presence of a probable unit
of analysis error. In subsequent versions of this review, should we include cluster RCTs, we will seek to contact first authors of studies to
obtain intra-class correlation coefficients for their clustered data and to adjust for this by using accepted methods (Gulliford 1999). Where
clustering has been incorporated into the analysis of primary studies, we plan to present these data as if from a non-cluster randomised
study but adjusted for the clustering effect.
We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'.
This is calculated using the mean number of participants per cluster (m) and the intra-class correlation coefficient (ICC) (design effect = 1
+ (m - 1)*ICC) (Donner 2002). If the ICC is not reported it was assumed to be 0.1 (Ukoumunne 1999).
If we had identified cluster trials, we would have analysed them taking into account intra-class correlation coefficients and relevant data
documented in the report. Synthesis with other studies would have been possible using the generic inverse variance technique.
2. Cross-over trials
None of the presently included studies employed a cross-over trial design. For the purposes of future updates of the review, a major
concern of cross-over trials is the carry-over effect. It occurs if an effect (for example, pharmacological, physiological or psychological)
of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants
can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the
condition of interest is unstable (Elbourne 2002). As both effects are very likely in severe mental illness, we proposed to only use the data
of the first phase of cross-over studies.
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3. Studies with multiple treatment groups
Where a study involves more than two treatment arms, if relevant, we presented the additional treatment arms in comparisons. If data
are binary we simply added these and combined them within the two-by-two table. If data were continuous we combined data following
the formula in section 7.7.3.8 (Combining groups) of the Cochrane Handbook for Systemic reviews of Interventions (Higgins 2011). Where
the additional treatment arms were not relevant, we did not reproduce these data.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up, data must lose credibility (Xia 2009). We chose that, for any particular outcome, should more than 50%
of data be unaccounted for we would not reproduce these data or use them within the analyses. If, however, more than 50% of those in
one arm of a study were lost, but the total loss was less than 50%, we would address this within the 'Summary of findings' tables by down-
rating quality. Finally, we would also downgrade quality within the 'Summary of findings' tables should loss be 25% to 50% in total.
2. Binary
In the case where attrition for a binary outcome is between 0 and 50% and where these data are not clearly described, we presented
data on a 'once-randomised-always-analyse' basis (an intention to treat analysis). Those leaving the study early were all assumed to have
the same rates of negative outcome as those who completed, with the exception of the outcome of death and adverse effects. For these
outcomes the rate of those who stay in the study - in that particular arm of the trial - was used for those who did not. We undertook a
sensitivity analysis testing how prone the primary outcomes are to change when data only from people who complete the study to that
point were compared to the intention to treat analysis using the above assumptions.
3. Continuous
3.1 Attrition
In the case where attrition for a continuous outcome is between 0% and 50%, and data only from people who complete the study to that
point are reported, we reproduced these.
3.2 Standard deviations
If standard deviations are not reported, we first tried to obtain the missing values from the authors. If not available, where there are missing
measures of variance for continuous data but an exact standard error and confidence intervals available for group means, and either a
P value or t value available for differences in mean, we can calculate them according to the rules described in the Cochrane Handbook
for Systemic reviews of Interventions (Higgins 2011). That is, when only the standard error (SE) is reported, standard deviations (SDs) are
calculated by the formula SD = SE * square root (n). Chapters 7.7.3 and 16.1.3 of the Cochrane Handbook for Systemic reviews of Interventions
(Higgins 2011) present detailed formulae for estimating SDs from P values, t or F values, confidence intervals, ranges or other statistics. If
these formulae did not apply, we calculated the SDs according to a validated imputation method which is based on the SDs of the other
included studies (Furukawa 2006). Although some of these imputation strategies can introduce error, the alternative would be to exclude
a given study’s outcome and thus to lose information. We nevertheless examined the validity of the imputations in a sensitivity analysis
by excluding the imputed values.
3.3 Last observation carried forward
We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed within the study report. As
with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (Leucht 2007).
Therefore, where LOCF data have been used in the trial, if less than 50% of the data have been assumed we would present and use these
data and indicate that they are the product of LOCF assumptions.
Assessment of heterogeneity
1. Clinical heterogeneity
We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all stud-
ies for clearly outlying people or situations which we had not predicted would arise. When such situations or participant groups arose,
we fully discussed these.
2. Methodological heterogeneity
We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspect-
ed all studies for clearly outlying methods which we had not predicted would arise. When such methodological outliers arose, we fully
discussed these.
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3. Statistical heterogeneity
3.1 Visual inspection
We visually inspected graphs to investigate the possibility of statistical heterogeneity.
3.2 Employing the I2 statistic
We investigated heterogeneity between studies by considering the I2 statistic alongside the Chi2 P value. The I2 provides an estimate of
the percentage of inconsistency thought to be due to chance (Higgins 2003). The importance of the observed value of I2 depends on: i)
magnitude and direction of effects, and ii) strength of evidence for heterogeneity (for example, P value from Chi2 test, or a confidence
interval for I2). An I2 estimate greater than or equal to around 50% accompanied by a statistically significant Chi2 statistic was interpreted
as evidence of substantial levels of heterogeneity (Higgins 2011). When substantial levels of heterogeneity were found in the primary
outcome, we explored reasons for the heterogeneity (Subgroup analysis and investigation of heterogeneity).
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (Egger 1997). These
are described in section 10 of the Cochrane Handbook for Systematic Reviews of Intervention (Higgins 2011). We are aware that funnel plots
may be useful in investigating reporting biases but are of limited power to detect small-study effects. We did not plan to use funnel plots
for outcomes where there were 10 or fewer studies, or where all studies were of similar sizes. As no meta-analyses of more than five studies
were undertaken, we did not conduct funnel plot analysis.
Data synthesis
We understand that there is no closed argument for preference for use of fixed-effect or random-effects models. The random-effects
method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems
to be true to us and the random-effects model takes into account differences between studies even if there is no statistically significant
heterogeneity. There is, however, a disadvantage to the random-effects model: it puts added weight onto small studies, which often are
the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose the ran-
dom-effects model for all analyses. The reader is, however, able to choose to inspect the data using the fixed-effect model.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses - only primary outcomes
1.1 Clinical state, stage or problem
We proposed to undertake this review and provide an overview of the effects of psychosocial interventions for people with schizophrenia
in general. In addition, however, we tried to report data on subgroups of people in the same clinical state, stage and with similar problems.
2. Investigation of heterogeneity
If inconsistency was high, we have reported this. First, we investigated whether data had been entered correctly. Second, if data were
correct, we visually inspected the graph and successively removed studies outside of the company of the rest to see if homogeneity was
restored. For this review we decided that should this occur, with data contributing to the summary finding of no more than around 10% of
the total weighting, we would present the data. If not, then we did not pool the data and discussed the issues. We know of no supporting
research for this 10% cut-oI, but we use prediction intervals as an alternative to this unsatisfactory state.
When unanticipated clinical or methodological heterogeneity is obvious we simply stated hypotheses regarding these for future reviews
or versions of this review. We do not anticipate undertaking analyses relating to these.
Sensitivity analysis
We conducted sensitivity analyses on outcomes of comparisons with four or more trials where studies with different quality were combined
to ascertain if there were substantial differences in the results when lesser quality trials or those comprising patients with schizophrenia
(or other psychoses) were compared to trials of higher quality or using mixed diagnostic groups. We applied all sensitivity analyses to the
primary outcomes based on randomised sequence, allocation concealment and blinding of outcome measurement. We only conducted
sensitivity analyses to comparisons with four or more studies as analyses with less than four trials would provide unclear decisions on
whether there have been any possible biases in the estimate of effects.
1. Implication of randomisation
We aimed to include trials in a sensitivity analysis if they were described in some way so as to imply randomisation. For the primary out-
comes we included these studies and if there was no substantive difference when the implied randomised studies were added to those
with a better description of randomisation then we entered all data from these studies.
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2. Assumptions for lost binary data
Where assumptions had to be made regarding people lost to follow-up (see Dealing with missing data) we compared the findings of the
primary outcomes when we used our assumptions and when we used data only from people who completed the study to that point. If
there was a substantial difference, we reported the results and discussed them but continued to employ our assumption.
Where assumptions had to be made regarding missing standard deviation (SD) data (see Dealing with missing data), we compared the
findings of the primary outcomes when we used our assumptions and when we used data only from people who completed the study to
that point. A sensitivity analysis was undertaken testing how prone results were to change when completer-only data were compared to
the imputed data using the above assumption. If there was a substantial difference, we reported results and discussed them but continued
to employ our assumption.
3. Risk of bias
We analysed the effects of excluding trials that were judged to be at high risk of bias across one or more of the domains of randomisation
(implied as randomised with no further details available), allocation concealment, blinding and outcome reporting for the meta-analysis
of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the
effect estimates, then we included data from these trials in the analysis.
4. Imputed values
A sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect
in cluster randomised trials was not needed for this update as there were no cluster randomised trials.
If we noted substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we did
not pool data from the excluded trials with the other trials contributing to the outcome but presented them separately.
Appendix 5. Previous plain language summaries
Dual diagnosis is the name often given to people who have a severe mental health problem and a drug and/or alcohol problem as well.
While the number of people with these problems varies, in some urban areas it can be over 50% of all those with mental health difficulties.
Although individuals may feel they are self-medicating when using these substances, drugs and alcohol can have a detrimental effect on
the symptoms of their illness, the way their medication works and their interaction with the wider world. They can also make people more
vulnerable to suicide, hepatitis C, HIV and homelessness, and can cause them to be aggressive or to do something that moves them into
the criminal justice system.
People who have a substance abuse problem but no mental health problem can be helped by a variety of interventions that look at their
motivation for change (motivational interviewing - MI), how to adapt their behaviour by improving coping strategies (cognitive behavioural
therapy - CBT), a supportive approach similar to the one used by Alcoholics Anonymous and skills training. These are all examples of
psychosocial interventions. However, using these interventions on people with mental health problems is more complex, because it is
unclear whether the intervention for the substance abuse should be offered with that for the mental health problem and whether the same
team should be responsible for both (integrated intervention).
This review attempts to assess all trials using psychosocial interventions compared to care as usual where they are used to help those
who have a substance abuse problem and a severe mental illness. Thirty-four studies were identified containing a total of 3397 people.
Three trials were based in a hospital, 21 in the community, eight in hospital and the community and two in the community and in jail. They
used different psychosocial interventions, with four trials using integrated models of care, four using non-integrated, seven combining MI
and CBT, two using CBT, eight using MI, two using contingency management and two using skills training. Trials lasted from three months
to three years. No trial showed any definitive difference between the psychosocial intervention and the usual treatment, although the
difference in the study designs made it difficult to compare one trial to another. There are also problems caused by high dropout rates,
differences in the outcome measures and dependability in the way psychological interventions were delivered. To allow more thorough
assessment of whether psychosocial interventions work for people with substance abuse problems and severe mental illnesses, more high
quality trials are needed which address these problems.
(Plain language summary prepared for this review by Janey Antoniou of RETHINK, UK www.rethink.org and updated by the authors)
Psychosocial interventions for people with both severe mental illness and substance misuse
‘Dual diagnosis’ is the term used to describe people who have a mental health problem and also have problems with drugs or alcohol. In
some areas, over 50% of all those with mental health difficulties will have problems with drugs or alcohol. For people with mental illness,
substance misuse often has a negative and damaging effect on the symptoms of their illness and the way their medication works. They
may become aggressive or engage in activities that are illegal. Substance misuse can also increase risk of suicide, hepatitis C, HIV, relapse,
incarceration and homelessness.
People who have substance misuse problems but no mental illness can be treated via a variety of psychosocial interventions. These in-
clude motivational interviewing, or MI, that looks at people’s motivation for change; cognitive behavioural therapy, or CBT, which helps
people adapt their behaviour by improving coping strategies; a supportive approach similar to that pioneered by Alcoholics Anonymous;
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family psycho-education observing the signs and effects of substance misuse; and group or individual skills training. However, using these
interventions for people with dual diagnosis is more complex.The aim of this review was to assess the effects of psychosocial interven-
tions for substance reduction in people with a serious mental illness compared to care as usual or standard care. A search for studies
was carried out in July 2012; 32 studies were included in the review with a total of 3165 people. These studies used a variety of different
psychosocial interventions (including CBT, MI, skills training, integrated models of care). In the main, evidence was graded as low or very
low quality and no study showed any great difference between psychosocial interventions and standard care. There was no compelling
evidence to support any one psychosocial treatment over another. However, differences in study designs made comparisons between
studies problematic. Studies also had high numbers of people leaving early, differences in outcomes measured, and differing ways in
which the psychosocial interventions were delivered. More large scale, high quality and better reported studies are required to address
these shortcomings. This will better address whether psychosocial interventions are effective and good for people with mental illness and
substance misuse problems.
This plain language summary has been written by a consumer, Ben Gray from RETHINK.
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Date Event Description
14 October 2019 New citation required but conclusions
have not changed
Results from 2018 search added to review. Overall conclusions
have not changed with the addition of new data.
2 May 2018 New search has been performed Search updated, 113 records identitified for screening.
 
H I S T O R Y
Protocol first published: Issue 1, 1998
Review first published: Issue 2, 1999
 
Date Event Description
7 April 2014 Amended Correction to number of new studies added.
26 September 2013 New citation required but conclusions
have not changed
Review is substantially updated with the addition of 7 new trials,
conclusions remain similar to previous versions of this review.
2 July 2013 New search has been performed Update with 7 new trials. Complete revision of previous review
with 'Risk of bias' added for all current and previous trials and
full GRADE assessments done on all comparisons.
20 March 2009 Amended New plain language summary added.
26 April 2008 Amended Converted to new review format.
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Glenn E. Hunt - searching, trial selection, contacting authors, data extraction and entry, 'Risk of bias' assessment, review writing. Corre-
sponding author.
Nandi Siegfried - protocol production, advice, 'Risk of bias' assessment, formulating and construction of GRADE 'Summary of findings'
tables, review writing.
Kirsten Morley - trial selection, data extraction and entry, review writing.
Carrie Brooke-Sumner - data extraction and 'Risk of bias' table entry.
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Nandi Siegfried - protocol production, advice, review writing.
Garry Walter - grant writing, review writing.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
1. In 2013, we have added contingency management to the list of interventions as there were no studies with usable data until then. The
authors feel that this is an area of research of fundamental value that merits inclusion as indicated by several ongoing trials using this
intervention, and should not be overlooked.
2. The cochrane Schizophrenia group currently excludes studies that do not involve any participants with schizophrenia in reviews, and
those studies that solely recruit patients with major depressive disorder or bipolar disorder are no longer included. Consequently, search
terms for depression and bipolar disorder have been dropped. We removed two studies from this 2013 update which were included in
prior review updates as they did not conform to this new guideline.
3. Where the protocol did not define the primary outcome of interest, this update has specified primary and secondary outcomes - this
decision was not influenced by examination of the results to date.
4. The addition of 'Summary of findings' tables using GRADE criteria were included in this update and 2013 to conform to the new format
of Cochrane Reviews.
5. The Cochrane Schizophrenia group maintains a method template. We have used the latest version of this template and updated our
methods section and naming of outcomes. This does not involve changes to the methodology but minor revisions such as clarification of
outcome presentation and updating of references. Previous method templates can be found in Appendices.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Cognitive Behavioral Therapy;   Diagnosis, Dual (Psychiatry);   Mental Disorders   [*therapy];   Motivational Interviewing;   Randomized
Controlled Trials as Topic;  Schizophrenia  [therapy];  Substance-Related Disorders  [*therapy]
MeSH check words
Humans
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